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A B S T R A C T
Background
Tumour necrosis factor (TNF)-alpha inhibitors are beneficial for the treatment of rheumatoid arthritis (RA) for reducing the risk of
joint damage, improving physical function and improving the quality of life. This review is an update of the 2014 Cochrane Review
of the treatment of RA with certolizumab pegol.
Objectives
To assess the clinical benefits and harms of certolizumab pegol (CZP) in people with RA who have not responded well to conventional
disease-modifying anti-rheumatic drugs (DMARDs).
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL: Cochrane Library 2016, Issue 9), MEDLINE, Embase,
Web of Knowledge, reference lists of articles, clinicaltrials.gov and ICTRP of WHO. The searches were updated from 2014 (date of
the last search for the previous version) to 26 September 2016.
Selection criteria
Randomised controlled trials that compared certolizumab pegol with any other agent, including placebo or methotrexate (MTX), in
adults with active RA, regardless of current or prior treatment with conventional disease-modifying anti-rheumatic drugs (DMARDs),
such as MTX.
Data collection and analysis
Two review authors independently checked search results, extracted data and assessed trial quality. We resolved disagreements by
discussion or referral to a third review author.
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Main results
We included 14 trials in this update, three more than previously. Twelve trials (5422 participants) included measures of benefit. We
pooled 11 of them, two more than previously. Thirteen trials included information on harms, (5273 participants). The duration of
follow-up varied from 12 to 52 weeks and the range of doses of certolizumab pegol varied from 50 to 400 mg given subcutaneously.
In Phase III trials, the comparator was placebo plus MTX in seven trials and placebo in five. In the two Phase II trials the comparator
was only placebo.
The approved dose of certolizumab pegol, 200 mg every other week, produced clinically important improvements at 24 weeks for the
following outcomes:
- AmericanCollege ofRheumatology (ACR) 50% improvement (pain, function andother symptomsofRA): 25%absolute improvement
(95% confidence interval (CI) 20% to 33%); number need to treat for an additional beneficial outcome (NNTB) of 4 (95% CI 3 to
5); risk ratio (RR) 3.80 (95% CI 2.42 to 5.95), 1445 participants, 5 studies.
- The Health Assessment Questionnaire (HAQ): -12% absolute improvement (95% CI -9% to -14%); NNTB of 8 (95% CI 7 to 11);
mean difference (MD) - 0.35 (95% CI -0.43 to -0.26; 1268 participants, 4 studies) (scale 0 to 3; lower scores mean better function).
- Proportion of participants achieving remission (Disease Activity Score (DAS) < 2.6) absolute improvement 10% (95% CI 8% to
16%); NNTB of 8 (95% CI 6 to 12); risk ratio (RR) 2.94 (95% CI 1.64 to 5.28), 2420 participants, six studies.
- Radiological changes: erosion score (ES) absolute improvement -0.29% (95% CI -0.42% to -0.17%); NNTB of 6 (95% CI 4 to 10);
MD -0.67 (95% CI -0.96 to -0.38); 714 participants, two studies (scale 0 to 230), but not a clinically important difference.
-Serious adverse events (SAEs) were statistically but not clinically significantly more frequent for certolizumab pegol (200 mg every
other week) with an absolute rate difference of 3% (95% CI 1% to 4%); number needed to treat for an additional harmful outcome
(NNTH) of 33 (95% CI 25 to 100); Peto odds ratio (OR) 1.47 (95% CI 1.13 to 1.91); 3927 participants, nine studies.
There was a clinically significant increase in all withdrawals in the placebo groups (for all doses and at all follow-ups) with an absolute
rate difference of -29% (95% CI -16% to -42%), NNTH of 3 (95% CI 2 to 6), RR 0.47 (95% CI 0.39 to 0.56); and there was a
clinically significant increase in withdrawals due to adverse events in the certolizumab groups (for all doses and at all follow-ups) with
an absolute rate difference of 2% (95% CI 0% to 3%); NNTH of 58 (95% CI 28 to 329); Peto OR 1.45 (95% CI 1.09 to 1.94) 5236
participants Twelve studies.
We judged the quality of evidence to be high for ACR50, DAS remission, SAEs and withdrawals due to adverse events, and moderate
for HAQ and radiological changes, due to concerns about attrition bias. For all withdrawals we judged the quality of evidence to be
moderate, due to inconsistency.
Authors’ conclusions
The results and conclusions did not change from the previous review. There is a moderate to high certainty of evidence from randomised
controlled trials that certolizumab pegol, alone or combined with methotrexate, is beneficial in the treatment of RA for improved
ACR50 and health-related quality of life, an increased chance of remission of RA, and reduced joint damage as seen on x-ray. Fewer
people stopped taking their treatment, but most of these who did stopped due to serious adverse events. Adverse events were more
frequent with active treatment. We found a clinically but not statistically significant risk of serious adverse events.
P L A I N L A N G U A G E S U M M A R Y
Certolizumab pegol for treating adults with rheumatoid arthritis
We conducted an updated review of the benefits and harms of certolizumab pegol (CZP) for adults with active rheumatoid arthritis
(RA). We searched for all relevant studies until September 2016 and found 14 trials with 5499 people.
The length of follow-up in most of the trials was 24 weeks; most participants were women.
What is rheumatoid arthritis and what is certolizumab pegol?
When you have RA, your immune system becomes overactive and attacks the lining of your joints. This makes your joints swollen,
stiff and painful.
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Certolizumab pegol is a biologic medication for the treatment of RA. It works by blocking a substance produced by the body known
as tumour necrosis factor alpha (TNFα). Certolizumab pegol is given by injections under the skin. The approved dose is 200 mg.
What happens to people with rheumatoid arthritis who take certolizumab pegol 200 mg every other week after six months?
ACR50 (standard: a 50% improvement in the number of tender or swollen joints and other outcomes such as pain and disability):
- 25more people out of 100 experienced improvements in the symptoms of their rheumatoid arthritis after sixmonthswith certolizumab
pegol (absolute improvement 25%).
- 36 people out of 100 who took certolizumab pegol experienced improvements compared to nine people out of 100 who took a
placebo (a fake injection).
We rate the quality of evidence for ACR50 as high.
Health-related quality of life (Health Assessment Questionnaire, HAQ: 0 to 3 scale, where a lower score means improvement):
- people who took certolizumab pegol scored 0.35 points lower than people who took placebo (absolute improvement 12%).
- people on certolizumab pegol scored 0.48 points lower compared to 0.13 points lower for people who took a placebo.
We rate the quality of evidence for the HAQ as moderate, downgraded, due to concerns about the high number of people dropping
out of the studies.
Remission (absence of clinical signs of inflammation):
- 10 people out of 100 experienced remission with certolizumab pegol (absolute improvement 10%).
- 22 people out of 100 who took certolizumab pegol experienced remission compared to 12 people out of 100 who took a placebo.
We rate the quality of evidence for the remission as high.
Radiological changes (x-rays of the joints, measured on a 0 to 230 unit scale):
- the joint damage in people who took certolizumab pegol was 0.67 units less (absolute improvement -0.29%).
- the damage to joints in people who took certolizumab pegol was 0.04 units less compared to people who took a placebo, whose joint
damage was 0.7 units more.
We rate the quality of evidence for the findings in the radiological changes as moderate, downgraded, due to concerns about the high
number of people dropping out of the studies.
Serious adverse events:
- three more people out of 100 experienced serious adverse events with certolizumab pegol (3% absolute harm).
- nine people out of 100 who took certolizumab pegol experienced serious adverse events compared to six people out of 100 who took
a placebo.
We rate the quality of evidence for serious adverse events as high.
All Withdrawals
- 29 fewer people out of 100 experienced withdrawals with certolizumab pegol (absolute harm 29%).
- 23 people out of 100 who took certolizumab pegol experienced withdrawals compared to 52 people out of 100 who took a placebo.
We rate the quality of evidence for all withdrawals as moderate.
Withdrawals due to adverse events
- two more people out of 100 stopped treatment because of SAEs with certolizumab pegol (2% absolute harm).
- five people out of 100 who took certolizumab pegol estopped treatment because of SAEs compared to three people out of 100 who
took a placebo.
We rate the quality of evidence for the withdrawals due to adverse events as high.
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In summary:
- certolizumab pegol improves ACR50, health-related quality of life, and remission of RA.
- certolizumab pegol probably reduces joint damage as seen on x-ray.
- certolizumab pegol increases serious adverse events.
- with certolizumab pegol, fewer people stop taking their treatment, but those who stop do so because of serious adverse events.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Certolizumab pegol 200 mg sc (with or without MTX) versus placebo (with or without MTX) for rheumatoid arthritis in adults
Patient or population: pat ients with rheumatoid arthrit is in adults
Settings: adults (18 years old or more) who have persistent disease act ivity
Intervention: certolizumab pegol 200 mg sc (with or without MTX) versus placebo (with or without MTX)
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cent change = 45% (9%
to 94%).
NNTH = 58 (28 to 329)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io; NNTB: number needed to treat for an addit ional benef icial outcome
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1We downgraded the quality of evidence by one level for risk of bias due to attrit ion bias analysed per protocol. We have
rated all the trials at low risk for attrit ion bias since reasons for attrit ion/ exclusions were reported in most of them, and
reasons were sim ilar. However, for HAQ-DI and radiological changes we can only conduct a per protocol analysis, as these
are cont inuous outcomes that count the average number of part icipants st ill in the trials. For DAS remission, ACR50, SAEs,
all withdrawals and withdrawals due to AEs we conducted an ITT analysis, which is a more conservat ive approach, not
requiring downgrading.
2We downgraded the quality of evidence by one level for inconsistency, due to heterogeneity (not all the conf idence intervals


































































































B A C K G R O U N D
Description of the condition
Rheumatoid arthritis (RA) is a chronic inflammatory disease char-
acterised by synovial inflammation of joints and other struc-
tures such as tendon sheaths and bursas, autoantibody produc-
tion (rheumatoid factor and anti-citrullinated protein antibody
(ACPA)), with both cartilage and bone destruction. RA typically
causes a symmetrical polyarticular arthritis with pain, swelling and
stiffness of the affected joints. If the disease is not controlled early,
damage may become permanent, leading to significant disability.
People with RA commonly experience fatigue and show changes
in the blood, such as anaemia due to chronic inflammation, and
an acute phase reaction. In some people organs such as the skin
(as rheumatoid nodules), lungs (pleural inflammation and alveoli-
tis), heart (pericarditis), blood vessels (vasculitis) and the eyes (dry
eyes or inflammation) may be affected (Tureson 2013). RA is also
associated with reduced life expectancy; in a Spanish cohort, the
standardised mortality ratio was 1.89 (Abasolo 2016), specifically
due to cardiovascular disease (Meune 2009).
Despite progress in understanding the pathogenesis of RA, its
cause remains unknown. Important genetic influences are recog-
nised, with more than 100 RA risk loci identified (Okada
2014). Based on twin studies, heritability is approximately 60%
(MacGregor 2000), so environment also plays a key role in RA
pathogenesis.Moreover, in recent years environmental factors have
gained importance in explaining the development of RA: smoking
has specifically been associated with the development of ACPA-
positive RA (Lundberg 2013), and cumulative evidence from a
large number of studies implicates the microbiome of the peri-
odontium, lung, and gut in RA pathogenesis (Kharlamova 2016).
People of all ages are affected, but the disease begins most com-
monly between the ages of 40 and 70 years, with incidence ris-
ing with increasing age (Doran 2002). The global prevalence is
0.24%, with twice as many women as men affected (Cross 2014).
Significant functional limitations occur in 15% of sufferers five
years after disease onset, with around a third of those in paid work
experiencing work disability (Young 2000). In Finland, the risk
of disability is seven times higher in people with RA compared
with the general population (Sokka 2003). Rapid induction of re-
mission translates to the maintenance of work capacity (Puolakka
2005).
Description of the intervention
The management of RA has undergone dramatic changes dur-
ing the last 15 years. The latest updated recommendations of
both the American College of Rheumatology (Singh 2016) and
the European League Against Rheumatism (Smolen 2014) em-
phasise the importance of starting therapy with disease-modify-
ing anti-rheumatic drugs (DMARDs) as soon as the diagnosis of
RA is made; the search for remission or low disease activity using
a treat-to-target approach; and close monitoring by using com-
posite measures of disease activity and appropriate switching of
drug treatment when the objectives are not reached.Methotrexate
(MTX) remains the drug of choice at the start of treatment of RA
(Lopez-Olivo 2014), although leflunomide or triple therapy are
considered excellent alternatives (Singh 2012).
People sometimes do not respond to or are unable to tolerate
DMARDs (Yee 2003). The newer biological drugs that have been
introduced and approved for the treatment of RA in recent decades
have been associated with clinical outcome improvement (Singh
2009), but also with higher rates of adverse events (Singh 2011).
How the intervention might work
RA is characterised by immunological activation ofmany cell types
and a network of cytokines, particularly tumour necrosis factor
alpha (TNFα) (Brennan 2008). Inhibitors of TNFα have been
a major development in the treatment of RA. Randomised trials
have shown that these drugs are highly beneficial in peoplewithRA
who have not responded well to conventional DMARDs. TNFα
inhibitors have been shown to reduce the risk of joint damage,
improve physical function and quality of life (Chen 2006). Five
TNFα inhibitors are currently licensed for use against RA in Eu-
rope and theUSA.These are adalimumab (Navarro-Sarabia 2005),
etanercept (Lethaby 2013), golimumab (Singh 2010), infliximab
(Blumenauer 2002) and certolizumab pegol (Ruiz Garcia 2014).
Comparative efficacy studies to evaluate variations between anti-
TNF and non-anti-TNF biologics have shown little difference be-
tween them (Navarro-Millán 2013). One pragmatic, open-label
controlled trial (Jobanputra 2012) has directly compared etan-
ercept and adalimumab, and reported similar persistence rates,
efficacy and safety over two years of treatment. Similar results
have been obtained with certolizumab pegol in extension studies,
with the American College of Rheumatology ACR20 at 57% and
ACR50 at 27% at eight years (NCT00160693), and ACR20 at
81% and ACR50 at 58% at seven years (NCT00175877). An im-
portant limitation of the wider use of TNF inhibitors is the high
cost, between USD 10,000 and USD 25,000 per person a year.
However, the recent entry of bio similars is causing a significant
drop in prices. Biosimilars are biological products that are copies of
an approved innovator biopharmaceutical, developed after the ex-
piration of the innovator’s patent and submitted for separate mar-
keting approval. The use of bio similars may dramatically increase
in the near future, mainly due to cost savings (Dörner 2016).
A systematic review of infliximab and adalimumab has shown that
the risks of malignancy and serious infection were increased, with
odds ratios (ORs) of 3.3 (95% confidence interval (CI) 1.2 to
9.1) and 2.0 (95% CI 1.3 to 3.1) respectively (Bongartz 2006).
However, more recent data show that therapy with anti-TNF
is not related to an increased risk of malignancies (skin cancer,
melanoma, lymphoma or solid tumours) (Lopez-Olivo 2012). A
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second review of nine biologic drugs (the five TNF inhibitors etan-
ercept, adalimumab, infliximab, golimumab and certolizumab pe-
gol; the interleukin (IL)-1 antagonist anakinra; the IL-6 antago-
nist tocilizumab; the anti-CD28 abatacept; and anti-B cell ritux-
imab) showed that biologics as a group were associated with a sta-
tistically significantly higher rate of total adverse events (OR 1.28,
95% CI 1.09 to 1.50) and withdrawals due to adverse events (OR
1.47, 95% CI 1.20 to 1.86), and an increased risk of tuberculosis
(TB) reactivation (OR 4.68, 95% CI 1.18 to 18.60) compared
to control (Singh 2011). Moreover, the risk of serious infection
is increased in people with RA treated with biological therapies
compared with conventional DMARDs (Singh 2015).
Certolizumab pegol (CZP) was approved by the US Food and
Drug Administration (FDA) and the European Medicines Evalu-
ation Agency (EMEA) in 2009 for adults suffering from moder-
ate to severe RA. Certolizumab pegol is an anti-TNF consisting
of a humanised immunoglobulin fragment (Fab) conjugated to
polyethylene glycol (PEG), also termed pegylation. This unique
molecular structure yields a longer half-life and reduces the need
for frequent dosing (Choy 2002). Certolizumab pegol in com-
bination with MTX is indicated for the treatment of moderate
to severe active RA in adults when the response to conventional
DMARDs, including MTX, has been inadequate. It is also in-
dicated in severe, active and progressive RA not treated previ-
ously with conventional DMARDs. In the case of intolerance,
side effects or contraindications to MTX it also can be given as
monotherapy. The drug has been shown to reduce the rate of pro-
gression of joint damage, as measured by x-ray, and to improve
physical function. Long-term follow-up studies of commercially-
sponsored randomised controlled trials (RCTs) show persistence
rates of 59.9% at week 232 (Smolen 2015), with 46.7% of par-
ticipants having low disease activity at two years (Keystone 2012).
Whether such rates can be replicated in routine care remains to be
seen.
Why it is important to do this review
Biological treatment has led to a radical change in the prognosis
and quality of life of people with RA. However, clinicians need
to take into account the potential risks associated with their use.
This review summarises the current data available on the benefits
and harms of certolizumab pegol, on its own and in combination
with MTX, for the treatment of RA. New evidence about efficacy,
safety and long-term persistence has become available since our
previous update. It is important to be sure that clinicians choose
the treatment for people with RA appropriately, using the best
medical evidence available (Emparanza 2015).
O B J E C T I V E S
To assess the clinical benefits and harms of certolizumab pegol
(CZP) in people with RA who have not responded well to con-
ventional disease-modifying anti-rheumatic drugs (DMARDs).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs).
Types of participants
Adults (18 years and older) with RA who have persistent disease
activity.
People with RA were defined as those meeting the American Col-
lege of Rheumatology (ACR) 1987 revised criteria (Arnett 1988)
for RA. That is to say, they had to have an active form of the disease
as demonstrated by at least two of the following symptoms:
1. Three or more tender joint areas as observed by a physician;
2. Three or more swollen joint areas as observed by a
physician;
3. Early morning stiffness with a duration > 30 minutes;
4. Acute phase reactants such as a Westergren erythrocyte
sedimentation rate (ESR) more than 30 mm/hour or C-reactive
protein (CRP) more than 10 mg/mL.
Types of interventions
Certolizumab pegol (CZP)) at any dose.
The comparators were placebo or any DMARD including other
biologic agents used to treat RA.
Types of outcome measures
Major outcomes
• The proportion of participants achieving an ACR50
• Health-related quality of life, such as the Health Assessment
Questionnaire (HAQ) or Short Form Health Survey (SF-36)
• Disease Activity Score (DAS28 or other versions of DAS)
• Radiological changes (erosion score (ES), modified total
Sharp score, joint space narrowing)
• Serious adverse events (SAEs)
• All withdrawals
• Withdrawals due to adverse events
The ACR50 is defined as a 50% improvement in the number of
tender and swollen joints and a 50% improvement in at least three
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of the following items: observer evaluation of overall disease activ-
ity, patient evaluation of overall disease activity, patient evaluation
of pain, a score of physical disability, or improvements in blood
acute-phase responses.
Scores in the HAQ range from 0 to 3, with 3 indicating a worse
health state, so a negative change indicates improvement. The
SF-36 is a scale from 0 to 100 where 0 is the worst and 100 the
best health state.
Serious adverse events are defined as malignancies and all infec-
tions, especially tuberculosis, and death.
We sought all causes of withdrawals from the medication.
Minor outcomes
• ACR20 and ACR70 (a 20% or 70% improvement
respectively in the parameters described above)
• Frequency of adverse events
• Withdrawals due to lack of efficacy
We sought reports of the following adverse events: headache,
fever, blood disorders, laboratory disorders, abdominal pain, na-
sopharyngitis, nausea, respiratory tract infections, urinary tract in-
fections, neck pain, congestive heart failure, pruritus and anaphy-
laxis.
Search methods for identification of studies
Electronic searches
The search strategy used the revision of the Cochrane highly
sensitive search strategy (HSSS) for PubMed (Glanville 2006),
the best sensitivity filter developed by the Hedges Team (Wong
2006a; Wong 2006b), and followed the Cochrane Musculoskele-
tal Review Group (CMSG) recommendations. Searches included
both MeSH headings and text terms for CDP870 and rheuma-
toid arthritis. Tamara Rader, Information Scientist of the CMSG,
conducted the searches. These included: MEDLINE (Appendix
1); Embase (Appendix 2); CINAHL (Appendix 3); Cochrane
Database of Systematic Reviews (CDSR) and Cochrane Central
Register of Controlled Trials (CENTRAL), HTA, DARE, NHS
EED (the Cochrane Library) (Appendix 4); SCOPUS (Appendix
5); TOXLINE (TOXNET) (Appendix 6).
Safety data were obtained from clinical trials.
We updated the searches in CENTRAL (the Cochrane Library
2014, Issue 5), MEDLINE (2009 to 5 June 2014), Embase (2009
to 5 June 2014), SCOPUS (2009 to 5 June 2014), TOXLINE
(2009 to 5 June 2014), Web of Knowledge (2009 to 5 June 2014)
and the websites of the FDA and EMEA (2009 to 5 June 2014).
For this updated review, we updated the searches of MEDLINE;
Embase, Cochrane Database of Systematic Reviews (CDSR) and
Cochrane Central Register of Controlled Trials (CENTRAL),
HTA, DARE, NHS EED (the Cochrane Library), and WOK in
January 2016 and again in September 2016 (see Appendix 10;
Appendix 11; Appendix 12; Appendix 13).
Searching other resources
1. We examined the information made available by the main
researchers and sponsors in ClinicalTrials.gov and the WHO
International Clinical Trials Registry Platform (apps.who.int/
trialsearch/).
2. We reviewed information on the clinical trial meta-register
database (www.controlled-trials.com/mrct/).
3. We inspected the reference lists of all identified studies for
more trials.
4. When published data were missing, incomplete, or
inconsistent with the trial protocols, we sought further
information from the authors and manufacturers (UCB).
Data collection and analysis
Selection of studies
Two review authors independently checked the search results for
studies that potentially met the inclusion criteria, resolving dis-
agreements by discussion or by referral to a third review author.
Inclusion criteria
1. RCTs that compared certolizumab pegol with any other
agent including placebo in adults with active RA despite current
or prior treatment with DMARDs.
2. Trials that were fully published as a paper or available as a
complete trial report. Where they were published only as
abstracts, we requested the trial reports from the manufacturers.
3. Studies having at least three months of follow-up to assess
benefits.
To assess harms we also sought studies having a suboptima length
of follow-up, from eight weeks.
Exclusion criteria
1. Trials of certolizumab pegol for juvenile arthritis, Crohn’s
disease, psoriatic arthritis and other forms of spondyloarthritis.
2. Trials of certolizumab pegol comparing different doses or
routes of administration without another active or placebo
control group (except for assessing harm outcomes).
3. Studies reporting solely on laboratory measures aimed at
investigating disease or treatment mechanisms and which did not
report relevant clinical outcomes.
4. Observational studies of certolizumab pegol.
5. Interim results of trials.
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Data extraction and management
Two review authors independently checked titles and abstracts of
studies found by the search, to assess which studies might poten-
tially meet the inclusion criteria; where there was doubt, we ac-
quired the full article for further inspection. We then obtained
studies identified by this process and two review authors indepen-
dently screened them to see if they met the review criteria using a
web interface.
We extracted data when possible for intention-to-treat popula-
tions, as raw numbers plus any summary measures with the stan-
dard deviations, confidence intervals and P values of the outcomes
reported. We compiled them in an Excel spreadsheet. We would
have resolved any differences of opinion and data discrepancies
by reference to a third review author (SB) but this proved to be
unnecessary.
Assessment of risk of bias in included studies
According to the recommendations in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011), we assessed the
risks of bias by creating a ’Risk of bias’ table for each study. We
present a summary below as a ’Risk of bias’ graph.
The main criteria used to assess the risks of bias included: ran-
dom sequence generation, allocation concealment, blinding of
participants, incomplete outcome data, selective reporting of out-
comes, and other potential biases (such as fraud or imbalance in
the groups, or the sponsor either owning the data or needing to
approve the manuscript). We rated the risk of bias in each study
on the basis of each criterion as: low risk of bias, high risk of bias,
unclear risk of bias (either lack of information or uncertainty over
the potential bias). We included these criteria in the tables, resolv-
ing disagreements by discussion between the two review authors
with recourse to a third review author if necessary, but in the event
there were no disagreements.
Measures of treatment effect
We used the risk difference to quantify the number needed to treat
for an additional beneficial outcome (NNTB) (Laupacis 1988).
We calculated the NNTB from the risk ratio according to the for-
mula NNTB = 1/ACR*(1 - RR), where ACR is the assumed con-
trol risk and RR the risk ratio. When events were very rare (fewer
than 10%) we used the Peto odds ratio (Peto OR). For continu-
ous data we used mean differences (MDs) when the results were
measured in the same way in the different studies. We used stan-
dardised mean differences (SMDs) when the results obtained were
conceptually the same but used different measurement scales. We
recorded the central estimate (mean) and standard deviation (SD).
Where these were not directly stated we calculated them from the
standard error or the different means and their respective confi-
dence intervals (CIs) or P values. When medians and interquartile
ranges were the only data provided, we used the median as a proxy
measure of the mean and we considered the difference between
the first and third interquartile to be equivalent to 1.35 of the SD.
Unit of analysis issues
Most of the clinical trials had a simple parallel-group design with
participants individually randomised to one of two intervention
groups. The unit of analysis was not an issue for this review.
Dealing with missing data
We carried out an intention-to-treat analysis. Every individual
allocated to the interventionwas counted, whether they completed
the follow-up or not.Wehave assumed that thosewhodroppedout
had no change in their outcome. This rule is conservative for the
response to treatment because it assumes that those discontinuing
the studies would not have responded. It is not conservative for
adverse effects. However, assuming that all those leaving early had
developed side effects could overestimate risk.
When published data were missing, incomplete or inconsistent
with the RCT protocols or meeting abstracts, we asked for further
information from the authors and manufacturers. We excluded
abstracts of studies only if they were interim reports of studies that
had not yet finished recruiting.
Assessment of heterogeneity
We have explored heterogeneity between the trials using the Chi
2 test for heterogeneity, with a 10% level of significance, and the
I2 statistic. We interpreted the ranges of I2 according to the rec-
ommendations in the Cochrane Handbook for Systematic Reviews
of Interventions:
0% to 40% might not be important;
30% to 60% may represent moderate heterogeneity;
50% to 90% may represent substantial heterogeneity;
75% to 100% represents considerable heterogeneity (Higgins
2011).
Assessment of reporting biases
We planned to explore reporting bias using funnel plots when
doing a meta-analysis for 10 or more studies.
Data synthesis
We explored the need to pool the results according to a fixed-
effect or random-effects model analysis (Laird 1990). We planned
to use the fixed-effect model to pool the data because statistical
heterogeneity in our preview review was not high. However, we
decided finally to perform a random-effects model, despite the
I2 values being low. Although it was the same drug, there was
clear clinical heterogeneity (different doses, allowing MTX or not,
different follow-up, different duration of RA, etc.).
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Subgroup analysis and investigation of heterogeneity
We planned subgroup analyses for the duration of the illness (ap-
proximately three years evolution), participants’ sex, drug dose and
administration, and methodological quality. If we had detected
heterogeneity then we would have conducted a subgroup analysis
(Yusuf 1991), or a meta-regression (Thompson 1999) to see if it
could be explained.
Sensitivity analysis
We planned the following sensitivity analyses in order to explore
effect size differences and the robustness of conclusions:
1. Effect of study quality, dened as random sequence generation,
allocation concealment, blinding of participants, incomplete out-
come data, selective outcome reporting and other potential sources
of bias.
2. Effect of imputation, size of trials, use of concomitant
methotrexate, and doses of certolizumab pegol.
’Summary of findings’ table
We used the GRADE approach, developed by the GRADE work-
ing group, to provide an overall assessment of the quality of the ev-
idence by outcome. The GRADE approach specifies four levels of
quality, with the highest quality rating for RCTs. Review authors
can, however, downgrade randomised trial evidence from ’high’ to
’moderate’, ’low’ or even ’very low’ quality evidence, depending on
the presence of specific factors: design or implementation, impre-
cision, inconsistency, indirectness, or reporting bias (see Cochrane
Handbook for Systematic Reviews of InterventionsChapter XII (sec-
tion 12.2) (Higgins 2011)).
R E S U L T S
Description of studies
Results of the search
See the flow chart (Figure 1) and ’Results of searches’ in Appendix
10; Appendix 11; Appendix 12; Appendix 13; Appendix 14;
Appendix 15; Appendix 16; Appendix 17.
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Figure 1. Update:Records identified through the databases: (n = 559)Additional records identified through
other sources (Clinicaltrials.gov, ICRTP)(n = 98)Flow diagram.
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We include 14 trials in this update. Eleven (5422 participants)
were included in the pooled analysis for benefits, two more than
previously, and 13 (5273 participants) in the pooled analysis for
safety. The duration of follow-up varied from 12 to 52 weeks
and the range of doses of certolizumab pegol varied from 50 to
400 mg given subcutaneously (sc). In Phase III trials, the control
was placebo plus MTX in seven trials and placebo alone in five
trials. In Phase II the comparator was placebo. So summarising 7
trials compared certolizumab plus MTX and 7 trials certolizumab
compared with placebo.
In accord with Cochrane MECIR standards, the Cochrane Mus-
culoskeletal Group (CMSG) updated the searches on 25 January
2016 and reran them on 27 September, 2016.
Included studies
We include 14 trials, 12 in the assessment of benefits (CDP870-
004 2001; Choy 2012; Smolen 2015; Fleischmann 2009;
Yamamoto (a) 2014; Yamamoto (b) 2014; NCT00993317;
Atsumi 2016; Emery 2015; Keystone 2008; Smolen 2009;
Weinblatt 2012) and 14 trials in the assessment of harms
(CDP870-004 2001; Choy 2012; Smolen 2015; Choy 2002;
Fleischmann 2009; Yamamoto (a) 2014; Yamamoto (b) 2014;
NCT00993317; Østergaard 2015; Atsumi 2016; Emery 2015;
Keystone 2008; Smolen 2009; Weinblatt 2012). See Table 1. See
the Characteristics of included studies and the demographics and
flow of participants in Table 2 and Table 4 for details. Only Choy
2002 and CDP870-004 2001 were Phase II studies. We found
a third Phase II study (Kaushik 2005) but we were advised by
UCB that: “this publication refers to the 2 previous phase II”. We
used all the Phase III studies to assess both benefits and harms.
CDP870-004 2001 only contributed data on benefits, as it did not
report any data on harms. Due to the short follow-up for assessing
benefits, we only included Choy 2002 for safety data. The data
from the two Phase II studies (CDP870-004 2001; Choy 2002)
were not pooled with the rest of the studies, due to the different
follow-ups and doses used.
We retrieved 12 Phase III trials (Choy 2012; Smolen 2015;
Fleischmann 2009; Yamamoto (a) 2014; Yamamoto (b) 2014;
NCT00993317; Østergaard 2015; Atsumi 2016; Emery 2015;
Keystone 2008; Smolen 2009;Weinblatt 2012). All the trials were
funded by UCB. Data from Choy 2012 were provided by UCB
from the clinical study summary (www.clinicalstudyresults.org/
documents/company-study˙4348˙0.pdf) and the EMA 2009 re-
ports; they were finally published in 2012 (the study was com-
pleted in 2004).
Table 2 shows the demographic and baseline characteristics for
the Phase III trials: age, gender, rheumatoid factor (RF) positivity,
MTX concomitant dose, number of previous DMARDs, basal
HAQ and basal DAS28, among other outcomes. Table 3 provides
the flow chart of participants in the Phase III studies.
Excluded studies
Themain reasons for exclusionwere: 1) reviews; 2) different drugs;
and 3) another outcome reported. See the Table Characteristics of
excluded studies.
Risk of bias in included studies
We present the judgements about each ’Risk of bias’ item as per-
centages across all included studies (Figure 2). We rated most of
the trials at low risk of bias. The overall likelihood of bias seemed
to be low.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
All studies except CDP870-004 2001 reported adequate meth-
ods of randomisation and allocation concealment. Eight stud-
ies (Choy 2012; Smolen 2015; Fleischmann 2009; Atsumi 2016;
Emery 2015; Keystone 2008; Smolen 2009;Weinblatt 2012) used
the interactive voice response system (IVRS) method of allocation
concealment. The Asian trials (Yamamoto (a) 2014; Yamamoto
(b) 2014; NCT00993317) were described as: ’external randomi-
sation’ (NCT00993317) or randomisation by blocks (Yamamoto
(a) 2014; Yamamoto (b) 2014), so the risk of bias seemed to be
low.
Blinding
All studies except CDP870-004 2001 reported adequate blinding.
Refer to Figure 3.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Phase II:
• CDP870-004 2001 did not disclose the methods of
blinding, and UCB explained to us: “CPD-870 and the placebo
utilized in this study (saline) did not have the same viscosity
therefore full blinding was not possible. Study drug was to be
prepared by a pharmacist having no other involvement in the
study; injections of study medications were given by a nurse or
physician who had no other involvement in the study...”;
• Choy 2002 disclosed the methods of blinding: “Placebo
(sodium acetate buffer) was given similarly as a single
intravenous infusion of 100 ml over 60 min”. It was unlikely that
the blinding could have been broken. UCB explained to us: “all
data were entered and Database locked after completion of the
clinical phase for the first study period and before ESR and CRP
were entered into the database. ESR and CRP data were
withheld from investigator and sponsor study personal during
the course of the study because knowledge of patient’s profile
could potentially unblind the study..., auto AB, anti CZP level,
TNFalpha, IL6 and IL1b were transferred into the database after
Database lock.”
Phase III:
• UCB told us, “in Fleischmann 2009, Choy 2012, Keystone
2008, Smolen 2009, Smolen 2015, Weinblatt 2012, all the study
staff, with the exception of the unblinded dispenser, was blind to
the treatment. Each study center was required to have a written
blinding plan in place signed by the Principal Investigator, which
detailed the study center’s steps for ensuring that the double
blind nature of the study was maintained. All the studies were
monitored by two different independent teams from the sponsor,
one devoted to blind data and one devoted to possibly unblinded
information (such as study medications related topics) and
completely separate documentation/filing systems were
maintained for the duration of the trials”;
• Keystone 2008: “Radiographs were read at a central
location by 3 independent readers. Readers were blinded as to
the patient’s identity, clinical data, treatment, and time point
(sequence) at which the radiograph was taken”;
• Smolen 2009: “Radiographs were read centrally and
blinded (for treatment, visit and patient identification) and
independently by two experienced readers”;
• Fleischmann 2009 disclosed methods of blinding:
“Solutions of active drug or placebo were prepared by the
pharmacist or other unblinded, qualified site personnel, before
distributing to blinded study personnel for administration”.
• in the Japanese and Korean trials (Yamamoto (a) 2014;
Yamamoto (b) 2014; NCT00993317) “All study staff with the
exception of the unblinded dispenser were blind to the
treatment, ... These unblinded personnel were not allowed to
engage in any other study activities”.
• in Østergaard 2015: “The personnel administering the
injections had no involvement in the study other than
performing the erythrocyte sedimentation rate analysis”
• in Atsumi 2016: “Drug administration was performed by
dedicated non blinded persons due to distinguish ability of CZP
from PBO; however, these personnel were not permitted to
engage in other study activities to maintain blinding. All
investigators and healthcare professionals involved in safety/
efficacy assessments were blind to study medications”
• in Emery 2015: “Sponsor, investigator site and vendor staff
involved will be blinded to the testaments assignment with the
following exceptions: sponsor clinical study supplies coordinator
and qualifier person unblinded site personnel involved in ESR
determination” (UCB private files). We do not have any
information about how the blinding was performed.
For these reasons, we rated the risk of bias for blinding as low.
Incomplete outcome data
All studies, except the small Phase II trial (CDP870-004 2001)
reported adequate methods of handling missing outcome data.
All other studies gave a full account of all withdrawals and rea-
sons for withdrawals. Where possible, we extracted data to allow
an intention-to-treat analysis in Choy 2012; Fleischmann 2009;
NCT00993317. Eight out of 11 studies reported less than 80%
completion rates. However, for ACR20, ACR50, ACR70 DAS re-
mission, SAEs, withdrawals and withdrawals due to adverse events
we conducted an ITT analysis. Only radiological scores and HAQ
were analysed per protocol. In consequence for the overall estima-
tion, we think the risk of bias is low. Refer to Figure 3.
The completion rates in the certolizumab pegol group ranged from
68% in Fleischmann 2009 to 90% in Weinblatt 2012. In all tri-
als, fewer participants in the placebo-treated group completed the
trial compared to the treatment arm. More participants who were
treated with placebo withdrew due to lack of efficacy. The percent-
age of those completing the trial in the placebo group ranged from
15% in the 12-month results of Yamamoto (a) 2014 to 86% in
the 12-week results of Weinblatt 2012.We imputed missing data
using last observation carried forward (LOCF) in most trials. The
new trials for this update (Atsumi 2016: Emery 2015) reported
low rates of participants who finished the trials.
In the Atsumi 2016 trial, “Patients who did not achieve an
improvement of RA symptoms (defined as the persistence of
DAS28[ESR] ≥3.2 for4 weeks or longer) after Week 24 were
eligible to withdraw from trial and move to rescue treatment
with open label trial of CZP” so, 22.6% in the certolizumab
pegol group and 44.6% in placebo group were withdrawn. We
did not find this assumption in the protocol in clinicaltrials.gov/
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ct2/show/NCT01451203. Similary in Emery 2015 the partic-
ipants “not achieving sufficient improvement defined as DAS
28 DAS28[ESR] ≥3.2 and or ≥ 1.2 point improvement in
DAS28(ESR) from BL at weeks 20 and 24 were withdrawn
to allow them to switch to a complementary medication”. In
this trial 15% of people withdrew from the placebo arm and
8% from the certolizumab pegol arm, but people also withdrew
for lack of efficacy, adverse events, protocol violation and be-
ing lost to follow-up. Total withdrawals in the placebo group
amounted to 34% of participants and 24% from the certolizumab
pegol group. We did not find in the protocol hold in clin-
icaltrials.gov again this assumption clinicaltrials.gov/ct2/show/
NCT01519791?term=NCT01519791&rank=1. In Keystone
2008 “certolizumab pegol or placebo patients who were ACR20
non-responders at both weeks 12 and 14 in RCT, were required
to withdraw at week 16” . One hundred-and-thirty-nine out of
199 left the placebo arm (70%) and 181 out of 783 in the cer-
tolizumab pegol arm (23%). In Østergaard 2015 three of 27 par-
ticipants discontinued due to adverse events and lack of efficacy,
while one of 17 in the placebo group discontinued for withdrawal
of consent. Newly we did not find any assumption in the protocol.
This trial was small (41 people) with very short follow-up of two
weeks, focused only on radiological changes. In summary, higher
rates of withdrawal in the certolizumab pegol arm with a long-
term follow-up can introduce a serious bias into the interpretation
of effectiveness of certolizumab pegol. Moreover, the assumption
that people could be withdrawn if they did not achieve a good
response was not prespecified in the protocols.
Selective reporting
All studies reported their prespecified outcomes, except for
Yamamoto (b) 2014. UCB gave ACR20/50/70 as a figure as well
as providing theDAS, but we could not pool DAS data and we had
no information about the modified Total Sharp Score (mTTS) for
radiographic progression.
We changed our previous assessment of the bias in Fleischmann
2009, because all the primary outcomes were described in the
paper.
In the previous version of the review Choy 2012 only reported
ACR20, but the ACR50, HAQ disability index and acute-phase
reactant (CRP) are now available, so we have revised our ’Risk of
bias’ assessment to low.
In summary, we think the risk of reporting bias in this update is
low. Refer to Figure 3.
Other potential sources of bias
We did not detect potential threats to validity, such as fraud or
imbalance in the groups (relating to the baseline characteristics).
All studies included in this review were sponsored by the manu-
facturer of certolizumab pegol. There is evidence that industry-
sponsored trials may overestimate the treatment effect (Bhandari
2004) and there is also evidence that most of the authors of pub-
lished trials have a conflict of interest. However, there is a lack of
consensus on whether these conflicts result in reduced quality of
the trials and, in view of this, we have decided to rate the risk of
bias for this domain as low.
We searched for more trials as well as for more information about
unpublished trials (see Characteristics of ongoing studies table),
but no information was available, either from the sponsors or from
any publication.
In summary, we think the risk of other potential sources of bias is
low for this update. Refer to Figure 3.
Summary assessment of risk of bias by outcomes
Figure 2 and Figure 3 provide a graphical summary of the results
of the ’Risk of bias’ assessments for the 14 included studies.
The main major outcomes
ACR 50 response at six months and 52 weeks: we rated six studies
at six months and three studies at 52 weeks included in the meta-
analysis at low risk for adequate allocation concealment, blinding
and reporting of appropriate outcomes. Although there were high
rates of withdrawals, we rated the trials at low risk of bias, since we
were able to conduct an ITT analysis. Another concern was that
all studies were sponsored by the manufacturer of certolizumab
pegol.
HAQ change from baseline, response at six months and 52 weeks:
we rated five studies at six months and two studies at 52 weeks
included in the meta-analysis at low risk for adequate allocation
concealment, blinding and reporting of appropriate outcomes.
However, we had concerns about bias for incomplete outcome
data due to the high dropout rates.This item was subject to a per
protocol analysis, which we downgraded by one level. Another
concern was that all studies were sponsored by the manufacturer
of certolizumab pegol.
Proportion of participants achieving remission (DAS < 2.6) at 24
weeks: six studies. We rated them at low risk of bias for all the
domains. Despite the rates of withdrawals, we conducted an ITT
analysis for this outcome. Another concern was that all studies
were sponsored by the manufacturer of certolizumab pegol.
Radiological changes (ES scores) at 24weeks: two studies.We rated
We rated all domains at low risk of bias. However, we had concerns
about bias for incomplete outcome data, due to the dropout rates
in both studies.This item was subject to per protocol analysis, and
we downgraded it by one level. Another concernwas that all studies
were sponsored by the manufacturer of certolizumab pegol.
Serious adverse events with certolizumab pegol 200 mg at any
follow-up: we rated nine studies included in the meta-analysis at
low risk of bias for adequate allocation concealment, blinding and
reporting of appropriate outcomes. We analysed all of them on an
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ITT basis for all randomised participants who received at least one
dose, but in two out of the nine studies the analysis was per proto-
col: in Smolen 2009 “two patients in the placebo group received
certolizumab pegol 200 mg and were included in the certolizumab
pegol 200mg group for safety evaluations”, and inWeinblatt 2012
nine participants fewer were analysed in the certolizumab pegol
arm and three participants fewer in the placebo group. In Atsumi
2016, an ITT analysis was performed. However, in Emery 2015,
the analysis was per protocol, with two participants fewer in the
control group and one less in the (CZP) group. We performed an
ITT analysis In Østergaard 2015 trial. Another concern was that
all studies were sponsored by the manufacturer of certolizumab
pegol.
Withdrawals for all doses and follow-up to 52 weeks: we rated 13
studies at low risk of bias in all the domains. We conducted an
ITT analysis for all the trials. Another concern was that all studies
were sponsored by the manufacturer of certolizumab pegol.
Withdrawals due to adverse events for all doses and follow-up
to 52 weeks: we rated 12 studies at low risk of bias in all the
domains. We conducted an ITT analysis for all the trials. Another
concern was that all studies were sponsored by the manufacturer
of certolizumab pegol.
Effects of interventions
See: Summary of findings for the main comparison
Certolizumab pegol 200 mg sc (with or without MTX) versus
placebo (with or without MTX) for rheumatoid arthritis in adults
We conducted our analyses based on the doses used in the trials,
i.e. the drug exposure time for subcutaneous (sc) doses of 200 mg
and 400mg. For 400mg themost usual was at four-week intervals,
and for 200 mg sc the most frequently-used was every other week,
but in some trials such as Keystone 2008 and Smolen 2009 the
interval was every two weeks for the 400 mg dose as well. As we
had two periods of follow-up (six months and one year) in one
study, we could not combine them, so we pooled each outcome at
each follow-up. We also had studies with more than one dose, so
we split the placebo arm to enable us to pool results. We did not
find strong differences that could justify our not combining the
results for benefits and harms. We decided to perform a random-
effects model, in spite of the low values of I2. Although it was the
same drug, there is clear clinical heterogeneity (different doses,




We noted significant improvements for all doses at any given time
point for the ACR50 compared to placebo (see ’Benefits’ tables,
ACR Table 4, Data and analyses).
The ACR50with 200mg certolizumab pegol showed, at 24weeks,
a risk ratio (RR) of 3.80 (95% confidence interval (CI) 2.42 to
5.95), five studies, involving 1445 participants (Analysis 2.1); The
ACR50 with 400 mg certolizumab pegol showed, at 24 weeks, a
RR of 4.65 (95% CI 3.09 to 6.99), five studies, involving 1591
participants (Analysis 3.1). We judged the quality of evidence for
ACR50 with 200 and 400 mg certolizumab pegol at 24 weeks to
be high .
The ACR50 with 200 mg certolizumab pegol showed, at 52 weeks
a RR of 1.54 (95% CI 1.38 to 1.73), three studies, involving 881
participants (Analysis 4.1). This analysis reported an High value
of I2. We explained this due to that the results of RAPID1 showed
a very high values RR 5.02 whereas the remaining trials showed
lowest values around RR of 1.41 or 1.21). Moreover the CI of
RAPID1 did not overlap the remaining trials.
The ACR50with 400mg certolizumab pegol showed, at 52weeks,
a RR of 5.27 (95% CI 3.19 to 8.71), one study, involving 589
participants (Analysis 5.1).
We judged the quality of evidence for ACR50 with 200 and 400
mg certolizumab pegol at 52 weeks to be high.
The NNTB was close to 4 for all the sub analyses (Table 4).
Health-related quality of life
We found an improvement in physical function and quality of life
measured with the HAQ and SF-36 (in the mental and physical
components) at all follow-ups (see ’Health-related quality of life’
tables, (Table 5)) with certolizumab pegol compared to placebo.
HAQ at 24 weeks, 200 mg: mean difference (MD) -0.35 (95%CI
-0.43 to -0.26), four studies, involving 1268 participants (Analysis
7.1).
We judged the quality of evidence for HAQ at 24 weeks, 200 mg
to be moderate. We downgraded the quality of evidence by one
level, due to a high risk of attrition bias (per protocol analysis).
HAQ disability index (HAQ-DI) at 24 weeks, 400 mg:MD -0.38
(95%CI -0.48 to -0.28), four studies, involving 1425 participants
(Analysis 7.2).
We judged the quality of evidence for HAQ-DI, 24 weeks, 400
mg to be moderate. We downgraded the quality of evidence by
one level, due to a high risk of attrition bias (per protocol analysis).
HAQ-DI at 24 weeks, any dose: MD -0.36 (95% CI -0.43 to
-0.29), five studies, involving 2246 participants (Analysis 8.1).
We judged the quality of evidence forHAQ-DI, 24weeks any dose
200 mg to be moderate. We downgraded the quality of evidence
by one level, due to a high risk of attrition bias (per protocol
analysis).
HAQ-Di, 52 weeks, any dose: MD -0.32 (95%CI -0.39 to -0.26),
two studies, involving 1837 participants (Analysis 9.1).
We judged the quality of evidence for HAQ-DI at 24 weeks, 200
mg to be moderate. We downgraded the quality of evidence by
one level, due to a high risk of attrition bias (per protocol analysis).
We judged the quality of evidence for HAQ-DI at 52 weeks, any
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dose to be to bemoderate.We downgraded the quality of evidence
by one level, due to a high risk of attrition bias (per protocol anal-
ysis). This analysis reported a High value of I2. We explained this
due to that the results of RAPID1 showed a very high values MD
-0.42 whereas the remaining trial showed lowest values around
MD of -0.18. Moreover the CI of RAPID1 did not overlap the
remaining trial.
SF-36 physical component summary (PCS) at 24 weeks, any dose:
MD 5.29 (95% CI 4.37 to 6.21), three studies, involving 1765
participants (Analysis 14.1).
SF-36 mental component summary (MCS) at 24 weeks, any dose:
MD 4.01 (95% CI 2.94 to 5.08), four studies, involving 2012
participants (Analysis 15.1);
We judged the quality of evidence for SF-36 PCS and SF-36MCS
at 24weeks, any dose, to bemoderate.We downgraded the quality
of evidence by one level due to a high risk of attrition bias (per
protocol analysis).
SF-36 PCS at 52 weeks, any dose: MD 6.47 (95% CI 5.13 to
7.81), one study, involving 982 participants (Analysis 16.1).
SF-36 MCS at 52 weeks, any dose: MD 4.30 (95% CI 2.57 to
6.03), one study, involving 982 participants (Analysis 17.1).
We judged the quality of evidence for SF-36 PCS and SF-36MCS
at 52weeks, any dose, to bemoderate.We downgraded the quality
of evidence by one level, due to a high risk of attrition bias (per
protocol analysis).
DAS-28
We observed significant improvements for all doses and at any
given time point compared to placebo.
At 24 weeks the proportion of participants achieving remission
(DAS < 2.6) was higher in the 200 mg certolizumab pegol group
than in the placebo group (RR 2.94, 95% CI 1.64 to 5.28), six
studies, involving 2420 participants (Analysis 19.1.1); and RR of
1.71 (95% CI 1.43 to 2.04) at 52 weeks, three studies, involving
1689 participants (Analysis 20.1.1.).
We judged the quality of evidence for DAS < 2.6, 200 mg at 24
and 52 weeks to be high.
The RR for participants achieving remission (DAS < 2.6) with
200 mg certolizumab pegol at 12 weeks was 1.99 (95% CI 1.44
to 2.76), two studies, involving 1942 participants (Analysis 21.1).
We judged the quality of evidence for DAS < 2.6 at 12 weeks, 200
mg to be high.
The RR for participants achieving remission (DAS < 2.6) with 400
mg certolizumab pegol was 7.18 (95% CI 3.12 to 16.50) at 24
weeks, three studies, involving 1201 participants (Analysis 21.3);
and at 52 weeks the RR was 12.49 (95% CI 3.99 to 39.12), one
study, involving 583 patients (Analysis 21.5).
We judged the quality of evidence for DAS < 2.6, 400 mg at 24
and 52 weeks to be high.
Radiological changes
Radiological changes were expressed as modified Total Sharp
Scores (mTSS), the erosion score (ES) and joint space narrowing
(JSN). All certolizumab pegol groups showed improvements com-
pared to placebo in the mean changes from baseline. There was
a clear radiological benefit, regardless of the dose, associated with
drug exposure time (see ’Radiological changes’, Table 6).
ES at 200 mg, 24 weeks: MD -0.35 (95% CI -0.50 to -0.21), two
studies, involving 859 participants (Analysis 29.1).
We judged the quality of evidence for ES at 200 mg, 24 weeks
to be moderate. We downgraded the quality of evidence by one
level, due to a high risk of attrition bias (per protocol analysis).
ES at 200 mg, 52 weeks: MD -1.14 (95% CI -1.54 to -0.74), two
studies, involving 1235 participants (Analysis 29.3).
We judged the quality of evidence for ES at 200 mg, 52 weeks
to be moderate. We downgraded the quality of evidence by one
level, due to a high risk of attrition bias (per protocol analysis).
ES at any dose, 24 weeks: MD -0.70 (95% CI -0.98 to -0.42),
two studies, involving 1437 participants (Analysis 30.1).
We judged the quality of evidence for ES at any dose, 24 weeks
to be moderate. We downgraded the quality of evidence by one
level, due to a high risk of attrition bias (per protocol analysis).
ES at any dose, 52 weeks: MD -1.16 (95% CI -1.56 to -0.77),
two studies, involving 1599 participants (Analysis 31.1).
We judged the quality of evidence for ES at any dose, 52 weeks
to be moderate. We downgraded the quality of evidence by one
level, due to a high risk of attrition bias (per protocol analysis).
Joint space narrowing (JSN) at 200 mg, 24 weeks: MD -0.45
(95% CI -0.77 to -0.13), two studies, involving 861 participants
(Analysis 32.1).
We judged the quality of evidence for JSN at 200 mg, 24 weeks
to be moderate. We downgraded the quality of evidence by one
level, due to a high risk of attrition bias (per protocol analysis).
JSN at 200 mg, 52 weeks: MD -0.67 (95% CI -1.02 to -0.32),
two studies, involving 1239 participants (Analysis 32.3).
We judged the quality of evidence for JSN at 200 mg, 52 weeks
to be moderate. We downgraded the quality of evidence by one
level, due to a high risk of attrition bias (per protocol analysis).
JSN at any dose, 24 weeks: MD -0.50 (95% CI -0.79 to -0.21),
two studies, involving 1439 participants (Analysis 33.1).
We judged the quality of evidence for JSN at any dose, 24 weeks
to be moderate. We downgraded the quality of evidence by one
level, due to a high risk of attrition bias (per protocol analysis).
JSN at any dose, 52 weeks: MD -0.70 (95% CI -1.04 to -0.36),
two studies, involving 1602 participants (Analysis 34.1).
We judged the quality of evidence for JSN at any dose, 52 weeks
to be moderate. We downgraded the quality of evidence by one
level, due to a high risk of attrition bias (per protocol analysis).
MTSS at any dose, 24 weeks: MD -0.86 (95% CI -1.19 to -0.53),
three studies, involving 1753 participants (Analysis 35.1).
We judged the quality of evidence for mTSS at any dose, 24 weeks
to be moderate. We downgraded the quality of evidence by one
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level, due to a high risk of attrition bias (per protocol analysis).
Modified Total Sharp Scores (mTSS) at 200 mg, 24 weeks: MD
-0.74 (95% CI -1.11 to -0.37), three studies, involving 1029 par-
ticipants (Analysis 35.1.1).
We judged the quality of evidence for mTSS at 200 mg, 24 weeks
to be moderate. We downgraded the quality of evidence by one
level, due to a high risk of attrition bias (per protocol analysis).
MTSS at any dose, 52 weeks: MD -1.63 (95% CI -2.13 to -1.13),
three studies, involving 1915 participants (Analysis 36.1).
We judged the quality of evidence for mTSS at any dose, 52 weeks
to be moderate. We downgraded the quality of evidence by one
level, due to a high risk of attrition bias (per protocol analysis).
MTSS at 200 mg, 52 weeks: MD -1.54 (95% CI -2.06 to -1.01),
three studies, involving 1462 participants (Analysis 36.1.1).
We judged the quality of evidence for mTSS 200 mg, 52 weeks
to be moderate. We downgraded the quality of evidence by one
level, due to a high risk of attrition bias (per protocol analysis).
Serious adverse events (SAEs) as defined in the studies
The clinical study summary of CDP870-004 2001 did not define
SAEs. All the new trials that were added in this update reported
on SAEs.
We reported adverse events grouped by the dosages:
SAEs for certolizumabpegol 200mgand any follow-up time point:
PetoOR1.47 (95%CI 1.13 to 1.91), nine studies, involving 3927
participants (Analysis 41.1);
We judged the quality of evidence for SAEs for certolizumab pegol
200 mg and any follow-up to be high.
SAEs for certolizumab pegol 400 mg and any follow-up time
point: RR 1.98 (95% CI 1.36 to 2.90), six studies, involving 1624
participants (Analysis 42.1); 95 events were reported in the cer-
tolizumab pegol groups versus 31 events in the control groups.
We judged the quality of evidence for SAEs for certolizumab pegol
400 mg at any follow-up time point to be high.
We decided to use Peto OR due to the low number of events in
both 200 and 400 mg of certolizumab pegol.
All withdrawals
There were more withdrawals “at any dose and at any follow-up”
in placebo groups (53%) versus the certolizumab pegol groups
(23%): RR 0.47 (95% CI 0.39 to 0.56), 13 studies, involving
5200 participants (Analysis 43.1).
We judged the quality of evidence for all withdrawals “at any dose
and at any follow-up” to bemoderate. We downgraded the quality
of evidence by one level for inconsistency due to heterogeneity
(not all of the confidence intervals overlap, and I2 is 79%).
Withdrawals due to adverse events
There were more withdrawals “at any dose and at any follow-
up due to adverse events” in the certolizumab pegol groups (5%)
versus placebo groups (4%).
Withdrawals at any dose and at any follow-up due to adverse
events: PetoOR1.45 (95%CI 1.09 to 1.94), 12 studies, involving
5236 participants (Analysis 43.2).
We judged the quality of evidence for withdrawals at any dose and
at any follow-up due to adverse events for certolizumab pegol to
be high.




We saw an improvement in ACR20 and ACR70 compared to
placebo for all doses and at any time point.
ACR20 for any dose at 24 weeks: RR 2.76 (95% CI 2.29 to 3.33),
eight studies, involving 2935 participants (Analysis 44.1).
ACR70 for any dose at 24 weeks: RR 4.15 (95% CI 2.68 to 6.42),
seven studies, involving 2705 participants (Analysis 44.3).
We judged the quality of evidence for ACR20 and ACR70 for any
dose at 24 weeks for certolizumab pegol to be high.
ACR20 for any dose at 52 weeks: RR 1.46 (95% CI 1.11 to 1.93),
three studies, involving 2180 participants (Analysis 45.1).
We judged the quality of evidence for ACR20 for any dose at 52
weeks for certolizumab pegol to bemoderate.Wedowngraded the
quality of evidence one level for inconsistency due to heterogeneity
(not all the confidence intervals overlap and I2 is 88%).
ACR70 for any dose at 52 weeks: RR 1.89 (95% CI 1.44 to 2.48),
three studies, involving 2180 participants (Analysis 45.3).
We judged the quality of evidence for ACR70 for any dose at 52
weeks for certolizumab pegol to be high.
Adverse events
We reported all adverse events in Data and analyses but we have
not commented on all of them in this section, but only those that
we thought were noteworthy (see Table 7).
Any adverse event
We pooled the data for any adverse event from nine trials: 200 mg
certolizumab pegol: RR 1.16 (95% CI 1.03 to 1.31), nine studies,
involving 3927 participants (Analysis 50.1).
We judged the quality evidence for any adverse event for 200 mg
certolizumab pegol to bemoderate. We downgraded the quality
of evidence one level for inconsistency due to heterogeneity (not
all the confidence intervals overlap and I2 is 74%).
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Safety, any adverse event at 400 mg certolizumab pegol: RR 1.19
(95% CI 1.05 to 1.34), six studies, involving 1624 participants
(Analysis 50.2).
We judged the quality of evidence for any adverse event for 400
mg certolizumab pegol to be high.
We excluded Choy 2002 because it showed more events than par-
ticipants in the certolizumab pegol group (62 events in 24 partic-
ipants) as well as in the placebo group (19 events in 12 partici-
pants). We therefore could not calculate the RR.
Adverse events: severe intensity as defined in the studies
There were no differences in the number of SAEs between partici-
pants treated with 200 mg: Peto OR 1.14 (95% CI 0.78 to 1.65),
four studies, involving 2249 participants Analysis 50.7).
We judged the quality of evidence for adverse events with severe
intensity for 200 mg certolizumab pegol to be moderate. We
downgraded the quality of evidence one level for imprecision due
to the 95% confidence interval around the pooled effect including
both harm and no harm.
Participants treated with 400 mg of certolizumab pegol: Peto OR
1.23 (95% CI 0.83 to 1.81), five studies involving 1462 partici-
pants (Analysis 50.8).
We judged the quality of evidence for adverse events with severe
intensity for 400 mg certolizumab pegol to be moderate. We
downgraded the quality of evidence one level for imprecision, due
to the 95% confidence interval around the pooled effect including
both harm and no harm.
Serious adverse infections (SAIs)
This composite outcome included any severe events of infec-
tions, infestations and tuberculous (disseminated tuberculosis,
peritoneal tuberculosis, pulmonary tuberculosis, lymph node tu-
berculosis, tuberculosis), lower respiratory tract infection, and ob-
structive chronic bronchitis with acute exacerbation. More SAIs
were reported in the 200 mg certolizumab pegol-treated group
(Peto OR 1.94, 95% CI 0.99 to 3.80), three studies, involving
1283 participants; and in the 400 mg certolizumab pegol-treated
group (Peto OR 3.25, 95% CI 1.65 to 6.39), four studies, involv-
ing 1422 participants; 63 events were reported in the certolizumab
pegol groups versus 13 events in the control groups. There were no
differences between the rates of SAIs in the 200 mg and 400 mg
certolizumab pegol groups. See more details in (Analysis 50.11;
Analysis 50.12)
We judged the quality of evidence for SAIs for 200 mg cer-
tolizumab pegol to be moderate. We downgraded the quality of
evidence one level for imprecision due to the 95% confidence in-
terval around the pooled effect including both harm and no harm.
We judged the quality of evidence for SAIs for 400 mg cer-
tolizumab pegol to be high.
Adverse events leading to death as defined in the studies
We did not find statistically significant differences in the num-
ber of adverse events leading to death between the placebo and
certolizumab pegol-treated groups. Eleven deaths due to adverse
events in the certolizumab pegol groups were reported, versus one
death in the control groups:
200 mg certolizumab pegol: PetoOR1.63 (95%CI 0.41 to 6.47),
six studies involving 3322 participants (Analysis 50.13).
We judged the quality of evidence for adverse events leading to
death for 200 mg certolizumab pegol to be moderate. We down-
graded the quality of evidence one level for imprecision due to the
95% confidence interval around the pooled effect including both
harm and no harm.
400 mg certolizumab pegol: Peto OR 2.16 (95% CI 0.40 to
11.79), three studies, involving 1179 participants ( Analysis
50.14).
We judged the quality of evidence for adverse events leading to
death for 400 mg certolizumab pegol to be moderate. We down-
graded the quality of evidence one level for imprecision due to the
95% confidence interval around the pooled effect including both
harm and no harm.
Death
In Keystone 2008, in the placebo-treated group one participant
died of myocardial infarction. In the 200 mg certolizumab pegol-
treated group one participant died of hepatic neoplasm, another
died of peritonitis and cirrhosis, and one died during the post-
treatment period (more than 84 days after the last injection). In
the 400 mg certolizumab pegol-treated group one died of cerebral
stroke, one of myocardial necrosis, one of cardiac arrest and one
of atrial fibrillation.
In Smolen 2009, in the 200 mg certolizumab pegol-treated group
one participant died of myocardial infarction; one died during the
study in the 400 mg certolizumab pegol-treated group (fracture,
shock), which was assessed as unlikely to be related to the study
medication.
In Choy 2002, in the open phase one participant in the cer-
tolizumab pegol-treated group (20 mg/kg CDP870) died from
complications following rapid drainage of a large, chronic rheuma-
toid pericardial effusion. In the opinion of the investigator, this
event was unrelated to treatment with CDP870.
In Weinblatt 2012, one participant died of sigmoid diverticulitis
and one of necrotising pneumonia; both deaths were ruled out as
possibly related to certolizumab pegol.
In Yamamoto (a) 2014, one participant died of a rupture of a dis-
secting aortic aneurysm in the thoracic region, but UCB consid-
ered this unlikely to have been related to the study medication.
In Emery 2015 “The single CZP-related death in this study oc-
curred in a 65-year-old patient of Indian origin, with hyperten-
sion and diabetes mellitus. The patient died of cardiorespiratory
failure and acute respiratory distress syndrome, secondary to sep-
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tic shock caused by bowel perforations. Acid-fast bacillus stains of
the gut and saliva were positive. This, in conjunction with the gut
pathology, led to a diagnosis of disseminated, non-characterised,
mycobacterium infection; the QuantiFERON test was negative
and there was no PCR confirmation of TB”.
Choy 2012; Smolen 2015; Fleischmann 2009; Yamamoto (b)
2014; Østergaard 2015; Atsumi 2016 did not report any deaths.
Overall certolizumab pegol deaths: Peto OR 2.63 (95% CI 0.78
to 8.91), 10 studies, involving 4745 participants (Analysis 50.19)
and Figure 4.
Figure 4. Forest plot of comparison 49: Summary of findings: certolizumab (with or without MTX) versus
placebo (with or without MTX), outcome: 49.8 Deaths.
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We judged the quality of evidence for deaths at any dose of cer-
tolizumab pegol to be moderate. We downgraded the quality of
evidence one level for imprecision due to the 95% confidence in-
terval around the pooled effect including both harm and no harm.
Tuberculosis
We noted a significant increase in the number of cases of tuber-
culosis in both certolizumab pegol-treated groups: 10 participants
(0.4%) in the certolizumab pegol 200mg group and five (0.7%) in
the certolizumab pegol 400 mg group, versus two and no cases in
their respective placebo groups: 200 mg certolizumab pegol Peto
OR 1.90 (95% CI 0.55 to 6.58),seven studies, involving 3538
participants (Analysis 50.20;); 400 mg certolizumab pegol Peto
OR 4.55 (95% CI 0.71 to 29.11), three studies, involving 1179
participants (Analysis 50.21). The overall analysis with both doses
(200 and 400 mg) did not reach statistical significance: Peto OR
1.91 (95% CI 0.61 to 5.96), seven studies, involving 4074 par-
ticipants (Analysis 50.22). In Smolen 2009, five participants in
the certolizumab pegol arms (three in certolizumab pegol 200 mg
and two in 400 mg) developed tuberculosis (three from Russia,
one each from Poland and Latvia). In NCT00993317 (200 mg
certolizumab pegol) two participants developed tuberculosis. For
this update, only five participants developed tuberculosis in the
Emery 2015 study, three in the certolizumab pegol group and two
in the placebo group.
We judged the quality of evidence for tuberculosis for 200 mg
and 400 mg of certolizumab pegol to be to be moderate. We
downgraded the quality of evidence one level for imprecision, due
to the 95% confidence interval around the pooled effect including
both harm and no harm.
Other infections
The types of different infections reported (pneumonitis, bacterial
arthritis, mastitis, urinary tract infection, herpes viral, bacterial
peritonitis, and opportunistic infection) are presented in Data and
analyses.
Upper respiratory tract infection was more frequent with 200 mg
certolizumab pegol than in the placebo group (Peto OR 1.68,
95% CI 1.28 to 2.20), eight studies, involving 3608 participants
(Analysis 50.34); and 400 mg certolizumab pegol (Peto OR 1.42,
95% CI 0.77 to 2.61), four studies, involving 1364 participants
(Analysis 50.35).
We judged the quality of evidence for upper respiratory tract in-
fection for 200 mg certolizumab pegol to be high.
We judged the quality of evidence for upper respiratory tract in-
fection for 400 mg certolizumab pegol to bemoderate. We down-
graded the quality of evidence one level for imprecision, due to
the 95% confidence interval around the pooled effect including
both harm and no harm.
Nasopharyngitis was more frequent with both doses of cer-
tolizumab pegol than in the placebo group: 200 mg certolizumab
pegol Peto OR 1.37 (95% CI 1.01 to 1.84) seven studies, involv-
ing 2553 participants (Analysis 50.44)); and 400 mg certolizumab
pegol PetoOR1.98 (95%CI 1.26 to 3.11), four studies, involving
1364 participants (Analysis 9.41). ( Analysis 50.45)
We judged the quality of evidence for nasopharyngitis for 200 mg
and 400 mg of certolizumab pegol to be moderate. We down-
graded the quality of evidence one level for imprecision, due to
the 95% confidence interval around the pooled effect including
both harm and no harm.
Pain at the site of injection
Pain at the site of injection was not statistically significant com-
pared with placebo: in the 200 mg certolizumab pegol-treated
group (Peto OR 1.85, 95% CI 0.49 to 6.92), three studies, in-
volving 1091 participants (Analysis 50.46); This analysis reported
a High value of I2. We explained this due to that the results of
RAPID1 showed a very high values RR 4.60 whereas the remain-
ing trial showed lowest values around RR of 0.05. Moreover the
CI of RAPID1 did not overlap the remaining trials.
When we studied 400 mg certolizumab pegol-treated group we
found (Peto OR 1.74, 95% CI 0.41 to 7.42), three studies, in-
volving 1179 participants (Analysis 50.47). The wide CIs were
due to the fact that, surprisingly, pain was not observed in any
placebo group. Similar data were observed for local reactions at
the injection site. We judged the quality of evidence pain for 200
mg and 400 mg of certolizumab pegol to be high.
Other adverse events
Hypertension was more frequent with both doses of certolizumab
pegol than with placebo: 200 mg certolizumab pegol Peto OR
3.09 (95% CI 1.64 to 5.84), four studies, involving 1353 partici-
pants (Analysis 50.48); 400 mg certolizumab pegol: Peto OR 3.35
(95% CI 1.80 to 6.20), three studies, involving 1121 participants
(Analysis 50.49).
We judged the quality of evidence for other adverse events for 200
mg and 400 mg of certolizumab pegol to be high.
The secondary events for headache, blood disorders, laboratory
disorders, back pain, nausea/vomiting, urinary tract infections,
pruritus and cough and others are described in detail in Data and
analyses.
Despite the report from the EMA (www.ema.europa.eu/docs/
en˙GB/document˙library/EPAR˙-˙Public˙assessment˙report/
human/001037/WC500069735.pdf), we could not extract more
data on adverse events, because the information was disclosed as
combined data without the number of events in each trial. More-
over, the adverse events were grouped by ’primary system organ
class’: cardiac disorders, endocrine disorders, neoplasms benign,
malignant and unspecified (excluding cysts and polyps).
Pain (VAS assessment)
Participants’ assessment of arthritis pain with a visual analogue
scale (VAS) score (0 to 100 mm) improved at all doses and at all
time points. At week 24, the overall mean difference (MD) was
-21.07 (95% CI -23.59 to -18.55), four studies, involving 2064
participants (Analysis 52.1); and at week 52 the MD was -23.48
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(95% CI -27.09 to -19.88), one study, involving 982 participants
(Analysis 53.1).
We judged the quality of evidence for patients’ assessment of arthri-
tis pain with a VAS for 200 mg and 400 mg of certolizumab pegol
to be high. .
Withdrawals due to lack of efficacy
There were more withdrawals “due to lack of efficacy” in placebo
groups (39%) versus the certolizumab pegol groups (13%)
Withdrawals at any dose and at any follow-up due to lack of ef-
ficacy: RR 0.31 (95% CI 0.26 to 0.37), eight studies, involving
3433 participants(Analysis 54.1).
We judged the quality of evidence for withdrawals due to lack of
efficacy at any dose and at any follow-up for certolizumab pegol
to be high.
Assessment of heterogeneity
When we analysed the ACR50 at 24 weeks (Analysis 44.2) we
found a low probability of statistical heterogeneity (I2 = 0%).
When we reviewed the demographics of Phase III studies (Table
2) we found similar proportions of men and women, similar mean
ages, and similar baseline HAQ-Di. We only found differences in
the mean disease duration in Fleischmann 2009 and Choy 2012,
around 9.4 years compared with around six years in most arms of
the other studieswhere datawere available (with lowheterogeneity,
I2 = 13%). Disease duration was not available for Smolen 2015;
Yamamoto (a) 2014; Yamamoto (b) 2014 (I2 = 6%, and an overall
I2 = 7%) (Analysis 56.5). Rheumatoid factor (RF) positivity varied
from around 74% in the certolizumab pegol-treated participants
in Weinblatt 2012 up to 100% in Fleischmann 2009. Similarly
disease activity measures such as CRP and swollen joint counts,
but not DAS-28 and HAQ-D1, were generally lower inWeinblatt
2012.
When we analysed the ACR50 at 52 weeks (Analysis 45.2) we
found a high probability of statistical heterogeneity (I2 = 84%).
When we compared the new trials Atsumi 2016 and Emery 2015
with the previous trial Keystone 2008,we observed that the average
period of persistent disease in the new trials is around four months,
whereas for Keystone 2008 it is 6.1 years. Baseline HAQ-Di in
Keystone 2008 and Emery 2015 is around 1.6 whereas in Atsumi
2016 it is around 1.1. Participants in Atsumi 2016 are MTX-
naïve, participants in Emery 2015 are DMARDS-naïve, whereas
in Keystone 2008 participants were treated on average with 1.3
DMARDS.
However, despite these differences there were no compelling rea-
sons for not combining the trial data for the most important vari-
ables.
Although we include 14 trials in this update, no more than seven
trials were analysed in each forest plot, so we did not produce a
funnel plot.
Subgroup analysis
We had planned subgroup analyses for the duration of the ill-
ness (approximately three years evolution), participants’ sex, drug
dose, administration and methodological quality, but only sub-
group analysis of the dose of certolizumab pegol was performed.
All Phase III trials were conducted in participants with a highmean
duration of RA (from 6.1 to 9.5 years) and we could not obtain
any data categorised by sex. All Phase III trials allowed previous
DMARD treatment (mean from 1.2 to two years). All Phase III
trials included in the meta-analysis were rated as high quality, and
so we did not perform more subgroup analysis.
Sensitivity analysis
We have done a sensitivity analysis with the major outcome
ACR50. In the previous version of this review we re-analysed qual-
ity (adequate sequence generation, good allocation concealment,
adequate blinding, etc.) and did not show any changes. For this
update we have more information about the quality of the trials
from UCB, and we rated most trials as high quality, so we did not
perform a sensitivity analysis based on quality.However, we sought
heterogeneity by analysing for doses of certolizumab pegol, size,
use of concomitant MTX, different populations (Japanese and
Korean trials versus other populations) and by published versus
unpublished trials, but found no statistical heterogeneity (Analysis
56.1; Analysis 56.2; Analysis 56.3; Analysis 56.4; Analysis 56.6).
These analysis were performed for 24 weeks in our previous review
and remain unchanged because the new trials included in this up-
date were conducted to 52 weeks. When we analysed for the same
categories we did find heterogeneity from the Keystone 2008 in all
the issues that were tested (Analysis 57.1; Analysis 57.2; Analysis
57.3; Analysis 57.4; Analysis 57.5).
Finnally we analysed imputing missing values in the same propor-
tion as reported ACR50% , imputing the 50 % of ACR50 % and
the results are robust for ACR50 200 mg to 24 weeks RR 3.34
(95% CI 2.68 to 4.17) and RR 1.17 (95% CI 1.04 to 1.32). Only
when we checked the worst case (all the missing values did not
reach ACR50 in certolizumab pegol) and did ACR50 in placebo
the results were favouring to placebo RR 0.47 (95% CI 0.43 to
0.52). Analysis 56.7; Analysis 56.8; Analysis 56.9.
D I S C U S S I O N
Summary of main results
This review evaluates the benefits and harms of certolizumab pegol
for the treatment of people with RA when compared to placebo,
using RCTs with at least three months of follow-up.
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The results and conclusions did not change from the previous ver-
sion of the review. There is low-level evidence from randomised
controlled trials that certolizumab pegol, alone or combined with
methotrexate, is beneficial in the treatment of RA: it improved
the American College of Rheumatology ACR50 (pain, function
and other symptoms of RA), health-related quality of life, and the
chance of remission of RA, reduced joint damage as seen on the
x-ray, and increased serious adverse events. Fewer people stopped
taking their treatment, but most of them stopped due to seri-
ous adverse events. Adverse events were more frequent with active
treatment. We found a potential risk of serious adverse events.
We found 14 studies, three more than in the previous version of
the review. The duration of follow-up was from 12 to 52 weeks
and the range of doses of certolizumab pegol varied from 50 to
400 mg given subcutaneously.
Certolizumab pegol at the standard dose (200 mg) was shown to
be clinically effective at 12, 24 and 52 weeks. However the data
from 52 weeks should be interpreted with caution, because a large
number of participants deemed not to be achieving a sufficient
response were withdrawn at week 24.
Important clinical differences between placebo and certolizumab
pegol were observed for measures of disease activity, in favour of
certolizumab pegol. The differences were both statistically signif-
icant and clinically important for the participant-reported out-
comes ACR50, HAQ, and SF-36 (physical (PCS) and mental
(MCS) component summary scores), and for structural damage
measures. Changes inHAQat 24weekswith 200mg certolizumab
pegol were -0.35 (mean changes in HAQ greater than -0.22 are
clinically meaningful). In addition, the results with SF-36 (phys-
ical and mental components) can be considered relevant because
in people with RA improvements in the SF-36 PCS and HAQ-DI
are associated with improved work productivity and reduced long-
term disability, healthcare use, costs and mortality (Hazes 2010).
All certolizumab pegol groups showed improvements in radiologi-
cal outcomes compared to placebo, measured as themean changes
from baseline. There was a clear radiological benefit, although it
should be borne in mind that radiographic changes occur in a
relatively small proportion of people with RA over the duration
of research studies, and the changes did not represent a clinically
meaningful benefit for participants.
Serious adverse events were more frequent in the certolizumab
pegol groups.
We observed more withdrawals in participants treated with cer-
tolizumab pegol. Participants in the placebo group were more
likely to discontinue treatment, due to lack of beneficial effect, but
more participants withdrew from the certolizumab pegol group,
due to adverse reactions. Themost frequent side effects were infec-
tions and nasopharyngitis. Unfortunately, the newer clinical trials
do not provide data on hypertension. However, as reported in the
previous version, hypertension is increased in the certolizumab
pegol group.
In the previous version we stated we would compare our data with
data from the EMA documents. We requested access to the drug
company submissions to the EMA for marketing authorisation of
certolizumab pegol. Our request was denied, despite an appeal.
The EMA stated that “...in the course of emerging legal proceed-
ings before the General Court of the European Union, the Agency
has been ordered to suspend the implementation of the certain
decisions granting access to documents submitted by marketing
authorisation holders of medicinal products”.
Mortality was increased with certolizumab pegol. These differ-
ences did not achieve statistical significance but it should be noted
that there was only one death in the placebo group compared with
14 in the certolizumab pegol group. Death was primarily related
to cardiovascular events, as reported by Bykerk 2013. However,
treatment with anti-TNF has been shown to reduce cardiovascular
events in people with RA (Roubille 2015).
We found an increased risk of serious infections with certolizumab
pegol. This risk is recognised with anti-TNFs, both in randomised
trials and in observational studies (FDA 2013).
Contrary to the findings of Lopez-Olivo 2012, we did not find
an increased risk of malignancies or lymphoma, for 200 mg or for
400 mg of certolizumab pegol.
We have found discordance between the number of cases of tu-
berculosis reported in ClinicalTrials.org and the one instance re-
ported in Emery 2015. Despite the difference, the frequency of tu-
berculosis has decreased in recent clinical trials. This could be due
to several reasons. In 2007 theWHO introduced stricter tubercu-
losis screening guidelines, considering a positive purified protein
derivative (PPD) test 5 mm or more (previously between 10 and
20 mm according to each national guideline), and tuberculosis
prophylaxis was recommended if active tuberculosis was ruled out.
Furthermore, fewer participants from areas of high tuberculosis
prevalence have been recruited, and latent tuberculosis is generally
an exclusion criterion.
The results and conclusions did not change from the previous
review.
Overall completeness and applicability of
evidence
We have included all available RCTs for certolizumab pegol in
people with RA, with a September 2016 search date. This up-
dated review provides confirmatory evidence of the benefit of cer-
tolizumab pegol for people with RA.
It is important to state that three studies had a follow-up of 52
weeks, and in twoof themnon-responderswerewithdrawn atweek
24. Thus there are important uncertainties about sustained effects
in a disease with a lifelong course and the need for therapy over
many years. An additional note of caution relates to the population
selection in terms of significant co morbidities and exclusion of
people with previous malignancy, for example.
In all trials except the Smolen 2015 trial (without a clear definition
of its inclusion and exclusion criteria in ClinicalTrials.org), people
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with previous neoplasia, any risk of infectious disease, previous
tuberculosis, or prior treatment with any TNFα inhibitor were
excluded. In the Yamamoto (a) 2014, Yamamoto (b) 2014 and
NCT00993317) trials, people with New York Heart Association
(NYHA) class III or IV heart failure were also excluded.Moreover,
in the Keystone 2008 trial “Patients who, in the investigator’s opin-
ion, were at a high risk of infection“ were excluded, as were those
who had a history of malignancy, demyelinating disease, blood
dyscrasias, or severe, progressive, and/or uncontrolled renal, hep-
atic, haematologic, gastrointestinal, endocrine, pulmonary, car-
diac, neurologic, or cerebral disease”. Thus, whilst it is clear that
certolizumab pegol is beneficial and has an acceptable safety pro-
file in people selected for clinical trials, careful clinical judgement
is needed to ensure benefits in routine care, particularly in peo-
ple susceptible to infections such as those with chronic respiratory
diseases.
We only have information about the comparison between cer-
tolizumab pegol and placebo. There is no head-to-head compar-
ison between certolizumab pegol and other anti-TNFs. For this
reason current evidence does not support the use of certolizumab
pegol over another anti-TNF.
Quality of the evidence
The quality of the evidence found in the trials included in this
review was high to moderate. Studies had high standards for treat-
ment allocation, concealment, blinding, and attrition bias. Other
GRADE considerations for downgrading are: imprecision, indi-
rectness and inconsistency or other bias.
Despite differences in the importance of the outcomes (higher
for ACR50, HAQ and DAS remission, and lower for radiological
changes), we rated the quality of the evidence as high for all the
outcomes except for the HAQ, radiological changes and all with-
drawals, which we rated as moderate quality.
Outcome measures in favour of certolizumab pegol were statisti-
cally significant in both random-effects and fixed-effect models.
We chose to apply a random-effects model, although statistical
heterogeneity was low. Clinical heterogeneity, however, was sub-
stantial (for example, with varying follow-up times, doses, use of
methotrexate) and, as expected, pooling resulted in wide confi-
dence intervals.
Major outcomes
Summary of findings for the main comparison for certolizumab
pegol 200 mg, structured according to the GRADE system
(GRADE Handbook), showed:
1) We judged the quality of evidence for the primary outcome
ACR 50% improvement at 24 weeks to be high.
2) We judged the quality of evidence for the primary outcome
HAQ at 24 weeks to be moderate. We downgraded the quality
of evidence by one level, due to a high risk of attrition bias (per
protocol analysis).
3) We judged the quality of evidence for the primary outcome
Proportion of participants achieving DAS < 2.6 (remission) at
24 weeks to be high.
4) We judged the quality of evidence for the primary outcome
Erosion score (ES), at 24 weeks to bemoderate. We downgraded
the quality of evidence by one level, due to a high risk of attrition
bias (per protocol analysis).
5) We judged the quality of evidence for the primary outcome
Serious adverse events at 24 weeks to be high.
6) We judged the quality of evidence for the primary outcome
Withdrawals, at 24 weeks to be moderate. We downgraded the
quality of evidence
one level for inconsistency, due to heterogeneity (not all the con-
fidence intervals overlap and I2 is 79%).
7) We judged the quality of evidence for the primary outcome
Withdrawals due to adverse events at 24 weeks to be high.
Minor outcomes
8) We judged the quality of evidence for the secondary outcome
ACR20 at 24 weeks to be high.
9) We judged the quality of evidence for the secondary outcome
ACR70 at 24 weeks to be high.
10) We judged the quality of evidence for Tuberculosis for 200
mg and 400 of certolizumab pegol to be to be moderate. We
downgraded the quality of evidence one level for imprecision, due
to the 95% confidence interval around the pooled effect including
both harm and no harm.
11) We judged the quality of evidence for Death for any dose of
certolizumab pegol to be moderate. We downgraded the quality
of evidence one level for imprecision, due to the 95% confidence
interval around the pooled effect including both harm and no
harm.
12) We judged the quality of evidence for the secondary outcome
Withdrawals due to lack of efficacy to be high.
Potential biases in the review process
This updated review has fewer limitations than the earlier version,
primarily because key data from a greater number of studies, in-
cluding key study quality data, were available either as published
reports or directly from the pharmaceutical company. From 14
included trials, 12 with over 5400 participants reported benefits
and 14 trials reported safety, providing a substantial evidence base.
We lacked detail that may have been available in submissions to
the EMA as part of this drug’s marketing authorisation and we
also did not have access to study protocols, so we were not able to
judge whether there was a concern about selective reporting. Lack
of availability of detailed study reports with individual patient data
denied us the opportunity of presenting a richer description of
adverse events, particularly serious adverse reactions.
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Agreements and disagreements with other
studies or reviews
The NICE 2009 and EMA 2009 reports, performed as systematic
reviews, have shown results quite similar to those in our review.
The meta-analysis by Singh 2011 described the adverse effects of
nine biologics and includedRCTs, controlled clinical trials (CCTs)
and open-label extensions (OLEs), showing similar overall results.
Moreover, Singh 2011 found similar results with certolizumab pe-
gol for serious adverse events and serious infections, but failed to
find an increased rate of withdrawals due to adverse events. In this
study the risk of serious infections was about four times higher for
certolizumab pegol and the authors performed sensitivity analyses
using different models to explain the results. However, the signifi-
cant differences between certolizumab pegol and five other biolog-
ics as determined in the standard dose model (main model) per-
sisted in the unadjusted and dose-adjusted models for each com-
parison, with the minor exception of certolizumab pegol versus
golimumab.
Zhou 2014 did not find differences in adverse events in a meta-
analysis of nine RCTs of certolizumab pegol in RA. Only six trials
for adverse events were included in this systematic review. The
reason for the difference from our results is that Zhou 2014 only
include adverse events until week 24. However, there was agree-
ment in ACR response rate at 24 weeks.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review confirms that certolizumab pegol compared with
placebo is clinically beneficial, improving ACR50, quality of life
and increasing the chance of remission. In addition certolizumab
pegol comparedwith placebo reduces the risk of radiographic dam-
age. There is a potential risk of serious adverse events, including
hypertension and tuberculosis in susceptible individuals, which
should be borne in mind when considering certolizumab pegol.
There was no direct evidence comparing certolizumab with other
TNF inhibitors.
There is a moderate to high certainty of evidence, obtained from
randomised controlled trials, that certolizumab pegol, alone or
combined with methotrexate, is beneficial in the treatment of RA.
It improved ACR50 (pain, function and other symptoms of RA),
health-related quality of life, and the chance of remission of RA,
reduced joint damage as seen on the x-ray, but increased seri-
ous adverse events. Fewer people stopped taking their treatment,
but most of those who did stopped because of serious adverse
events. Adverse events were more frequent with active treatment.
We found a clinically but not statistically significant risk of serious
adverse events.
Implications for research
Treatment options for RA have expanded considerably in recent
years and include biologic agents targeting a variety of elements
of the inflammatory process. It is important that we undertake
studies to compare the new drugs that have been shown to be
effective in clinically-relevant populations.
We must emphasize that complete remission is the major target
in clinical practice, and it should be considered as an outcome for
future clinical trials using ACR/EULAR remission criteria (Felson
2011).
New agents continue to target people who have failed to respond
to methotrexate. Given that there are a number of biologics that
have been found to be effective in this patient group, ethics review
boards need to consider whether it is justifiable to undertake stud-
ies of new agents for this population that compare the effectiveness
to placebo or to background methotrexate.
Longer-term studies and observational data are important for the
assessment of longer-term drug toxicity and rarer adverse events.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Atsumi 2016
Methods Randomised clinical trial, double-blind
Participants Eligible patients were 20-64 years old with RA fulfilling the 2010 ACR/EULAR classi-
fication criteria
Interventions 1. 400 mg of CDP870 plus MTX given at week 0, 2. 4, and thereafter 200 mg CDP870
given every 2 weeks (n=159)
2. Placebo plus MTX given every 2 weeks (n=157)
Outcomes Primary outcome measures: Inhibition of radiographic progression at week 52
Secondary outcomes measures: Inhibition of radiographic progression at week 24;
Clinical remission rate at week 24 and week 52
Notes C-OPERA Trial
Countries/Cities: 73 sites in Japan
Dates conducted: from October 2011 to August 2013
Eligibility criteria: Eligible patients were 20-64 years old with RA fulfilling the 2010
ACR/EULAR classification criteria. Patients had ≤12 months of persistent arthritic
symptoms, at least moderate disease activity (Disease Activity Score 28-joint assessment
(DAS28) with erythrocyte sedimentation rate (ESR) ≥3.2) and were MTX-naive. In
addition, patients hadpoor prognostic factors: high anti-cyclic citrullinated peptide (anti-
CCP) anti- body (≥3× upper limit of normal (ULN)) and either positive rheumatoid
factor (RF) and/or presence of bone erosions (based on radiographs of hands/feet, assessed
by the investigator at each study site)
Adverse events as a specified outcome: adverse events and serious adverse events were
reported
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”Patients were randomised 1:1“
Allocation concealment (selection bias) Low risk ”via an interactive web-response system“
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Blinding (performance bias and detection
bias)
ACR50
Low risk ACR50 is a clinical outcome determined by
healthcare professionals who were blinded to
study medications
Blinding (performance bias and detection
bias)
All outcomes
Low risk As above
Incomplete outcome data (attrition bias)
ACR50
Low risk Participants who did not achieve an improve-
ment of symptoms at or after week 24, i.e. if
moderate or higher disease activity (DAS28
(ESR) ≥3.2) persisted ≥ 4 weeks in either
treatment arm, were eligible to receive rescue
treatmentwith open-label certolizumabpegol
after discontinuing D-B period. As a conse-
quence, the withdrawal rate in CTZ arm was
22.6%; withdrawal rate in Placebo arm was
44.6%
Incomplete outcome data (attrition bias)
All outcomes
Low risk As above
Selective reporting (reporting bias) Low risk Data from all radiological (except for JSN
outcome), clinical and safety outcomes were
provided
Other bias Low risk The study appears to be free of other sources
of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study did not report blinding of participants.
Drug administration was performed by ded-
icated non-blinded persons, because obvious
differences between certolizumab pegol and
Placebo; however, these personnel were not
permitted to engage in other study activities,
to maintain blinding. All investigators and
healthcare professionals involved in safety/ef-
ficacy assessments were blind to study medi-
cations
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All investigators and healthcare professionals
involved in safety/efficacy assessments were
blind to study medications. mTSS as main
outcome assessed by radiologist (namely,
healthcare professionals)
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CDP870-004 2001
Methods Double-blind, multiple dose, 12-week, placebo-controlled dose-ranging study
Participants 326 participants with a history of inadequate response or intolerance to at least 1
DMARD and active RA at screening
Interventions 1. Placebo
2. 50, 100, 200, 400, 600 and 800 mg sc
Given every 4 weeks in 2 dose groups, panel 1 and panel 2
”Placebo: 40; active: 40-41/arm); Panel 2: 122 (Placebo 44, active: 39/arm). PP: 186,
and 113 pts.“
Outcomes ACR20, ACR50, ACR70, subset of the ACR criterion, DAS responder rates at week 12
Follow-up 12 weeks
Notes Countries/Cities: Not stated
Dates conducted (“not stated”)
Eligibility criteria: RA with a history of inadequate response or intolerance to at least
1 DMARD and active RA at screening
Adverse events as a specified outcome: ‘not reported’.
We only have data from ACR20 at week 12
Funding sources: no data
Conflict of interest: no data
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk UCB reported: ”Randomized code gener-
ated by Pharmaceutical Packaging Service
and based on instruction of the randomi-
sation procedure prepared by Celltech R&
D statistic“
Allocation concealment (selection bias) Unclear risk UCB reported: ”Patients were randomly
assigned to treatment groups during the
DB phase (week 0 12) and received either
placebo or CDP-870 SC“
Blinding (performance bias and detection
bias)
ACR50
High risk UCB reported as blinded but stated:
”CPD-870 and the placebo utilized in this
study (saline) did not have the same viscos-
ity therefore full blinding was not possible.
Study drug was to be prepared by a phar-
macist having no other involvement in the
study; injections of study medications were
given by a nurse or physician who had no
other involvement in the study...“
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CDP870-004 2001 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
High risk See above
Incomplete outcome data (attrition bias)
ACR50
High risk Data were not available
Incomplete outcome data (attrition bias)
All outcomes
High risk Data were not available
Selective reporting (reporting bias) Low risk Efficacy was defined as ACR improvement
in disease activity at week 12 and was de-
scribed
Other bias Unclear risk There were so few data that was impossible
to judge
Blinding of participants and personnel
(performance bias)
All outcomes
High risk See above
Blinding of outcome assessment (detection
bias)
All outcomes
High risk See above
Choy 2002
Methods Randomised double-blind placebo-controlled trial
Participants 36 people with RA defined by ACR classification criteria. People with active diseased
defined as having 3 or the following 4 criteria: tender joint count (TJC) ≥ 6, swollen
joint count (SJC) ≥ 3 (based on 28 joint counts), morning stiffness of ≥ 45 minutes,
and ESR≥ 28 mm/H. Participants had to have failed treatment with at least 1 DMARD
and have been off treatment for at least 4 weeks
Interventions 1. Single intravenous infusion of placebo (n = 12)
2. 1, 5 or 20 mg/kg of certolizumab pegol (each n = 8) for 8 weeks
Outcomes ACR20, ACR50, ACR70, pain score (0 - 10 cm), DAS, TJC, SJC, Health Assessment
Questionnaire (HAQ), C-reactive protein (CRP)
Follow-up 8 weeks
Notes This study was only considered to assess safety because follow-up was less than 12 weeks
In the open-label phase, 1 participant who received 20 mg/kg died from complications
following rapid drainage of a large, chronic rheumatoid pericardial effusion. No infective
agent was isolated from either the pericardial fluid or peripheral blood. In the opinion
of the investigator, this event was unrelated to treatment
Countries/Cities: patients recruited from out-patient rheumatology clinics in London,
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Cambridge, Norfolk and Norwich (UK)
Dates conducted: not reported
Eligibility criteria: Patients aged 18-75 yr who satisfied the 1987 revised American
College of Rheumatology (ACR) diagnostic criteria for RA
Adverse events: were reported
Funding sources: not stated, but UCB had all the data and sent us details of how was
done
Conflict of interest: DA Isenberg, worked for Celltech Research and Development,
Slough, UK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were divided into 4 groups. In
each group of 12 patients 8 received active
treatment and 4 received placebo. UCB ex-
plain to us: ”Methods for sequence gener-
ation was randomised, DB, sequential as-
cending dose“
Allocation concealment (selection bias) Low risk Central allocation
Blinding (performance bias and detection
bias)
ACR50
Low risk The studywas blinded andUCBstated: ”all
datawere entered andDatabase locked after
completion of the clinical phase for the first
study period and before ESR andCRPwere
entered into the database. ESR and CRP
data were withheld from investigator and
sponsor study personal during the course
of the study because knowledge of patient’s
profile could potentially unblind the study.
.., auto AB, anti certolizumab pegol level,
TNFalpha, IL6 and IL1b were transferred
into the database after DB lock“
Blinding (performance bias and detection
bias)
All outcomes
Low risk See above
Incomplete outcome data (attrition bias)
ACR50
Low risk Reasons for withdrawals were disclosed
92% of certolizumab pegol group and 50%
of placebo completed 8weeks of treatment.
We imputed missing data for analysis
Incomplete outcome data (attrition bias)
All outcomes
Low risk Safety analysis also imputed missing data
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Choy 2002 (Continued)
Selective reporting (reporting bias) Low risk All the outcomes were available in the clin-
ical study report as figures
Other bias Low risk The study appears to be free of other
sources of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk UCB stated: ” the study pharmacist pre-
pared for infusion the study medication
and diluent, the pharmacy covered the so-
lutionwith an opaquematerial and labelled
it with “130mL CDP870 Engineered Fab’
Conjugated to PEG or sodium acetate
placebo diluent” “For IV use only”, admin-
istration details, the patient number, pa-
tient initials, date and time to use the med-
ication by and name of investigator.“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above
Choy 2012
Methods Phase III, randomised double-blind placebo-controlled multicentre trial
The primary objective of this study was to compare the efficacy of certolizumab pegol
(CDP870 or CZP) in combination with methotrexate (MTX) toMTX alone in treating
the signs and symptoms of subjects with rheumatoid arthritis (RA) who are partial
responders to MTX
Participants People with RA who are partial responders to MTX.
250 participants with RA, aged 18+ years, were randomised to 1 of 2 regimens of sc
certolizumab pegol 400 mg or placebo sc every 4 weeks for a total of 6 injections.
Methotrexate treatment continue during the study taken prior to enrolment in the study.
Participants who completed the current study or who withdrew on or after the Week 12
visit were eligible to participate in the open-label safety study (CDP870-015)
Inclusion and exclusion criteria were identical to Keystone 2008, but discontinued all
DMARDs at least 28 days or 5 half-lives prior to first dose of study drug
Interventions 1. Certolizumab pegol 400 mg plus MTX (n=125)
2. Placebo sc plus MTX (n=125 )
Every 4 weeks for a total of 6 injections
Outcomes Primary: ACR20 and safety at 24 weeks
Secondary endpoints: Participant’s assessment of pain (VAS), participant’s global assess-
ment of arthritis, physician’s global assessment of arthritis, participant’s assessment of
physical function by HAQ-DI, acute phase reactant value (only CRP for this study)
Follow-up 24 weeks
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Notes NCT00544154. Clinical study summary provided by UCB
Countries/Cities: 7 countries (Austria, Belgium, Czech Republic, Germany, Ireland,
USA and the UK)
Dates conducted: between October 2002 and January 2004.
Eligibility criteria: patients were aged 18-75 years, with adult-onset RA of at least 6
months’ duration as defined by the 1987 ACR criteria and active disease defined as nine
or more tender joints, nine or more swollen joints and at least one of the three following
criteria: ≥45min of morning stiffness, ESR ≥28mm/h (Westergren) or CRP >10mg/l.
Patients were required to have been receiving MTX for at least 6 months and on a stable
dosage of 15-25mg/week for at least 8 weeks before the first dose of study medication
(10-15mg/week was deemed acceptable in cases where a dosage reduction had been
necessary because of toxicity). All other DMARDs were to have been discontinued at
least 28 days before the first study medication dose
Adverse events as a specified outcome: AEs were reported at each study visit. Treat-
ment-emergent AEs were those reported after the first dose of study medication, includ-
ing worsening of pre-existing conditions. Serious AEs (SAEs) were those that resulted in
death or were life-threatening, caused or prolonged hospitalizations, required parenteral
antibiotics, and/or that resulted in persistent or significant disability, incapacity or con-
genital abnormality/birth defect
Funding sources: UCB
Conflict of interest: J.V. was a speaker at the meeting organized by UCB and is a mem-
ber of a UCB advisory board. E.C. has received grants/research support from Abbott
Laboratories, Allergan, Boehringer Ingelheim, Chelsea Therapeutics, GSK, Jazz Phar-
maceuticals, Merrimack Pharmaceutical,MSD, Pfizer, Pierre Fabre Medicament, Roche,
Chugai and Wyeth and UCB Pharma
E.C. has also received consultancy fees from Abbott Laboratories, Allergan, Boehringer
Ingelheim, Chelsea Therapeutics, Eli Lilly, GSK, Jazz Pharmaceuticals,Merrimack Phar-
maceutical, MSD, Pfizer, Pierre Fabre Medicament, Roche, Schering Plough, Synovate,
Chugai, MedImmune and Wyeth and UCB Pharma. E.C. is a member of a Speaker’s
Bureau for Abbott Laboratories, Allergan, Boehringer Ingelheim, Chelsea Therapeutics,
Eli Lilly, GSK, Jazz Pharmaceuticals, Merrimack Pharmaceutical, MSD, Pfizer, Pierre
Fabre Medicament, Roche, Schering Plough, Chugai and Wyeth and UCB Pharma
B.V. is a UCB Pharma employee and has been granted UCB Pharma stock appreciation
rights
N.G. is a former employee of UCB Pharma, and is currently an employee of Array
Biopharma, Inc. N.G. owns UCB Pharma stock
O.D. is an employee of UCB Pharma and holds stock options.
R.A. has received research grants from Abbott, BMS, Merck Pharma GmbH, Novartis,
Pfizer, Roche and UCB Pharma. R.A. is a member of a speaker’s bureau for Abbott
Laboratories, BMS, Horizon Pharma, Merck Pharma GmbH, Novartis, Roche, and has
received consulting fees from Abbott Laboratories, Horizon Pharma, Merck Pharma
GmbH, Novartis and Roche. R.A. has held non-remunerative positions of influence for
Abbott Laboratories, BMS, Novartis Pharmaceuticals Corporation and Roche. All other
authors have declared no conflicts of interest
Risk of bias
Bias Authors’ judgement Support for judgement
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Choy 2012 (Continued)
Random sequence generation (selection
bias)
Low risk The randomisation code was generated by
an independent group following instruc-
tion of the randomisation procedures, pre-
pared by the project statistician (EMEA re-
port for the Phase III trial)
Allocation concealment (selection bias) Low risk Via IVRS
Blinding (performance bias and detection
bias)
ACR50
Low risk UCB: “All the study staff with the excep-
tion of the unblinded dispenser, was blind
to the treatment”. “Each study center was
required to have a written blinding plan in
place signed by the principal investigator,
which detailed the study center’s steps for
ensuring that the double blind nature of
the study was maintained”
Blinding (performance bias and detection
bias)
All outcomes
Low risk See above
Incomplete outcome data (attrition bias)
ACR50
Low risk Full account of all withdrawals and reasons
for withdrawals
77.8% of certolizumab pegol group and
53.7% of placebo completed 6 months of
treatment. We imputed missing data for
analysis
Incomplete outcome data (attrition bias)
All outcomes
Low risk Analysis per protocol for HAQ and safety
“Of the 247 patients randomised, 124 pa-
tients in the certolizumab pegol plus MTX
group (98%) and 119 in the placebo plus
MTX group (98%) received at least one in-
jection (243 total)“
Selective reporting (reporting bias) Low risk All the prespecified outcomeswere reported
Other bias Low risk The study appears to be free of other
sources of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk See above
”To preserve the blind to clinical research
staff, the study site pharmacist labelled clin-
ical supplies (study medication syringes),
and a sorbitol placebo was used to match
the viscosity of certolizumab pegol“
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above
Emery 2015
Methods Randomised clinical trial, double-blind
Participants 880 participants were randomised. 3 were randomised in error, were not dosed, and were
withdrawn shortly afterwards as screen failures. 2 were included in the randomised Set
1 (RS1) only, and 1 of the 3 was conservatively excluded from any output. Therefore,
879 subjects are in RS1
Interventions 1. Placebo + MTX ( n= 219)
2. MTX + certolizumab pegol 400 mg at 0, 2, 4 weeks, followed by a maintenance dose
of certolizumab pegol 200 mg until week 50 ( n=660)
Outcomes Primary: Percentage of participants in sustained remission at week 52
Secondary: Radiographic changes (mTTs, JNS, JE), ACR20, ACR50 and ACR70 at
52 weeks; Percentage of participants with clinical remission (ACR/EULAR) at week 52
DAS 28 < 2.6 at week 52 Change in CDAI SDAI at week 52 HAQ-DI week 52 Work
product survey at week 52. Serious adverse events; other adverse events
Notes C-EARLY trial
Countries/Cities: Europe, Australia, North America and Latin America at 181 sites
Dates conducted: from January 2012 to September 2015
Eligibility criteria: Eligible patients were DMARD-naïve, diagnosed with RA ≤1year
prior to randomisation, fulfilled the 2010 American College of Rheumatology (ACR)
/European League Against Rheumatism (EULAR) classification criteria and had poor
prognostic factors for severe disease progression (positive for rheumatoid factor (RF) or
anticitrullinated peptide antibody (ACPA) at screening)
Adverse events as a specified outcome: adverse events and serious adverse events were
reported
Funding sources: UCB Pharma SA
Conflict of interest:Principal Investigators areNOTemployed by the organization spon-
soring the study.The only disclosure restriction on the PI is that the sponsor can review
results communications prior to public release and can embargo communications re-
garding trial results for a period that ismore than 60 days but less than or equal to 180
days. The sponsor cannot require changes to the communication and cannot extend the
embargo
PE received consultancy and speaker’s fee from Pfizer, MSD, AbbVie, UCB Pharma,
Roche, Bristol-Myers Squibb, Schering-Plough,Novartis and Samsung. COBIII received
consultancy fees fromUCBPharma.GRB received consultancy fees fromAbbVie,MSD,
Pfizer, Roche and UCB Pharma. DEF received research grants from Abbott, Actelion,
Amgen, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, NIH, Novartis, Pfizer, Roche/
Genentech and UCB Pharma; consultancy fees from Abbott, Actelion, Amgen, Bristol-
Myers Squibb, Biogen IDEC, Janssen, Gilead, GlaxoSmithKline, NIH, Novartis, Pfizer,
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Emery 2015 (Continued)
Roche/Genentech and UCB Pharma and other fees from Abbott, Actelion, Amgen,
Bristol-Myers Squibb, Biogen, IDEC, Janssen, Gilead, NIH, Roche/Genentech, Abbott,
Actelion and UCB Pharma
XM received research grants from Pfizer, GlaxoSmithKline and Roche and consultancy
fees from Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, Roche, UCB Pharma and
Sanofi-Aventis. DvdH received consultancy fees from AbbVie, Amgen, AstraZeneca,
Augurex, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Centocor, Chugai, Co-
vagen, Daiichi, Eli-Lilly, Galapagos, GlaxoSmithKline, Janssen, Merck, Novo-Nordisk,
Otsuka, Pfizer, Roche, Sanofi-Aventis, UCB Pharma and Vertex; research grants from
AbbVie, Amgen, AstraZeneca, Augurex, Bristol-Myers Squibb, Boehringer Ingelheim,
Celgene, Centocor, Chugai, Covagen, Daiichi, Eli-Lilly, Galapagos, GlaxoSmithKline,
Janssen, Merck, Novo-Nordisk, Otsuka, Pfizer, Roche, Sanofi-Aventis, UCB Pharma
and Vertex and is Director of Imaging at Rheumatology BV
RvV received research support from AbbVie, Bristol-Myers Squibb, GlaxoSmithKline,
Pfizer, Roche and UCB Pharma and consultancy fees from AbbVie, Biotest, Bristol-
Myers Squibb, GlaxoSmithKline, Janssen, Eli-Lilly, Merck, Pfizer, Roche, UCB Pharma
and Vertex
CA is an employee of UCB Pharma.
IM is an employee of UCB Pharma. OP is an employee of UCB Pharma
DT is an employee of UCB Pharma.
BV is an employee of UCB Pharma.
MEWreceived research grants fromAmgen, Bristol-Myers Squibb,CrescendoBioscience
and UCB Pharma and consultancy fees from AbbVie, Amgen, AstraZeneca, Bristol-
Myers Squibb, Crescendo Bioscience, Eli-Lilly, MedImmune, Merck, Novartis, Pfizer,
Roche and UCB Pharma
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk UCB Pharma explained to us that was a ex-
ternal central of randomisation
Allocation concealment (selection bias) Low risk UCB private files: ”An IXRS (interactive
voice/web response system) is used for sub-
ject registration as well as randomisation and
treatment allocation“. The system stratified
by disease duration of more or less than 4
months
Blinding (performance bias and detection
bias)
ACR50
Low risk UCB private files; ”Sponsor, investigator site
and vendor staff involved will be blinded to
the testaments assignment with the following
exceptions: sponsor clinical study supplies co-
ordinator and qualifier person unblinded site
personnel involved in ESR determination“
Blinding (performance bias and detection
bias)
Low risk UCB private files: ”Sponsor, investigator site
and vendor staff involved will be blinded to
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All outcomes the testaments assignment with the following
exceptions: sponsor clinical study supplies co-
ordinator and qualifier person unblinded site
personnel involved in ESR determination“
Incomplete outcome data (attrition bias)
ACR50
Low risk Participants not achieving sufficient improve-
ment (defined asDAS (ESR) < 3.2 and/or > 1.
2 point improvement in DAS 28 (ESR)) from
baseline at weeks 20 and 24 were withdrawn
to allow them to switch to a complementary
medication. There were 34% of withdrawals
in placebo group and 24% in certolizumab
pegol group at week 52
Incomplete outcome data (attrition bias)
All outcomes
Low risk See above
Selective reporting (reporting bias) Low risk All the outcomes in the protocol in
www.clinicaltrials.gov were available
Other bias Low risk The study appears to be free of other sources
of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk UCB private files: ”Sponsor, investigator site
and vendor staff involved will be blinded to
the testaments assignment with the following
exceptions: sponsor clinical study supplies co-
ordinator and qualifier person unblinded site
personnel involved in ESR determination“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk UCB private files: ”Sponsor, investigator site
and vendor staff involved will be blinded to
the testaments assignment with the following
exceptions: sponsor clinical study supplies co-
ordinator and qualifier person unblinded site
personnel involved in ESR determination“
Fleischmann 2009
Methods Randomised double-blind trial
Participants 220 people aged 18 - 75 years
Interventions 1. Certolizumab pegol 400 mg sc every 4 weeks (n = 111)
2. Placebo (n = 109) for 24 weeks
Outcomes ACR20, 50, 70, HAQ-DI, pain (VAS and mBPI), DAS-28, fatigue, and SF-36
Follow-up 24 weeks
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Countries/Cities: conducted at 36 sites in Austria, Czech Republic and the USA
Dates conducted: June 2003 to July 2004
Eligibility criteria: withRAdefinedby theACRclassification criteriawhohadpreviously
failed at least 1 DMARD were included. Those previously treated with a TNF inhibitor
were excluded. Participants had to have a TJC of ≥ 9 (out of 68), SJC of ≥ 9 (out of
66) and 1 of the following: morning stiffness of ≥ 45 minutes; ESR ≥ 28 mm/H; or
CRP > 10 mg/L. People with a previous history of a serious or life-threatening infection
were excluded. People with a history of TB, or evidence of TB on a chest radiograph, or
those with a positive reaction to PPD reaction were also excluded. Patients on concurrent
corticosteroids were allowed entry provided the dose was the equivalent of 10 mg or less
of prednisolone. Parenteral corticosteroids were not permitted
Adverse events as a specified outcome:safety were assessed at baseline and weeks 1, 2,
4, 8, 12, 16, 20 and 24, with additional safety assessments at 4 and 12 weeks post final
dose. Additional plasma samples were taken at weeks 21 and 22
Funding sources: UCB
Conflict of interest: JV has received a fee fromUCB for speaking at aNational Congress;
RFvV has received consulting fees from UCB; DB has received reimbursement from
UCB for attending a symposium and funds for research; JB has received reimbursement
fromUCB for attending a symposium and funds for research; GC is a full time employee
of and holds stocks in UCB; AI is a full time employee at UCB and has shares in the
company; NG is a full time employee of UCB and has shares and stock options in the
company; VS has worked as an independent biopharmaceutical consultant in clinical
development and regulatory affairs since September 1991 and is currently a consultant
to various companies, but has not and does not now hold stock in any company. RF has
received consulting fees and funds for clinical research from UCB
JV has received a fee from UCB for speaking at a National Congress;
RFvV has received consulting fees from UCB; DB has received reimbursement from
UCB for attending a symposium and funds for research; JB has received reimbursement
from UCB for attending a symposium and funds for research;
GC is a full time employee of and holds stocks in UCB; AI is a full time employee at
UCB and has shares in the company;
NG is a full time employee of UCB and has shares and stock options in the company;
VS has worked as an independent biopharmaceutical consultant in clinical development
and regulatory affairs since September 1991 and is currently a consultant to various
companies, but has not and does not now hold stock in any company
RF has received consulting fees and funds for clinical research from UCB
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Code list prepared by independent group
Allocation concealment (selection bias) Low risk Via IVRS
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Blinding (performance bias and detection
bias)
ACR50
Low risk UCB stated: ”All the study staff with the exception
of the unblinded dispenser, was blind to the treat-
ment“. ”Each study center was required to have a writ-
ten blinding plan in place signed by the principal in-
vestigator, which detailed the study center’s steps for
ensuring that the double blind nature of the study was
maintained“
Blinding (performance bias and detection
bias)
All outcomes
Low risk See above
Incomplete outcome data (attrition bias)
ACR50
Low risk 68.5% of certolizumab pegol group and 25.7% of
placebo completed 6 months of treatment. We im-
puted missing data for analysis
Incomplete outcome data (attrition bias)
All outcomes
Low risk Full account of all withdrawals and reasons for with-
drawals
Quote: “All efficacy analyses were performed on the
modified intent to treat (mITT) population (all ran-
domised patientswhohad taken>1 dose of studymed-
ication). The actual number of subjects in the sum-
maries varies slightly from the mITT numbers due
to non-imputable missing data for each parameter.
For the primary analysis, patients were considered “re-
sponders” if they achieved anACR20 response vs base-
line at week 24. Patients who withdrew for any reason
were considered non responders.”
The safety analysis was based on the ’last observation
carried forward’ approach
Selective reporting (reporting bias) Low risk All the outcomes were available
Other bias Low risk The study appears to be free of other sources of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk See above
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above
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Methods Randomised double-blind trial
Participants 982 participants aged > 18 years
Participants were randomised 2:2:1
Interventions 1. Certolizumab pegol sc at an initial dosage of 400 mg given at weeks 0, 2, and 4, with
a subsequent dosage of 200 mg ( n= 393)or 400 mg given every 2 weeks, plus MTX (
n=390)
2. Placebo plus MTX, same regimen (n=199)
Outcomes Co-primary endpoints: ACR20 at week 24 and the mean change from baseline in the
mTSS at week 52
Major secondary end points: Change from baseline in mTSS at week 24
Change from baseline in the HAQ-DI at weeks 24 and 52
ACR20 responder rate at week 52
ACR50 and ACR70 responder rates at weeks 24 and 52
Follow-up 24 - 52 weeks
Notes RAPID1 Trial
Countries/Cities:79 sites fromEEUU,Argentina, Australia, Belgium, Bulgaria, Canada,
Chile, Croatia, Czech Republic, Israel, Latvia, Russian Federation,Ukraine
Dates conducted: from February 2005 to October 2006
Eligibility criteria: patients were aged 18 years or older with active RA (according to
the 1987 ACR RA classification criteria with an inadequate response to MTX therapy
(≥ 10 mg weekly for ≥ 6 months with stable doses for ≥ 2 months prior to baseline).
Patients were ineligible if they had previously failed to respond to treatment with a TNF
inhibitor. People with a history of TB or a chest radiograph showing active or latent TB
or those with a positive reaction to PPD were also excluded
Adverse events as a specified outcome: adverse events and serious adverse events were
reported
Funding sources: UCB Pharma
Conflict of interest: Dr. Keystone has received consulting fees, speaking fees, and/or
honoraria from Abbott, Amgen, Wyeth, Centocor, UCB, Roche, Genentech, Schering-
Plough, and Bristol-Myers Squibb (less than USD 10,000 each)
Dr. van der Heijde has received consulting fees, speaking fees, and/or honoraria from
Abbott, Amgen, Centocor, UCB, Roche, Schering-Plough, and Bristol-Myers Squibb
(less than USD 10,000 each). Dr. Landewe´ has received consulting fees, speaking
fees, and/or honoraria from Abbott, Amgen, Bristol-Myers Squibb, Centocor, Schering-
Plough, UCB, and Wyeth (less than USD 10,000 each)
Dr. van Vollenhoven has received consulting fees, speaking fees, and/or honoraria from
UCB (more than USD 10,000)
Dr. Combe has received consulting fees, speaking fees, and/or honoraria from Abbott,
Bristol-Myers Squibb, Merck, Sharp, & Dohme, Roche, Schering, UCB, and Wyeth
(less than USD 10,000 each)
Dr. Emery has received consulting fees from UCB (less than USD 10,000). Dr. Strand
receives consulting fees (her primary source of income) from Abbott Immunology, Al-
lergan, Almirall, AlPharma, Amgen, AstraZeneca, Bayhill, Bexel, Biogen Idec, Can-Fite,
Centocor, Chelsea, Cypress Bioscience, Dianippon Sumitomo, Euro-Diagnostica, Fi-
broGen, Forest, Genelabs, Genentech, Human Genome Sciences, Idera, Incyte, Jazz,
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Keystone 2008 (Continued)
Lexicon Genetics Lux Biosciences, Merck Serono, Novartis, Novo Nordisk, Noxxon
Pharma, Nuon, Ono Pharmaceutical, Pfizer, Procter & Gamble, Rigel, RiGEN, Roche,
Sanofi-Aventis, Savient, Schering-Plough, Scios, SKK, UCB, VLST, Wyeth, XDx, and
Zelos Therapeutics (less than USD 10,000 each) and receives fees as a member of the
advisory board for Abbott, Amgen, Biogen Idec, Bioseek, Bristol-Myers Squibb, Can-
Fite, Centocor, Chelsea, Cypress, Euro-Diagnostica, Forest, Idera, Incyte, Jazz, Novartis,
Pfizer, Rigel, RiGEN, Roche, Savient, Schering-Plough, UCB, XDx, and Wyeth (less
than USD 10,000 each)
Dr. Mease has received consulting fees, speaking fees, and/or honoraria from UCB (less
than USD 10,000)
Mr. Desai owns stock or stock options in UCB
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Code list prepared by independent group
Allocation concealment (selection bias) Low risk IVRS used to allocate participant to treatment group
(2:2:1 ratio)
Blinding (performance bias and detection
bias)
ACR50
Low risk UCB stated: ”All the study staff with the exception of
the unblinded dispenser, was blind to the treatment.
Each study center was required to have awritten blind-
ing plan in place signed by the principal investigator,
which detailed the study center’s steps for ensuring
that the double blind nature of the study was main-
tained“
Blinding (performance bias and detection
bias)
All outcomes
Low risk See above
Incomplete outcome data (attrition bias)
ACR50
Low risk 65%of certolizumab200mgand70.3%certolizumab
400 mg of group and 22% of placebo completed 12
months of treatment. We imputed missing data for
analysis
Incomplete outcome data (attrition bias)
All outcomes
Low risk Full account of all withdrawals and reasons for with-
drawals
HAQ, quote: ”Analyses were performed using the last
observation carried forward (LOCF) method for im-
putation of missing scores in the total ITT population
and the actual scores (observed) in those who with-
drew at week 16“
Safety: ITT analysis
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Keystone 2008 (Continued)
Selective reporting (reporting bias) Low risk All the outcomes that are of interest to this review have
been reported in the prespecified way
Other bias Low risk The study appears to be free of other sources of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk See above
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above
NCT00993317
Methods Randomised, double-blind (participant, investigator, outcomes assessor), placebo-con-
trolled, parallel-assignment, safety/efficacy study
Participants Adult-onset RA ( 18 Years to 75 Years ) of at least 6 months but not longer than 15 years,
as defined by the 1987 ARA’s criteria, with active disease
Interventions 1. CDP870 200 mg, 400 mg CDP870 given at weeks 0, 2, 4, and thereafter 200 mg
CDP870 given every 2 weeks until week 22 (sc) plus MTX (n= 85 )
2. Placebo plus MTX, same regimen ( n= 42 )
Outcomes ACR20, ACR50, ACR70 responder rate; changes in HAQ-Di
Follow-up 24 weeks
Notes See clinicaltrials.gov/ct2/show/study/NCT00993317
Countries/Cities: 15 hospital in Korea
Dates conducted: from October 2009 to August 2011
Eligibility criteria:
• Adult-onset RA of at least 6 months but not longer than 15 years in duration as
defined by the 1987 American College of Rheumatology classification criteria
• Active RA disease as defined by at least 9 tender joints and 9 swollen joints, ESR
of 30 mm/hour or CRP of 1.5 mg/dL
• MTX (with or without folic acid) for at least 24 weeks prior to the Baseline visit,
The dose of MTX and route of administration must have been stable for at least 8
weeks prior to the baseline visit. The minimum stable dose of MTX allowed is 10 mg
weekly.
Adverse events as a specified outcome: adverse events and serious adverse events were
reported
Funding sources: Korea Otsuka Pharmaceutical Co Ltd
Conflict of interest: ”Principal Investigators are NOT employed by the organization
sponsoring the study“. ”There isNOT an agreement between Principal Investigators and
the Sponsor (or its agents) that restricts the PI’s rights to discuss or publish trial results
after the trial is completed“
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk External central randomisation
Allocation concealment (selection bias) Low risk The allocation sequence was generate using
uniform random numbers from SAS RA-
NUNI function
Blinding (performance bias and detection
bias)
ACR50
Low risk ”All study staff with the exception of the
unblindeddispenserwere blind to the treat-
ment, ... These unblinded personnel were
not allowed to engage in any other study
activities“
Blinding (performance bias and detection
bias)
All outcomes
Low risk See above
Incomplete outcome data (attrition bias)
ACR50
Low risk 70% of certolizumab pegol group and 50%
of placebo completed 6 months of treat-
ment. We imputed missing data for analy-
sis
Incomplete outcome data (attrition bias)
All outcomes
Low risk Full account of all withdrawals and reasons
for withdrawals
Raw data
Per protocol analysis in change in HAQ-
DI; 95% of certolizumab pegol group and
95% of placebo were imputed for analysis
Safety: ITT
Judged at high risk of bias due to > 20%
dropout rate at 24 months in the treatment
group
Selective reporting (reporting bias) Low risk The study protocol is available and all of
the study’s prespecified (primary and sec-
ondary) outcomes that are of interest in the
review have been reported in the prespeci-
fied way
Other bias Low risk The study appears to be free of other
sources of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk See above
56Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT00993317 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above
Smolen 2009
Methods Randomised double-blind trial
Participants 619 participants aged > 18 years
Participants were randomised 2:2:1
Interventions 1. Certolizumab pegol sc, 400 mg at weeks 0, 2 and 4, followed by 200 (n= 246 )or 400
mg every 2 weeks, plus MTX (n= 246)
2. Placebo (saline) plus MTX (n= 127)
Outcomes Primary endpoints: ACR20 response at week 24, and physician’s global assessment of
disease activity, participant’s assessment of pain, HAQ-DI and serum CRP or ESR
Secondary endpoints: ACR50, ACR70, mean change from baseline in van der Heijde
mTSS, SF-36 Health Survey,and individual ACR core set variables. Disease activity was
assessed using the DAS-28 (ESR)
Follow-up 24 weeks
Notes RAPID2 Trial
Countries/Cities: 121 sites from EEUU, Argentina, Australia, Belgium, Bulgaria,
Canada, Chile, Croatia, Czech Republic, Estonia, Finland, France, Hungary, Israel,
Latvia, Lithuania, Mexico, New Zealand, Russian Federation, Serbia, Slovakia, Ukraine
Dates conducted: from June 2005 to February 2012
Eligibility criteria: RA of at least 6months and defined by the ACR classification criteria
who had received MTX for ≥ 6 months at a stable dose of ≥ 10 mg/week for at least
2 months before baseline were included. At inclusion, participants had to have active
disease as defined by: TJC and SJC of ≥ 9, ESR ≥ 30 mm/H, and a CRP of ≥15 mg/
L. People with a disease duration of > 15 years were excluded. People previously treated
with a TNF inhibitor were also excluded if they had previously failed to respond to
treatment. Participants with history of, or positive chest x-ray findings for TB, or a PPD
skin test (defined as positive indurations by local medical practice) were excluded. As per
protocol, if a positive PPD skin test was assumed by the local investigators to be related
to previous bacille Calmette-Guerin (BCG) vaccination and was not associated with
clinical or radiographic suspicion of TB, the person could be enrolled at the discretion
of the investigator. In total, 101 participants (16%) were enrolled with a PPD test > 5
mm at baseline. Participants who did not show an ACR20 response at both weeks 12
and 14 were to be withdrawn from the study, designated ACR20 non-responders in the
primary analysis and allowed to enter an open-label extension study at week 16 with
certolizumab pegol 400 mg every 2 weeks
Adverse events as a specified outcome: adverse events and serious adverse events were
reported
Funding sources: UCB Pharma
Conflict of interest: J Smolen, R B Landewé, P Mease, RF van Vollenhoven, A Ka-
vanaugh, M Schiff, GR Burmester, V Strand and D van der Heijde serve as consultants
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to UCB, Inc
RB Landewé, A Kavanaugh, M Schiff and D van der Heijde receive research funding
from UCB, Inc and GR Burmester
J Vencovsky have received honorarium from UCB, Inc for speaking
D Mason and K Luijtens are employees of UCB, Inc.
J Brzezicki has nothing to disclose
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Code list prepared by independent group
Allocation concealment (selection bias) Low risk IVRS used to allocate participant to treatment group
(2:2:1 ratio)
Blinding (performance bias and detection
bias)
ACR50
Low risk UCB stated: ”All the study staff with the exception of
the unblinded dispenser, was blind to the treatment.
Each study center was required to have awritten blind-
ing plan in place signed by the principal investigator,
which detailed the study center’s steps for ensuring
that the double blind nature of the study was main-
tained“
Blinding (performance bias and detection
bias)
All outcomes
Low risk See above
Incomplete outcome data (attrition bias)
ACR50
Low risk 71% of certolizumab pegol 200 mg and 74% of cer-
tolizumab pegol 400 mg respectively and 13% of
placebo groups completed 6 months of treatment. We
imputed missing data for analysis
Incomplete outcome data (attrition bias)
All outcomes
Low risk Full account of all withdrawals and reasons for with-
drawals
Safety: ITT analysis. Quote: ”two patients in the
placebo group received certolizumab pegol 200 mg
and were included in the certolizumab pegol 200 mg
group for safety evaluations“
Selective reporting (reporting bias) Low risk All the outcomes that are of interest in the review have
been reported in the prespecified way
Other bias Low risk The study appears to be free of other sources of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk See above
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Radiographswere read centrally andblinded (for treat-
ment, visit and participant identification) and checked
independently by 2 experienced readers
Smolen 2015
Methods A Phase IIIB, multicentre, double-blind, placebo-controlled, parallel-group study to
evaluate the safety and efficacy of certolizumab pegol, administered with DMARD
Participants People with low to moderate disease activity RA on DMARDs therapy for at least 6
months
Interventions 1. 2 x 200 mg certolizumab pegol sc injections at week 0, week 2, (96 patients)and week
4, followed by 200 mg injections every 2 weeks until the last drug administration (Week
22)
2. Placebo (98 patients) , same regimen
Outcomes Efficacy evaluations were performed every 4 weeks from weeks 0 to 52. Adverse events
(AEs) were assessed every two weeks. Primary efficacy endpoint was the proportion of
patients in stable CDAI remission (CDAI≤2.8) at both weeks 20 and 24. Secondary
outcomes included: DAS remission, ACR20, ACR50, ACR70, SDAI, HAQ-DI, SF-36,
Change From Baseline in Patient’s Global Assessment of Disease Activity - Visual Analog





Countries/Cities: All patients, recruited from centres in Austria, France, Germany, Italy
and Poland
Dates conducted: conducted between June 2008 and December 2010.
Eligibility criteria: Eligible patients (≥18 years of age) had a diagnosis of RA23 (6
months-10 years), LDA/MDA at screening and baseline (defined by CDAI >6 and
≤16, ≥2 tender joints (28-joint count, TJC), ≥2 swollen joints (28-joint count, SJC)
and either erythrocyte sedimentation rate (Westergren-ESR) ≥28 mm/h or C-reactive
protein (CRP) >10 mg/L). Patients must have received mono or combination DMARD
therapy (MTX, leflunomide, sulfasalazine and/or hydroxychloroquine) for ≥6 months
(dose stable ≥2 months) prior to baseline, with corticosteroid dose stable >1 month (for
exclusion criteria, see online supplementary material)
Adverse events as a specified outcome: Safety analysis was performed up to week 52
plus 12-week safety follow-up
Funding sources: UCB
Conflict of interest: This study is not published. Despite this, the following statement
was on the trials registry, ”Principal Investigators areNOT employed by the organization
sponsoring the study“
JS has received grants from and provided expert advice to UCB Pharma. PE has received
grants and consultancy fees fromUCB Pharma, Pfizer, Merck, Abbott, Roche and BMS.
GF has received speaking fees from UCB Pharma
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WS has acted as a consultant for UCB Pharma.
FB has received consultancy fees for UCB Pharma.
HB is a consultant for UCB Pharma.
OD is an employee and a shareholder for UCB Pharma.
WK and OP are employees of UCB Pharma.
BB is a former employee of UCB Pharma and also holds stock options with UCBPharma
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomised in a 1:1 ratio;
Randomisation was performed centrally
using an interactive voice-response system
Allocation concealment (selection bias) Low risk Allocation by IVRS; so done remotely and
therefore concealment satisfactory
Blinding (performance bias and detection
bias)
ACR50
Low risk UCB stated: ”All the study staff with the
exception of the unblinded dispenser, was
blind to the treatment. Each study center
was required tohave awritten blindingplan
inplace signedby the principal investigator,
which detailed the study center’s steps for
ensuring that the double blind nature of
the study was maintained“
Blinding (performance bias and detection
bias)
All outcomes
Low risk See above
Incomplete outcome data (attrition bias)
ACR50
Low risk Full account of all withdrawals and reasons
for withdrawals
87.5% of certolizumab pegol group and
81% of placebo completed 6 months of
treatment. We imputed missing data for
analysis
Incomplete outcome data (attrition bias)
All outcomes
Low risk 85% in SF-36, 84% in Pain VAS, and 94%
inHAQ of certolizumab pegol group com-
pleted 24 months of treatment. We im-
puted missing data for analysis. ITT in sa-
fety analysis
Selective reporting (reporting bias) Low risk All the prespecified outcomeswere reported
Other bias Low risk The study appears to be free of other
sources of bias
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ”Subject, caregiver, investigator and out-
come assessor“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ”Subject, caregiver, investigator and out-
come assessor“
Weinblatt 2012
Methods Randomised, double-blind (subject, outcomes assessor), parallel-assignment, safety/effi-
cacy study
Participants Adults with established moderate-to-severe rheumatoid arthritis
Interventions 1. 400 mg certolizumab pegol given as 2 x 200 mg sc injections at weeks 0, 2, and 4,
followed by 200 mg certolizumab pegol given as 1 sc injection at weeks 6, 8, and 10.
At Week 12 participants enter the open-label phase and receive 200 mg of certolizumab
pegol every other week for a minimum 16 additional weeks until certolizumab pegol is
commercially available (n=851)
2. Placebo (0.9% saline) given as 2 sc injections at weeks 0, 2, and 4, followed by placebo
given as 1 sc injection at weeks 6, 8, and 10. At week 12 participants enter the open-
label phase and receive 200 mg of certolizumab pegol every other week for a minimum
16 additional weeks until certolizumab pegol is commercially available (n=212)
Outcomes Primary outcome: ACR20 response rate at week 12.
Other outcomes: responder rate, disease activity, fatigue, physical functioning. Time




Countries/Cities: 181 sites in EEUU, Canada, Frannce, Italy, Netherlands and Spain
Dates conducted: from July 2008 to March 2011
Eligibility criteria: Eligible patients were ≥18 years of age, had adult-onset RA as
defined by the 1987 ACR criteria for at least 3 months and showed an unsatisfactory
response or intolerance to at least one DMARD (MTX, LEF, SSZ, chloroquine or HCQ,
AZA and/or gold). Subjects had active disease as defined by at least five tender and at
least four swollen joints (28-joint count) and either ≥10 mg/l CRP or ≥28 mm/h ESR
(Westergren method) at screening
Adverse events as a specified outcome: adverse events and serious adverse events were
reported
Funding sources: UCB Pharma
Conflict of interest: ”Principal Investigators are NOT employed by the organization
sponsoring the study.“. ” There IS an agreement between Principal Investigators and the
Sponsor (or its agents) that restricts the PI’s rights to discuss or publish trial results after
the trial is completed.“ ” Restriction Description: UCB has > 60 but <= 180 days to
review results communications prior to public release and may delete information that is
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confidential and compromises ongoing studies or is considered proprietary. This restric-
tion is not intended to compromise the objective scientific integrity of the manuscript,
it being understood that the results shall be published regardless of outcome“
M.D. has received research grants and consulting fees from Abbott Laboratories, Bristol-
Myers Squibb, Pfizer, Roche and UCB Pharma
T.W.J.H. has received consulting fees from UCB Pharma.
R.F.v.V. has received research grants and consulting fees from UCB Pharma. C.O.B. has
served as an investigator and received consulting fees fromUCBPharma. J.P. has received
research grants and consulting fees from UCB Pharma, Abbott Laboratories, Actelion,
Amgen, AstraZeneca, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Johnson &
Johnson,MedImmune,Merck, Novartis, Pfizer, Roche, Sanofi, Sorono, Teva andUnited
Therapeutics
N.G. is a former employee of UCB Pharma and is currently an employee of Quintiles.
N.G. owns UCB Pharma stock
R.F. has received research grants and consulting fees from UCB Pharma
M.E.W. has received research grants from Abbott, Bristol-Myers Squibb, Roche, Biogen/
Idec, Medimmune, Cresendo Bioscience and UCB Pharma, and consulting fees from
UCB Pharma, Abbott Laboratories, Amgen, Bristol-Myers Squibb, Roche, Biogen/Idec,
Medimmune, Cresendo Bioscience Pfizer and Centocor
J.W. has received consultancy fees from, and participated in a speakers bureau for, UCB
Pharma.O.D. is aUCBPharma employee and has stocks, stock options or bond holdings
in UCB Pharma
P.E. has received research grants and consulting fees from Pfizer, Merck, Abbott Labora-
tories, Roche, Bristol-Myers Squibb andUCB Pharma. B.D. is a UCB Pharma employee
and owns UCB Pharma stock
E.M. has received consulting fees from UCB Pharma, Amplimmune, Constellation
Pharmaceuticals and Wachovia; has worked as an investigator for Bristol-Myers Squibb
and Roche; and has received honorarium from the ACR and Up to Date
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”Patients were randomised 4:1 via an inter-
active voice response system“
Allocation concealment (selection bias) Low risk ”Patients were randomised 4:1 via an inter-
active voice response system“
Blinding (performance bias and detection
bias)
ACR50
Low risk Blinding of participants and key study per-
sonnel ensured, andunlikely that the blind-
ing could have been broken. UCB stated:
”All the study staff with the exceptionof the
unblinded dispenser, was blind to the treat-
ment“. ”Each study center was required
to have a written blinding plan in place
signed by the principal investigator, which
detailed the study center’s steps for ensuring
that the double blind nature of the study
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was maintained“
Blinding (performance bias and detection
bias)
All outcomes
Low risk See above
Incomplete outcome data (attrition bias)
ACR50
Low risk 90% of certolizumab pegol group and 86%
of placebo completed 12 weeks of treat-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Full account of all withdrawals and reasons
for withdrawals
ITT analysis for efficacy outcomes but per
protocol analysis for safety: 9 participants
fewer in certolizumab pegol arm and 3
fewer in placebo group
Selective reporting (reporting bias) Low risk All the outcomes that are of interest to this
review have been reported in the prespeci-
fied way
Other bias Low risk The study appears to be free of other
sources of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Although blinding is not described, blind-
ing of participants and key study person-
nel ensured, and unlikely that the blinding
could have been broken
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of participants and key study per-
sonnel ensured, andunlikely that the blind-
ing could have been broken
Yamamoto (a) 2014
Methods Randomised, double-blind trial
Participants Eligible patients were aged 20-74 years, Certoluzimab pegol (n= 116 ) Placebo ( n= 114
)
Interventions 1. Induction dose of 400 mg in weeks 0, 2 and 4, and thereafter 200 mg CDP870 given
sc every 2 weeks until week 22
2. Placebo, same regimen
Outcomes Primary outcome: ACR20 at week 12
Secondary outcome: ACR20 at week 24
Follow-up 24 weeks
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Notes clinicaltrials.gov/ct2/show/NCT00791921?term=00791921&rank=1
HIKARI Trial
Countries/Cities: 66 centers across Japan
Dates conducted: between 19 November 2008 and 16 September 2010
Eligibility criteria: patients with active RA who could not receive MTX due to insuffi-
cient efficacy, safety concerns or previous discontinuation for safety reasons
inclusion criteria:
• Must have a diagnosis of adult-onset RA of at least 6 months but not longer than
15 years as defined by the 1987 ACR classification criteria
• Must have active RA disease as defined by: at least 6 tender joints and 6 swollen
joints; ESR of 28 mm/hour or CRP of 2.0 mg/dL
• Have failed to respond or have been resistant to at least 1 DMARD (including
MTX)
• MTX cannot be administered for any of the reasons: incomplete response/safety
concerns
Exclusion criteria:
• A diagnosis of any other inflammatory arthritis
• Have a secondary, non-inflammatory type of arthritis (e.g. osteoarthritis,
fibromyalgia)
• Currently have, or who have a history of, a demyelinating or convulsive disease of
the central nervous system (e.g. multiple sclerosis, epilepsy)
• Have NYHA Class III or IV congestive heart failure
• Have, or who have a history of, tuberculosis
• Have a high risk of infection (with a current infectious disease, a chronic
infectious disease, a history of serious infectious disease)
• Currently have, or who have a history of, malignancy
• Women who are breastfeeding or pregnant, who are of childbearing potential
• Previously received treatment with 2 or more anti-TNFα drugs or who previously
failed to respond to treatment with 1 or more anti-TNFα drugs
Fewer than 10% of the participants were exposed to a previous TNF with a wash-out
period minimum of 3 months for etanercept or 6 months for other biologics
Adverse events as a specified outcome: Treatment-emergent AEs (TEAEs) included all
events fromafter administration of study druguntil the last evaluation visit (not including
the safety follow-up visit). TEAEs were coded by system organ class and preferred term
using Medical Dictionary for Regulatory Activities (MedDRA)
Funding sources: Otsuka Pharmaceutical Co., Ltd. and UCB Japan
Conflict of interest: This study is already not published. This statement was in the trials
registry: ”Principal Investigators are NOT employed by the organization sponsoring the
study. There is NOT an agreement between Principal Investigators and the Sponsor (or
its agents) that restricts the PI’s rights to discuss or publish trial results after the trial is
completed“
KY has served as a consultant for UCB Pharma, Pfizer, Abbott, BMS, Roche, Chugai,
Mitsubishi-Tanabe and Eisai and has received research funding from UCB Pharma,
Pfizer, Abbott, Santen, Mitsubishi-Tanabe and Eisai
TT has served as a consultant for AstraZeneca, Eli Lilly, Novartis,Mitsubishi-Tanabe and
Asahi Kasei, has received research support from Abott, Astellas, BMS, Chugai, Daiichi-
Sankyo, Eisai, Janssen, Mitsubishi-Tanabe, Nippon Shinyaku, Otsuka, Pfizer, Sanofi-
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Aventis, Santen, Takeda and Teijin, and has served on speaker bureaus for Abbott, BMS,
Chugai, Eisai, Janssen, Mitsubishi-Tanabe, Pfizer and Takeda
HY has served as a consultant for, and received research funding from, UCB Pharma,
Abbott, Astellas, BMS, Chugai, Eisai, Janssen, Mitsubishi-Tanabe, Pfizer and Takeda
NI has received research funding from Takeda, Mitsubishi- Tanabe, Astellas, Chugai,
Abbott, BMS, Eisai, Janssen, Kaken and Pfizer and has served on speaker bureaus for
Takeda,Mitsubishi-Tanabe, Astellas, Chugai, Abbott, BMS,Eisai, Janssen,Kaken, Pfizer,
Taisho-Toyama and Otsuka
YT has received research funding from BMS, MSD, Chugai, Mitsubishi-Tanabe, Astel-
las, Abbott, Eisai and Janssen and has served on speaker bureaus for UCB Pharma, Mit-
subishi- Tanabe, Abbott, Eisai, Chugai, Janssen, Santen, Pfizer, Astellas, Daiichi-Sankyo,
GSK, AstraZeneca, Otsuka, Actelion, Eli Lilly, Nippon Kayaku, Quintiles Transnational
and Ono
KE has served as a consultant for UCB Pharma
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk External central of randomisation. Randomization by
blocks
Allocation concealment (selection bias) Low risk The allocation sequence was generate using uniform
random numbers from SAS RANUNI function
Blinding (performance bias and detection
bias)
ACR50
Low risk ”All study staff with the exception of the unblinded
dispenser were blind to the treatment, ... These un-
blinded personnel were not allowed to engage in any
other study activities“
Blinding (performance bias and detection
bias)
All outcomes
Low risk See above
Incomplete outcome data (attrition bias)
ACR50
Low risk 71%of certolizumabpegol group and15%of placebo
completed 6 months of treatment. We imputed miss-
ing data for analysis
Incomplete outcome data (attrition bias)
All outcomes
Low risk Full account of all withdrawals and reasons for with-
drawals
ITT analysis.
Quote: ”Of the 230 subjects in the Full Analysis Set
(FAS), 230 are included in the adverse event reporting
based upon the Safety Set (SS) population. The Safety
Set includes all subjects randomised who received at
least 1 dosing“
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Selective reporting (reporting bias) Low risk The study protocol is available and all of the study’s
prespecified (primary and secondary) outcomes that
are of interest to this review have been reported in the
prespecified way
Other bias Low risk The study appears to be free of other sources of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Without any details
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above
Yamamoto (b) 2014
Methods Treatment, randomised, double-blind (participant, caregiver, investigator, outcomes as-
sessor), dose-comparison, parallel-assignment, safety/efficacy study
Participants Eligible patients were aged from 20-74 years and had a diagnosis of RA defined by ACR
(1987) criteria for 0.5-15 years
Interventions Patients were randomised 1:1:1:1 to subcutaneous CZP 100, 200, or 400 mg plusMTX,
or saline placebo plus MTX, every 2 weeks (Q2W)
1. Drug: CDP870 400 mg (n= 85)
2. Drug: CDP870 200 mg ( n= 82)
3. Drug: CDP870 100 mg ( n= 72 )
4. Drug: placebo of CDP870 ( n=77 )
Outcomes Primary outcome measures:ACR20 responder rate: week 12, 24
Secondary outcome measures:ACR20/50/70 responder rate: weeks 1, 2, 4, 6, 8, 12, 14,
16, 20, 24DAS-28 (ESR): weeks 1, 2, 4, 6, 8, 12, 14, 16, 20, 24




Countries/Cities: 67 centers across Japan
Dates conducted: conducted between 19 November 2008 and 18 August 2010
Eligibility criteria: patients with active RA and an inadequate response toMTX received
CZP or placebo while continuing to take their previous dosage of MTX. The MTX
regimen could not be changed after initiation of the study treatment
Adverse events as a specified outcome: Treatment-emergent AEs (TEAEs) included
all events from after the administration of the study drug until the last evaluation visit
(not including the safety follow-up visit). TEAEs were coded by system organ class and
preferred term using MedDRA terminology (v11.1)
Funding sources: Otsuka Pharmaceutical Co., Ltd; UCB Japan Co. Ltd
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Conflict of interest: ”Principal Investigators are NOT employed by the organization
sponsoring the study“. ”There isNOT an agreement between Principal Investigators and
the Sponsor (or its agents) that restricts the PI’s rights to discuss or publish trial results
after the trial is completed“
The competing interests of all authors are provided below.
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NI has received research funding from Takeda, Mitsubishi-Tanabe, Astellas, Chugai,
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las, Abbott, Eisai and Janssen, and has served on speaker bureaus for UCB Pharma, Mit-
subishi-Tanabe, Abbott, Eisai, Chugai, Janssen, Santen, Pfizer, Astellas, Daiichi-Sankyo,
GSK, AstraZeneca, Otsuka, Actelion, Eli Lilly, Nippon Kayaku, Quintiles Transnational
and Ono
KE has served as a consultant for UCB Pharma.
AW has received research support from Astellas, Daiichi- Sankyo, Kyorin, Shionogi,
Taisho, Dainippon-Sumitomo, Taiho, Toyama Chemical andMeiji Seika, and has served
on speaker bureaus for Abott, MSD, Otsuka, GSK, Shionogi, Daiichi-Sankyo, Taisho-
Toyama,Dainippon-Sumitomo,Mitsubishi-Tanabe,ToyamaChemical, Bayer andPfizer
HO has served as a consultant for UCB Pharma and Astellas.
TS is an employee of Otsuka.
YS is an employee of UCB Pharma.
DvH has served as a consultant for, and received research support from, AbbVie, Amgen,
AstraZeneca, BMS, Centocor, Chugai, Daiichi, Eli Lilly, GSK, Janssen, Merck,Novartis,
Novo-Nordisk, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB Pharma
and Vertex. DvH is also director of Imaging Rheumatology bv
NM has received research support from Pfizer, Takeda, Mitsubishi-Tanabe, Chugai,
Abbott, Eisai and Astellas
TK has served on speaker bureaus for UCB Pharma, Pfizer, Chugai, Abbott, Mitsubishi-
Tanabe,Takeda, Eisai, Santen, Astellas, Taisho-Toyama, BMS,Teijin andDaiichi-Sankyo
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk External central of randomisation. Ran-
domization by blocks
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Yamamoto (b) 2014 (Continued)
Allocation concealment (selection bias) Low risk The allocation sequence was generate using
uniform random numbers from SAS RA-
NUNI function
Blinding (performance bias and detection
bias)
ACR50
Low risk ”All study staff with the exception of the
unblindeddispenserwere blind to the treat-
ment, ... These unblinded personnel were
not allowed to engage in any other study
activities“
Blinding (performance bias and detection
bias)
All outcomes
Low risk See above
Incomplete outcome data (attrition bias)
ACR50
Low risk 66% of certolizumab pegol 100 mg, 80%
of certolizumab pegol 200 mg, and 76%
of certolizumab pegol 400 mg group (over-
all 74% in certolizumab pegol groups) and
32% of placebo completed 6 months of
treatment. We imputed missing data for
analysis
Incomplete outcome data (attrition bias)
All outcomes
Low risk Safety, quote: ”Of the 316 subjects in the
Full Analysis Set (FAS), 316 are included
in the adverse event reporting based upon
the Safety Set (SS) population. The Safety
Set includes all subjects randomised who
received at least 1 dosing“
Selective reporting (reporting bias) High risk Participants were recruited in Japan be-
tween 2008 and 2010. In 2008, DAS28
(ESR) andModifiedTotal Sharp Scorewere
secondary outcomes. In 2012 these out-




Other bias Low risk The study appears to be free of other
sources of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No details available
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk See above
68Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Østergaard 2015
Methods Randomised, double-blind, placebo-controlled
Participants 41 participants with active RA despite DMARD. Participants were randomised 2:1
Interventions 1. certolizumab pegol (loading dose 400 mg every 2 weeks at weeks 0 - 4; certolizumab
pegol 200 mg every 2 weeks at weeks 6 - 16) (n= 27)
2. Placebo, then certolizumab pegol ( placebo at weeks 0 - 2; certolizumab pegol loading
dose at weeks 2 - 6; certolizumab pegol 200 mg every 2 weeks at weeks 8 - 16) (n= 13)
Outcomes Primary: Change in synovitis measured by Outcome Measures in Rheumatoid Arthritis
Clinical Trials (OMERACT), Rheumatoid ArthritisMagnetic Resonance Image Scoring
System (RAMRIS) score at weeks 1, 2, 4, 8 and 16
Secondary: Change From Baseline to Week 16 in the Dynamic Magnetic Resonance
Image (MRI) Parameter, Initiation Rate of Enhancement (IRE);
Change frombaseline toweek 16 in the dynamicMRIparameter,Maximal Enhancement
(ME);
Change from baseline to week 16 in the dynamic MRI parameter, number of voxels
(Nvox) with plateau and washout pattern; Percentage of participants achieving a good
European League Against Rheumatism (EULAR) response at week 16; Percentage of
participants meeting the ACR 20% criteria at week 16
Notes MARVELOUS Trial
Only the data obtained at week 2 were useful. After week 2 both arms were treated with
certolizumab pegol. Out of all the primary and secondary outcomes studied, only DAS
and ACR20 measured at week 2 were reported. However since they are shown as a figure
we are unable to use them. Only adverse event data were reported at week 2
Countries/Cities: Denmark, Polland, Netherlands, Sweden
Dates conducted: From NOvember 2010 to September 2013
Eligibility criteria: The study population was ≥18years of age with adult-onset RA of
between 3months and 15years duration, as defined by the 1987 American College of
Rheumatology (ACR) classification criteria
Adverse events as a specified outcome: adverse events and serious adverse events were
reported
Funding sources: UCB
Conflict of interest:Principal Investigators areNOTemployed by the organization spon-
soring the study.The only disclosure restriction on the PI is that the sponsor can review
results communications prior to public release and can embargo communications re-
garding trial results for a period that ismore than 60 days but less than or equal to 180
days. The sponsor cannot require changes to the communication and cannot extend the
embargo
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Østergaard 2015 (Continued)
and has received consultancy fees from Roche, UCB, Pfizer, MSD, BMS and Jansen;
FS, RH and BS-E are employees of UCB Pharma;
HB has received consulting fees, honoraria, research or institutional support, educational
grants, equipment, services or expenses from Abbott, Amgen, AstraZeneca, Aventis,
Bristol Myers Squibb, Cambridge Nutritional Foods, Dansk Droge, Eurovita, Ferrosan,
GlaxoSmithKline, Hoechst, LEO, Lundbeck, MSD, Mundipharma, Norpharma, Nu-
triCare, Nycomed, Pfizer, Pharmacia, Pierre-Fabre, Proctor&Gamble, Rhone-Poulenc,
Roche, Roussel, Schering-Plough, Searle, Serono, UCB Pharma and Wyeth
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk External central of randomisation
Allocation concealment (selection bias) Low risk IVRS
Blinding (performance bias and detection
bias)
ACR50
Unclear risk Not measured at 2 weeks. Not applicable
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Due to differences in the presentation
and viscosity of certolizumab pegol and
placebo, all study treatments (certolizumab
pegol and placebo) were administered by
unblinded study centre personnel to main-
tain study blinding. The personnel admin-
istering the injections had no involvement
in the study other than performing the ESR
analysis
Incomplete outcome data (attrition bias)
ACR50
Low risk Not measured. Not applicable
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 participant withdrew prior to treatment
and was not included in the Full Anal-
ysis Set (FAS), but it is not clear from
which arm the participant withdrew. The
FAS comprised 27 participants in the cer-
tolizumab pegol group and 13 in the
placebo→certolizumab pegol group. Dur-
ing the double-blind phase, 4 partici-
pants discontinued treatment: 1 from the
placebo→certolizumab pegol group due to
withdrawal of consent, and 3 from the cer-
tolizumab pegol group, 2 due to AEs and 1
due to lack of efficacy. Since it is not clear
at which point of the double-blind phase
70Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Østergaard 2015 (Continued)
the withdrawals occurred, we did not input
these data to the analysis
Selective reporting (reporting bias) Low risk All the outcomes listed in the protocol are
reported in www.ClinicalTrial.gov. How-
ever, the data were measured at week 16
and so cannot be used
Other bias Low risk The study appears to be free of other
sources of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ”The personnel administering the injec-
tions had no involvement in the study“
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk ”Due to differences in the presentation
and viscosity of certolizumab pegol and
placebo, all study treatments (certolizumab
pegol and placebo) were administered by
unblinded study centre personnel to main-
tain study blinding. The personnel admin-
istering the injections had no involvement
in the study other than performing the ery-
throcyte sedimentation rate analysis“
ACR: American College of Rheumatology
ARA: American Rheumatology Association
CDAI: coronary diffuse atheromatous index
CRP: C-reactive protein
DAS: disease activity score
DMARD: disease-modifying anti-rheumatic drug
ESR: erythrocyte sedimentation rate
HAQ-DI: health assessment questionnaire - disability index
ITT: intention-to-treat
IVRS: Interactive voice recognition system
mBPI: modified brief pain inventory
mTSS: modified total sharp score
MTX: methotrexate
NYHA: New York Heart Association
PPD: purified protein derivative
Q2W every two weeks
RA: rheumatoid arthritis
sc: subcutaneous
SDAI: Simplified Disease Activity Index
SF-36: short form 36
SJC: swollen joint count
TB: tuberculosis
TJC: tender joint count
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VAS: visual analogue scale
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alten 2013 OLE
Bykerk 2015 The outcomes reported (Disease Burden on Workplace and Household Productivity) are not covered
in our review
Curtis 2014 There is only one arm without placebo or any comparator
Curtis 2015a There is only one arm without placebo or any comparator
Curtis 2015b There is only one arm without placebo or any comparator
Dose Flex 2007 RCT that tested clinical efficacy of 2 dosing regimens of CZP (200 mg every 2 weeks or 400 mg every
four weeks + MTX) compared to MTX alone for maintenance of clinical response up to 34 weeks in
participants who have achieved ACR20 after a 16-week open-label run-in period of CZP treatment




Kavanaugh 2014 There is only one arm without placebo or any comparator
Kivitz 2014 Phase IV clinical trial
NCT00160641 One simple group
NCT00160693 It is an OLE with just one simple group
NCT00753454 One simple group
NCT00843778 One simple group
NCT00851318 OLE
NCT00993668 Excluded because adverse events were studied in the blinded period just at 4 weeks
NCT01197066 OLE
NCT01255761 PREDICT Phase IV. Both arms were treated with CZP 200 mg
NCT01292265 Phase IV
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Characteristics of ongoing studies [ordered by study ID]
NCT01295151
Trial name or title SWITCH Clinical trial for patients with rheumatoid arthritis who have failed an initial TNF-blocking drug
(SWITCH)
Methods Randomised controlled trial
Participants People that have failed an anti-TNF therapy (the first of the biological therapies to be introduced)
Interventions Etanercept; abatacept; rituximab; adalimumab; certolizumab pegol; infliximab; golimumab
Outcomes Change in disease activity at 6 months; EULAR and ACR scores; CDAI; quality of life
Starting date 2011
Contact information Julia Brown, Director of Leeds Institute of Clinical Trials Research, University of Leeds
Notes Only published the protocol : EXCLUDE
Infliximab, adalimumab, certolizumab or golimumab if initial failure to the receptor fusion protein etanercept
(choice of TNFi at investigator’s discretion)
NCT01489384
Trial name or title Cimzia treatment in rheumatoid arthritis: randomising to stop versus continue disease-modifying anti-
rheumatic drug(s)
Methods Randomised controlled trial
Participants 125 people with moderate to severe RA who are being prescribed CZP
Interventions CZP plus DMRA vs CZP alone
73Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT01489384 (Continued)
Outcomes DAS28 < 3.2 at 18 months
Starting date 2011
Contact information Janet Pope, MD (Pope Research Corporation)
Notes The recruitment status of this study is unknown because the information has not been verified recently
NCT01491815
Trial name or title Active conventional therapy compared to three different biologic treatments in early rheumatoid arthritis
with subsequent dose reduction: NORD-STAR trial
Methods This is an international (Nordic) trial designed to compare the safety and efficacy of active conventional
therapy (ACT) and 3 biologic treatments in people with early rheumatoid arthritis (RA). The global aim of
this study is to assess and compare
1. the proportion of participants who achieve remission with ACT versus 3 different biologic therapies
(Certolizumab pegol, abatacept or tocilizumab)
2. 2 alternative de-escalation strategies in participants who respond to first-line therapy.
Participants Estimated enrolment: 800
Interventions Certolizumabl pegol, abatacept, tocilizumab
Outcomes • The proportion of participants in remission at week 24 from baseline according to CDAI.
• The proportion of participants in remission at week 24 after dose-reduction according to CDAI.
• The radiographic progression of total Sharp van der Heijde score after 48 weeks from baseline
Starting date 2012; estimated completion data: 2020
Contact information Contact: Ronald van Vollenhoven, MD, Prof. +46(0)851776077 ronald.van.vollenhoven@ki.se
Notes
NCT01500278
Trial name or title Study to assess the short- and long-term efficacy of certolizumab pegol plus methotrexate compared to




Interventions CZP plus MTX vs adalimumab plus MTX
Outcomes ACR20 at 12 and 104 weeks
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NCT01500278 (Continued)
Starting date 2011
Contact information UCB Pharma
Notes Without results in clinicaltrials.gov/ct2/show/study/NCT01500278?term=certolizumab&rank=34, nor ab-
stract of proceedings
NCT01602302
Trial name or title Ultrasound and withdrawal of biological DMARDs in rheumatoid arthritis (RA-BioStop)
Methods Phase IV
Participants Estimated enrolment: 110
Interventions
Outcomes Primary outcomemeasures: Active inflammation at the time ofDMARDwithdrawal indicated by the presence
of a PD-score ≥ 1 in at least 1 joint out of a sonographic 14-joint count predicts relapse rate at week 16
Starting date Estimated completion data: September 2017
Contact information Contact: Christian Dejaco, MD, PhD +43-316-80595 christian.dejaco@gmx.net
Notes This study is currently recruiting participants
NCT02151851
Trial name or title A study of certolizumab pegol as additional therapy in Chinese patients with active rheumatoid arthritis
(RAPID-C)
Methods Phase 3, multi centre, double-blind, placebo-controlled, parallel-group, randomised 24-week trial
Participants 400 participants ( 300 with CZP/100 placebo)
Interventions CZP 400 mg (200 mg prefilled syringe [PFS], i.e. 2 injections) at baseline, and weeks 2 and 4; then CZP 200
mg (1 injection) every 2 weeks until week 22
Outcomes ACR20
Starting date June 2014; completion data: June 2016
Contact information UCB Cares; UCB Pharma
Notes
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NCT02293590
Trial name or title Remission by Intra-articular injection plus CErtolizumab (RICE)
Methods An open-label, randomised study to compare the efficacy of certolizumab pegol (CZP) plus a dynamic or
fixed dose treatment strategy in patients with rheumatoid arthritis; a Phase II study
Participants 48
Interventions Intensive, adapted treatment strategy Certolizumab pegol (CZP, Cimzia (R)): 200 mg every 2 weeks after
loading dose of 400 mg at Weeks 0, 2 and 4
Outcomes ACR50 at 24 weeks
Starting date October 2014
Contact information Rüdiger B. Müller, Cantonal Hospital of St. Gallen
Notes Recruiting participants
NCT02430909
Trial name or title Multiple dose study of UCB4940 as add-on to certolizumab pegol in subjects with rheumatoid arthritis
Methods Phase II double-blind, randomised, placebo-controlled study
Participants No data
Interventions Certolizumab pegol (400 mg at weeks 0, 2, and 4 followed by 200 mg every 2 weeks) until week 30 + placebo
from week 8 to week 18 versus
Certolizumab pegol (400 mg at weeks 0, 2, and 4 followed by 200 mg every 2 weeks) until week 30 +
UCB4940 from week 8 until week 18
Outcomes Adverse events; Change in DAS28 at week 20
Starting date 2015
Contact information UCB Cares +1 887 822 9493 (UCB)
Notes
NCT02466581
Trial name or title Dose reduction for early rheumatoid arthritis patients with low disease activity
Methods Phase IV. This is an international (Nordic) trial designed to compare the safety and efficacy of active conven-
tional therapy (ACT) and 3 biologic treatments (certolizumab pegol, abatacept or tocilizumab) in people with
early rheumatoid arthritis. The global aim of this study is to assess and compare 2 alternative de-escalation
strategies in participants who achieved low disease activity during first-line therapy in the NORD-STAR
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Interventions Active Comparator: Arm 1
Participants keep the intervention they had in the NORD-STAR-study (NCT01491815), i.e. 1 of the 4
below:
1. Sulphasalazine + hydroxychloroquine OR prednisolone plus methotrexate and steroids
2. Cimzia plus methotrexate and steroids
3. Orencia plus methotrexate and steroids
4. RoActemra plus methotrexate and steroids
Active Comparator: Arm 2
Participants keep the intervention they had in the NORD-STAR-study (NCT01491815), i.e. 1 of the 4
below:
1. Sulphasalazine + hydroxychloroquine OR prednisolone plus methotrexate and steroids
2. Cimzia plus methotrexate and steroids
3. Orencia plus methotrexate and steroids
3. RoActemra plus methotrexate and steroids.
This intervention is de-escalated starting 24 weeks after randomisation
Outcomes Proportion of participants maintaining low disease activity after dose reduction
The proportion of participants, with early dose reduction vs late dose reduction, who maintain low disease
activity (2.8 < CDAI ≤ 10.0) at 24 weeks after the dose was first reduced
Starting date May 2015
Contact information Ronald van Vollenhoven
+46(0)851776077 ronald.van.vollenhoven@ki.se
Notes This study is currently recruiting participants
CDAI: coronary diffuse atheromatous index
DMARD: disease-modifying anti-rheumatic drug
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D A T A A N D A N A L Y S E S
Comparison 1. Efficacy at 12 weeks, any dose




participants Statistical method Effect size
1 ACR20 6 2902 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.79, 1.63]
1.1 certolizumab 50 mg sc 1 47 Risk Ratio (M-H, Random, 95% CI) 0.27 [0.13, 0.57]
1.2 certolizumab 100 mg sc 2 145 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.09, 7.05]
1.3 certolizumab 200 mg sc 6 2456 Risk Ratio (M-H, Random, 95% CI) 1.66 [0.97, 2.85]
1.4 certolizumab 400 mg sc 2 161 Risk Ratio (M-H, Random, 95% CI) 1.40 [0.38, 5.23]
1.5 certolizumab 600 mg sc 1 47 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.51, 0.90]
1.6 certolizumab 800 mg sc 1 46 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.66, 1.04]
2 ACR50 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 certolizumab 50 mg sc 1 47 Risk Ratio (M-H, Random, 95% CI) 1.58 [0.09, 27.88]
2.2 certolizumab 100 mg sc 1 48 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.06, 20.96]
2.3 certolizumab 200 mg sc 4 2118 Risk Ratio (M-H, Random, 95% CI) 1.89 [1.06, 3.37]
2.4 certolizumab 400 mg sc 1 50 Risk Ratio (M-H, Random, 95% CI) 7.33 [0.48, 110.96]
3 ACR70 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 certolizumab 50 mg sc 1 47 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.06, 21.47]
3.2 certolizumab 100 mg sc 1 48 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.03, 14.89]
3.3 certolizumab 200 mg sc 4 2118 Risk Ratio (M-H, Random, 95% CI) 2.78 [1.20, 6.41]
3.4 certolizumab 400 mg sc 1 50 Risk Ratio (M-H, Random, 95% CI) 5.23 [0.34, 80.54]
Comparison 2. ACR50 24 weeks, 200 mg certolizumab pegol




participants Statistical method Effect size
1 ACR 50 5 1445 Risk Ratio (M-H, Random, 95% CI) 3.80 [2.42, 5.95]
Comparison 3. ACR50 at 24 weeks, 400 mg certolizumab




participants Statistical method Effect size
1 ACR 50 5 1591 Risk Ratio (M-H, Random, 95% CI) 4.65 [3.09, 6.99]
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Comparison 4. ACR50 at 52 weeks, 200 mg certolizumab




participants Statistical method Effect size
1 ACR 50 3 1790 Risk Ratio (M-H, Fixed, 95% CI) 1.54 [1.38, 1.73]
Comparison 5. ACR50 at 52 weeks, 400 mg certolizumab




participants Statistical method Effect size
1 ACR 50 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 6. Mean HAQ-DI from baseline at week 12




participants Statistical method Effect size
1 certolizumab pegol 200 mg sc 1 1063 Mean Difference (IV, Fixed, 95% CI) -0.22 [-0.23, -0.21]
Comparison 7. Mean HAQ-DI from baseline at week 24




participants Statistical method Effect size
1 certolizumab pegol 200 mg sc 4 1268 Mean Difference (IV, Random, 95% CI) -0.35 [-0.43, -0.26]
2 certolizumab 400 mg sc 4 1425 Mean Difference (IV, Random, 95% CI) -0.38 [-0.48, -0.28]
Comparison 8. HAQ-DI at 24 weeks, any dose




participants Statistical method Effect size
1 Change from baseline 5 2246 Mean Difference (IV, Random, 95% CI) -0.36 [-0.43, -0.29]
1.1 certolizumab pegol 200
mg sc
3 985 Mean Difference (IV, Random, 95% CI) -0.33 [-0.44, -0.23]
1.2 certolizumab pegol 400
mg sc
4 1261 Mean Difference (IV, Random, 95% CI) -0.38 [-0.48, -0.27]
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Comparison 9. HAQ-DI at 52 weeks, any dose




participants Statistical method Effect size
1 Change from baseline 2 1837 Mean Difference (IV, Fixed, 95% CI) -0.32 [-0.39, -0.26]
1.1 certolizumab pegol 200
mg sc
2 1348 Mean Difference (IV, Fixed, 95% CI) -0.27 [-0.35, -0.20]
1.2 certolizumab pegol 400
mg sc
1 489 Mean Difference (IV, Fixed, 95% CI) -0.45 [-0.57, -0.33]
Comparison 10. SF-36 Physical Component Summary (PCS), week 24




participants Statistical method Effect size
1 certolizumab pegol 200 mg sc 3 1129 Mean Difference (IV, Random, 95% CI) 5.03 [3.90, 6.16]
2 certolizumab pegol 400 mg sc 3 1205 Mean Difference (IV, Random, 95% CI) 5.54 [4.11, 6.97]
Comparison 11. SF-36 Mental Component Summary (MCS), week 24




participants Statistical method Effect size
1 certolizumab pegol 200 mg sc 2 965 Mean Difference (IV, Random, 95% CI) 4.18 [2.70, 5.66]
2 certolizumab pegol 400 mg sc 3 1205 Mean Difference (IV, Random, 95% CI) 4.05 [2.77, 5.34]
Comparison 12. SF-36 Physical Component Summary (PCS), week 52




participants Statistical method Effect size
1 certolizumab 200 mg sc 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 certolizumab 400 mg sc 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
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Comparison 13. SF-36 Mental Component Summary (MCS), week 52




participants Statistical method Effect size
1 certolizumab pegol 200 mg sc 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 certolizumab pegol 400 mg sc 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 14. SF-36 Physical Component Summary (PCS) at week 24, any dose




participants Statistical method Effect size
1 Change from baseline 3 1765 Mean Difference (IV, Random, 95% CI) 5.29 [4.37, 6.21]
1.1 certolizumab pegol 200
mg sc
3 967 Mean Difference (IV, Random, 95% CI) 4.99 [3.79, 6.20]
1.2 certolizumab pegol 400
mg sc
2 798 Mean Difference (IV, Random, 95% CI) 5.62 [3.70, 7.54]
Comparison 15. SF-36 Mental Component Summary (MCS) at week 24, any dose




participants Statistical method Effect size
1 Change from baseline 4 2012 Mean Difference (IV, Random, 95% CI) 4.01 [2.94, 5.08]
1.1 certolizumab pegol 200
mg sc
3 971 Mean Difference (IV, Random, 95% CI) 4.11 [2.62, 5.61]
1.2 certolizumab pegol 400
mg sc
3 1041 Mean Difference (IV, Random, 95% CI) 3.91 [2.38, 5.44]
Comparison 16. SF-36 Physical Component Summary (PCS) at week 52, any dose




participants Statistical method Effect size
1 Change from baseline 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 certolizumab pegol 200
mg sc
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 certolizumab pegol 400
mg sc
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 17. SF-36 Mental Component Summary (MCS) at week 52, any dose




participants Statistical method Effect size
1 Change from baseline 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 certolizumab pegol 200
mg sc
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 certolizumab pegol 400
mg sc
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 18. Disease Activity Score (DAS-28) (ESR) remission (< 2.6), any doses, 12 weeks




participants Statistical method Effect size
1 Proportion of participants
achieving remission 12 weeks
certolizumab 200 mg
2 1942 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.94 [1.44, 2.61]
Comparison 19. Disease Activity Score (DAS-28) (ESR) remission (< 2.6), any dose, 24 weeks




participants Statistical method Effect size
1 Proportion of participants
achieving remission 24 weeks
7 3462 Risk Ratio (M-H, Random, 95% CI) 3.27 [1.96, 5.46]
1.1 certolizumab pegol 200
mg sc
6 2420 Risk Ratio (M-H, Random, 95% CI) 2.94 [1.64, 5.28]
1.2 certolizumab pegol 400
mg sc
3 1042 Risk Ratio (M-H, Random, 95% CI) 4.46 [1.95, 10.21]
Comparison 20. Disease Activity Score (DAS-28) (ESR) remission (< 2.6), any dose, 52 weeks




participants Statistical method Effect size
1 Proportion of participants
achieving remission 52 weeks
3 2175 Risk Ratio (M-H, Fixed, 95% CI) 1.85 [1.55, 2.21]
1.1 certolizumab pegol 200
mg sc
3 1689 Risk Ratio (M-H, Fixed, 95% CI) 1.71 [1.43, 2.04]
1.2 certolizumab pegol 400
mg sc
1 486 Risk Ratio (M-H, Fixed, 95% CI) 6.31 [2.03, 19.59]
82Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Comparison 21. Disease Activity Score (DAS-28) (ESR) remission (< 2.6), any time




participants Statistical method Effect size
1 Proportion of participants
achieving remission 12 weeks
certolizumab 200 mg
2 1942 Risk Ratio (M-H, Fixed, 95% CI) 1.99 [1.44, 2.76]
2 Proportion of participants
achieving remission 24 weeks
certolizumab 200 mg
6 2579 Risk Ratio (M-H, Random, 95% CI) 3.79 [1.90, 7.56]
3 Proportion of participants
achieving remission 24 weeks
certolizumab 400 mg
3 1201 Risk Ratio (M-H, Random, 95% CI) 7.18 [3.12, 16.50]
4 Proportion of participants
achieving remission 52 weeks
certolizumab 200 mg
3 1785 Risk Ratio (M-H, Fixed, 95% CI) 1.83 [1.53, 2.18]
5 Proportion of participants
achieving remission 52 weeks
certolizumab 400 mg
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 22. DAS-28 at 12 weeks, 200 mg certolizumab




participants Statistical method Effect size
1 DAS 28 (ESR) change from
baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 23. DAS-28 at 24 weeks, 400 mg certolizumab




participants Statistical method Effect size
1 DAS 28 (ESR) change from
baseline
2 593 Mean Difference (IV, Random, 95% CI) -1.46 [-2.49, -0.42]
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Comparison 24. DAS-28 at week 52, certolizumab 200 mg




participants Statistical method Effect size
1 DAS 28 (ESR) Change from
baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 25. DAS-28 at week 52, certolizumab 400 mg




participants Statistical method Effect size
1 DAS 28 (ESR) Change from
baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 26. DAS-28 at 24 weeks, any dose




participants Statistical method Effect size
1 Change from baseline 2 839 Mean Difference (IV, Random, 95% CI) -1.59 [-2.10, -1.08]
1.1 certolizumab pegol 200
mg sc
1 310 Mean Difference (IV, Random, 95% CI) -1.77 [-2.08, -1.46]
1.2 certolizumab pegol 400
mg sc
2 529 Mean Difference (IV, Random, 95% CI) -1.45 [-2.49, -0.41]
Comparison 27. DAS-28 at 52 weeks, any dose




participants Statistical method Effect size
1 Change from baseline 2 1838 Mean Difference (IV, Fixed, 95% CI) -0.78 [-0.93, -0.63]
1.1 certolizumab pegol 200
mg sc
2 1349 Mean Difference (IV, Fixed, 95% CI) -0.71 [-0.88, -0.53]
1.2 certolizumab pegol 400
mg sc
1 489 Mean Difference (IV, Fixed, 95% CI) -1.0 [-1.29, -0.71]
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Comparison 28. DAS-28 at 24 weeks, 200 mg certolizumab




participants Statistical method Effect size
1 DAS 28 (ESR) change from
baseline
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 29. Erosion score (ES)




participants Statistical method Effect size
1 Change from the baseline mean
ES at week 24, certolizumab
pegol 200 mg
2 859 Std. Mean Difference (IV, Fixed, 95% CI) -0.35 [-0.50, -0.21]
2 Change from the baseline mean
ES at week 24, certolizumab
pegol 400 mg
2 869 Mean Difference (IV, Random, 95% CI) -0.76 [-1.14, -0.37]
3 Change from the baseline mean
ES at week 52, certolizumab
pegol 200 mg
2 1235 Mean Difference (IV, Fixed, 95% CI) -1.14 [-1.54, -0.74]
4 Change from the baseline mean
ES at week 52, certolizumab
pegol 400 mg
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 30. Erosion score (ES) at 24 weeks, any dose




participants Statistical method Effect size
1 Change from baseline 2 1437 Mean Difference (IV, Random, 95% CI) -0.70 [-0.98, -0.42]
1.1 certolizumab pegol 200
mg sc
2 714 Mean Difference (IV, Random, 95% CI) -0.67 [-1.06, -0.28]
1.2 certolizumab pegol 400
mg sc
2 723 Mean Difference (IV, Random, 95% CI) -0.73 [-1.14, -0.32]
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Comparison 31. Erosion score (ES) at 52 weeks, any dose




participants Statistical method Effect size
1 Change from baseline 2 1599 Mean Difference (IV, Fixed, 95% CI) -1.16 [-1.56, -0.77]
1.1 certolizumab pegol 200
mg sc
2 1146 Mean Difference (IV, Fixed, 95% CI) -1.09 [-1.52, -0.65]
1.2 certolizumab pegol 400
mg sc
1 453 Mean Difference (IV, Fixed, 95% CI) -1.5 [-2.44, -0.56]
Comparison 32. Joint space narrowing (JSN)




participants Statistical method Effect size
1 Change from the baseline mean
JSN 24 weeks, certolizumab
pegol 200 mg
2 861 Mean Difference (IV, Random, 95% CI) -0.45 [-0.77, -0.13]
2 Change from the baseline mean
JSN 24 weeks,certolizumab
pegol 400 mg
2 869 Mean Difference (IV, Random, 95% CI) -0.55 [-0.86, -0.24]
3 Change from the baseline mean
JSN 52 weeks,certolizumab
pegol 200 mg
2 1239 Mean Difference (IV, Fixed, 95% CI) -0.67 [-1.02, -0.32]
4 Change from the baseline mean
JSN 52 weeks, certolizumab
pegol 400 mg
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 33. Joint space narrowing (JSN) at 24 weeks, any dose




participants Statistical method Effect size
1 Change from baseline 2 1439 Mean Difference (IV, Random, 95% CI) -0.50 [-0.79, -0.21]
1.1 certolizumab pegol 200
mg sc
2 716 Mean Difference (IV, Random, 95% CI) -0.46 [-0.87, -0.04]
1.2 certolizumab pegol 400
mg sc
2 723 Mean Difference (IV, Random, 95% CI) -0.54 [-0.96, -0.13]
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Comparison 34. Joint space narrowing (JSN) at 52 weeks, any dose




participants Statistical method Effect size
1 Change from baseline 2 1602 Mean Difference (IV, Fixed, 95% CI) -0.70 [-1.04, -0.36]
1.1 certolizumab pegol 200
mg sc
2 1149 Mean Difference (IV, Fixed, 95% CI) -0.64 [-1.00, -0.28]
1.2 certolizumab pegol 400
mg sc
1 453 Mean Difference (IV, Fixed, 95% CI) -1.2 [-2.27, -0.13]
Comparison 35. Modified Total Sharp Scores (mTSS) at 24 weeks, any dose




participants Statistical method Effect size
1 Change from baseline 3 1753 Mean Difference (IV, Random, 95% CI) -0.86 [-1.19, -0.53]
1.1 certolizumab pegol 200
mg sc
3 1029 Mean Difference (IV, Random, 95% CI) -0.74 [-1.11, -0.37]
1.2 certolizumab pegol 400
mg sc
2 724 Mean Difference (IV, Random, 95% CI) -1.30 [-1.99, -0.60]
Comparison 36. Modified Total Sharp Scores (mTSS) at 52 weeks, any dose




participants Statistical method Effect size
1 Change from baseline 3 1915 Mean Difference (IV, Fixed, 95% CI) -1.63 [-2.13, -1.13]
1.1 certolizumab pegol 200
mg sc
3 1462 Mean Difference (IV, Fixed, 95% CI) -1.54 [-2.06, -1.01]
1.2 certolizumab pegol 400
mg sc
1 453 Mean Difference (IV, Fixed, 95% CI) -2.60 [-4.29, -0.91]
Comparison 37. Modified total Sharp scores (mTSS)




participants Statistical method Effect size
1 Change from the baseline mean
mTSS 24 weeks, certolizumab
pegol 200 mg
2 859 Mean Difference (IV, Random, 95% CI) -1.06 [-1.58, -0.55]
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2 Change from the baseline mean
mTSS 24 weeks, certolizumab
400 mg
2 869 Mean Difference (IV, Random, 95% CI) -1.32 [-1.85, -0.78]
3 Change from the baseline mean
mTSS 52 weeks, certolizumab
pegol 200 mg
1 545 Mean Difference (IV, Fixed, 95% CI) -2.4 [-3.68, -1.12]
4 Change from the baseline mean
mTSS 52 weeks, certolizumab
pegol 400 mg
1 544 Mean Difference (IV, Fixed, 95% CI) -2.60 [-3.84, -1.36]
Comparison 38. Certolizumab pegol 1mg/kg/day sc




participants Statistical method Effect size
1 Headache 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
2 Lower respiratory tract infection 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
3 Adverse events Intensity severe 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
4 Antinuclear antibodies (ANA) 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
5 Urinary tract infection 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
Comparison 39. Certolizumab 5 mg/kg/day sc




participants Statistical method Effect size
1 Lower respiratory tract infection 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
2 Urinary tract infection 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
Comparison 40. Certolizumab 20 mg/kg/day sc




participants Statistical method Effect size
1 Headache 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Lower respiratory tract infection 1 20 Risk Ratio (M-H, Fixed, 95% CI) 3.00 [0.32, 27.83]
3 Death 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
4 Antinuclear antibodies (ANA) 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
5 Urinary tract infection 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
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Comparison 41. Safety, SAE certolizumab 200 mg




participants Statistical method Effect size
1 Serious Adverse Events (SAE) 9 3927 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.47 [1.13, 1.91]
Comparison 42. Safety, SAE certolizumab 400 mg




participants Statistical method Effect size
1 Serious Adverse Events (SAEs) 6 1624 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.98 [1.36, 2.90]
Comparison 43. Withdrawals




participants Statistical method Effect size
1 All Withdrawn: any doses any
follow-up
13 5200 Risk Ratio (M-H, Random, 95% CI) 0.47 [0.39, 0.56]
2 Withdrawals due to adverse
events
12 5236 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.45 [1.09, 1.94]
Comparison 44. ACR at 24 weeks, any dose




participants Statistical method Effect size
1 ACR20 8 2935 Risk Ratio (M-H, Random, 95% CI) 2.76 [2.29, 3.33]
1.1 certolizumab 100 mg sc 1 98 Risk Ratio (M-H, Random, 95% CI) 2.65 [1.28, 5.47]
1.2 certolizumab 200 mg sc 6 1462 Risk Ratio (M-H, Random, 95% CI) 2.92 [2.17, 3.95]
1.3 certolizumab 400 mg sc 5 1375 Risk Ratio (M-H, Random, 95% CI) 2.65 [1.98, 3.56]
2 ACR50 7 2705 Risk Ratio (M-H, Random, 95% CI) 2.95 [2.37, 3.68]
2.1 certolizumab 100 mg sc 1 98 Risk Ratio (M-H, Random, 95% CI) 2.89 [1.13, 7.38]
2.2 certolizumab 200 mg sc 5 1232 Risk Ratio (M-H, Random, 95% CI) 2.76 [2.02, 3.78]
2.3 certolizumab 400 mg sc 5 1375 Risk Ratio (M-H, Random, 95% CI) 3.18 [2.29, 4.41]
3 ACR70 7 2705 Risk Ratio (M-H, Random, 95% CI) 4.15 [2.68, 6.42]
3.1 certolizumab 100 mg sc 1 98 Risk Ratio (M-H, Random, 95% CI) 6.86 [0.97, 48.72]
3.2 certolizumab 200 mg sc 5 1232 Risk Ratio (M-H, Random, 95% CI) 4.29 [2.36, 7.77]
3.3 certolizumab 400 mg sc 5 1375 Risk Ratio (M-H, Random, 95% CI) 4.04 [1.37, 11.90]
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Comparison 45. ACR at 52 weeks, any dose




participants Statistical method Effect size
1 ACR20 3 2180 Risk Ratio (M-H, Random, 95% CI) 1.46 [1.11, 1.93]
1.1 certolizumab 200 mg sc 3 1691 Risk Ratio (M-H, Random, 95% CI) 1.30 [1.03, 1.65]
1.2 certolizumab 400 mg sc 1 489 Risk Ratio (M-H, Random, 95% CI) 2.08 [1.48, 2.93]
2 ACR50 3 2180 Risk Ratio (M-H, Random, 95% CI) 1.69 [1.22, 2.33]
2.1 certolizumab 200 mg sc 3 1691 Risk Ratio (M-H, Random, 95% CI) 1.48 [1.11, 1.96]
2.2 certolizumab 400 mg sc 1 489 Risk Ratio (M-H, Random, 95% CI) 2.62 [1.62, 4.25]
3 ACR70 3 2180 Risk Ratio (M-H, Random, 95% CI) 1.89 [1.44, 2.48]
3.1 certolizumab 200 mg sc 3 1691 Risk Ratio (M-H, Random, 95% CI) 1.71 [1.39, 2.11]
3.2 certolizumab 400 mg sc 1 489 Risk Ratio (M-H, Random, 95% CI) 3.26 [1.56, 6.82]
Comparison 46. ACR20-ACR70, 24 weeks, 200 mg certolizumab pegol




participants Statistical method Effect size
1 ACR 20 6 1675 Risk Ratio (M-H, Random, 95% CI) 3.71 [2.68, 5.13]
2 ACR 70 5 1445 Risk Ratio (M-H, Random, 95% CI) 7.26 [3.83, 13.76]
Comparison 47. ACR20-ACR70 at 24 weeks, 400 mg certolizumab




participants Statistical method Effect size
1 ACR 20 5 1591 Risk Ratio (M-H, Random, 95% CI) 3.73 [2.43, 5.72]
2 ACR 70 5 1591 Risk Ratio (M-H, Random, 95% CI) 7.20 [2.25, 23.03]
Comparison 48. ACR20-ACR70 at 52 weeks, 200 mg certolizumab




participants Statistical method Effect size
1 ACR 20 3 1790 Risk Ratio (M-H, Fixed, 95% CI) 1.44 [1.30, 1.58]
2 ACR 70 3 1790 Risk Ratio (M-H, Fixed, 95% CI) 1.64 [1.41, 1.90]
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Comparison 49. ACR20-ACR70 at 52 weeks, 400 mg certolizumab




participants Statistical method Effect size
1 ACR 20 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 ACR 70 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 50. Safety




participants Statistical method Effect size
1 Any adverse event certolizumab
200 mg
9 3927 Risk Ratio (M-H, Random, 95% CI) 1.16 [1.03, 1.31]
2 Any adverse events certolizumab
400 mg
6 1624 Risk Ratio (M-H, Random, 95% CI) 1.19 [1.05, 1.34]
3 Adverse events: Intensity mild
certolizumab 200 mg
4 2249 Risk Ratio (M-H, Random, 95% CI) 1.18 [1.00, 1.41]
4 Adverse events: Intensity mild
certolizumab 400 mg
5 1462 Risk Ratio (M-H, Random, 95% CI) 1.25 [1.06, 1.47]
5 Adverse events: Intensity
moderate certolizumab 200 mg
4 2249 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.86, 1.32]
6 Adverse events: Intensity
moderate certolizumab 400 mg
5 1462 Risk Ratio (M-H, Random, 95% CI) 1.21 [0.99, 1.47]
7 Adverse events: Intensity severe
certolizumab 200 mg
4 2249 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.14 [0.78, 1.65]
8 Adverse events: Intensity severe
certolizumab 400 mg
5 1462 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.23 [0.83, 1.81]
9 Adverse events related to study
drug certolizumab 200 mg
2 964 Risk Ratio (M-H, Random, 95% CI) 1.59 [1.27, 1.99]
10 Adverse events related to study
drug certolizumab 400 mg
4 1219 Risk Ratio (M-H, Fixed, 95% CI) 1.47 [1.20, 1.80]
11 Serious Infections certolizumab
200 mg
3 1283 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.94 [0.99, 3.80]
12 Serious infections certolizumab
400 mg
4 1422 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.25 [1.65, 6.39]
13 Adverse events leading to death
certolizumab 200 mg
6 3322 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.63 [0.41, 6.47]
14 Adverse events leading to death
certolizumab 400 mg
3 1179 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.16 [0.40, 11.79]
15 Adverse events leading to
withdrawal certolizumab 200
mg
8 3608 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.32 [0.95, 1.84]
16 Adverse events leading to
withdrawal certolizumab 400
mg
6 1624 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.01 [1.20, 3.36]
17 Death certolizumab 200 mg 6 3320 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.66 [0.63, 11.16]
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18 Death certolizumab 400 mg 5 1462 Risk Ratio (M-H, Fixed, 95% CI) 1.87 [0.31, 11.34]
19 Deaths overall 10 4745 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.63 [0.78, 8.91]
19.1 Certolizumab pegol 200
mg
7 3266 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.10 [0.44, 10.08]
19.2 Certolizumab pegol 400
mg
5 1349 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.53 [0.40, 31.39]
19.3 Other doses 2 130 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.48 [0.07, 286.49]
20 Tuberculosis certolizumab 200
mg
7 3538 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.90 [0.55, 6.58]
21 Tuberculosis certolizumab 400
mg
3 1179 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.55 [0.71, 29.11]
22 Tuberculosis overall 7 4074 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.91 [0.61, 5.96]
22.1 Certolizumab pegol 200
mg
6 3058 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.53 [0.40, 5.77]
22.2 Certolizumab pegol 400
mg








3 1179 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.26 [0.26, 6.08]
25 Injection side reactions
certolizumab 200 mg
5 2497 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.34 [1.85, 6.06]
26 Injection side reactions
certolizumab 400 mg
5 1584 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.34 [0.20, 0.56]








2 591 Peto Odds Ratio (Peto, Fixed, 95% CI) 6.70 [2.18, 20.55]
29 Systemic lupus erythematosus
certolizumab 200 mg
2 567 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.50 [0.07, 286.06]
30 Prolonged activated partial
thromboplastin time (aPTT)
certolizumab 200 mg
2 500 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.73 [0.98, 7.61]
31 Prolonged activated partial
thromboplastin time (aPTT)
certolizumab 400 mg
1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
32 Urinary tract infection
certolizumab 200 mg
6 3219 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.98 [0.68, 1.40]
33 Urinary tract infection
certolizumab 400 mg
2 959 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.87 [0.50, 1.52]
34 Upper respiratory tract
infection certolizumab 200 mg
8 3608 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.68 [1.28, 2.20]
35 Upper respiratory tract
infection certolizumab 400 mg
4 1364 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.42 [0.77, 2.61]
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36 Lower respiratory tract
infection/ lung infection
certolizumab 200 mg
6 2356 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.12 [0.76, 5.95]
37 Lower respiratory tract
infection/ lung infection
certolizumab 400 mg
3 993 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.11 [0.75, 5.95]
38 Pneumonia certolizumab 200
mg
6 2804 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.94 [0.45, 1.97]
39 Pneumonitis certolizumab 400
mg
1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
40 Headache certolizumab 200
mg
6 3251 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.33 [0.94, 1.87]
41 Headache certolizumab 400
mg
4 1364 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.30 [0.76, 2.20]
42 Bacteriuria certolizumab 200
mg
1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
43 Bacteriuria certolizumab 400
mg
1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
44 Nasopharyngitis/Pharyngitis
certolizumab 200 mg
7 2553 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.37 [1.01, 1.84]
45 Nasopharyngitis/Pharyngitis
certolizumab 400 mg
4 1364 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.98 [1.26, 3.11]
46 Injection site pain certolizumab
200 mg
3 1091 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.85 [0.49, 6.92]
47 Injection site pain certolizumab
400 mg
3 1179 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.74 [0.41, 7.42]
48 Hypertension certolizumab
200 mg
4 1353 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.09 [1.64, 5.84]
49 Hypertension certolizumab
400 mg
3 1121 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.35 [1.80, 6.20]
50 Hematuria certolizumab 200
mg
1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
51 Haematuria certolizumab 400
mg
1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
52 Hepatic enzyme increased
certolizumab 200 mg
3 851 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.84 [0.56, 1.27]
53 Hepatic enzyme increased
certolizumab 400 mg
2 533 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.69 [0.25, 1.92]
54 AST increased certolizumab
200 mg
1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
55 AST increased certolizumab
400 mg
1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
56 ALT increased certolizumab
200 mg
2 1252 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.85 [0.48, 1.50]
57 ALT increased certolizumab
400 mg
1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
58 Diarrhoea certolizumab 200
mg
3 1200 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.71 [0.25, 2.03]
59 Gastroenteritis certolizumab
200 mg
2 785 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.97 [0.33, 2.87]
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60 Gastrointestinal disorders
certolizumab 400 mg
2 831 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.05 [0.54, 2.03]
61 Back pain certolizumab 200 mg 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
62 Back pain certolizumab 400 mg 2 831 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.11 [1.48, 6.55]
63 Hematologic abnormalities
certolizumab 200 mg
2 821 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.02 [0.27, 15.21]
64 Haematologic abnormalities
certolizumab 400 mg
2 750 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.13 [0.21, 6.07]
65 Herpes viral infection
certolizumab 200 mg
2 821 Peto Odds Ratio (Peto, Fixed, 95% CI) 5.80 [0.34, 100.23]
66 Herpes viral infection
certolizumab 400 mg
1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
67 Bacterial peritonitis
certolizumab 200 mg
1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
68 Bacterial peritonitis
certolizumab 400 mg
1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
69 Opportunistic infections
certolizumab 200 mg
4 2070 Peto Odds Ratio (Peto, Fixed, 95% CI) 7.33 [0.46, 117.85]
70 Opportunistic infections
certolizumab 400 mg
1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
71 Infections and infestations
certolizumab 200 mg
9 3910 Risk Ratio (M-H, Random, 95% CI) 1.27 [1.10, 1.46]
72 Infections and infestations
certolizumab 400 mg
5 1404 Risk Ratio (M-H, Random, 95% CI) 1.43 [1.03, 1.98]
73 Decreased haemoglobin
certolizumab 200 mg
1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
74 Decreased haemoglobin
certolizumab 400 mg
1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
75 Increased platelet count
certolizumab 200 mg
1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
76 Increased platelet count
certolizumab 400 mg




2 321 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.27 [0.12, 13.50]
78 Ischaemic stroke certolizumab
400 mg
1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
79 Nausea/vomiting certolizumab
200 mg
4 2447 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.13 [0.84, 1.54]
80 Vomiting certolizumab 400 mg 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
81 Acute miocardial infarction
certolizumab 200 mg
2 1073 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.79 [0.04, 351.89]
82 Acute myocardial infarction
certolizumab 400 mg




1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
84 Constipation certolizumab 200
mg
1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
85 Skin and subcutaneous tissue
disorders certolizumab 200 mg
4 1395 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.83 [1.46, 5.48]
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86 Skin and subcutaneous tissue
disorders certolizumab 400 mg
1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
87 Cough certolizumab 200 mg 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
88 Pruritus certolizumab 200 mg 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
89 Fatigue certolizumab 200 mg 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
90 Fatigue certolizumab 400 mg 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
91 Periodontitis certolizumab 200
mg
1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
92 Arthritis bacterial certolizumab
400 mg
1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
93 Mastitis certolizumab 400 mg 1 220 Peto Odds Ratio (Peto, Fixed, 95% CI) 7.26 [0.14, 365.79]
94 Benign tumour certolizumab
400 mg
1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
95 Dizziness postural certolizumab
400 mg
1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
96 Menorrhagia certolizumab 400
mg
1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
97 Corneal perforation
certolizumab 400 mg
1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
98 Conjunctivitis allergic
certolizumab 400 mg
1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
99 Periodontitis certolizumab 400
mg
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 51. Participant’s assessment of arthritis pain (VAS score 0 to 100 mm)




participants Statistical method Effect size
1 Mean change at 24 weeks
certolizumab pegol 200 mg
2 965 Mean Difference (IV, Random, 95% CI) -20.49 [-23.43, -17.
55]
2 Mean change at 24 weeks
certolizumab pegol 400 mg
3 1182 Mean Difference (IV, Random, 95% CI) -22.69 [-25.53, -19.
84]
3 Mean change at 52 weeks
certolizumab pegol 200 mg
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4 Mean change at 52 weeks
certolizumab pegol 400 mg
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
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Comparison 52. Participant’s assessment of arthritis pain (VAS score 0 to 100 mm) at 24 weeks, any dose




participants Statistical method Effect size
1 Change from baseline 4 2064 Mean Difference (IV, Random, 95% CI) -21.07 [-23.59, -18.
55]
1.1 certolizumab pegol 200
mg sc
2 803 Mean Difference (IV, Random, 95% CI) -20.48 [-24.26, -16.
69]
1.2 certolizumab pegol 400
mg sc
4 1261 Mean Difference (IV, Random, 95% CI) -21.35 [-25.08, -17.
61]
Comparison 53. Participant’s assessment of arthritis pain (VAS score 0 to 100 mm) at 52 weeks, any dose




participants Statistical method Effect size
1 Change from baseline 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 certolizumab pegol 200
mg sc
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 certolizumab pegol 400
mg sc
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 54. Withdrawals Withdrawn due to lack of efficacy: any doses any follow-up




participants Statistical method Effect size
1 Withdrawn due to lack of
efficacy: any doses any
follow-up
8 3433 Risk Ratio (M-H, Random, 95% CI) 0.31 [0.26, 0.37]
Comparison 55. Summary of findings: certolizumab (with or without MTX) versus placebo (with or without
MTX)




participants Statistical method Effect size
1 ACR 50 200 mg certolizumab
24 weeks
5 1445 Risk Ratio (M-H, Random, 95% CI) 3.80 [2.42, 5.95]
2 HAQ change from baseline 200
mg certolizumab 24 weeks
4 1268 Mean Difference (IV, Random, 95% CI) -0.35 [-0.43, -0.26]
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3 Serious adverse events
certolizumab 200 mg sc
9 3927 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.47 [1.13, 1.91]
4 Proportion of participants
achieving remission 24 weeks
certolizumab 200 mg
4 1381 Risk Ratio (M-H, Random, 95% CI) 8.47 [4.15, 17.28]
5 Radiological changes: Erosion
Scores (ES) certolizumab 200
mg sc
2 859 Mean Difference (IV, Random, 95% CI) -0.67 [-0.96, -0.38]
5.1 certolizumab 200 mg sc
24 weeks
2 859 Mean Difference (IV, Random, 95% CI) -0.67 [-0.96, -0.38]
6 All Withdrawals: 10 3962 Risk Ratio (M-H, Random, 95% CI) 0.42 [0.36, 0.50]
7 Withdrawals due to adverse
events
9 3998 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.66 [1.15, 2.37]
8 Deaths 10 4745 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.63 [0.78, 8.91]
8.1 Certolizumab pegol 200
mg
7 3266 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.10 [0.44, 10.08]
8.2 Certolizumab pegol 400
mg
5 1349 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.53 [0.40, 31.39]
8.3 Other doses 2 130 Peto Odds Ratio (Peto, Fixed, 95% CI) 4.48 [0.07, 286.49]
9 Tuberculosis 7 4074 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.91 [0.61, 5.96]
9.1 Certolizumab pegol 200
mg
6 3058 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.53 [0.40, 5.77]
9.2 Certolizumab pegol 400
mg
3 1016 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.52 [0.40, 31.33]
10 Upper respiratory tract
infections
8 3692 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.17 [0.86, 1.59]
10.1 Certolizumab pegol 200
mg
7 2528 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.28 [0.91, 1.80]
10.2 Certolizumab pegol 400
mg
4 1164 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.81 [0.41, 1.61]
11 Lower respiratory tract
infections
7 3073 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.66 [0.77, 3.58]
11.1 Certolizumab pegol 200
mg
6 2218 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.81 [0.62, 5.26]
11.2 Certolizumab pegol 400
mg
3 855 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.52 [0.50, 4.59]
12 Malignancies including
lymphoma
7 3749 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.90 [0.39, 2.08]
12.1 Certolizumab pegol 200
mg
6 2570 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.79 [0.29, 2.12]
12.2 Certolizumab pegol 400
mg
3 1179 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.26 [0.26, 6.08]
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Comparison 56. Analysis of sensitivity ACR50 24 weeks




participants Statistical method Effect size
1 Doses 8 3768 Risk Ratio (M-H, Random, 95% CI) 2.89 [2.38, 3.51]
1.1 certolizumab 100 mg sc 1 98 Risk Ratio (M-H, Random, 95% CI) 2.89 [1.13, 7.38]
1.2 certolizumab 200 mg sc 6 2295 Risk Ratio (M-H, Random, 95% CI) 2.73 [2.13, 3.51]
1.3 certolizumab 400 mg sc 5 1375 Risk Ratio (M-H, Random, 95% CI) 3.18 [2.29, 4.41]
2 Size 8 3768 Risk Ratio (M-H, Random, 95% CI) 2.89 [2.38, 3.51]
2.1 certolizumab < 200
patients
2 321 Risk Ratio (M-H, Random, 95% CI) 2.44 [1.45, 4.10]
2.2 certolizumab > 200
patients
6 3447 Risk Ratio (M-H, Random, 95% CI) 2.97 [2.41, 3.67]
3 Use of MTX 8 3768 Risk Ratio (M-H, Random, 95% CI) 2.89 [2.38, 3.51]
3.1 With MTX 5 3038 Risk Ratio (M-H, Random, 95% CI) 2.77 [2.21, 3.46]
3.2 Without MTX 3 730 Risk Ratio (M-H, Random, 95% CI) 3.32 [2.23, 4.95]
4 Population 8 3768 Risk Ratio (M-H, Random, 95% CI) 2.89 [2.38, 3.51]
4.1 Asian trials 2 443 Risk Ratio (M-H, Random, 95% CI) 2.66 [1.77, 4.00]
4.2 Other trials 6 3325 Risk Ratio (M-H, Random, 95% CI) 2.96 [2.37, 3.70]
5 Duration of previous disease 6 3258 Risk Ratio (M-H, Random, 95% CI) 2.87 [2.31, 3.57]
5.1 Long previous disease
duration (9 years or more)
2 467 Risk Ratio (M-H, Random, 95% CI) 4.02 [2.02, 7.98]
5.2 Short previous disease
duration (less than 7 years)
4 2791 Risk Ratio (M-H, Random, 95% CI) 2.75 [2.18, 3.47]
6 Published vs unpublished studies 8 3768 Risk Ratio (M-H, Random, 95% CI) 2.89 [2.38, 3.51]
6.1 Published studies 5 3131 Risk Ratio (M-H, Random, 95% CI) 2.97 [2.36, 3.73]
6.2 Unpublished studies 3 637 Risk Ratio (M-H, Random, 95% CI) 2.71 [1.89, 3.90]
7 Imputing to ACR50 200 mg
from 24 missing values with
same proportion as reported
outcomes
5 1445 Risk Ratio (M-H, Fixed, 95% CI) 3.34 [2.68, 4.17]
7.1 Imputing missing values
with same proportion as
reported outcomes
5 1445 Risk Ratio (M-H, Fixed, 95% CI) 3.34 [2.68, 4.17]
8 Imputing to ACR50 200 mg
from 24 weeks 50 % of missing
outcomes
5 1445 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [1.04, 1.32]
8.1 Imputing the 50 % of
missing outcomes
5 1445 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [1.04, 1.32]
9 Imputing to ACR50 200 mg
from 24 weeks: the worst case
5 1445 Risk Ratio (M-H, Fixed, 95% CI) 0.47 [0.43, 0.52]
9.1 Analysis in the worst case.
All missing values did not reach
ACR50 in certolizumab group
and did in placebo group
5 1445 Risk Ratio (M-H, Fixed, 95% CI) 0.47 [0.43, 0.52]
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Comparison 57. Analysis of sensitivity ACR50 52 weeks




participants Statistical method Effect size
1 Doses 3 2180 Risk Ratio (M-H, Random, 95% CI) 1.69 [1.22, 2.33]
1.1 certolizumab 200 mg sc 3 1691 Risk Ratio (M-H, Random, 95% CI) 1.48 [1.11, 1.96]
1.2 certolizumab 400 mg sc 1 489 Risk Ratio (M-H, Random, 95% CI) 2.62 [1.62, 4.25]
2 Size 3 2180 Risk Ratio (M-H, Random, 95% CI) 1.69 [1.22, 2.33]
2.1 certolizumab <200
patients
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 certolizumab >200
patients
3 2180 Risk Ratio (M-H, Random, 95% CI) 1.69 [1.22, 2.33]
3 Use of MTX 3 2180 Risk Ratio (M-H, Random, 95% CI) 1.69 [1.22, 2.33]
3.1 Use of MTX 3 2180 Risk Ratio (M-H, Random, 95% CI) 1.69 [1.22, 2.33]
3.2 Without MTX 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Population 3 2180 Risk Ratio (M-H, Random, 95% CI) 1.69 [1.22, 2.33]
4.1 Asian trials 1 319 Risk Ratio (M-H, Random, 95% CI) 1.41 [1.17, 1.68]
4.2 Other trials 2 1861 Risk Ratio (M-H, Random, 95% CI) 1.94 [1.01, 3.72]
5 Duration of previous disease 3 2180 Risk Ratio (M-H, Random, 95% CI) 1.69 [1.22, 2.33]
5.1 Long previous disease
duration (6 years or more)
1 982 Risk Ratio (M-H, Random, 95% CI) 2.58 [1.83, 3.62]
5.2 Short previous disease
duration (less than 1 year)
2 1198 Risk Ratio (M-H, Random, 95% CI) 1.29 [1.10, 1.50]
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Analysis 1.1. Comparison 1 Efficacy at 12 weeks, any dose, Outcome 1 ACR20.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 1 Efficacy at 12 weeks, any dose
Outcome: 1 ACR20








1 certolizumab 50 mg sc
CDP870-004 2001 8/39 6/8 6.6 % 0.27 [ 0.13, 0.57 ]
Subtotal (95% CI) 39 8 6.6 % 0.27 [ 0.13, 0.57 ]
Total events: 8 (Certolizumab pegol), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.45 (P = 0.00056)
2 certolizumab 100 mg sc
CDP870-004 2001 8/40 6/8 6.6 % 0.27 [ 0.13, 0.56 ]
Yamamoto (b) 2014 (1) 45/72 7/25 7.0 % 2.23 [ 1.16, 4.29 ]
Subtotal (95% CI) 112 33 13.5 % 0.78 [ 0.09, 7.05 ]
Total events: 53 (Certolizumab pegol), 13 (Control)
Heterogeneity: Tau2 = 2.41; Chi2 = 20.04, df = 1 (P<0.00001); I2 =95%
Test for overall effect: Z = 0.22 (P = 0.82)
3 certolizumab 200 mg sc
CDP870-004 2001 14/41 6/8 7.3 % 0.46 [ 0.25, 0.82 ]
Emery 2015 (2) 480/660 148/219 8.9 % 1.08 [ 0.97, 1.19 ]
NCT00993317 52/85 15/42 7.9 % 1.71 [ 1.10, 2.66 ]
Weinblatt 2012 435/851 55/212 8.6 % 1.97 [ 1.55, 2.50 ]
Yamamoto (a) 2014 78/116 17/114 7.9 % 4.51 [ 2.86, 7.12 ]
Yamamoto (b) 2014 63/82 7/26 7.0 % 2.85 [ 1.50, 5.44 ]
Subtotal (95% CI) 1835 621 47.7 % 1.66 [ 0.97, 2.85 ]
Total events: 1122 (Certolizumab pegol), 248 (Control)
Heterogeneity: Tau2 = 0.40; Chi2 = 89.85, df = 5 (P<0.00001); I2 =94%
Test for overall effect: Z = 1.85 (P = 0.064)
4 certolizumab 400 mg sc
CDP870-004 2001 25/42 6/8 7.8 % 0.79 [ 0.50, 1.27 ]
Yamamoto (b) 2014 66/85 8/26 7.3 % 2.52 [ 1.40, 4.54 ]
Subtotal (95% CI) 127 34 15.1 % 1.40 [ 0.38, 5.23 ]
Total events: 91 (Certolizumab pegol), 14 (Control)
Heterogeneity: Tau2 = 0.83; Chi2 = 12.22, df = 1 (P = 0.00047); I2 =92%
Test for overall effect: Z = 0.50 (P = 0.62)
0.05 0.2 1 5 20
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(Continued . . . )
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5 certolizumab 600 mg sc
CDP870-004 2001 (3) 25/39 8/8 8.5 % 0.68 [ 0.51, 0.90 ]
Subtotal (95% CI) 39 8 8.5 % 0.68 [ 0.51, 0.90 ]
Total events: 25 (Certolizumab pegol), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.73 (P = 0.0064)
6 certolizumab 800 mg sc
CDP870-004 2001 (4) 30/38 8/8 8.7 % 0.83 [ 0.66, 1.04 ]
Subtotal (95% CI) 38 8 8.7 % 0.83 [ 0.66, 1.04 ]
Total events: 30 (Certolizumab pegol), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.61 (P = 0.11)
Total (95% CI) 2190 712 100.0 % 1.13 [ 0.79, 1.63 ]
Total events: 1329 (Certolizumab pegol), 297 (Control)
Heterogeneity: Tau2 = 0.39; Chi2 = 183.28, df = 12 (P<0.00001); I2 =93%
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Chi2 = 17.38, df = 5 (P = 0.00), I2 =71%
0.05 0.2 1 5 20
Favours control Favours certolizumab pego
(1) We need to split the results in placebo 22 of 77 patients by 3
(2) Calculations of events were done according to the percentages of FAS (Full Analysis Set) 213 patients in placebo group and 655 in CZP group. We did AIT and
denominators were 219 and 660 in placebo and CZP group, respectively).
(3) From EMEA report, only data for ACR20
(4) From EMEA report, only data for ACR20
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Analysis 1.2. Comparison 1 Efficacy at 12 weeks, any dose, Outcome 2 ACR50.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 1 Efficacy at 12 weeks, any dose
Outcome: 2 ACR50








1 certolizumab 50 mg sc
CDP870-004 2001 3/39 0/8 100.0 % 1.58 [ 0.09, 27.88 ]
Subtotal (95% CI) 39 8 100.0 % 1.58 [ 0.09, 27.88 ]
Total events: 3 (Certolizumab pegol), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
2 certolizumab 100 mg sc
CDP870-004 2001 2/40 0/8 100.0 % 1.10 [ 0.06, 20.96 ]
Subtotal (95% CI) 40 8 100.0 % 1.10 [ 0.06, 20.96 ]
Total events: 2 (Certolizumab pegol), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
3 certolizumab 200 mg sc
CDP870-004 2001 7/41 0/8 3.9 % 3.21 [ 0.20, 51.33 ]
Emery 2015 (1) 334/660 87/219 40.7 % 1.27 [ 1.06, 1.52 ]
NCT00993317 21/85 5/42 20.8 % 2.08 [ 0.84, 5.12 ]
Weinblatt 2012 226/851 21/212 34.6 % 2.68 [ 1.76, 4.08 ]
Subtotal (95% CI) 1637 481 100.0 % 1.89 [ 1.06, 3.37 ]
Total events: 588 (Certolizumab pegol), 113 (Control)
Heterogeneity: Tau2 = 0.21; Chi2 = 12.34, df = 3 (P = 0.01); I2 =76%
Test for overall effect: Z = 2.16 (P = 0.031)
4 certolizumab 400 mg sc
CDP870-004 2001 17/42 0/8 100.0 % 7.33 [ 0.48, 110.96 ]
Subtotal (95% CI) 42 8 100.0 % 7.33 [ 0.48, 110.96 ]
Total events: 17 (Certolizumab pegol), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.44 (P = 0.15)
Test for subgroup differences: Chi2 = 1.09, df = 3 (P = 0.78), I2 =0.0%
0.01 0.1 1 10 100
Favours control Favours certolizumab pego
(1) Calculations of events were done according to the percentages of FAS (Full Analysis Set) 213 patients in placebo group and 655 in CZP group. We did AIT and
denominators were 219 and 660 in placebo and CZP group, respectively).
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Analysis 1.3. Comparison 1 Efficacy at 12 weeks, any dose, Outcome 3 ACR70.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 1 Efficacy at 12 weeks, any dose
Outcome: 3 ACR70








1 certolizumab 50 mg sc
CDP870-004 2001 2/39 0/8 100.0 % 1.13 [ 0.06, 21.47 ]
Subtotal (95% CI) 39 8 100.0 % 1.13 [ 0.06, 21.47 ]
Total events: 2 (Certolizumab pegol), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
2 certolizumab 100 mg sc
CDP870-004 2001 1/40 0/8 100.0 % 0.66 [ 0.03, 14.89 ]
Subtotal (95% CI) 40 8 100.0 % 0.66 [ 0.03, 14.89 ]
Total events: 1 (Certolizumab pegol), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.79)
3 certolizumab 200 mg sc
CDP870-004 2001 3/41 0/8 7.3 % 1.50 [ 0.08, 26.57 ]
Emery 2015 (1) 217/660 42/219 49.7 % 1.71 [ 1.28, 2.30 ]
NCT00993317 11/85 0/42 7.6 % 11.50 [ 0.69, 190.57 ]
Weinblatt 2012 110/851 6/212 35.4 % 4.57 [ 2.04, 10.24 ]
Subtotal (95% CI) 1637 481 100.0 % 2.78 [ 1.20, 6.41 ]
Total events: 341 (Certolizumab pegol), 48 (Control)
Heterogeneity: Tau2 = 0.34; Chi2 = 7.16, df = 3 (P = 0.07); I2 =58%
Test for overall effect: Z = 2.39 (P = 0.017)
4 certolizumab 400 mg sc
CDP870-004 2001 12/42 0/8 100.0 % 5.23 [ 0.34, 80.54 ]
Subtotal (95% CI) 42 8 100.0 % 5.23 [ 0.34, 80.54 ]
Total events: 12 (Certolizumab pegol), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.24)
Test for subgroup differences: Chi2 = 1.32, df = 3 (P = 0.72), I2 =0.0%
0.01 0.1 1 10 100
Favours control Favours certolizumab pego
(1) Calculations of events were done according to the percentages of FAS (Full Analysis Set) 213 patients in placebo group and 655 in CZP group. We did AIT and
denominators were 219 and 660 in placebo and CZP group, respectively).
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Analysis 2.1. Comparison 2 ACR50 24 weeks, 200 mg certolizumab pegol, Outcome 1 ACR 50.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 2 ACR50 24 weeks, 200 mg certolizumab pegol
Outcome: 1 ACR 50
Study or subgroup
Certolizumab








Keystone 2008 144/393 15/199 25.3 % 4.86 [ 2.94, 8.04 ]
NCT00993317 35/85 8/42 20.2 % 2.16 [ 1.10, 4.24 ]
Smolen 2009 80/246 4/127 13.4 % 10.33 [ 3.87, 27.54 ]
Smolen 2015 20/96 7/98 16.7 % 2.92 [ 1.29, 6.58 ]
Yamamoto (b) 2014 45/82 13/77 24.4 % 3.25 [ 1.91, 5.54 ]
Total (95% CI) 902 543 100.0 % 3.80 [ 2.42, 5.95 ]
Total events: 324 (Certolizumab pegol 200 mg), 47 (Placebo)
Heterogeneity: Tau2 = 0.14; Chi2 = 9.05, df = 4 (P = 0.06); I2 =56%
Test for overall effect: Z = 5.82 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control Favours certolizumab pego
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Analysis 3.1. Comparison 3 ACR50 at 24 weeks, 400 mg certolizumab, Outcome 1 ACR 50.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 3 ACR50 at 24 weeks, 400 mg certolizumab
Outcome: 1 ACR 50








Choy 2012 (1) 22/126 7/121 17.1 % 3.02 [ 1.34, 6.81 ]
Fleischmann 2009 25/111 4/109 12.3 % 6.14 [ 2.21, 17.05 ]
Keystone 2008 155/390 15/199 29.5 % 5.27 [ 3.19, 8.71 ]
Smolen 2009 81/246 4/127 13.1 % 10.45 [ 3.92, 27.88 ]
Yamamoto (b) 2014 46/85 13/77 27.9 % 3.21 [ 1.88, 5.46 ]
Total (95% CI) 958 633 100.0 % 4.65 [ 3.09, 6.99 ]
Total events: 329 (Certolizumab pegol), 43 (Control)
Heterogeneity: Tau2 = 0.08; Chi2 = 6.53, df = 4 (P = 0.16); I2 =39%
Test for overall effect: Z = 7.37 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control Favours certolizumab pego
(1) EMEA report quotes 126 and 121 patients in certoluzimab and placebo group. Clinical Study Summary (CSS) from UCB quotes n=125 for both groups for effectiveness
and 119 and 124 for certolizumab and placebo groups for safety.
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Analysis 4.1. Comparison 4 ACR50 at 52 weeks, 200 mg certolizumab, Outcome 1 ACR 50.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 4 ACR50 at 52 weeks, 200 mg certolizumab
Outcome: 1 ACR 50
Study or subgroup Certolizumab pegol Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Atsumi 2016 116/161 81/158 30.3 % 1.41 [ 1.17, 1.68 ]
Emery 2015 (1) 405/660 112/219 62.3 % 1.20 [ 1.04, 1.38 ]
Keystone 2008 149/393 15/199 7.4 % 5.03 [ 3.04, 8.32 ]
Total (95% CI) 1214 576 100.0 % 1.54 [ 1.38, 1.73 ]
Total events: 670 (Certolizumab pegol), 208 (Control)
Heterogeneity: Chi2 = 34.25, df = 2 (P<0.00001); I2 =94%
Test for overall effect: Z = 7.38 (P < 0.00001)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours control Favours certolizumab pego
(1) Calculations of events were done according to the percentages of FAS (Full Analysis Set) 213 patients in placebo group and 655 in CZP group. We did AIT and
denominators were 219 and 660 in placebo and CZP group, respectively).
Analysis 5.1. Comparison 5 ACR50 at 52 weeks, 400 mg certolizumab, Outcome 1 ACR 50.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 5 ACR50 at 52 weeks, 400 mg certolizumab
Outcome: 1 ACR 50
Study or subgroup Certolizumab pegol Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Keystone 2008 155/390 15/199 5.27 [ 3.19, 8.71 ]
0.01 0.1 1 10 100
Favours control Favours certolizumab pego
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Analysis 6.1. Comparison 6 Mean HAQ-DI from baseline at week 12, Outcome 1 certolizumab pegol 200
mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 6 Mean HAQ-DI from baseline at week 12
Outcome: 1 certolizumab pegol 200 mg sc
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Weinblatt 2012 851 -0.43 (0.02) 212 -0.21 (0.04) 100.0 % -0.22 [ -0.23, -0.21 ]
Total (95% CI) 851 212 100.0 % -0.22 [ -0.23, -0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 77.70 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours certolizumab pego Favours control
Analysis 7.1. Comparison 7 Mean HAQ-DI from baseline at week 24, Outcome 1 certolizumab pegol 200
mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 7 Mean HAQ-DI from baseline at week 24
Outcome: 1 certolizumab pegol 200 mg sc
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Keystone 2008 393 -0.58 (0.59) 199 -0.17 (0.56) 33.9 % -0.41 [ -0.51, -0.31 ]
NCT00993317 81 -0.54 (0.51) 40 -0.17 (0.7) 9.6 % -0.37 [ -0.61, -0.13 ]
Smolen 2009 246 -0.5 (0.47) 127 -0.14 (0.45) 33.7 % -0.36 [ -0.46, -0.26 ]
Smolen 2015 91 -0.25 (0.46) 91 -0.03 (0.49) 22.8 % -0.22 [ -0.36, -0.08 ]
Total (95% CI) 811 457 100.0 % -0.35 [ -0.43, -0.26 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 4.92, df = 3 (P = 0.18); I2 =39%
Test for overall effect: Z = 8.32 (P < 0.00001)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours certolizumab pego Favours control
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Analysis 7.2. Comparison 7 Mean HAQ-DI from baseline at week 24, Outcome 2 certolizumab 400 mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 7 Mean HAQ-DI from baseline at week 24
Outcome: 2 certolizumab 400 mg sc
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Choy 2012 (1) 124 -0.32 (0.7) 119 -0.09 (0.15) 23.2 % -0.23 [ -0.36, -0.10 ]
Fleischmann 2009 (2) 111 -0.36 (0.51) 109 0.13 (0.51) 22.0 % -0.49 [ -0.62, -0.36 ]
Keystone 2008 390 -0.6 (0.59) 199 -0.17 (0.56) 27.4 % -0.43 [ -0.53, -0.33 ]
Smolen 2009 246 -0.5 (0.47) 127 -0.14 (0.45) 27.4 % -0.36 [ -0.46, -0.26 ]
Total (95% CI) 871 554 100.0 % -0.38 [ -0.48, -0.28 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 9.17, df = 3 (P = 0.03); I2 =67%
Test for overall effect: Z = 7.53 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours certolizumab pego Favours Control
(1) In CDP870-014 we have obtained standard deviations from p values according to the Handbook section 7.7.3.7. calculating t values , EE and finally SD
(2) In FAST4WARD we have obtained standard deviations from p values according to the Handbook section 7.7.3.7
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Analysis 8.1. Comparison 8 HAQ-DI at 24 weeks, any dose, Outcome 1 Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 8 HAQ-DI at 24 weeks, any dose
Outcome: 1 Change from baseline





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 certolizumab pegol 200 mg sc
Keystone 2008 393 -0.58 (0.59) 100 -0.17 (0.56) 14.7 % -0.41 [ -0.53, -0.29 ]
Smolen 2009 246 -0.5 (0.47) 64 -0.14 (0.45) 14.6 % -0.36 [ -0.48, -0.24 ]
Smolen 2015 91 -0.25 (0.46) 91 -0.03 (0.49) 13.3 % -0.22 [ -0.36, -0.08 ]
Subtotal (95% CI) 730 255 42.7 % -0.33 [ -0.44, -0.23 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 4.21, df = 2 (P = 0.12); I2 =53%
Test for overall effect: Z = 6.05 (P < 0.00001)
2 certolizumab pegol 400 mg sc
Choy 2012 (1) 124 -0.32 (0.7) 119 -0.09 (0.15) 14.5 % -0.23 [ -0.36, -0.10 ]
Fleischmann 2009 111 -0.36 (0.51) 109 0.13 (0.51) 13.7 % -0.49 [ -0.62, -0.36 ]
Keystone 2008 390 -0.6 (0.59) 99 -0.17 (0.56) 14.6 % -0.43 [ -0.55, -0.31 ]
Smolen 2009 246 -0.5 (0.47) 63 -0.14 (0.45) 14.5 % -0.36 [ -0.49, -0.23 ]
Subtotal (95% CI) 871 390 57.3 % -0.38 [ -0.48, -0.27 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 8.67, df = 3 (P = 0.03); I2 =65%
Test for overall effect: Z = 6.79 (P < 0.00001)
Total (95% CI) 1601 645 100.0 % -0.36 [ -0.43, -0.29 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 13.43, df = 6 (P = 0.04); I2 =55%
Test for overall effect: Z = 9.67 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.30, df = 1 (P = 0.59), I2 =0.0%
-0.5 -0.25 0 0.25 0.5
Favours certolizumab pego Favours control
(1) In CDP870-014 we have obtained standard deviations from p values according to the Handbook section 7.7.3.7. calculating t values , EE and finally SD
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Analysis 9.1. Comparison 9 HAQ-DI at 52 weeks, any dose, Outcome 1 Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 9 HAQ-DI at 52 weeks, any dose
Outcome: 1 Change from baseline





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 certolizumab pegol 200 mg sc
Emery 2015 (1) 645 -0.997 (0.71) 210 -0.82 (0.63) 43.1 % -0.18 [ -0.28, -0.08 ]
Keystone 2008 393 -0.6 (0.59) 100 -0.18 (0.56) 28.6 % -0.42 [ -0.54, -0.30 ]
Subtotal (95% CI) 1038 310 71.7 % -0.27 [ -0.35, -0.20 ]
Heterogeneity: Chi2 = 8.75, df = 1 (P = 0.003); I2 =89%
Test for overall effect: Z = 6.85 (P < 0.00001)
2 certolizumab pegol 400 mg sc
Keystone 2008 390 -0.63 (0.59) 99 -0.18 (0.56) 28.3 % -0.45 [ -0.57, -0.33 ]
Subtotal (95% CI) 390 99 28.3 % -0.45 [ -0.57, -0.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.06 (P < 0.00001)
Total (95% CI) 1428 409 100.0 % -0.32 [ -0.39, -0.26 ]
Heterogeneity: Chi2 = 14.18, df = 2 (P = 0.00083); I2 =86%
Test for overall effect: Z = 9.56 (P < 0.00001)
Test for subgroup differences: Chi2 = 5.43, df = 1 (P = 0.02), I2 =82%
-0.5 -0.25 0 0.25 0.5
Favours certoluzimab pego Favours control
(1) TO check becasue the results were opposite to proceedings SAT 0165
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Analysis 10.1. Comparison 10 SF-36 Physical Component Summary (PCS), week 24, Outcome 1
certolizumab pegol 200 mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 10 SF-36 Physical Component Summary (PCS), week 24
Outcome: 1 certolizumab pegol 200 mg sc
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Keystone 2008 393 7.7 (7.93) 199 1.8 (8.46) 45.6 % 5.90 [ 4.49, 7.31 ]
Smolen 2009 246 5.23 (8.31) 127 0.93 (8) 33.5 % 4.30 [ 2.56, 6.04 ]
Smolen 2015 82 6 (7.5) 82 1.7 (7.56) 20.9 % 4.30 [ 2.00, 6.60 ]
Total (95% CI) 721 408 100.0 % 5.03 [ 3.90, 6.16 ]
Heterogeneity: Tau2 = 0.21; Chi2 = 2.51, df = 2 (P = 0.29); I2 =20%
Test for overall effect: Z = 8.72 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
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Analysis 10.2. Comparison 10 SF-36 Physical Component Summary (PCS), week 24, Outcome 2
certolizumab pegol 400 mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 10 SF-36 Physical Component Summary (PCS), week 24
Outcome: 2 certolizumab pegol 400 mg sc
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Choy 2012 (1) 124 8.44 (19.76) 119 3.44 (8.07) 12.4 % 5.00 [ 1.23, 8.77 ]
Keystone 2008 390 8.3 (7.9) 199 1.8 (8.46) 48.5 % 6.50 [ 5.09, 7.91 ]
Smolen 2009 246 5.46 (8.31) 127 0.93 (8) 39.1 % 4.53 [ 2.79, 6.27 ]
Total (95% CI) 760 445 100.0 % 5.54 [ 4.11, 6.97 ]
Heterogeneity: Tau2 = 0.58; Chi2 = 3.10, df = 2 (P = 0.21); I2 =36%
Test for overall effect: Z = 7.60 (P < 0.00001)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours control Favours certolizumab pego
(1) Calculating SD according to Handbook from p values
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Analysis 11.1. Comparison 11 SF-36 Mental Component Summary (MCS), week 24, Outcome 1
certolizumab pegol 200 mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 11 SF-36 Mental Component Summary (MCS), week 24
Outcome: 1 certolizumab pegol 200 mg sc
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Keystone 2008 393 6.3 (11.89) 199 2.3 (11.29) 56.9 % 4.00 [ 2.04, 5.96 ]
Smolen 2009 246 6.05 (10.82) 127 1.63 (10.36) 43.1 % 4.42 [ 2.17, 6.67 ]
Total (95% CI) 639 326 100.0 % 4.18 [ 2.70, 5.66 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 5.54 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
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Analysis 11.2. Comparison 11 SF-36 Mental Component Summary (MCS), week 24, Outcome 2
certolizumab pegol 400 mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 11 SF-36 Mental Component Summary (MCS), week 24
Outcome: 2 certolizumab pegol 400 mg sc
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Choy 2012 (1) 124 4.6 (13.87) 119 1.58 (4.76) 24.7 % 3.02 [ 0.43, 5.61 ]
Keystone 2008 390 6.5 (11.85) 199 2.3 (11.29) 43.0 % 4.20 [ 2.24, 6.16 ]
Smolen 2009 246 6.28 (10.98) 127 1.63 (10.36) 32.2 % 4.65 [ 2.39, 6.91 ]
Total (95% CI) 760 445 100.0 % 4.05 [ 2.77, 5.34 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.90, df = 2 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 6.18 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours control Favours certolizumab pego
(1) Calculating SD according to Handbook from p values
Analysis 12.1. Comparison 12 SF-36 Physical Component Summary (PCS), week 52, Outcome 1
certolizumab 200 mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 12 SF-36 Physical Component Summary (PCS), week 52
Outcome: 1 certolizumab 200 mg sc
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Keystone 2008 393 7.79 (8.72) 199 1.73 (8.61) 6.06 [ 4.59, 7.53 ]
-100 -50 0 50 100
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Analysis 12.2. Comparison 12 SF-36 Physical Component Summary (PCS), week 52, Outcome 2
certolizumab 400 mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 12 SF-36 Physical Component Summary (PCS), week 52
Outcome: 2 certolizumab 400 mg sc
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Keystone 2008 390 8.61 (8.49) 199 1.73 (8.61) 6.88 [ 5.42, 8.34 ]
-100 -50 0 50 100
Favours control Favours certolizumab pego
Analysis 13.1. Comparison 13 SF-36 Mental Component Summary (MCS), week 52, Outcome 1
certolizumab pegol 200 mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 13 SF-36 Mental Component Summary (MCS), week 52
Outcome: 1 certolizumab pegol 200 mg sc
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Keystone 2008 393 6.35 (11.1) 199 2.05 (11.14) 4.30 [ 2.40, 6.20 ]
-100 -50 0 50 100
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Analysis 13.2. Comparison 13 SF-36 Mental Component Summary (MCS), week 52, Outcome 2
certolizumab pegol 400 mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 13 SF-36 Mental Component Summary (MCS), week 52
Outcome: 2 certolizumab pegol 400 mg sc
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Keystone 2008 390 6.35 (11.06) 199 2.05 (11.14) 4.30 [ 2.40, 6.20 ]
-100 -50 0 50 100
Favours control Favours certolizumab pego
Analysis 14.1. Comparison 14 SF-36 Physical Component Summary (PCS) at week 24, any dose, Outcome
1 Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 14 SF-36 Physical Component Summary (PCS) at week 24, any dose
Outcome: 1 Change from baseline





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 certolizumab pegol 200 mg sc
Keystone 2008 393 7.7 (7.93) 100 1.8 (8.46) 25.1 % 5.90 [ 4.07, 7.73 ]
Smolen 2009 246 5.23 (8.31) 64 0.93 (8) 17.2 % 4.30 [ 2.08, 6.52 ]
Smolen 2015 82 6 (7.5) 82 1.7 (7.56) 15.9 % 4.30 [ 2.00, 6.60 ]
Subtotal (95% CI) 721 246 58.2 % 4.99 [ 3.79, 6.20 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.66, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 8.12 (P < 0.00001)
2 certolizumab pegol 400 mg sc
Keystone 2008 390 8.3 (7.9) 99 1.8 (8.46) 24.9 % 6.50 [ 4.66, 8.34 ]
Smolen 2009 246 5.46 (8.31) 63 0.93 (8) 17.0 % 4.53 [ 2.30, 6.76 ]
-4 -2 0 2 4
Favours control Favours certolizumab pego
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(. . . Continued)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 636 162 41.8 % 5.62 [ 3.70, 7.54 ]
Heterogeneity: Tau2 = 0.85; Chi2 = 1.78, df = 1 (P = 0.18); I2 =44%
Test for overall effect: Z = 5.74 (P < 0.00001)
Total (95% CI) 1357 408 100.0 % 5.29 [ 4.37, 6.21 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 4.00, df = 4 (P = 0.41); I2 =0%
Test for overall effect: Z = 11.28 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.30, df = 1 (P = 0.59), I2 =0.0%
-4 -2 0 2 4
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Analysis 15.1. Comparison 15 SF-36 Mental Component Summary (MCS) at week 24, any dose, Outcome 1
Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 15 SF-36 Mental Component Summary (MCS) at week 24, any dose
Outcome: 1 Change from baseline





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 certolizumab pegol 200 mg sc
Keystone 2008 393 6.3 (11.89) 100 2.3 (11.29) 18.2 % 4.00 [ 1.49, 6.51 ]
Smolen 2009 246 6.05 (10.82) 64 1.63 (10.36) 13.8 % 4.42 [ 1.54, 7.30 ]
Smolen 2015 83 5.2 (8.43) 85 1.2 (7.72) 19.1 % 4.00 [ 1.55, 6.45 ]
Subtotal (95% CI) 722 249 51.2 % 4.11 [ 2.62, 5.61 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 2 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 5.39 (P < 0.00001)
2 certolizumab pegol 400 mg sc
Choy 2012 (1) 124 4.6 (13.87) 119 1.58 (4.76) 17.1 % 3.02 [ 0.43, 5.61 ]
Keystone 2008 390 6.5 (11.85) 99 2.3 (11.29) 18.1 % 4.20 [ 1.68, 6.72 ]
Smolen 2009 246 6.28 (10.98) 63 1.63 (10.36) 13.6 % 4.65 [ 1.75, 7.55 ]
-4 -2 0 2 4
Favours control Favours certolizumab pego
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 760 281 48.8 % 3.91 [ 2.38, 5.44 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.76, df = 2 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 5.00 (P < 0.00001)
Total (95% CI) 1482 530 100.0 % 4.01 [ 2.94, 5.08 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.85, df = 5 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 7.35 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.85), I2 =0.0%
-4 -2 0 2 4
Favours control Favours certolizumab pego
(1) Calculating SD according to Handbook from p values
Analysis 16.1. Comparison 16 SF-36 Physical Component Summary (PCS) at week 52, any dose, Outcome
1 Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 16 SF-36 Physical Component Summary (PCS) at week 52, any dose
Outcome: 1 Change from baseline





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 certolizumab pegol 200 mg sc
Keystone 2008 393 7.79 (8.72) 100 1.73 (8.61) 6.06 [ 4.17, 7.95 ]
2 certolizumab pegol 400 mg sc
Keystone 2008 390 8.61 (8.49) 99 1.73 (8.61) 6.88 [ 4.99, 8.77 ]
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Analysis 17.1. Comparison 17 SF-36 Mental Component Summary (MCS) at week 52, any dose, Outcome 1
Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 17 SF-36 Mental Component Summary (MCS) at week 52, any dose
Outcome: 1 Change from baseline





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 certolizumab pegol 200 mg sc
Keystone 2008 393 6.35 (11.1) 100 2.05 (11.14) 4.30 [ 1.86, 6.74 ]
2 certolizumab pegol 400 mg sc
Keystone 2008 390 6.35 (11.06) 99 2.05 (11.14) 4.30 [ 1.85, 6.75 ]
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Analysis 18.1. Comparison 18 Disease Activity Score (DAS-28) (ESR) remission (< 2.6), any doses, 12
weeks, Outcome 1 Proportion of participants achieving remission 12 weeks certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 18 Disease Activity Score (DAS-28) (ESR) remission (< 2.6), any doses, 12 weeks
Outcome: 1 Proportion of participants achieving remission 12 weeks certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Emery 2015 124/660 26/219 53.4 % 1.63 [ 1.09, 2.45 ]
Weinblatt 2012 136/851 12/212 46.6 % 2.36 [ 1.53, 3.65 ]
Total (95% CI) 1511 431 100.0 % 1.94 [ 1.44, 2.61 ]
Total events: 260 (Certolizumab pegol 200 mg), 38 (Control)
Heterogeneity: Chi2 = 1.51, df = 1 (P = 0.22); I2 =34%
Test for overall effect: Z = 4.37 (P = 0.000012)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 19.1. Comparison 19 Disease Activity Score (DAS-28) (ESR) remission (< 2.6), any dose, 24 weeks,
Outcome 1 Proportion of participants achieving remission 24 weeks.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 19 Disease Activity Score (DAS-28) (ESR) remission (< 2.6), any dose, 24 weeks
Outcome: 1 Proportion of participants achieving remission 24 weeks








1 certolizumab pegol 200 mg sc
Atsumi 2016 84/161 57/158 22.7 % 1.45 [ 1.12, 1.87 ]
Emery 2015 171/660 28/219 21.4 % 2.03 [ 1.40, 2.93 ]
Keystone 2008 (1) 45/391 3/100 10.9 % 3.84 [ 1.22, 12.09 ]
Smolen 2009 (2) 23/245 1/62 5.2 % 5.82 [ 0.80, 42.27 ]
Smolen 2015 19/96 3/98 10.5 % 6.47 [ 1.98, 21.14 ]
Yamamoto (a) 2014 19/116 1/114 5.2 % 18.67 [ 2.54, 137.17 ]
Subtotal (95% CI) 1669 751 76.0 % 2.94 [ 1.64, 5.28 ]
Total events: 361 (Certolizumab pegol), 93 (Control)
Heterogeneity: Tau2 = 0.28; Chi2 = 18.85, df = 5 (P = 0.002); I2 =73%
Test for overall effect: Z = 3.62 (P = 0.00030)
2 certolizumab pegol 400 mg sc
Choy 2012 9/126 2/121 7.8 % 4.32 [ 0.95, 19.60 ]
Keystone 2008 (3) 50/387 3/99 11.0 % 4.26 [ 1.36, 13.38 ]
Smolen 2009 (4) 21/246 1/63 5.2 % 5.38 [ 0.74, 39.22 ]
Subtotal (95% CI) 759 283 24.0 % 4.46 [ 1.95, 10.21 ]
Total events: 80 (Certolizumab pegol), 6 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 2 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 3.53 (P = 0.00041)
Total (95% CI) 2428 1034 100.0 % 3.27 [ 1.96, 5.46 ]
Total events: 441 (Certolizumab pegol), 99 (Control)
Heterogeneity: Tau2 = 0.28; Chi2 = 24.38, df = 8 (P = 0.002); I2 =67%
Test for overall effect: Z = 4.52 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.64, df = 1 (P = 0.42), I2 =0.0%
0.01 0.1 1 10 100
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(1) UCB report for NICE quoted Certolizumab n=391 and placebo n=196
(2) In NICE report UCB quoted certoluzimab n= 245 and placebo n =125
(3) In NICE report UCB quoted Certolizumab n= 387 and placebo n = 196
(4) In NICE report UCB quoted placebo n =125
Analysis 20.1. Comparison 20 Disease Activity Score (DAS-28) (ESR) remission (< 2.6), any dose, 52 weeks,
Outcome 1 Proportion of participants achieving remission 52 weeks.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 20 Disease Activity Score (DAS-28) (ESR) remission (< 2.6), any dose, 52 weeks
Outcome: 1 Proportion of participants achieving remission 52 weeks
Study or subgroup Certolizumab pegol Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 certolizumab pegol 200 mg sc
Atsumi 2016 91/161 58/158 38.1 % 1.54 [ 1.20, 1.97 ]
Emery 2015 279/660 57/219 55.7 % 1.62 [ 1.28, 2.07 ]
Keystone 2008 (1) 62/391 3/100 3.1 % 5.29 [ 1.69, 16.49 ]
Subtotal (95% CI) 1212 477 96.9 % 1.71 [ 1.43, 2.04 ]
Total events: 432 (Certolizumab pegol), 118 (Control)
Heterogeneity: Chi2 = 4.65, df = 2 (P = 0.10); I2 =57%
Test for overall effect: Z = 5.99 (P < 0.00001)
2 certolizumab pegol 400 mg sc
Keystone 2008 (2) 74/387 3/99 3.1 % 6.31 [ 2.03, 19.59 ]
Subtotal (95% CI) 387 99 3.1 % 6.31 [ 2.03, 19.59 ]
Total events: 74 (Certolizumab pegol), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.19 (P = 0.0014)
Total (95% CI) 1599 576 100.0 % 1.85 [ 1.55, 2.21 ]
Total events: 506 (Certolizumab pegol), 121 (Control)
Heterogeneity: Chi2 = 11.07, df = 3 (P = 0.01); I2 =73%
Test for overall effect: Z = 6.88 (P < 0.00001)
Test for subgroup differences: Chi2 = 4.99, df = 1 (P = 0.03), I2 =80%
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(1) In NICE report UCB quoted placebo certoluzimab n= 391 and placebo n =196
(2) UCB report for NICE quoted Certolizumab n=387
Analysis 21.1. Comparison 21 Disease Activity Score (DAS-28) (ESR) remission (< 2.6), any time, Outcome
1 Proportion of participants achieving remission 12 weeks certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 21 Disease Activity Score (DAS-28) (ESR) remission (< 2.6), any time
Outcome: 1 Proportion of participants achieving remission 12 weeks certolizumab 200 mg
Study or subgroup
Certolizumab
pegol 200 mg Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Emery 2015 124/660 26/219 67.0 % 1.58 [ 1.07, 2.35 ]
Weinblatt 2012 136/851 12/212 33.0 % 2.82 [ 1.60, 5.00 ]
Total (95% CI) 1511 431 100.0 % 1.99 [ 1.44, 2.76 ]
Total events: 260 (Certolizumab pegol 200 mg), 38 (Control)
Heterogeneity: Chi2 = 2.74, df = 1 (P = 0.10); I2 =64%
Test for overall effect: Z = 4.15 (P = 0.000033)
Test for subgroup differences: Not applicable
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Analysis 21.2. Comparison 21 Disease Activity Score (DAS-28) (ESR) remission (< 2.6), any time, Outcome
2 Proportion of participants achieving remission 24 weeks certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 21 Disease Activity Score (DAS-28) (ESR) remission (< 2.6), any time
Outcome: 2 Proportion of participants achieving remission 24 weeks certolizumab 200 mg
Study or subgroup
Certolizumab








Atsumi 2016 84/161 57/158 26.7 % 1.45 [ 1.12, 1.87 ]
Emery 2015 171/660 28/219 25.7 % 2.03 [ 1.40, 2.93 ]
Smolen 2015 19/96 3/98 15.3 % 6.47 [ 1.98, 21.14 ]
Keystone 2008 (1) 45/391 3/196 15.6 % 7.52 [ 2.37, 23.89 ]
Smolen 2009 (2) 23/245 1/125 8.4 % 11.73 [ 1.60, 85.89 ]
Yamamoto (a) 2014 19/116 1/114 8.4 % 18.67 [ 2.54, 137.17 ]
Total (95% CI) 1669 910 100.0 % 3.79 [ 1.90, 7.56 ]
Total events: 361 (Certolizumab pegol 200 mg), 93 (Control)
Heterogeneity: Tau2 = 0.45; Chi2 = 27.23, df = 5 (P = 0.00005); I2 =82%
Test for overall effect: Z = 3.78 (P = 0.00016)
Test for subgroup differences: Not applicable
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Analysis 21.3. Comparison 21 Disease Activity Score (DAS-28) (ESR) remission (< 2.6), any time, Outcome
3 Proportion of participants achieving remission 24 weeks certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 21 Disease Activity Score (DAS-28) (ESR) remission (< 2.6), any time
Outcome: 3 Proportion of participants achieving remission 24 weeks certolizumab 400 mg
Study or subgroup
Certolizumab








Choy 2012 9/126 2/121 30.3 % 4.32 [ 0.95, 19.60 ]
Keystone 2008 (1) 50/387 3/196 52.2 % 8.44 [ 2.67, 26.72 ]
Smolen 2009 21/246 1/125 17.4 % 10.67 [ 1.45, 78.41 ]
Total (95% CI) 759 442 100.0 % 7.18 [ 3.12, 16.50 ]
Total events: 80 (Certolizumab 400 mg), 6 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.69, df = 2 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 4.64 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 21.4. Comparison 21 Disease Activity Score (DAS-28) (ESR) remission (< 2.6), any time, Outcome
4 Proportion of participants achieving remission 52 weeks certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 21 Disease Activity Score (DAS-28) (ESR) remission (< 2.6), any time
Outcome: 4 Proportion of participants achieving remission 52 weeks certolizumab 200 mg
Study or subgroup
Certolizumab
pegol 200 mg Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Atsumi 2016 91/161 58/158 39.5 % 1.54 [ 1.20, 1.97 ]
Emery 2015 279/660 57/219 57.8 % 1.62 [ 1.28, 2.07 ]
Keystone 2008 (1) 62/391 3/196 2.7 % 10.36 [ 3.29, 32.58 ]
Total (95% CI) 1212 573 100.0 % 1.83 [ 1.53, 2.18 ]
Total events: 432 (Certolizumab pegol 200 mg), 118 (Control)
Heterogeneity: Chi2 = 11.59, df = 2 (P = 0.003); I2 =83%
Test for overall effect: Z = 6.76 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 21.5. Comparison 21 Disease Activity Score (DAS-28) (ESR) remission (< 2.6), any time, Outcome
5 Proportion of participants achieving remission 52 weeks certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 21 Disease Activity Score (DAS-28) (ESR) remission (< 2.6), any time
Outcome: 5 Proportion of participants achieving remission 52 weeks certolizumab 400 mg
Study or subgroup
Certolizumab
pegol 400 mg Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Keystone 2008 (1) 74/387 3/196 12.49 [ 3.99, 39.12 ]
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Analysis 22.1. Comparison 22 DAS-28 at 12 weeks, 200 mg certolizumab, Outcome 1 DAS 28 (ESR) change
from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 22 DAS-28 at 12 weeks, 200 mg certolizumab








N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Weinblatt 2012 851 -1.64 (0) 212 -0.78 (0) Not estimable
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Analysis 23.1. Comparison 23 DAS-28 at 24 weeks, 400 mg certolizumab, Outcome 1 DAS 28 (ESR) change
from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 23 DAS-28 at 24 weeks, 400 mg certolizumab
Outcome: 1 DAS 28 (ESR) change from baseline
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Fleischmann 2009 111 -1.5 (2) 109 -0.6 (2) 47.5 % -0.90 [ -1.43, -0.37 ]
Smolen 2009 246 -2.46 (1.31) 127 -0.5 (1.05) 52.5 % -1.96 [ -2.21, -1.71 ]
Total (95% CI) 357 236 100.0 % -1.46 [ -2.49, -0.42 ]
Heterogeneity: Tau2 = 0.52; Chi2 = 12.71, df = 1 (P = 0.00036); I2 =92%
Test for overall effect: Z = 2.75 (P = 0.0059)
Test for subgroup differences: Not applicable
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Analysis 24.1. Comparison 24 DAS-28 at week 52, certolizumab 200 mg, Outcome 1 DAS 28 (ESR) Change
from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 24 DAS-28 at week 52, certolizumab 200 mg
Outcome: 1 DAS 28 (ESR) Change from baseline
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Keystone 2008 393 -3.3 (1.3) 199 -2.4 (1.3) -0.90 [ -1.12, -0.68 ]
-100 -50 0 50 100
Favours certolizumab pego Favours control
Analysis 25.1. Comparison 25 DAS-28 at week 52, certolizumab 400 mg, Outcome 1 DAS 28 (ESR) Change
from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 25 DAS-28 at week 52, certolizumab 400 mg
Outcome: 1 DAS 28 (ESR) Change from baseline
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Keystone 2008 390 -3.4 (1.4) 199 -2.4 (1.3) -1.00 [ -1.23, -0.77 ]
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Analysis 26.1. Comparison 26 DAS-28 at 24 weeks, any dose, Outcome 1 Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 26 DAS-28 at 24 weeks, any dose
Outcome: 1 Change from baseline





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 certolizumab pegol 200 mg sc
Smolen 2009 246 -2.27 (1.38) 64 -0.5 (1.05) 35.7 % -1.77 [ -2.08, -1.46 ]
Subtotal (95% CI) 246 64 35.7 % -1.77 [ -2.08, -1.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 11.20 (P < 0.00001)
2 certolizumab pegol 400 mg sc
Fleischmann 2009 111 -1.5 (2) 109 -0.6 (2) 28.6 % -0.90 [ -1.43, -0.37 ]
Smolen 2009 246 -2.46 (1.31) 63 -0.5 (1.05) 35.8 % -1.96 [ -2.27, -1.65 ]
Subtotal (95% CI) 357 172 64.3 % -1.45 [ -2.49, -0.41 ]
Heterogeneity: Tau2 = 0.51; Chi2 = 11.56, df = 1 (P = 0.00067); I2 =91%
Test for overall effect: Z = 2.74 (P = 0.0061)
Total (95% CI) 603 236 100.0 % -1.59 [ -2.10, -1.08 ]
Heterogeneity: Tau2 = 0.17; Chi2 = 11.70, df = 2 (P = 0.003); I2 =83%
Test for overall effect: Z = 6.07 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.33, df = 1 (P = 0.57), I2 =0.0%
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Analysis 27.1. Comparison 27 DAS-28 at 52 weeks, any dose, Outcome 1 Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 27 DAS-28 at 52 weeks, any dose
Outcome: 1 Change from baseline





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 certolizumab pegol 200 mg sc
Emery 2015 646 -3.61 (0.17) 210 -3.01 (1.58) 47.6 % -0.60 [ -0.81, -0.38 ]
Keystone 2008 393 -3.3 (1.3) 100 -2.4 (1.3) 26.8 % -0.90 [ -1.19, -0.61 ]
Subtotal (95% CI) 1039 310 74.3 % -0.71 [ -0.88, -0.53 ]
Heterogeneity: Chi2 = 2.79, df = 1 (P = 0.09); I2 =64%
Test for overall effect: Z = 8.07 (P < 0.00001)
2 certolizumab pegol 400 mg sc
Keystone 2008 390 -3.4 (1.4) 99 -2.4 (1.3) 25.7 % -1.00 [ -1.29, -0.71 ]
Subtotal (95% CI) 390 99 25.7 % -1.00 [ -1.29, -0.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.73 (P < 0.00001)
Total (95% CI) 1429 409 100.0 % -0.78 [ -0.93, -0.63 ]
Heterogeneity: Chi2 = 5.71, df = 2 (P = 0.06); I2 =65%
Test for overall effect: Z = 10.37 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.92, df = 1 (P = 0.09), I2 =66%
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Analysis 28.1. Comparison 28 DAS-28 at 24 weeks, 200 mg certolizumab, Outcome 1 DAS 28 (ESR) change
from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 28 DAS-28 at 24 weeks, 200 mg certolizumab
Outcome: 1 DAS 28 (ESR) change from baseline
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Smolen 2009 246 -2.27 (1.38) 127 -0.5 (1.05) -1.77 [ -2.02, -1.52 ]
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Analysis 29.1. Comparison 29 Erosion score (ES), Outcome 1 Change from the baseline mean ES at week
24, certolizumab pegol 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 29 Erosion score (ES)
Outcome: 1 Change from the baseline mean ES at week 24, certolizumab pegol 200 mg
Study or subgroup
Certolizumab







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Keystone 2008 353 0 (1.5) 180 0.7 (2.1) 61.6 % -0.41 [ -0.59, -0.22 ]
Smolen 2009 214 0.1 (2) 112 0.7 (2.6) 38.4 % -0.27 [ -0.50, -0.04 ]
Total (95% CI) 567 292 100.0 % -0.35 [ -0.50, -0.21 ]
Heterogeneity: Chi2 = 0.83, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 4.86 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 29.2. Comparison 29 Erosion score (ES), Outcome 2 Change from the baseline mean ES at week
24, certolizumab pegol 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 29 Erosion score (ES)
Outcome: 2 Change from the baseline mean ES at week 24, certolizumab pegol 400 mg





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Keystone 2008 355 0.1 (2.4) 180 0.7 (2.1) 60.7 % -0.60 [ -1.00, -0.20 ]
Smolen 2009 222 -0.3 (1.8) 112 0.7 (2.6) 39.3 % -1.00 [ -1.54, -0.46 ]
Total (95% CI) 577 292 100.0 % -0.76 [ -1.14, -0.37 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 1.38, df = 1 (P = 0.24); I2 =28%
Test for overall effect: Z = 3.88 (P = 0.00011)
Test for subgroup differences: Not applicable
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Analysis 29.3. Comparison 29 Erosion score (ES), Outcome 3 Change from the baseline mean ES at week
52, certolizumab pegol 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 29 Erosion score (ES)
Outcome: 3 Change from the baseline mean ES at week 52, certolizumab pegol 200 mg





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Emery 2015 528 0.1 (2.1) 163 1.1 (3) 65.4 % -1.00 [ -1.49, -0.51 ]
Keystone 2008 364 0.1 (2.5) 180 1.5 (4.3) 34.6 % -1.40 [ -2.08, -0.72 ]
Total (95% CI) 892 343 100.0 % -1.14 [ -1.54, -0.74 ]
Heterogeneity: Chi2 = 0.87, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 5.59 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 29.4. Comparison 29 Erosion score (ES), Outcome 4 Change from the baseline mean ES at week
52, certolizumab pegol 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 29 Erosion score (ES)
Outcome: 4 Change from the baseline mean ES at week 52, certolizumab pegol 400 mg





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Keystone 2008 363 0 (3) 180 1.5 (4.3) -1.50 [ -2.20, -0.80 ]
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Analysis 30.1. Comparison 30 Erosion score (ES) at 24 weeks, any dose, Outcome 1 Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 30 Erosion score (ES) at 24 weeks, any dose
Outcome: 1 Change from baseline





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 certolizumab pegol 200 mg sc
Keystone 2008 353 0 (1.5) 91 0.7 (2.1) 37.9 % -0.70 [ -1.16, -0.24 ]
Smolen 2009 214 0.1 (2) 56 0.7 (2.6) 14.9 % -0.60 [ -1.33, 0.13 ]
Subtotal (95% CI) 567 147 52.8 % -0.67 [ -1.06, -0.28 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 3.39 (P = 0.00071)
2 certolizumab pegol 400 mg sc
Keystone 2008 355 0.1 (2.4) 90 0.7 (2.1) 31.9 % -0.60 [ -1.10, -0.10 ]
Smolen 2009 222 -0.3 (1.8) 56 0.7 (2.6) 15.4 % -1.00 [ -1.72, -0.28 ]
Subtotal (95% CI) 577 146 47.2 % -0.73 [ -1.14, -0.32 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.80, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 3.48 (P = 0.00050)
Total (95% CI) 1144 293 100.0 % -0.70 [ -0.98, -0.42 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.89, df = 3 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 4.85 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.84), I2 =0.0%
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Analysis 31.1. Comparison 31 Erosion score (ES) at 52 weeks, any dose, Outcome 1 Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 31 Erosion score (ES) at 52 weeks, any dose
Outcome: 1 Change from baseline





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 certolizumab pegol 200 mg sc
Emery 2015 528 0.1 (2.1) 163 1.1 (3) 63.9 % -1.00 [ -1.49, -0.51 ]
Keystone 2008 364 0.1 (2.5) 91 1.5 (4.3) 18.4 % -1.40 [ -2.32, -0.48 ]
Subtotal (95% CI) 892 254 82.4 % -1.09 [ -1.52, -0.65 ]
Heterogeneity: Chi2 = 0.56, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 4.91 (P < 0.00001)
2 certolizumab pegol 400 mg sc
Keystone 2008 363 0 (3) 90 1.5 (4.3) 17.6 % -1.50 [ -2.44, -0.56 ]
Subtotal (95% CI) 363 90 17.6 % -1.50 [ -2.44, -0.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.13 (P = 0.0018)
Total (95% CI) 1255 344 100.0 % -1.16 [ -1.56, -0.77 ]
Heterogeneity: Chi2 = 1.17, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 5.76 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.60, df = 1 (P = 0.44), I2 =0.0%
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Analysis 32.1. Comparison 32 Joint space narrowing (JSN), Outcome 1 Change from the baseline mean JSN
24 weeks, certolizumab pegol 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 32 Joint space narrowing (JSN)
Outcome: 1 Change from the baseline mean JSN 24 weeks, certolizumab pegol 200 mg
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Keystone 2008 355 0.2 (2.5) 180 0.7 (2.4) 53.2 % -0.50 [ -0.94, -0.06 ]
Smolen 2009 214 0.1 (1.4) 112 0.5 (2.3) 46.8 % -0.40 [ -0.87, 0.07 ]
Total (95% CI) 569 292 100.0 % -0.45 [ -0.77, -0.13 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 2.79 (P = 0.0053)
Test for subgroup differences: Not applicable
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Analysis 32.2. Comparison 32 Joint space narrowing (JSN), Outcome 2 Change from the baseline mean JSN
24 weeks,certolizumab pegol 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 32 Joint space narrowing (JSN)
Outcome: 2 Change from the baseline mean JSN 24 weeks,certolizumab pegol 400 mg
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Keystone 2008 355 0.2 (2.4) 180 0.7 (2.4) 51.8 % -0.50 [ -0.93, -0.07 ]
Smolen 2009 222 -0.1 (1) 112 0.5 (2.3) 48.2 % -0.60 [ -1.05, -0.15 ]
Total (95% CI) 577 292 100.0 % -0.55 [ -0.86, -0.24 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 3.47 (P = 0.00052)
Test for subgroup differences: Not applicable
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Analysis 32.3. Comparison 32 Joint space narrowing (JSN), Outcome 3 Change from the baseline mean JSN
52 weeks,certolizumab pegol 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 32 Joint space narrowing (JSN)
Outcome: 3 Change from the baseline mean JSN 52 weeks,certolizumab pegol 200 mg





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Emery 2015 528 0.1 (1.7) 163 0.7 (2.3) 83.1 % -0.60 [ -0.98, -0.22 ]
Keystone 2008 367 0.4 (4.2) 181 1.4 (5) 16.9 % -1.00 [ -1.85, -0.15 ]
Total (95% CI) 895 344 100.0 % -0.67 [ -1.02, -0.32 ]
Heterogeneity: Chi2 = 0.71, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 3.76 (P = 0.00017)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
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Analysis 32.4. Comparison 32 Joint space narrowing (JSN), Outcome 4 Change from the baseline mean JSN
52 weeks, certolizumab pegol 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 32 Joint space narrowing (JSN)
Outcome: 4 Change from the baseline mean JSN 52 weeks, certolizumab pegol 400 mg





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Keystone 2008 363 0.2 (2.8) 181 1.4 (5) -1.20 [ -1.98, -0.42 ]
-2 -1 0 1 2
Favours certolizumab Favours control
Analysis 33.1. Comparison 33 Joint space narrowing (JSN) at 24 weeks, any dose, Outcome 1 Change from
baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 33 Joint space narrowing (JSN) at 24 weeks, any dose
Outcome: 1 Change from baseline





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 certolizumab pegol 200 mg sc
Keystone 2008 355 0.2 (2.5) 91 0.7 (2.4) 27.7 % -0.50 [ -1.06, 0.06 ]
Smolen 2009 214 0.1 (1.4) 56 0.5 (2.3) 21.6 % -0.40 [ -1.03, 0.23 ]
Subtotal (95% CI) 569 147 49.4 % -0.46 [ -0.87, -0.04 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 2.14 (P = 0.032)
2 certolizumab pegol 400 mg sc
Keystone 2008 355 0.2 (2.4) 90 0.7 (2.4) 28.0 % -0.50 [ -1.06, 0.06 ]
Smolen 2009 222 -0.1 (1) 56 0.5 (2.3) 22.7 % -0.60 [ -1.22, 0.02 ]
Subtotal (95% CI) 577 146 50.6 % -0.54 [ -0.96, -0.13 ]
-1 -0.5 0 0.5 1
Favours certolizumab pego Favours control
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(. . . Continued)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 2.59 (P = 0.0097)
Total (95% CI) 1146 293 100.0 % -0.50 [ -0.79, -0.21 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.20, df = 3 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 3.35 (P = 0.00082)
Test for subgroup differences: Chi2 = 0.09, df = 1 (P = 0.77), I2 =0.0%
-1 -0.5 0 0.5 1
Favours certolizumab pego Favours control
Analysis 34.1. Comparison 34 Joint space narrowing (JSN) at 52 weeks, any dose, Outcome 1 Change from
baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 34 Joint space narrowing (JSN) at 52 weeks, any dose
Outcome: 1 Change from baseline





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 certolizumab pegol 200 mg sc
Emery 2015 528 0.1 (1.7) 163 0.7 (2.3) 80.4 % -0.60 [ -0.98, -0.22 ]
Keystone 2008 367 0.4 (4.2) 91 1.4 (5) 9.4 % -1.00 [ -2.11, 0.11 ]
Subtotal (95% CI) 895 254 89.8 % -0.64 [ -1.00, -0.28 ]
Heterogeneity: Chi2 = 0.44, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 3.49 (P = 0.00049)
2 certolizumab pegol 400 mg sc
Keystone 2008 363 0.2 (2.8) 90 1.4 (5) 10.2 % -1.20 [ -2.27, -0.13 ]
Subtotal (95% CI) 363 90 10.2 % -1.20 [ -2.27, -0.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.19 (P = 0.028)
Total (95% CI) 1258 344 100.0 % -0.70 [ -1.04, -0.36 ]
Heterogeneity: Chi2 = 1.38, df = 2 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 4.00 (P = 0.000063)
Test for subgroup differences: Chi2 = 0.93, df = 1 (P = 0.33), I2 =0.0%
-4 -2 0 2 4
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Analysis 35.1. Comparison 35 Modified Total Sharp Scores (mTSS) at 24 weeks, any dose, Outcome 1
Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 35 Modified Total Sharp Scores (mTSS) at 24 weeks, any dose
Outcome: 1 Change from baseline





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 certolizumab pegol 200 mg sc
Atsumi 2016 159 0.26 (1.55) 157 0.86 (2.37) 54.8 % -0.60 [ -1.04, -0.16 ]
Keystone 2008 353 0.2 (3.2) 90 1.3 (3.8) 14.7 % -1.10 [ -1.95, -0.25 ]
Smolen 2009 214 0.2 (2.7) 56 1.2 (4.1) 8.3 % -1.00 [ -2.13, 0.13 ]
Subtotal (95% CI) 726 303 77.9 % -0.74 [ -1.11, -0.37 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.27, df = 2 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 3.90 (P = 0.000098)
2 certolizumab pegol 400 mg sc
Keystone 2008 355 0.2 (4.2) 91 1.3 (3.8) 13.4 % -1.10 [ -1.99, -0.21 ]
Smolen 2009 222 -0.4 (2.1) 56 1.2 (4.1) 8.7 % -1.60 [ -2.71, -0.49 ]
Subtotal (95% CI) 577 147 22.1 % -1.30 [ -1.99, -0.60 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.47, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 3.65 (P = 0.00026)
Total (95% CI) 1303 450 100.0 % -0.86 [ -1.19, -0.53 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.68, df = 4 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 5.16 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.93, df = 1 (P = 0.16), I2 =48%
-2 -1 0 1 2
Favours certolizumab pego Favours control
139Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 36.1. Comparison 36 Modified Total Sharp Scores (mTSS) at 52 weeks, any dose, Outcome 1
Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 36 Modified Total Sharp Scores (mTSS) at 52 weeks, any dose
Outcome: 1 Change from baseline





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 certolizumab pegol 200 mg sc
Atsumi 2016 159 0.36 (2.7) 157 1.58 (4.86) 33.3 % -1.22 [ -2.09, -0.35 ]
Emery 2015 528 0.2 (3.2) 163 1.8 (4.3) 49.2 % -1.60 [ -2.31, -0.89 ]
Keystone 2008 364 0.4 (5.7) 91 2.8 (7.8) 8.6 % -2.40 [ -4.11, -0.69 ]
Subtotal (95% CI) 1051 411 91.2 % -1.54 [ -2.06, -1.01 ]
Heterogeneity: Chi2 = 1.52, df = 2 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 5.74 (P < 0.00001)
2 certolizumab pegol 400 mg sc
Keystone 2008 363 0.2 (4.8) 90 2.8 (7.8) 8.8 % -2.60 [ -4.29, -0.91 ]
Subtotal (95% CI) 363 90 8.8 % -2.60 [ -4.29, -0.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.02 (P = 0.0025)
Total (95% CI) 1414 501 100.0 % -1.63 [ -2.13, -1.13 ]
Heterogeneity: Chi2 = 2.92, df = 3 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 6.38 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.39, df = 1 (P = 0.24), I2 =28%
-20 -10 0 10 20
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Analysis 37.1. Comparison 37 Modified total Sharp scores (mTSS), Outcome 1 Change from the baseline
mean mTSS 24 weeks, certolizumab pegol 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 37 Modified total Sharp scores (mTSS)
Outcome: 1 Change from the baseline mean mTSS 24 weeks, certolizumab pegol 200 mg
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Keystone 2008 353 0.2 (3.2) 180 1.3 (3.8) 62.8 % -1.10 [ -1.75, -0.45 ]
Smolen 2009 214 0.2 (2.7) 112 1.2 (4.1) 37.2 % -1.00 [ -1.84, -0.16 ]
Total (95% CI) 567 292 100.0 % -1.06 [ -1.58, -0.55 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 4.06 (P = 0.000049)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours certolizumab pego Favours control
Analysis 37.2. Comparison 37 Modified total Sharp scores (mTSS), Outcome 2 Change from the baseline
mean mTSS 24 weeks, certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 37 Modified total Sharp scores (mTSS)
Outcome: 2 Change from the baseline mean mTSS 24 weeks, certolizumab 400 mg
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Keystone 2008 355 0.2 (4.2) 180 1.3 (3.8) 56.7 % -1.10 [ -1.81, -0.39 ]
Smolen 2009 222 -0.4 (2.1) 112 1.2 (4.1) 43.3 % -1.60 [ -2.41, -0.79 ]
Total (95% CI) 577 292 100.0 % -1.32 [ -1.85, -0.78 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.83, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 4.85 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours certolizumab pego Favours control
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Analysis 37.3. Comparison 37 Modified total Sharp scores (mTSS), Outcome 3 Change from the baseline
mean mTSS 52 weeks, certolizumab pegol 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 37 Modified total Sharp scores (mTSS)








N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Keystone 2008 364 0.4 (5.7) 181 2.8 (7.8) 100.0 % -2.40 [ -3.68, -1.12 ]
Total (95% CI) 364 181 100.0 % -2.40 [ -3.68, -1.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.68 (P = 0.00023)
Test for subgroup differences: Not applicable
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Analysis 37.4. Comparison 37 Modified total Sharp scores (mTSS), Outcome 4 Change from the baseline
mean mTSS 52 weeks, certolizumab pegol 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 37 Modified total Sharp scores (mTSS)
Outcome: 4 Change from the baseline mean mTSS 52 weeks, certolizumab pegol 400 mg
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Keystone 2008 363 0.2 (4.8) 181 2.8 (7.8) 100.0 % -2.60 [ -3.84, -1.36 ]
Total (95% CI) 363 181 100.0 % -2.60 [ -3.84, -1.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.11 (P = 0.000039)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours certolizumab pego Favours control
Analysis 38.1. Comparison 38 Certolizumab pegol 1mg/kg/day sc, Outcome 1 Headache.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults









n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Choy 2002 3/8 1/12 5.65 [ 0.64, 49.98 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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Analysis 38.2. Comparison 38 Certolizumab pegol 1mg/kg/day sc, Outcome 2 Lower respiratory tract
infection.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 38 Certolizumab pegol 1mg/kg/day sc
Outcome: 2 Lower respiratory tract infection
Study or subgroup
certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Choy 2002 0/8 1/12 0.19 [ 0.00, 10.32 ]
0.01 0.1 1 10 100
Favours certolizumab 1mg/Kg/day sc Favours control
Analysis 38.3. Comparison 38 Certolizumab pegol 1mg/kg/day sc, Outcome 3 Adverse events Intensity
severe.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 38 Certolizumab pegol 1mg/kg/day sc
Outcome: 3 Adverse events Intensity severe
Study or subgroup
certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Choy 2002 1/8 0/12 12.18 [ 0.22, 665.65 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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Analysis 38.4. Comparison 38 Certolizumab pegol 1mg/kg/day sc, Outcome 4 Antinuclear antibodies
(ANA).
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 38 Certolizumab pegol 1mg/kg/day sc
Outcome: 4 Antinuclear antibodies (ANA)
Study or subgroup
certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Choy 2002 2/8 1/12 3.46 [ 0.30, 39.80 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
Analysis 38.5. Comparison 38 Certolizumab pegol 1mg/kg/day sc, Outcome 5 Urinary tract infection.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 38 Certolizumab pegol 1mg/kg/day sc
Outcome: 5 Urinary tract infection
Study or subgroup
certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Choy 2002 1/8 0/12 12.18 [ 0.22, 665.65 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
145Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 39.1. Comparison 39 Certolizumab 5 mg/kg/day sc, Outcome 1 Lower respiratory tract infection.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 39 Certolizumab 5 mg/kg/day sc
Outcome: 1 Lower respiratory tract infection
Study or subgroup
certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Choy 2002 1/8 1/12 1.55 [ 0.08, 28.40 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
Analysis 39.2. Comparison 39 Certolizumab 5 mg/kg/day sc, Outcome 2 Urinary tract infection.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 39 Certolizumab 5 mg/kg/day sc
Outcome: 2 Urinary tract infection
Study or subgroup
certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Choy 2002 1/8 0/12 12.18 [ 0.22, 665.65 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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Analysis 40.1. Comparison 40 Certolizumab 20 mg/kg/day sc, Outcome 1 Headache.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults




pegol 20 mg Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Choy 2002 3/8 1/12 4.50 [ 0.56, 35.98 ]
0.01 0.1 1 10 100
Favours certolizumab pego Control
Analysis 40.2. Comparison 40 Certolizumab 20 mg/kg/day sc, Outcome 2 Lower respiratory tract infection.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 40 Certolizumab 20 mg/kg/day sc
Outcome: 2 Lower respiratory tract infection
Study or subgroup
certolizumab
pegol 20 mg Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Choy 2002 2/8 1/12 100.0 % 3.00 [ 0.32, 27.83 ]
Total (95% CI) 8 12 100.0 % 3.00 [ 0.32, 27.83 ]
Total events: 2 (certolizumab pegol 20 mg), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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Analysis 40.3. Comparison 40 Certolizumab 20 mg/kg/day sc, Outcome 3 Death.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults









n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Choy 2002 1/8 0/12 12.18 [ 0.22, 665.65 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
Analysis 40.4. Comparison 40 Certolizumab 20 mg/kg/day sc, Outcome 4 Antinuclear antibodies (ANA).
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 40 Certolizumab 20 mg/kg/day sc
Outcome: 4 Antinuclear antibodies (ANA)
Study or subgroup
certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Choy 2002 1/8 1/12 1.55 [ 0.08, 28.40 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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Analysis 40.5. Comparison 40 Certolizumab 20 mg/kg/day sc, Outcome 5 Urinary tract infection.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 40 Certolizumab 20 mg/kg/day sc
Outcome: 5 Urinary tract infection
Study or subgroup
certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Choy 2002 1/8 0/12 12.18 [ 0.22, 665.65 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
Analysis 41.1. Comparison 41 Safety, SAE certolizumab 200 mg, Outcome 1 Serious Adverse Events (SAE).
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 41 Safety, SAE certolizumab 200 mg
Outcome: 1 Serious Adverse Events (SAE)
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Smolen 2015 5/96 7/98 5.0 % 0.72 [ 0.22, 2.30 ]
Atsumi 2016 13/161 14/158 11.0 % 0.90 [ 0.41, 1.99 ]
Weinblatt 2012 52/846 12/209 17.0 % 1.07 [ 0.57, 2.02 ]
Emery 2015 70/660 20/219 26.9 % 1.17 [ 0.71, 1.94 ]
Keystone 2008 45/392 11/199 20.1 % 2.00 [ 1.12, 3.58 ]
Smolen 2009 18/248 4/125 8.2 % 2.07 [ 0.83, 5.16 ]
Yamamoto (b) 2014 4/82 1/77 2.2 % 3.21 [ 0.54, 19.00 ]
Yamamoto (a) 2014 13/116 3/114 6.6 % 3.74 [ 1.36, 10.31 ]
NCT00993317 8/85 0/42 3.0 % 4.86 [ 1.07, 22.14 ]
Total (95% CI) 2686 1241 100.0 % 1.47 [ 1.13, 1.91 ]
0.05 0.2 1 5 20
Favours certolizumab pego Favours control
(Continued . . . )
149Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Total events: 228 (Certolizumab pegol 200 mg), 72 (Control)
Heterogeneity: Chi2 = 12.65, df = 8 (P = 0.12); I2 =37%
Test for overall effect: Z = 2.90 (P = 0.0037)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours certolizumab pego Favours control
Analysis 42.1. Comparison 42 Safety, SAE certolizumab 400 mg, Outcome 1 Serious Adverse Events
(SAEs).
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 42 Safety, SAE certolizumab 400 mg
Outcome: 1 Serious Adverse Events (SAEs)
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Choy 2012 16/124 12/119 23.2 % 1.32 [ 0.60, 2.89 ]
Fleischmann 2009 8/111 3/109 9.8 % 2.54 [ 0.76, 8.53 ]
Keystone 2008 48/389 11/199 44.4 % 2.12 [ 1.20, 3.75 ]
Smolen 2009 18/246 4/125 17.3 % 2.09 [ 0.84, 5.19 ]
Yamamoto (b) 2014 5/85 1/77 5.4 % 3.59 [ 0.70, 18.26 ]
stergaard 2015 0/27 0/13 Not estimable
Total (95% CI) 982 642 100.0 % 1.98 [ 1.36, 2.90 ]
Total events: 95 (Certolizumab pegol 400 mg), 31 (Control)
Heterogeneity: Chi2 = 1.78, df = 4 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 3.55 (P = 0.00038)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours certolizumab pego Favours control
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Analysis 43.1. Comparison 43 Withdrawals, Outcome 1 All Withdrawn: any doses any follow-up.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 43 Withdrawals
Outcome: 1 All Withdrawn: any doses any follow-up








Atsumi 2016 50/161 85/158 9.7 % 0.58 [ 0.44, 0.76 ]
Choy 2002 2/24 6/12 1.5 % 0.17 [ 0.04, 0.71 ]
Choy 2012 28/126 56/121 8.1 % 0.48 [ 0.33, 0.70 ]
Emery 2015 160/660 76/219 10.3 % 0.70 [ 0.56, 0.88 ]
Fleischmann 2009 35/111 81/109 9.3 % 0.42 [ 0.32, 0.57 ]
Keystone 2008 254/783 156/199 11.5 % 0.41 [ 0.37, 0.47 ]
NCT00993317 25/85 21/42 7.1 % 0.59 [ 0.38, 0.92 ]
Smolen 2009 137/492 110/127 11.2 % 0.32 [ 0.27, 0.38 ]
Smolen 2015 12/96 18/98 4.7 % 0.68 [ 0.35, 1.34 ]
Weinblatt 2012 80/851 28/212 7.7 % 0.71 [ 0.48, 1.07 ]
Yamamoto (a) 2014 34/116 96/114 9.3 % 0.35 [ 0.26, 0.47 ]
Yamamoto (b) 2014 (1) 36/167 52/77 8.8 % 0.32 [ 0.23, 0.44 ]
stergaard 2015 (2) 3/27 1/13 0.7 % 1.44 [ 0.17, 12.58 ]
Total (95% CI) 3699 1501 100.0 % 0.47 [ 0.39, 0.56 ]
Total events: 856 (certolizumab pegol), 786 (Control)
Heterogeneity: Tau2 = 0.07; Chi2 = 56.21, df = 12 (P<0.00001); I2 =79%
Test for overall effect: Z = 8.04 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
(1) Only for 200 and 400 mg of CTZ
(2) A withdrawal after randomisation and prior to treatment. It is undisclosed in which arm
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Analysis 43.2. Comparison 43 Withdrawals, Outcome 2 Withdrawals due to adverse events.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 43 Withdrawals
Outcome: 2 Withdrawals due to adverse events





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Atsumi 2016 9/161 6/158 7.9 % 1.49 [ 0.53, 4.20 ]
Choy 2012 7/126 6/121 6.8 % 1.13 [ 0.37, 3.44 ]
Emery 2015 51/660 17/219 25.9 % 1.00 [ 0.56, 1.76 ]
Fleischmann 2009 5/111 2/109 3.8 % 2.37 [ 0.53, 10.64 ]
Keystone 2008 39/783 3/199 14.3 % 2.33 [ 1.08, 5.03 ]
NCT00993317 4/85 2/42 2.8 % 0.99 [ 0.17, 5.60 ]
Smolen 2009 17/492 2/127 6.6 % 1.88 [ 0.61, 5.82 ]
Smolen 2015 6/96 6/98 6.2 % 1.02 [ 0.32, 3.28 ]
Weinblatt 2012 33/851 6/212 13.2 % 1.34 [ 0.60, 2.99 ]
Yamamoto (a) 2014 8/116 2/114 5.3 % 3.42 [ 0.97, 12.13 ]
Yamamoto (b) 2014 13/239 3/77 6.2 % 1.38 [ 0.43, 4.44 ]
stergaard 2015 (1) 2/27 0/13 0.9 % 4.57 [ 0.23, 91.66 ]
Total (95% CI) 3747 1489 100.0 % 1.45 [ 1.09, 1.94 ]
Total events: 194 (Certolizumab pegol), 55 (Control)
Heterogeneity: Chi2 = 6.86, df = 11 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 2.52 (P = 0.012)
Test for subgroup differences: Not applicable
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(1) A withdrawal after randomisation and prior to treatment. It is undisclosed in which arm
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Analysis 44.1. Comparison 44 ACR at 24 weeks, any dose, Outcome 1 ACR20.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 44 ACR at 24 weeks, any dose
Outcome: 1 ACR20








1 certolizumab 100 mg sc
Yamamoto (b) 2014 44/72 6/26 5.1 % 2.65 [ 1.28, 5.47 ]
Subtotal (95% CI) 72 26 5.1 % 2.65 [ 1.28, 5.47 ]
Total events: 44 (Certolizumab pegol), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.63 (P = 0.0085)
2 certolizumab 200 mg sc
Keystone 2008 228/393 27/100 13.1 % 2.15 [ 1.54, 3.00 ]
NCT00993317 54/85 11/42 8.0 % 2.43 [ 1.42, 4.13 ]
Smolen 2009 141/246 11/64 7.7 % 3.33 [ 1.93, 5.77 ]
Smolen 2015 35/96 15/98 7.9 % 2.38 [ 1.39, 4.07 ]
Yamamoto (a) 2014 74/116 13/114 8.0 % 5.59 [ 3.29, 9.50 ]
Yamamoto (b) 2014 60/82 6/26 5.3 % 3.17 [ 1.55, 6.47 ]
Subtotal (95% CI) 1018 444 50.0 % 2.92 [ 2.17, 3.95 ]
Total events: 592 (Certolizumab pegol), 83 (Control)
Heterogeneity: Tau2 = 0.07; Chi2 = 10.25, df = 5 (P = 0.07); I2 =51%
Test for overall effect: Z = 7.01 (P < 0.00001)
3 certolizumab 400 mg sc
Choy 2012 56/126 27/121 11.5 % 1.99 [ 1.35, 2.93 ]
Fleischmann 2009 50/111 10/109 6.4 % 4.91 [ 2.63, 9.18 ]
Keystone 2008 236/390 27/99 13.1 % 2.22 [ 1.59, 3.09 ]
Smolen 2009 141/246 11/63 7.7 % 3.28 [ 1.90, 5.68 ]
Yamamoto (b) 2014 61/85 7/25 6.2 % 2.56 [ 1.35, 4.87 ]
Subtotal (95% CI) 958 417 44.9 % 2.65 [ 1.98, 3.56 ]
Total events: 544 (Certolizumab pegol), 82 (Control)
Heterogeneity: Tau2 = 0.05; Chi2 = 7.42, df = 4 (P = 0.12); I2 =46%
Test for overall effect: Z = 6.53 (P < 0.00001)
Total (95% CI) 2048 887 100.0 % 2.76 [ 2.29, 3.33 ]
Total events: 1180 (Certolizumab pegol), 171 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 18.18, df = 11 (P = 0.08); I2 =39%
Test for overall effect: Z = 10.61 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.22, df = 2 (P = 0.89), I2 =0.0%
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Analysis 44.2. Comparison 44 ACR at 24 weeks, any dose, Outcome 2 ACR50.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 44 ACR at 24 weeks, any dose
Outcome: 2 ACR50








1 certolizumab 100 mg sc
Yamamoto (b) 2014 32/72 4/26 5.5 % 2.89 [ 1.13, 7.38 ]
Subtotal (95% CI) 72 26 5.5 % 2.89 [ 1.13, 7.38 ]
Total events: 32 (Certolizumab pegol), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.22 (P = 0.027)
2 certolizumab 200 mg sc
Keystone 2008 144/393 15/100 20.5 % 2.44 [ 1.50, 3.96 ]
NCT00993317 35/85 8/42 10.6 % 2.16 [ 1.10, 4.24 ]
Smolen 2009 80/246 4/64 5.2 % 5.20 [ 1.98, 13.67 ]
Smolen 2015 20/96 7/98 7.3 % 2.92 [ 1.29, 6.58 ]
Yamamoto (b) 2014 45/82 4/26 5.7 % 3.57 [ 1.42, 8.97 ]
Subtotal (95% CI) 902 330 49.3 % 2.76 [ 2.02, 3.78 ]
Total events: 324 (Certolizumab pegol), 38 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.81, df = 4 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 6.37 (P < 0.00001)
3 certolizumab 400 mg sc
Choy 2012 22/126 7/121 7.3 % 3.02 [ 1.34, 6.81 ]
Fleischmann 2009 25/111 4/109 4.6 % 6.14 [ 2.21, 17.05 ]
Keystone 2008 155/390 15/99 20.8 % 2.62 [ 1.62, 4.25 ]
Smolen 2009 81/246 4/63 5.2 % 5.19 [ 1.98, 13.61 ]
Yamamoto (b) 2014 46/85 5/25 7.4 % 2.71 [ 1.21, 6.07 ]
Subtotal (95% CI) 958 417 45.2 % 3.18 [ 2.29, 4.41 ]
Total events: 329 (Certolizumab pegol), 35 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.42, df = 4 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 6.94 (P < 0.00001)
Total (95% CI) 1932 773 100.0 % 2.95 [ 2.37, 3.68 ]
Total events: 685 (Certolizumab pegol), 77 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.62, df = 10 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 9.66 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.38, df = 2 (P = 0.83), I2 =0.0%
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Analysis 44.3. Comparison 44 ACR at 24 weeks, any dose, Outcome 3 ACR70.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 44 ACR at 24 weeks, any dose
Outcome: 3 ACR70








1 certolizumab 100 mg sc
Yamamoto (b) 2014 19/72 1/26 4.9 % 6.86 [ 0.97, 48.72 ]
Subtotal (95% CI) 72 26 4.9 % 6.86 [ 0.97, 48.72 ]
Total events: 19 (Certolizumab pegol), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.93 (P = 0.054)
2 certolizumab 200 mg sc
Keystone 2008 83/393 6/100 29.8 % 3.52 [ 1.58, 7.83 ]
NCT00993317 14/85 1/42 4.8 % 6.92 [ 0.94, 50.85 ]
Smolen 2009 39/246 1/64 4.9 % 10.15 [ 1.42, 72.45 ]
Smolen 2015 9/96 3/98 11.7 % 3.06 [ 0.85, 10.97 ]
Yamamoto (b) 2014 24/82 0/26 2.5 % 15.94 [ 1.00, 253.38 ]
Subtotal (95% CI) 902 330 53.6 % 4.29 [ 2.36, 7.77 ]
Total events: 169 (Certolizumab pegol), 11 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.55, df = 4 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 4.79 (P < 0.00001)
3 certolizumab 400 mg sc
Choy 2012 0/126 2/121 2.1 % 0.19 [ 0.01, 3.96 ]
Fleischmann 2009 6/111 0/109 2.3 % 12.77 [ 0.73, 223.93 ]
Keystone 2008 80/390 6/99 29.7 % 3.38 [ 1.52, 7.53 ]
Smolen 2009 26/246 1/63 4.9 % 6.66 [ 0.92, 48.13 ]
Yamamoto (b) 2014 26/85 0/25 2.5 % 16.02 [ 1.01, 253.98 ]
Subtotal (95% CI) 958 417 41.4 % 4.04 [ 1.37, 11.90 ]
Total events: 138 (Certolizumab pegol), 9 (Control)
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Heterogeneity: Tau2 = 0.50; Chi2 = 5.94, df = 4 (P = 0.20); I2 =33%
Test for overall effect: Z = 2.53 (P = 0.011)
Total (95% CI) 1932 773 100.0 % 4.15 [ 2.68, 6.42 ]
Total events: 326 (Certolizumab pegol), 21 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 8.81, df = 10 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 6.40 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.23, df = 2 (P = 0.89), I2 =0.0%
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Analysis 45.1. Comparison 45 ACR at 52 weeks, any dose, Outcome 1 ACR20.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 45 ACR at 52 weeks, any dose
Outcome: 1 ACR20








1 certolizumab 200 mg sc
Atsumi 2016 125/161 108/158 28.8 % 1.14 [ 0.99, 1.30 ]
Emery 2015 452/660 131/219 29.2 % 1.14 [ 1.02, 1.29 ]
Keystone 2008 208/393 26/100 21.0 % 2.04 [ 1.44, 2.87 ]
Subtotal (95% CI) 1214 477 79.0 % 1.30 [ 1.03, 1.65 ]
Total events: 785 (Certolizumab pegol), 265 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 11.66, df = 2 (P = 0.003); I2 =83%
Test for overall effect: Z = 2.16 (P = 0.030)
2 certolizumab 400 mg sc
Keystone 2008 213/390 26/99 21.0 % 2.08 [ 1.48, 2.93 ]
Subtotal (95% CI) 390 99 21.0 % 2.08 [ 1.48, 2.93 ]
Total events: 213 (Certolizumab pegol), 26 (Control)
Heterogeneity: not applicable
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Test for overall effect: Z = 4.19 (P = 0.000028)
Total (95% CI) 1604 576 100.0 % 1.46 [ 1.11, 1.93 ]
Total events: 998 (Certolizumab pegol), 291 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 24.18, df = 3 (P = 0.00002); I2 =88%
Test for overall effect: Z = 2.68 (P = 0.0074)
Test for subgroup differences: Chi2 = 4.84, df = 1 (P = 0.03), I2 =79%
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Analysis 45.2. Comparison 45 ACR at 52 weeks, any dose, Outcome 2 ACR50.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 45 ACR at 52 weeks, any dose
Outcome: 2 ACR50








1 certolizumab 200 mg sc
Atsumi 2016 116/161 81/158 30.3 % 1.41 [ 1.17, 1.68 ]
Emery 2015 (1) 405/660 112/219 31.4 % 1.20 [ 1.04, 1.38 ]
Keystone 2008 149/393 15/100 19.1 % 2.53 [ 1.56, 4.10 ]
Subtotal (95% CI) 1214 477 80.8 % 1.48 [ 1.11, 1.96 ]
Total events: 670 (Certolizumab pegol), 208 (Control)
Heterogeneity: Tau2 = 0.05; Chi2 = 9.68, df = 2 (P = 0.01); I2 =79%
Test for overall effect: Z = 2.70 (P = 0.0069)
2 certolizumab 400 mg sc
Keystone 2008 155/390 15/99 19.2 % 2.62 [ 1.62, 4.25 ]
Subtotal (95% CI) 390 99 19.2 % 2.62 [ 1.62, 4.25 ]
Total events: 155 (Certolizumab pegol), 15 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.92 (P = 0.000088)
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Total (95% CI) 1604 576 100.0 % 1.69 [ 1.22, 2.33 ]
Total events: 825 (Certolizumab pegol), 223 (Control)
Heterogeneity: Tau2 = 0.08; Chi2 = 18.63, df = 3 (P = 0.00033); I2 =84%
Test for overall effect: Z = 3.17 (P = 0.0015)
Test for subgroup differences: Chi2 = 4.04, df = 1 (P = 0.04), I2 =75%
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(1) Calculations of events were done according to the percentages of FAS (Full Analysis Set) 213 patients in placebo group and 655 in CZP group. We did AIT and
denominators were 219 and 660 in placebo and CZP group, respectively).
Analysis 45.3. Comparison 45 ACR at 52 weeks, any dose, Outcome 3 ACR70.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 45 ACR at 52 weeks, any dose
Outcome: 3 ACR70








1 certolizumab 200 mg sc
Atsumi 2016 91/161 54/158 38.2 % 1.65 [ 1.28, 2.13 ]
Emery 2015 279/660 57/219 39.7 % 1.62 [ 1.28, 2.07 ]
Keystone 2008 83/393 7/100 11.0 % 3.02 [ 1.44, 6.32 ]
Subtotal (95% CI) 1214 477 88.9 % 1.71 [ 1.39, 2.11 ]
Total events: 453 (Certolizumab pegol), 118 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 2.59, df = 2 (P = 0.27); I2 =23%
Test for overall effect: Z = 5.11 (P < 0.00001)
2 certolizumab 400 mg sc
Keystone 2008 90/390 7/99 11.1 % 3.26 [ 1.56, 6.82 ]
Subtotal (95% CI) 390 99 11.1 % 3.26 [ 1.56, 6.82 ]
Total events: 90 (Certolizumab pegol), 7 (Control)
Heterogeneity: not applicable
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Test for overall effect: Z = 3.15 (P = 0.0017)
Total (95% CI) 1604 576 100.0 % 1.89 [ 1.44, 2.48 ]
Total events: 543 (Certolizumab pegol), 125 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 5.77, df = 3 (P = 0.12); I2 =48%
Test for overall effect: Z = 4.58 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.72, df = 1 (P = 0.10), I2 =63%
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Analysis 46.1. Comparison 46 ACR20-ACR70, 24 weeks, 200 mg certolizumab pegol, Outcome 1 ACR 20.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 46 ACR20-ACR70, 24 weeks, 200 mg certolizumab pegol
Outcome: 1 ACR 20
Study or subgroup
Certolizumab








Smolen 2015 35/96 15/98 15.5 % 2.38 [ 1.39, 4.07 ]
NCT00993317 54/85 11/42 15.5 % 2.43 [ 1.42, 4.13 ]
Yamamoto (b) 2014 60/82 19/77 18.7 % 2.97 [ 1.96, 4.48 ]
Keystone 2008 228/393 27/199 20.1 % 4.28 [ 2.98, 6.13 ]
Yamamoto (a) 2014 74/116 13/114 15.6 % 5.59 [ 3.29, 9.50 ]
Smolen 2009 141/246 11/127 14.5 % 6.62 [ 3.72, 11.76 ]
Total (95% CI) 1018 657 100.0 % 3.71 [ 2.68, 5.13 ]
Total events: 592 (Certolizumab pegol 200 mg), 96 (Placebo)
Heterogeneity: Tau2 = 0.10; Chi2 = 13.68, df = 5 (P = 0.02); I2 =63%
Test for overall effect: Z = 7.92 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 46.2. Comparison 46 ACR20-ACR70, 24 weeks, 200 mg certolizumab pegol, Outcome 2 ACR 70.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 46 ACR20-ACR70, 24 weeks, 200 mg certolizumab pegol
Outcome: 2 ACR 70
Study or subgroup
Certolizumab








Keystone 2008 83/393 6/199 47.8 % 7.00 [ 3.11, 15.76 ]
NCT00993317 14/85 1/42 9.8 % 6.92 [ 0.94, 50.85 ]
Smolen 2009 39/246 1/127 10.0 % 20.13 [ 2.80, 144.86 ]
Smolen 2015 9/96 3/98 22.4 % 3.06 [ 0.85, 10.97 ]
Yamamoto (b) 2014 24/82 1/77 10.0 % 22.54 [ 3.12, 162.58 ]
Total (95% CI) 902 543 100.0 % 7.26 [ 3.83, 13.76 ]
Total events: 169 (Certolizumab pegol 200 mg), 12 (Placebo)
Heterogeneity: Tau2 = 0.05; Chi2 = 4.38, df = 4 (P = 0.36); I2 =9%
Test for overall effect: Z = 6.07 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 47.1. Comparison 47 ACR20-ACR70 at 24 weeks, 400 mg certolizumab, Outcome 1 ACR 20.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 47 ACR20-ACR70 at 24 weeks, 400 mg certolizumab
Outcome: 1 ACR 20








Choy 2012 56/126 27/121 21.8 % 1.99 [ 1.35, 2.93 ]
Fleischmann 2009 50/111 10/109 16.9 % 4.91 [ 2.63, 9.18 ]
Keystone 2008 236/390 27/199 22.3 % 4.46 [ 3.11, 6.39 ]
Smolen 2009 141/246 11/127 17.9 % 6.62 [ 3.72, 11.76 ]
Yamamoto (b) 2014 61/85 19/77 21.2 % 2.91 [ 1.93, 4.39 ]
Total (95% CI) 958 633 100.0 % 3.73 [ 2.43, 5.72 ]
Total events: 544 (Certolizumab pegol), 94 (Control)
Heterogeneity: Tau2 = 0.18; Chi2 = 17.77, df = 4 (P = 0.001); I2 =77%
Test for overall effect: Z = 6.03 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 47.2. Comparison 47 ACR20-ACR70 at 24 weeks, 400 mg certolizumab, Outcome 2 ACR 70.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 47 ACR20-ACR70 at 24 weeks, 400 mg certolizumab
Outcome: 2 ACR 70








Choy 2012 (1) 0/126 2/121 11.2 % 0.19 [ 0.01, 3.96 ]
Fleischmann 2009 6/111 0/109 12.1 % 12.77 [ 0.73, 223.93 ]
Keystone 2008 80/390 6/199 37.4 % 6.80 [ 3.02, 15.32 ]
Smolen 2009 26/246 1/127 19.6 % 13.42 [ 1.84, 97.78 ]
Yamamoto (b) 2014 26/85 1/77 19.7 % 23.55 [ 3.27, 169.46 ]
Total (95% CI) 958 633 100.0 % 7.20 [ 2.25, 23.03 ]
Total events: 138 (Certolizumab pegol), 10 (Control)
Heterogeneity: Tau2 = 0.77; Chi2 = 7.46, df = 4 (P = 0.11); I2 =46%
Test for overall effect: Z = 3.33 (P = 0.00088)
Test for subgroup differences: Not applicable
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Analysis 48.1. Comparison 48 ACR20-ACR70 at 52 weeks, 200 mg certolizumab, Outcome 1 ACR 20.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 48 ACR20-ACR70 at 52 weeks, 200 mg certolizumab
Outcome: 1 ACR 20
Study or subgroup Certolizumab pegol Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Atsumi 2016 125/161 108/158 32.0 % 1.14 [ 0.99, 1.30 ]
Emery 2015 452/660 131/219 57.8 % 1.14 [ 1.02, 1.29 ]
Keystone 2008 208/393 26/199 10.1 % 4.05 [ 2.80, 5.87 ]
Total (95% CI) 1214 576 100.0 % 1.44 [ 1.30, 1.58 ]
Total events: 785 (Certolizumab pegol), 265 (Control)
Heterogeneity: Chi2 = 55.50, df = 2 (P<0.00001); I2 =96%
Test for overall effect: Z = 7.37 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 48.2. Comparison 48 ACR20-ACR70 at 52 weeks, 200 mg certolizumab, Outcome 2 ACR 70.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 48 ACR20-ACR70 at 52 weeks, 200 mg certolizumab
Outcome: 2 ACR 70
Study or subgroup Certolizumab pegol Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Atsumi 2016 91/161 54/158 28.5 % 1.65 [ 1.28, 2.13 ]
Emery 2015 336/660 85/219 66.7 % 1.31 [ 1.09, 1.57 ]
Keystone 2008 83/393 7/199 4.9 % 6.00 [ 2.83, 12.74 ]
Total (95% CI) 1214 576 100.0 % 1.64 [ 1.41, 1.90 ]
Total events: 510 (Certolizumab pegol), 146 (Control)
Heterogeneity: Chi2 = 17.14, df = 2 (P = 0.00019); I2 =88%
Test for overall effect: Z = 6.50 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 49.1. Comparison 49 ACR20-ACR70 at 52 weeks, 400 mg certolizumab, Outcome 1 ACR 20.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 49 ACR20-ACR70 at 52 weeks, 400 mg certolizumab
Outcome: 1 ACR 20
Study or subgroup Certolizumab pegol Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Keystone 2008 213/390 26/199 4.18 [ 2.89, 6.05 ]
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Analysis 49.2. Comparison 49 ACR20-ACR70 at 52 weeks, 400 mg certolizumab, Outcome 2 ACR 70.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 49 ACR20-ACR70 at 52 weeks, 400 mg certolizumab
Outcome: 2 ACR 70
Study or subgroup Certolizumab pegol Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Keystone 2008 90/390 7/199 6.56 [ 3.10, 13.89 ]
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Analysis 50.1. Comparison 50 Safety, Outcome 1 Any adverse event certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 1 Any adverse event certolizumab 200 mg
Study or subgroup
Certolizumab








Atsumi 2016 153/161 148/158 18.2 % 1.01 [ 0.96, 1.07 ]
Emery 2015 113/660 31/219 6.7 % 1.21 [ 0.84, 1.75 ]
Keystone 2008 293/392 115/199 15.3 % 1.29 [ 1.13, 1.48 ]
NCT00993317 60/85 21/42 7.6 % 1.41 [ 1.01, 1.97 ]
Smolen 2009 139/248 66/125 12.3 % 1.06 [ 0.87, 1.30 ]
Smolen 2015 37/96 41/98 7.3 % 0.92 [ 0.65, 1.30 ]
Weinblatt 2012 571/846 129/209 16.0 % 1.09 [ 0.97, 1.23 ]
Yamamoto (a) 2014 (1) 59/116 44/114 8.8 % 1.32 [ 0.98, 1.77 ]
Yamamoto (b) 2014 48/82 31/77 7.7 % 1.45 [ 1.05, 2.02 ]
Total (95% CI) 2686 1241 100.0 % 1.16 [ 1.03, 1.31 ]
Total events: 1473 (Certolizumab pegol 200 mg), 626 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 31.27, df = 8 (P = 0.00013); I2 =74%
Test for overall effect: Z = 2.48 (P = 0.013)
Test for subgroup differences: Not applicable
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(1) UCB provides us different number of AE that appears in clinicaltrials.org. 67 in CZP 200 mg and 83 in control groups Check with UCB again
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Analysis 50.2. Comparison 50 Safety, Outcome 2 Any adverse events certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 2 Any adverse events certolizumab 400 mg
Study or subgroup
Certolizumab








Choy 2012 97/124 83/119 24.0 % 1.12 [ 0.96, 1.30 ]
Fleischmann 2009 84/111 63/109 19.7 % 1.31 [ 1.08, 1.59 ]
Keystone 2008 298/389 115/199 26.3 % 1.33 [ 1.16, 1.51 ]
Smolen 2009 125/246 66/125 18.3 % 0.96 [ 0.78, 1.18 ]
Yamamoto (b) 2014 46/85 31/77 10.0 % 1.34 [ 0.96, 1.88 ]
stergaard 2015 7/27 5/13 1.7 % 0.67 [ 0.26, 1.72 ]
Total (95% CI) 982 642 100.0 % 1.19 [ 1.05, 1.34 ]
Total events: 657 (Certolizumab pegol 400 mg), 363 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 10.08, df = 5 (P = 0.07); I2 =50%
Test for overall effect: Z = 2.69 (P = 0.0071)
Test for subgroup differences: Not applicable
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Analysis 50.3. Comparison 50 Safety, Outcome 3 Adverse events: Intensity mild certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 3 Adverse events: Intensity mild certolizumab 200 mg
Study or subgroup
Certolizumab








Keystone 2008 244/392 90/199 37.2 % 1.38 [ 1.16, 1.63 ]
Smolen 2009 108/248 45/125 23.6 % 1.21 [ 0.92, 1.59 ]
Weinblatt 2012 248/846 56/209 26.5 % 1.09 [ 0.85, 1.40 ]
Yamamoto (a) 2014 (1) 29/116 33/114 12.7 % 0.86 [ 0.56, 1.32 ]
Total (95% CI) 1602 647 100.0 % 1.18 [ 1.00, 1.41 ]
Total events: 629 (Certolizumab pegol 200 mg), 224 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 5.26, df = 3 (P = 0.15); I2 =43%
Test for overall effect: Z = 1.94 (P = 0.053)
Test for subgroup differences: Not applicable
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Analysis 50.4. Comparison 50 Safety, Outcome 4 Adverse events: Intensity mild certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 4 Adverse events: Intensity mild certolizumab 400 mg
Study or subgroup
Certolizumab








Choy 2012 64/124 61/119 24.0 % 1.01 [ 0.79, 1.29 ]
Fleischmann 2009 62/111 43/109 20.1 % 1.42 [ 1.06, 1.88 ]
Keystone 2008 254/389 90/199 33.2 % 1.44 [ 1.22, 1.71 ]
Smolen 2009 101/246 45/125 20.8 % 1.14 [ 0.86, 1.51 ]
stergaard 2015 7/27 3/13 1.9 % 1.12 [ 0.35, 3.65 ]
Total (95% CI) 897 565 100.0 % 1.25 [ 1.06, 1.47 ]
Total events: 488 (Certolizumab pegol 400 mg), 242 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 6.84, df = 4 (P = 0.14); I2 =42%
Test for overall effect: Z = 2.67 (P = 0.0077)
Test for subgroup differences: Not applicable
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Analysis 50.5. Comparison 50 Safety, Outcome 5 Adverse events: Intensity moderate certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 5 Adverse events: Intensity moderate certolizumab 200 mg
Study or subgroup
Certolizumab








Keystone 2008 174/392 66/199 30.9 % 1.34 [ 1.07, 1.68 ]
Smolen 2009 61/248 32/125 19.4 % 0.96 [ 0.66, 1.39 ]
Weinblatt 2012 257/846 58/209 29.5 % 1.09 [ 0.86, 1.39 ]
Yamamoto (a) 2014 36/116 44/114 20.2 % 0.80 [ 0.56, 1.15 ]
Total (95% CI) 1602 647 100.0 % 1.07 [ 0.86, 1.32 ]
Total events: 528 (Certolizumab pegol 200 mg), 200 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 6.36, df = 3 (P = 0.10); I2 =53%
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Not applicable
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Analysis 50.6. Comparison 50 Safety, Outcome 6 Adverse events: Intensity moderate certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 6 Adverse events: Intensity moderate certolizumab 400 mg
Study or subgroup
Certolizumab








Choy 2012 59/124 45/119 25.1 % 1.26 [ 0.94, 1.69 ]
Fleischmann 2009 52/111 40/109 23.1 % 1.28 [ 0.93, 1.75 ]
Keystone 2008 177/389 66/199 32.8 % 1.37 [ 1.10, 1.72 ]
Smolen 2009 57/246 32/125 18.6 % 0.91 [ 0.62, 1.32 ]
stergaard 2015 0/27 2/13 0.4 % 0.10 [ 0.01, 1.94 ]
Total (95% CI) 897 565 100.0 % 1.21 [ 0.99, 1.47 ]
Total events: 345 (Certolizumab pegol 400 mg), 185 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 6.32, df = 4 (P = 0.18); I2 =37%
Test for overall effect: Z = 1.89 (P = 0.059)
Test for subgroup differences: Not applicable
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Analysis 50.7. Comparison 50 Safety, Outcome 7 Adverse events: Intensity severe certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 7 Adverse events: Intensity severe certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Yamamoto (a) 2014 2/116 6/114 7.0 % 0.35 [ 0.09, 1.43 ]
Weinblatt 2012 66/846 15/209 42.8 % 1.09 [ 0.62, 1.93 ]
Keystone 2008 32/392 13/199 33.5 % 1.26 [ 0.66, 2.40 ]
Smolen 2009 17/248 5/125 16.7 % 1.67 [ 0.67, 4.16 ]
Total (95% CI) 1602 647 100.0 % 1.14 [ 0.78, 1.65 ]
Total events: 117 (Certolizumab pegol 200 mg), 39 (Control)
Heterogeneity: Chi2 = 3.49, df = 3 (P = 0.32); I2 =14%
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 50.8. Comparison 50 Safety, Outcome 8 Adverse events: Intensity severe certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 8 Adverse events: Intensity severe certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Choy 2012 17/124 14/119 26.5 % 1.19 [ 0.56, 2.53 ]
Fleischmann 2009 8/111 11/109 17.0 % 0.69 [ 0.27, 1.78 ]
Keystone 2008 38/389 13/199 40.8 % 1.50 [ 0.82, 2.76 ]
Smolen 2009 14/246 5/125 15.8 % 1.41 [ 0.53, 3.75 ]
stergaard 2015 0/27 0/13 Not estimable
Total (95% CI) 897 565 100.0 % 1.23 [ 0.83, 1.81 ]
Total events: 77 (Certolizumab pegol 400 mg), 43 (Control)
Heterogeneity: Chi2 = 1.93, df = 3 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Not applicable
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Analysis 50.9. Comparison 50 Safety, Outcome 9 Adverse events related to study drug certolizumab 200
mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 9 Adverse events related to study drug certolizumab 200 mg
Study or subgroup
Certolizumab








Keystone 2008 167/392 50/199 72.2 % 1.70 [ 1.30, 2.21 ]
Smolen 2009 61/248 23/125 27.8 % 1.34 [ 0.87, 2.05 ]
Total (95% CI) 640 324 100.0 % 1.59 [ 1.27, 1.99 ]
Total events: 228 (Certolizumab pegol 200 mg), 73 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.85, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 4.01 (P = 0.000062)
Test for subgroup differences: Not applicable
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Analysis 50.10. Comparison 50 Safety, Outcome 10 Adverse events related to study drug certolizumab 400
mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 10 Adverse events related to study drug certolizumab 400 mg
Study or subgroup
Certolizumab
pegol 400 mg Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fleischmann 2009 27/111 24/109 19.8 % 1.10 [ 0.68, 1.79 ]
Keystone 2008 166/389 50/199 54.1 % 1.70 [ 1.30, 2.22 ]
Smolen 2009 56/246 23/125 25.0 % 1.24 [ 0.80, 1.91 ]
stergaard 2015 4/27 1/13 1.1 % 1.93 [ 0.24, 15.56 ]
Total (95% CI) 773 446 100.0 % 1.47 [ 1.20, 1.80 ]
Total events: 253 (Certolizumab pegol 400 mg), 98 (Control)
Heterogeneity: Chi2 = 3.15, df = 3 (P = 0.37); I2 =5%
Test for overall effect: Z = 3.70 (P = 0.00022)
Test for subgroup differences: Not applicable
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Analysis 50.11. Comparison 50 Safety, Outcome 11 Serious Infections certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 11 Serious Infections certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Atsumi 2016 5/161 7/158 33.9 % 0.69 [ 0.22, 2.20 ]
Keystone 2008 16/392 2/199 45.7 % 2.83 [ 1.05, 7.63 ]
Smolen 2009 8/248 0/125 20.5 % 4.63 [ 1.05, 20.39 ]
Total (95% CI) 801 482 100.0 % 1.94 [ 0.99, 3.80 ]
Total events: 29 (Certolizumab pegol 200 mg), 9 (Control)
Heterogeneity: Chi2 = 4.94, df = 2 (P = 0.08); I2 =59%
Test for overall effect: Z = 1.94 (P = 0.052)
Test for subgroup differences: Not applicable
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Analysis 50.12. Comparison 50 Safety, Outcome 12 Serious infections certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 12 Serious infections certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Choy 2012 3/124 2/119 14.6 % 1.44 [ 0.25, 8.44 ]
Fleischmann 2009 2/111 0/109 5.9 % 7.32 [ 0.46, 117.84 ]
Keystone 2008 23/389 2/199 63.8 % 3.33 [ 1.43, 7.76 ]
Smolen 2009 6/246 0/125 15.7 % 4.61 [ 0.84, 25.36 ]
Total (95% CI) 870 552 100.0 % 3.25 [ 1.65, 6.39 ]
Total events: 34 (Certolizumab pegol 400 mg), 4 (Control)
Heterogeneity: Chi2 = 1.31, df = 3 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 3.42 (P = 0.00063)
Test for subgroup differences: Not applicable
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Analysis 50.13. Comparison 50 Safety, Outcome 13 Adverse events leading to death certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 13 Adverse events leading to death certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Emery 2015 (1) 2/660 1/219 27.7 % 0.64 [ 0.05, 8.74 ]
Keystone 2008 2/392 1/199 33.1 % 1.02 [ 0.09, 11.18 ]
Smolen 2009 1/248 0/125 11.0 % 4.50 [ 0.07, 286.06 ]
Smolen 2015 0/96 0/98 Not estimable
Weinblatt 2012 2/846 0/209 15.7 % 3.48 [ 0.11, 112.96 ]
Yamamoto (a) 2014 (2) 1/116 0/114 12.4 % 7.26 [ 0.14, 366.07 ]
Total (95% CI) 2358 964 100.0 % 1.63 [ 0.41, 6.47 ]
Total events: 8 (Certolizumab pegol 200 mg), 2 (Control)
Heterogeneity: Chi2 = 1.62, df = 4 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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(1) Calculations of events were done according to the percentages of FAS (Full Analysis Set) 213 patients in placebo group and 655 in CZP group. We did AIT and
denominators were 219 and 660 in placebo and CZP group, respectively).
(2) 1 patient died of a rupture of a dissecting aortic aneurysm in the thoracic region, but UCB considered that in unlikely to have beeen related to study medication
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Analysis 50.14. Comparison 50 Safety, Outcome 14 Adverse events leading to death certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 14 Adverse events leading to death certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Fleischmann 2009 0/111 0/109 Not estimable
Keystone 2008 4/389 1/199 83.3 % 1.86 [ 0.29, 11.96 ]
Smolen 2009 1/246 0/125 16.7 % 4.52 [ 0.07, 285.66 ]
Total (95% CI) 746 433 100.0 % 2.16 [ 0.40, 11.79 ]
Total events: 5 (Certolizumab pegol 400 mg), 1 (Control)
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Not applicable
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Analysis 50.15. Comparison 50 Safety, Outcome 15 Adverse events leading to withdrawal certolizumab 200
mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 15 Adverse events leading to withdrawal certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Emery 2015 (1) 57/660 20/219 36.8 % 0.94 [ 0.55, 1.61 ]
Keystone 2008 17/392 3/199 12.1 % 2.37 [ 0.92, 6.09 ]
NCT00993317 4/85 2/42 3.6 % 0.99 [ 0.17, 5.60 ]
Smolen 2009 12/248 2/125 8.4 % 2.45 [ 0.79, 7.57 ]
Smolen 2015 6/96 6/98 7.9 % 1.02 [ 0.32, 3.28 ]
Weinblatt 2012 40/846 8/209 20.4 % 1.23 [ 0.60, 2.54 ]
Yamamoto (a) 2014 8/116 2/114 6.7 % 3.42 [ 0.97, 12.13 ]
Yamamoto (b) 2014 3/82 3/77 4.1 % 0.94 [ 0.18, 4.77 ]
Total (95% CI) 2525 1083 100.0 % 1.32 [ 0.95, 1.84 ]
Total events: 147 (Certolizumab pegol 200 mg), 46 (Control)
Heterogeneity: Chi2 = 6.83, df = 7 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 1.68 (P = 0.093)
Test for subgroup differences: Not applicable
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(1) Calculations of events were done according to the percentages of FAS (Full Analysis Set) 213 patients in placebo group and 655 in CZP group. We did AIT and
denominators were 219 and 660 in placebo and CZP group, respectively).
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Analysis 50.16. Comparison 50 Safety, Outcome 16 Adverse events leading to withdrawal certolizumab 400
mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 16 Adverse events leading to withdrawal certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Choy 2012 7/124 6/119 21.3 % 1.13 [ 0.37, 3.44 ]
Fleischmann 2009 5/111 2/109 11.8 % 2.37 [ 0.53, 10.64 ]
Keystone 2008 22/389 3/199 37.1 % 2.77 [ 1.19, 6.44 ]
Smolen 2009 7/246 2/125 13.6 % 1.69 [ 0.42, 6.84 ]
Yamamoto (b) 2014 7/85 3/77 16.3 % 2.11 [ 0.59, 7.55 ]
stergaard 2015 0/27 0/13 Not estimable
Total (95% CI) 982 642 100.0 % 2.01 [ 1.20, 3.36 ]
Total events: 48 (Certolizumab pegol 400 mg), 16 (Control)
Heterogeneity: Chi2 = 1.69, df = 4 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 2.65 (P = 0.0081)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours certolizumab pego Favours control
180Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 50.17. Comparison 50 Safety, Outcome 17 Death certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 17 Death certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Emery 2015 (1) 1/660 0/219 10.0 % 3.79 [ 0.04, 351.89 ]
Keystone 2008 (2) 3/392 1/199 47.6 % 1.48 [ 0.18, 11.81 ]
Smolen 2009 1/246 0/125 12.0 % 4.52 [ 0.07, 285.66 ]
Smolen 2015 0/96 0/98 Not estimable
Weinblatt 2012 2/846 0/209 17.0 % 3.48 [ 0.11, 112.96 ]
Yamamoto (a) 2014 (3) 1/116 0/114 13.4 % 7.26 [ 0.14, 366.07 ]
Total (95% CI) 2356 964 100.0 % 2.66 [ 0.63, 11.16 ]
Total events: 8 (Certolizumab pegol 200 mg), 1 (Control)
Heterogeneity: Chi2 = 0.67, df = 4 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.34 (P = 0.18)
Test for subgroup differences: Not applicable
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(1) Calculations of events were done according to the percentages of FAS (Full Analysis Set) 213 patients in placebo group and 655 in CZP group. We did AIT and
denominators were 219 and 660 in placebo and CZP group, respectively).
(2) One patient died of hepatic neoplam and other for cardiac arrest. One patient died in placebo group of a myocardial infarction
(3) 1 patient died of a rupture of a dissecting aortic aneurysm in the thoracic region, but UCB considered that in unlikely to have beeen related to study medication
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Analysis 50.18. Comparison 50 Safety, Outcome 18 Death certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 18 Death certolizumab 400 mg
Study or subgroup
Certolizumab
pegol 400 mg Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Choy 2012 0/124 0/119 Not estimable
Fleischmann 2009 0/111 0/109 Not estimable
Keystone 2008 4/389 1/199 66.6 % 2.05 [ 0.23, 18.19 ]
Smolen 2009 1/246 0/125 33.4 % 1.53 [ 0.06, 37.30 ]
stergaard 2015 0/27 0/13 Not estimable
Total (95% CI) 897 565 100.0 % 1.87 [ 0.31, 11.34 ]
Total events: 5 (Certolizumab pegol 400 mg), 1 (Control)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.68 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 50.19. Comparison 50 Safety, Outcome 19 Deaths overall.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 19 Deaths overall





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Certolizumab pegol 200 mg
Emery 2015 (1) 1/660 0/219 7.2 % 3.79 [ 0.04, 351.89 ]
Keystone 2008 (2) 3/392 1/100 24.9 % 0.75 [ 0.07, 8.60 ]
Smolen 2009 (3) 1/246 0/63 6.3 % 3.51 [ 0.03, 455.29 ]
Smolen 2015 0/96 0/98 Not estimable
Weinblatt 2012 (4) 2/846 0/209 12.3 % 3.48 [ 0.11, 112.96 ]
Yamamoto (a) 2014 (5) 1/116 0/114 9.7 % 7.26 [ 0.14, 366.07 ]
Yamamoto (b) 2014 0/82 0/25 Not estimable
Subtotal (95% CI) 2438 828 60.3 % 2.10 [ 0.44, 10.08 ]
Total events: 8 (Certolizumab pegol), 1 (Placebo)
Heterogeneity: Chi2 = 1.26, df = 4 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
2 Certolizumab pegol 400 mg
Choy 2012 0/124 0/119 Not estimable
Fleischmann 2009 0/111 0/109 Not estimable
Keystone 2008 (6) 4/389 0/99 24.9 % 3.53 [ 0.31, 40.72 ]
Smolen 2009 (7) 1/246 0/62 6.2 % 3.50 [ 0.03, 464.09 ]
Yamamoto (b) 2014 0/65 0/25 Not estimable
Subtotal (95% CI) 935 414 31.1 % 3.53 [ 0.40, 31.39 ]
Total events: 5 (Certolizumab pegol), 0 (Placebo)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26)
3 Other doses
Choy 2002 1/24 0/12 8.6 % 4.48 [ 0.07, 286.49 ]
Yamamoto (b) 2014 0/72 0/22 Not estimable
Subtotal (95% CI) 96 34 8.6 % 4.48 [ 0.07, 286.49 ]
Total events: 1 (Certolizumab pegol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Total (95% CI) 3469 1276 100.0 % 2.63 [ 0.78, 8.91 ]
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(Continued . . . )
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n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Total events: 14 (Certolizumab pegol), 1 (Placebo)
Heterogeneity: Chi2 = 1.47, df = 7 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.56 (P = 0.12)
Test for subgroup differences: Chi2 = 0.21, df = 2 (P = 0.90), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours certolizumab pego Favours control
(1) Calculations of events were done according to the percentages of FAS (Full Analysis Set) 213 patients in placebo group and 655 in CZP group. We did AIT and
denominators were 219 and 660 in placebo and CZP group, respectively).
(2) Two deaths: one participant of hepatic neoplasm, and the other of cardiac arrest. One more died of peritonitis, cirrhosis, and general deterioration of physical health
during the post-treatment period). In Placebo 1 death (myocardial necrosis)
(3) 1 participant died of myocardial infarction
(4) Two deaths in the CZP group: one case of sigmoid diverticulitis in a 73-year-old man with pancreatitis, and one of necrotising pneumonia, both deaths were ruled as
possibly related to CZP
(5) 1 participant died of a rupture of a dissecting aortic aneurysm in the thoracic region, but UCB considered that in unlikely to have beeen related to study medication
(6) Four deaths: 1 cerebral stroke, 1 myocardial necrosis, 1 cardiac arrest and 1 atrial fibrillation)
(7) 1 participant died by fracture and shock
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Analysis 50.20. Comparison 50 Safety, Outcome 20 Tuberculosis certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 20 Tuberculosis certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Atsumi 2016 0/161 0/158 Not estimable
Emery 2015 3/660 2/219 37.5 % 0.44 [ 0.06, 3.39 ]
Keystone 2008 2/392 0/199 18.0 % 4.53 [ 0.24, 85.22 ]
NCT00993317 2/85 0/42 17.7 % 4.51 [ 0.23, 86.80 ]
Smolen 2009 3/248 0/125 26.8 % 4.54 [ 0.41, 50.19 ]
Smolen 2015 0/96 0/98 Not estimable
Weinblatt 2012 0/846 0/209 Not estimable
Total (95% CI) 2488 1050 100.0 % 1.90 [ 0.55, 6.58 ]
Total events: 10 (Certolizumab pegol 200 mg), 2 (Control)
Heterogeneity: Chi2 = 3.13, df = 3 (P = 0.37); I2 =4%
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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Analysis 50.21. Comparison 50 Safety, Outcome 21 Tuberculosis certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 21 Tuberculosis certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Fleischmann 2009 0/111 0/109 Not estimable
Keystone 2008 3/389 0/199 60.0 % 4.56 [ 0.42, 50.01 ]
Smolen 2009 2/246 0/125 40.0 % 4.54 [ 0.24, 85.48 ]
Total (95% CI) 746 433 100.0 % 4.55 [ 0.71, 29.11 ]
Total events: 5 (Certolizumab pegol 400 mg), 0 (Control)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.60 (P = 0.11)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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Analysis 50.22. Comparison 50 Safety, Outcome 22 Tuberculosis overall.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 22 Tuberculosis overall





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Certolizumab pegol 200 mg
Emery 2015 3/660 2/219 31.3 % 0.44 [ 0.06, 3.39 ]
Keystone 2008 2/392 0/100 10.9 % 3.52 [ 0.11, 110.51 ]
NCT00993317 2/85 0/42 14.7 % 4.51 [ 0.23, 86.80 ]
Smolen 2009 3/248 0/63 16.2 % 3.53 [ 0.21, 59.55 ]
Smolen 2015 0/96 0/98 Not estimable
Weinblatt 2012 0/846 0/209 Not estimable
Subtotal (95% CI) 2327 731 73.0 % 1.53 [ 0.40, 5.77 ]
Total events: 10 (Certolizumab pegol), 2 (Placebo)
Heterogeneity: Chi2 = 2.50, df = 3 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.53)
2 Certolizumab pegol 400 mg
Fleischmann 2009 0/111 0/109 Not estimable
Keystone 2008 3/389 0/99 16.2 % 3.52 [ 0.21, 59.11 ]
Smolen 2009 2/246 0/62 10.8 % 3.51 [ 0.11, 111.96 ]
Subtotal (95% CI) 746 270 27.0 % 3.52 [ 0.40, 31.33 ]
Total events: 5 (Certolizumab pegol), 0 (Placebo)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26)
Total (95% CI) 3073 1001 100.0 % 1.91 [ 0.61, 5.96 ]
Total events: 15 (Certolizumab pegol), 2 (Placebo)
Heterogeneity: Chi2 = 2.90, df = 5 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Chi2 = 0.41, df = 1 (P = 0.52), I2 =0.0%
0.005 0.1 1 10 200
Favours certolizumab pego Favours control
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Analysis 50.23. Comparison 50 Safety, Outcome 23 Malignancies included lymphoma certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 23 Malignancies included lymphoma certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Atsumi 2016 1/161 0/158 4.4 % 7.25 [ 0.14, 365.57 ]
Emery 2015 6/660 2/219 26.3 % 1.00 [ 0.20, 4.97 ]
Keystone 2008 (1) 7/392 1/199 31.3 % 2.61 [ 0.60, 11.41 ]
NCT00993317 (2) 0/85 0/42 Not estimable
Smolen 2009 1/248 1/125 7.9 % 0.48 [ 0.03, 9.01 ]
Smolen 2015 0/96 2/98 8.8 % 0.14 [ 0.01, 2.20 ]
Weinblatt 2012 4/846 2/209 16.8 % 0.43 [ 0.06, 3.18 ]
Yamamoto (a) 2014 0/116 1/114 4.4 % 0.13 [ 0.00, 6.70 ]
Total (95% CI) 2604 1164 100.0 % 0.92 [ 0.40, 2.11 ]
Total events: 19 (Certolizumab pegol 200 mg), 9 (Control)
Heterogeneity: Chi2 = 6.50, df = 6 (P = 0.37); I2 =8%
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours certolizumab pego Favours control
(1) One patient in the arm of placebo suffered a thyroid neoplasm and 7 in the arm of certolizumab 200 mg sc suffered: three basal cell carcinomas [one with metastasis
to the central nervous system], one adrenal adenoma, one hepatic neoplasm one esophageal carcinoma, and uterine cancer
(2) Data provided by UCB
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Analysis 50.24. Comparison 50 Safety, Outcome 24 Malignancies included lymphoma certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 24 Malignancies included lymphoma certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Fleischmann 2009 0/111 0/109 Not estimable
Keystone 2008 (1) 4/389 1/199 71.4 % 1.86 [ 0.29, 11.96 ]
Smolen 2009 (2) 1/246 1/125 28.6 % 0.48 [ 0.03, 9.06 ]
Total (95% CI) 746 433 100.0 % 1.26 [ 0.26, 6.08 ]
Total events: 5 (Certolizumab pegol 400 mg), 2 (Control)
Heterogeneity: Chi2 = 0.58, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
(1) In the placebo arm one patient suffered a thyroid neoplasm and 4 in the certolizumab 400 mg sc suffered two tongue neoplasm, 1 extranodal marginal zone B cell
limphoma and one papilloma.
(2) One case of malignant neoplasm was reported in each arm, namely bladder cancer in the placebo group and colon cancer in certolizumab pegol 400 mg group
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Analysis 50.25. Comparison 50 Safety, Outcome 25 Injection side reactions certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 25 Injection side reactions certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Atsumi 2016 1/161 0/158 2.3 % 7.25 [ 0.14, 365.57 ]
Keystone 2008 9/392 0/199 18.2 % 4.61 [ 1.15, 18.55 ]
Smolen 2009 3/248 0/125 6.1 % 4.54 [ 0.41, 50.19 ]
Weinblatt 2012 49/846 2/209 71.0 % 2.86 [ 1.41, 5.79 ]
Yamamoto (b) 2014 1/82 0/77 2.3 % 6.95 [ 0.14, 351.04 ]
Total (95% CI) 1729 768 100.0 % 3.34 [ 1.85, 6.06 ]
Total events: 63 (Certolizumab pegol 200 mg), 2 (Control)
Heterogeneity: Chi2 = 0.74, df = 4 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 3.98 (P = 0.000069)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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Analysis 50.26. Comparison 50 Safety, Outcome 26 Injection side reactions certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 26 Injection side reactions certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Choy 2012 (1) 5/124 34/119 54.6 % 0.16 [ 0.08, 0.32 ]
Fleischmann 2009 5/111 15/109 30.3 % 0.33 [ 0.13, 0.82 ]
Keystone 2008 3/389 0/199 4.4 % 4.56 [ 0.42, 50.01 ]
Smolen 2009 5/246 0/125 7.3 % 4.59 [ 0.71, 29.64 ]
Yamamoto (b) 2014 2/85 0/77 3.3 % 6.81 [ 0.42, 110.13 ]
Total (95% CI) 955 629 100.0 % 0.34 [ 0.20, 0.56 ]
Total events: 20 (Certolizumab pegol 400 mg), 49 (Control)
Heterogeneity: Chi2 = 20.89, df = 4 (P = 0.00033); I2 =81%
Test for overall effect: Z = 4.21 (P = 0.000025)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours certolizumab pego Favours control
(1) Authors explained that ”possibly due to the use of the sorbitol placebo”
Analysis 50.27. Comparison 50 Safety, Outcome 27 Antinuclear antibodies (ANA) Anti-certolizumab pegol
antibodies certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 27 Antinuclear antibodies (ANA) Anti-certolizumab pegol antibodies certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Smolen 2009 5/248 0/125 4.57 [ 0.71, 29.59 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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Analysis 50.28. Comparison 50 Safety, Outcome 28 Anti-certolizumab pegol antibodies certolizumab 400
mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 28 Anti-certolizumab pegol antibodies certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Fleischmann 2009 9/111 0/109 71.0 % 7.82 [ 2.07, 29.62 ]
Smolen 2009 4/246 0/125 29.0 % 4.57 [ 0.57, 36.68 ]
Total (95% CI) 357 234 100.0 % 6.70 [ 2.18, 20.55 ]
Total events: 13 (Certolizumab pegol 400 mg), 0 (Control)
Heterogeneity: Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 3.32 (P = 0.00089)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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Analysis 50.29. Comparison 50 Safety, Outcome 29 Systemic lupus erythematosus certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 29 Systemic lupus erythematosus certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Smolen 2009 1/248 0/125 100.0 % 4.50 [ 0.07, 286.06 ]
Smolen 2015 0/96 0/98 Not estimable
Total (95% CI) 344 223 100.0 % 4.50 [ 0.07, 286.06 ]
Total events: 1 (Certolizumab pegol 200 mg), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
Analysis 50.30. Comparison 50 Safety, Outcome 30 Prolonged activated partial thromboplastin time
(aPTT) certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 30 Prolonged activated partial thromboplastin time (aPTT) certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
NCT00993317 3/85 0/42 17.8 % 4.56 [ 0.40, 51.56 ]
Smolen 2009 12/248 2/125 82.2 % 2.45 [ 0.79, 7.57 ]
Total (95% CI) 333 167 100.0 % 2.73 [ 0.98, 7.61 ]
Total events: 15 (Certolizumab pegol 200 mg), 2 (Control)
Heterogeneity: Chi2 = 0.21, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.92 (P = 0.054)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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Analysis 50.31. Comparison 50 Safety, Outcome 31 Prolonged activated partial thromboplastin time
(aPTT) certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 31 Prolonged activated partial thromboplastin time (aPTT) certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Smolen 2009 12/246 2/125 2.46 [ 0.80, 7.60 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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Analysis 50.32. Comparison 50 Safety, Outcome 32 Urinary tract infection certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 32 Urinary tract infection certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Emery 2015 63/660 18/219 46.7 % 1.17 [ 0.69, 1.99 ]
Keystone 2008 23/392 13/199 25.6 % 0.89 [ 0.44, 1.82 ]
NCT00993317 1/85 0/42 0.8 % 4.46 [ 0.07, 287.18 ]
Smolen 2009 11/248 9/125 14.3 % 0.58 [ 0.22, 1.51 ]
Smolen 2015 6/96 5/98 8.8 % 1.24 [ 0.37, 4.17 ]
Weinblatt 2012 5/846 2/209 3.7 % 0.57 [ 0.09, 3.70 ]
Total (95% CI) 2327 892 100.0 % 0.98 [ 0.68, 1.40 ]
Total events: 109 (Certolizumab pegol 200 mg), 47 (Control)
Heterogeneity: Chi2 = 2.63, df = 5 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.89)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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Analysis 50.33. Comparison 50 Safety, Outcome 33 Urinary tract infection certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 33 Urinary tract infection certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Keystone 2008 33/389 13/199 75.9 % 1.31 [ 0.69, 2.47 ]
Smolen 2009 5/246 9/125 24.1 % 0.24 [ 0.08, 0.75 ]
Total (95% CI) 635 324 100.0 % 0.87 [ 0.50, 1.52 ]
Total events: 38 (Certolizumab pegol 400 mg), 22 (Control)
Heterogeneity: Chi2 = 6.54, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours certolizumab pego Favours control
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Analysis 50.34. Comparison 50 Safety, Outcome 34 Upper respiratory tract infection certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 34 Upper respiratory tract infection certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Emery 2015 86/660 12/219 31.3 % 2.14 [ 1.32, 3.48 ]
Keystone 2008 24/392 5/199 11.8 % 2.16 [ 0.98, 4.77 ]
NCT00993317 12/85 5/42 6.3 % 1.21 [ 0.41, 3.56 ]
Smolen 2009 11/248 2/125 5.4 % 2.32 [ 0.72, 7.47 ]
Smolen 2015 6/96 4/98 4.6 % 1.55 [ 0.44, 5.53 ]
Weinblatt 2012 112/846 19/209 35.0 % 1.46 [ 0.93, 2.32 ]
Yamamoto (a) 2014 3/116 4/114 3.3 % 0.73 [ 0.16, 3.29 ]
Yamamoto (b) 2014 2/82 3/77 2.3 % 0.62 [ 0.11, 3.67 ]
Total (95% CI) 2525 1083 100.0 % 1.68 [ 1.28, 2.20 ]
Total events: 256 (Certolizumab pegol 200 mg), 54 (Control)
Heterogeneity: Chi2 = 4.74, df = 7 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 3.75 (P = 0.00018)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours certolizumab pego Favours control
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Analysis 50.35. Comparison 50 Safety, Outcome 35 Upper respiratory tract infection certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 35 Upper respiratory tract infection certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Choy 2012 4/124 4/119 18.9 % 0.96 [ 0.23, 3.91 ]
Keystone 2008 21/389 5/199 54.2 % 1.98 [ 0.86, 4.54 ]
Smolen 2009 4/246 2/125 12.9 % 1.02 [ 0.18, 5.59 ]
Yamamoto (b) 2014 3/85 3/77 14.1 % 0.90 [ 0.18, 4.60 ]
Total (95% CI) 844 520 100.0 % 1.42 [ 0.77, 2.61 ]
Total events: 32 (Certolizumab pegol 400 mg), 14 (Control)
Heterogeneity: Chi2 = 1.36, df = 3 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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Analysis 50.36. Comparison 50 Safety, Outcome 36 Lower respiratory tract infection/ lung infection
certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 36 Lower respiratory tract infection/ lung infection certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Keystone 2008 3/392 0/199 18.5 % 4.54 [ 0.41, 49.96 ]
NCT00993317 2/85 0/42 12.2 % 4.51 [ 0.23, 86.80 ]
Smolen 2015 0/96 1/98 6.9 % 0.14 [ 0.00, 6.96 ]
Weinblatt 2012 7/846 1/209 34.9 % 1.59 [ 0.28, 9.09 ]
Yamamoto (a) 2014 (1) 2/116 0/114 13.8 % 7.33 [ 0.46, 117.85 ]
Yamamoto (b) 2014 1/82 1/77 13.7 % 0.94 [ 0.06, 15.16 ]
Total (95% CI) 1617 739 100.0 % 2.12 [ 0.76, 5.95 ]
Total events: 15 (Certolizumab pegol 200 mg), 3 (Control)
Heterogeneity: Chi2 = 3.70, df = 5 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 1.43 (P = 0.15)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
(1) 2(1 pneumonia neumococcal and 1 pneumocystis jirobenzi pneumonia)
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Analysis 50.37. Comparison 50 Safety, Outcome 37 Lower respiratory tract infection/ lung infection
certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 37 Lower respiratory tract infection/ lung infection certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Choy 2012 3/124 3/119 41.1 % 0.96 [ 0.19, 4.83 ]
Keystone 2008 4/389 0/199 24.9 % 4.57 [ 0.57, 36.44 ]
Yamamoto (b) 2014 4/85 1/77 34.0 % 3.10 [ 0.52, 18.35 ]
Total (95% CI) 598 395 100.0 % 2.11 [ 0.75, 5.95 ]
Total events: 11 (Certolizumab pegol 400 mg), 4 (Control)
Heterogeneity: Chi2 = 1.63, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 1.41 (P = 0.16)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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Analysis 50.38. Comparison 50 Safety, Outcome 38 Pneumonia certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 38 Pneumonia certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Smolen 2015 0/96 1/98 3.5 % 0.14 [ 0.00, 6.96 ]
Emery 2015 4/660 3/219 18.3 % 0.38 [ 0.07, 2.12 ]
Atsumi 2016 7/161 8/158 50.4 % 0.85 [ 0.30, 2.40 ]
Weinblatt 2012 7/846 1/209 17.7 % 1.59 [ 0.28, 9.09 ]
NCT00993317 1/85 0/42 3.1 % 4.46 [ 0.07, 287.18 ]
Yamamoto (a) 2014 2/116 0/114 7.0 % 7.33 [ 0.46, 117.85 ]
Total (95% CI) 1964 840 100.0 % 0.94 [ 0.45, 1.97 ]
Total events: 21 (Certolizumab 200 mg pegol), 13 (Control)
Heterogeneity: Chi2 = 5.00, df = 5 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.16 (P = 0.88)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
Analysis 50.39. Comparison 50 Safety, Outcome 39 Pneumonitis certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 39 Pneumonitis certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Fleischmann 2009 0/111 1/109 0.13 [ 0.00, 6.70 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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Analysis 50.40. Comparison 50 Safety, Outcome 40 Headache certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 40 Headache certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Emery 2015 66/660 11/219 40.5 % 1.86 [ 1.09, 3.20 ]
Keystone 2008 22/392 11/199 21.5 % 1.02 [ 0.48, 2.13 ]
Smolen 2009 9/248 1/125 6.7 % 2.95 [ 0.78, 11.14 ]
Smolen 2015 1/96 5/98 4.5 % 0.26 [ 0.05, 1.31 ]
Weinblatt 2012 47/846 11/209 26.8 % 1.06 [ 0.54, 2.05 ]
Yamamoto (b) 2014 0/82 0/77 Not estimable
Total (95% CI) 2324 927 100.0 % 1.33 [ 0.94, 1.87 ]
Total events: 145 (Certolizumab pegol 200 mg), 39 (Control)
Heterogeneity: Chi2 = 7.73, df = 4 (P = 0.10); I2 =48%
Test for overall effect: Z = 1.61 (P = 0.11)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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Analysis 50.41. Comparison 50 Safety, Outcome 41 Headache certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 41 Headache certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Choy 2012 12/124 9/119 35.1 % 1.31 [ 0.53, 3.19 ]
Keystone 2008 18/389 11/199 45.1 % 0.83 [ 0.38, 1.82 ]
Smolen 2009 8/246 1/125 14.4 % 2.81 [ 0.69, 11.36 ]
Yamamoto (b) 2014 3/85 0/77 5.4 % 6.89 [ 0.70, 67.36 ]
Total (95% CI) 844 520 100.0 % 1.30 [ 0.76, 2.20 ]
Total events: 41 (Certolizumab pegol 400 mg), 21 (Control)
Heterogeneity: Chi2 = 4.50, df = 3 (P = 0.21); I2 =33%
Test for overall effect: Z = 0.96 (P = 0.34)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Favours certolizumab pego Favours control
Analysis 50.42. Comparison 50 Safety, Outcome 42 Bacteriuria certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 42 Bacteriuria certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Smolen 2009 8/248 4/125 1.01 [ 0.30, 3.40 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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Analysis 50.43. Comparison 50 Safety, Outcome 43 Bacteriuria certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 43 Bacteriuria certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Smolen 2009 6/246 4/125 0.75 [ 0.20, 2.82 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
Analysis 50.44. Comparison 50 Safety, Outcome 44 Nasopharyngitis/Pharyngitis certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 44 Nasopharyngitis/Pharyngitis certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Emery 2015 60/660 17/219 30.6 % 1.18 [ 0.69, 2.03 ]
Keystone 2008 21/392 3/199 12.0 % 2.68 [ 1.13, 6.36 ]
NCT00993317 10/85 4/42 6.5 % 1.25 [ 0.39, 4.06 ]
Smolen 2009 8/248 1/125 4.6 % 2.79 [ 0.69, 11.32 ]
Smolen 2015 10/96 11/98 11.0 % 0.92 [ 0.37, 2.27 ]
Yamamoto (a) 2014 26/116 21/114 21.9 % 1.28 [ 0.67, 2.42 ]
Yamamoto (b) 2014 16/82 12/77 13.5 % 1.31 [ 0.58, 2.95 ]
Total (95% CI) 1679 874 100.0 % 1.37 [ 1.01, 1.84 ]
Total events: 151 (Certolizumab pegol 200 mg), 69 (Control)
Heterogeneity: Chi2 = 4.44, df = 6 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 2.04 (P = 0.041)
Test for subgroup differences: Not applicable
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Analysis 50.45. Comparison 50 Safety, Outcome 45 Nasopharyngitis/Pharyngitis certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 45 Nasopharyngitis/Pharyngitis certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Choy 2012 15/124 8/119 27.6 % 1.87 [ 0.79, 4.40 ]
Keystone 2008 30/389 3/199 36.8 % 3.22 [ 1.53, 6.76 ]
Smolen 2009 4/246 1/125 5.8 % 1.86 [ 0.29, 11.99 ]
Yamamoto (b) 2014 15/85 12/77 29.8 % 1.16 [ 0.51, 2.64 ]
Total (95% CI) 844 520 100.0 % 1.98 [ 1.26, 3.11 ]
Total events: 64 (Certolizumab pegol 400 mg), 24 (Control)
Heterogeneity: Chi2 = 3.29, df = 3 (P = 0.35); I2 =9%
Test for overall effect: Z = 2.97 (P = 0.0029)
Test for subgroup differences: Not applicable
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Analysis 50.46. Comparison 50 Safety, Outcome 46 Injection site pain certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 46 Injection site pain certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Keystone 2008 8/392 0/199 80.1 % 4.60 [ 1.05, 20.10 ]
NCT00993317 0/85 2/42 19.9 % 0.05 [ 0.00, 0.91 ]
Smolen 2009 0/248 0/125 Not estimable
Total (95% CI) 725 366 100.0 % 1.85 [ 0.49, 6.92 ]
Total events: 8 (Certolizumab pegol 200 mg), 2 (Control)
Heterogeneity: Chi2 = 7.36, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours certolizumab pego Favours control
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Analysis 50.47. Comparison 50 Safety, Outcome 47 Injection site pain certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 47 Injection site pain certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Fleischmann 2009 0/111 2/109 27.2 % 0.13 [ 0.01, 2.12 ]
Keystone 2008 5/389 0/199 60.7 % 4.58 [ 0.71, 29.39 ]
Smolen 2009 1/246 0/125 12.2 % 4.52 [ 0.07, 285.66 ]
Total (95% CI) 746 433 100.0 % 1.74 [ 0.41, 7.42 ]
Total events: 6 (Certolizumab pegol 400 mg), 2 (Control)
Heterogeneity: Chi2 = 4.56, df = 2 (P = 0.10); I2 =56%
Test for overall effect: Z = 0.75 (P = 0.45)
Test for subgroup differences: Not applicable
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Analysis 50.48. Comparison 50 Safety, Outcome 48 Hypertension certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 48 Hypertension certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Keystone 2008 25/392 2/199 60.8 % 3.42 [ 1.51, 7.74 ]
Smolen 2009 6/248 2/125 18.4 % 1.48 [ 0.34, 6.50 ]
Yamamoto (a) 2014 4/116 1/114 13.0 % 3.33 [ 0.57, 19.54 ]
Yamamoto (b) 2014 3/82 0/77 7.8 % 7.13 [ 0.73, 69.59 ]
Total (95% CI) 838 515 100.0 % 3.09 [ 1.64, 5.84 ]
Total events: 38 (Certolizumab pegol 200 mg), 5 (Control)
Heterogeneity: Chi2 = 1.54, df = 3 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 3.48 (P = 0.00051)
Test for subgroup differences: Not applicable
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Analysis 50.49. Comparison 50 Safety, Outcome 49 Hypertension certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 49 Hypertension certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Keystone 2008 32/389 2/199 71.3 % 3.76 [ 1.81, 7.80 ]
Smolen 2009 9/246 2/125 23.7 % 2.04 [ 0.57, 7.25 ]
Yamamoto (b) 2014 2/85 0/77 4.9 % 6.81 [ 0.42, 110.13 ]
Total (95% CI) 720 401 100.0 % 3.35 [ 1.80, 6.20 ]
Total events: 43 (Certolizumab pegol 400 mg), 4 (Control)
Heterogeneity: Chi2 = 0.93, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 3.83 (P = 0.00013)
Test for subgroup differences: Not applicable
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Favours certolizumab pego Favours control
Analysis 50.50. Comparison 50 Safety, Outcome 50 Hematuria certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 50 Hematuria certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Smolen 2009 4/248 5/125 0.36 [ 0.09, 1.47 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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Analysis 50.51. Comparison 50 Safety, Outcome 51 Haematuria certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 51 Haematuria certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Smolen 2009 4/246 5/125 0.37 [ 0.09, 1.49 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
Analysis 50.52. Comparison 50 Safety, Outcome 52 Hepatic enzyme increased certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 52 Hepatic enzyme increased certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Atsumi 2016 68/161 70/158 85.9 % 0.92 [ 0.59, 1.43 ]
Smolen 2009 3/248 4/125 6.7 % 0.34 [ 0.07, 1.66 ]
Yamamoto (b) 2014 3/82 4/77 7.4 % 0.70 [ 0.15, 3.15 ]
Total (95% CI) 491 360 100.0 % 0.84 [ 0.56, 1.27 ]
Total events: 74 (Certolizumab pegol 200 mg), 78 (Control)
Heterogeneity: Chi2 = 1.47, df = 2 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Not applicable
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Analysis 50.53. Comparison 50 Safety, Outcome 53 Hepatic enzyme increased certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 53 Hepatic enzyme increased certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Smolen 2009 3/246 4/125 41.9 % 0.34 [ 0.07, 1.67 ]
Yamamoto (b) 2014 5/85 4/77 58.1 % 1.14 [ 0.30, 4.36 ]
Total (95% CI) 331 202 100.0 % 0.69 [ 0.25, 1.92 ]
Total events: 8 (Certolizumab pegol 400 mg), 8 (Control)
Heterogeneity: Chi2 = 1.28, df = 1 (P = 0.26); I2 =22%
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
Analysis 50.54. Comparison 50 Safety, Outcome 54 AST increased certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 54 AST increased certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Smolen 2009 2/248 5/125 0.18 [ 0.04, 0.86 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
211Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 50.55. Comparison 50 Safety, Outcome 55 AST increased certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 55 AST increased certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Smolen 2009 6/246 5/125 0.58 [ 0.16, 2.07 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
Analysis 50.56. Comparison 50 Safety, Outcome 56 ALT increased certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 56 ALT increased certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Emery 2015 46/660 13/219 87.0 % 1.18 [ 0.64, 2.17 ]
Smolen 2009 1/248 6/125 13.0 % 0.09 [ 0.02, 0.45 ]
Total (95% CI) 908 344 100.0 % 0.85 [ 0.48, 1.50 ]
Total events: 47 (Certolizumab pegol 200 mg), 19 (Control)
Heterogeneity: Chi2 = 8.66, df = 1 (P = 0.003); I2 =88%
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Not applicable
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Analysis 50.57. Comparison 50 Safety, Outcome 57 ALT increased certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 57 ALT increased certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Smolen 2009 8/246 6/127 0.67 [ 0.22, 2.05 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
Analysis 50.58. Comparison 50 Safety, Outcome 58 Diarrhoea certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 58 Diarrhoea certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Emery 2015 1/660 0/219 5.4 % 3.79 [ 0.04, 351.89 ]
NCT00993317 1/85 2/42 19.0 % 0.21 [ 0.02, 2.42 ]
Smolen 2015 5/96 6/98 75.6 % 0.84 [ 0.25, 2.84 ]
Total (95% CI) 841 359 100.0 % 0.71 [ 0.25, 2.03 ]
Total events: 7 (Certolizumab 200 mg pegol), 8 (Control)
Heterogeneity: Chi2 = 1.54, df = 2 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Not applicable
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Analysis 50.59. Comparison 50 Safety, Outcome 59 Gastroenteritis certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 59 Gastroenteritis certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Keystone 2008 0/392 1/199 6.8 % 0.05 [ 0.00, 3.25 ]
Smolen 2015 7/96 6/98 93.2 % 1.20 [ 0.39, 3.70 ]
Total (95% CI) 488 297 100.0 % 0.97 [ 0.33, 2.87 ]
Total events: 7 (Certolizumab 200 mg pegol), 7 (Control)
Heterogeneity: Chi2 = 2.07, df = 1 (P = 0.15); I2 =52%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Not applicable
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Analysis 50.60. Comparison 50 Safety, Outcome 60 Gastrointestinal disorders certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 60 Gastrointestinal disorders certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Choy 2012 22/124 19/119 97.4 % 1.13 [ 0.58, 2.22 ]
Keystone 2008 0/389 1/199 2.6 % 0.05 [ 0.00, 3.28 ]
Total (95% CI) 513 318 100.0 % 1.05 [ 0.54, 2.03 ]
Total events: 22 (Certolizumab pegol 400 mg), 20 (Control)
Heterogeneity: Chi2 = 2.07, df = 1 (P = 0.15); I2 =52%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Not applicable
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Analysis 50.61. Comparison 50 Safety, Outcome 61 Back pain certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 61 Back pain certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Keystone 2008 17/392 2/199 2.91 [ 1.11, 7.65 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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Analysis 50.62. Comparison 50 Safety, Outcome 62 Back pain certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 62 Back pain certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Choy 2012 7/124 2/119 31.4 % 3.03 [ 0.80, 11.43 ]
Keystone 2008 20/389 2/199 68.6 % 3.15 [ 1.28, 7.74 ]
Total (95% CI) 513 318 100.0 % 3.11 [ 1.48, 6.55 ]
Total events: 27 (Certolizumab pegol 400 mg), 4 (Control)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 2.98 (P = 0.0028)
Test for subgroup differences: Not applicable
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Favours certolizumab pego Favours control
Analysis 50.63. Comparison 50 Safety, Outcome 63 Hematologic abnormalities certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 63 Hematologic abnormalities certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Keystone 2008 2/392 0/199 47.3 % 4.53 [ 0.24, 85.22 ]
Yamamoto (a) 2014 1/116 1/114 52.7 % 0.98 [ 0.06, 15.81 ]
Total (95% CI) 508 313 100.0 % 2.02 [ 0.27, 15.21 ]
Total events: 3 (Certolizumab 200 mg pegol), 1 (Control)
Heterogeneity: Chi2 = 0.55, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.68 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 50.64. Comparison 50 Safety, Outcome 64 Haematologic abnormalities certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 64 Haematologic abnormalities certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Keystone 2008 3/389 2/199 81.7 % 0.76 [ 0.12, 4.86 ]
Yamamoto (b) 2014 (1) 1/85 0/77 18.3 % 6.73 [ 0.13, 340.56 ]
Total (95% CI) 474 276 100.0 % 1.13 [ 0.21, 6.07 ]
Total events: 4 (Certolizumab pegol 400 mg), 2 (Control)
Heterogeneity: Chi2 = 0.97, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Not applicable
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(1) 1 patinet with bone marrow failure
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Analysis 50.65. Comparison 50 Safety, Outcome 65 Herpes viral infection certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 65 Herpes viral infection certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Keystone 2008 1/392 0/199 47.2 % 4.52 [ 0.07, 285.70 ]
Yamamoto (a) 2014 1/116 0/114 52.8 % 7.26 [ 0.14, 366.07 ]
Total (95% CI) 508 313 100.0 % 5.80 [ 0.34, 100.23 ]
Total events: 2 (Certolizumab 200 mg pegol), 0 (Control)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 50.66. Comparison 50 Safety, Outcome 66 Herpes viral infection certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 66 Herpes viral infection certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Keystone 2008 1/389 0/199 4.53 [ 0.07, 285.35 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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Analysis 50.67. Comparison 50 Safety, Outcome 67 Bacterial peritonitis certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 67 Bacterial peritonitis certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Keystone 2008 1/392 0/199 4.52 [ 0.07, 285.70 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
Analysis 50.68. Comparison 50 Safety, Outcome 68 Bacterial peritonitis certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 68 Bacterial peritonitis certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Keystone 2008 0/389 0/199 Not estimable
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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Analysis 50.69. Comparison 50 Safety, Outcome 69 Opportunistic infections certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 69 Opportunistic infections certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Keystone 2008 0/392 0/199 Not estimable
Smolen 2015 0/96 0/98 Not estimable
Weinblatt 2012 0/846 0/209 Not estimable
Yamamoto (a) 2014 (1) 2/116 0/114 100.0 % 7.33 [ 0.46, 117.85 ]
Total (95% CI) 1450 620 100.0 % 7.33 [ 0.46, 117.85 ]
Total events: 2 (Certolizumab 200 mg pegol), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
(1) 2 (1 Herpes Zoster and 1pneumocystis jirobenzi pneumonia)
Analysis 50.70. Comparison 50 Safety, Outcome 70 Opportunistic infections certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 70 Opportunistic infections certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Keystone 2008 0/389 0/199 Not estimable
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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Analysis 50.71. Comparison 50 Safety, Outcome 71 Infections and infestations certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 71 Infections and infestations certolizumab 200 mg
Study or subgroup
Certolizumab








Atsumi 2016 97/161 87/158 19.9 % 1.09 [ 0.91, 1.32 ]
Emery 2015 235/660 55/219 15.7 % 1.42 [ 1.10, 1.82 ]
Keystone 2008 171/392 52/199 15.2 % 1.67 [ 1.29, 2.16 ]
NCT00993317 30/85 9/42 4.2 % 1.65 [ 0.86, 3.14 ]
Smolen 2009 26/108 69/248 9.3 % 0.87 [ 0.59, 1.28 ]
Smolen 2015 27/96 26/98 7.3 % 1.06 [ 0.67, 1.68 ]
Weinblatt 2012 245/846 48/209 14.6 % 1.26 [ 0.96, 1.65 ]
Yamamoto (a) 2014 33/116 27/114 7.9 % 1.20 [ 0.78, 1.86 ]
Yamamoto (b) 2014 27/82 16/77 5.8 % 1.58 [ 0.93, 2.70 ]
Total (95% CI) 2546 1364 100.0 % 1.27 [ 1.10, 1.46 ]
Total events: 891 (Certolizumab 200 mg pegol), 389 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 13.25, df = 8 (P = 0.10); I2 =40%
Test for overall effect: Z = 3.26 (P = 0.0011)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours certolizumab pego Favours control
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Analysis 50.72. Comparison 50 Safety, Outcome 72 Infections and infestations certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 72 Infections and infestations certolizumab 400 mg
Study or subgroup
Certolizumab








Choy 2012 33/124 17/119 20.1 % 1.86 [ 1.10, 3.16 ]
Keystone 2008 184/389 52/199 33.9 % 1.81 [ 1.40, 2.34 ]
Smolen 2009 53/246 26/125 25.2 % 1.04 [ 0.68, 1.57 ]
Yamamoto (b) 2014 23/85 16/77 18.9 % 1.30 [ 0.74, 2.28 ]
stergaard 2015 1/27 2/13 1.9 % 0.24 [ 0.02, 2.42 ]
Total (95% CI) 871 533 100.0 % 1.43 [ 1.03, 1.98 ]
Total events: 294 (Certolizumab pegol 400 mg), 113 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 8.34, df = 4 (P = 0.08); I2 =52%
Test for overall effect: Z = 2.16 (P = 0.031)
Test for subgroup differences: Not applicable
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Favours certolizumab pego Favours control
Analysis 50.73. Comparison 50 Safety, Outcome 73 Decreased haemoglobin certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 73 Decreased haemoglobin certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Keystone 2008 2/392 1/199 1.02 [ 0.09, 11.18 ]
0.01 0.1 1 10 100
Favours control Favours certolizumab pego
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Analysis 50.74. Comparison 50 Safety, Outcome 74 Decreased haemoglobin certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 74 Decreased haemoglobin certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Keystone 2008 1/389 1/199 0.49 [ 0.03, 9.10 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
Analysis 50.75. Comparison 50 Safety, Outcome 75 Increased platelet count certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 75 Increased platelet count certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Keystone 2008 0/392 1/199 0.05 [ 0.00, 3.25 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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Analysis 50.76. Comparison 50 Safety, Outcome 76 Increased platelet count certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 76 Increased platelet count certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Keystone 2008 2/389 1/199 1.02 [ 0.09, 11.23 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
Analysis 50.77. Comparison 50 Safety, Outcome 77 Cerebral haemorrhage including subarachnoid
certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 77 Cerebral haemorrhage including subarachnoid certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
NCT00993317 2/85 0/42 63.7 % 4.51 [ 0.23, 86.80 ]
Smolen 2015 0/96 1/98 36.3 % 0.14 [ 0.00, 6.96 ]
Total (95% CI) 181 140 100.0 % 1.27 [ 0.12, 13.50 ]
Total events: 2 (Certolizumab 200 mg pegol), 1 (Control)
Heterogeneity: Chi2 = 1.94, df = 1 (P = 0.16); I2 =48%
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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Analysis 50.78. Comparison 50 Safety, Outcome 78 Ischaemic stroke certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 78 Ischaemic stroke certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Fleischmann 2009 1/111 0/109 7.26 [ 0.14, 365.79 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
Analysis 50.79. Comparison 50 Safety, Outcome 79 Nausea/vomiting certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 79 Nausea/vomiting certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Atsumi 2016 39/161 32/158 33.1 % 1.26 [ 0.74, 2.13 ]
Emery 2015 83/660 22/219 41.4 % 1.27 [ 0.79, 2.04 ]
Smolen 2015 5/96 5/98 5.7 % 1.02 [ 0.29, 3.64 ]
Weinblatt 2012 42/846 13/209 19.8 % 0.78 [ 0.39, 1.53 ]
Total (95% CI) 1763 684 100.0 % 1.13 [ 0.84, 1.54 ]
Total events: 169 (Certolizumab 200 mg pegol), 72 (Control)
Heterogeneity: Chi2 = 1.59, df = 3 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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Analysis 50.80. Comparison 50 Safety, Outcome 80 Vomiting certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 80 Vomiting certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Fleischmann 2009 0/111 1/109 0.13 [ 0.00, 6.70 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
Analysis 50.81. Comparison 50 Safety, Outcome 81 Acute miocardial infarction certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 81 Acute miocardial infarction certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Emery 2015 1/660 0/219 100.0 % 3.79 [ 0.04, 351.89 ]
Smolen 2015 0/96 0/98 Not estimable
Total (95% CI) 756 317 100.0 % 3.79 [ 0.04, 351.89 ]
Total events: 1 (Certolizumab 200 mg pegol), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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Analysis 50.82. Comparison 50 Safety, Outcome 82 Acute myocardial infarction certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 82 Acute myocardial infarction certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Yamamoto (b) 2014 1/85 0/77 6.73 [ 0.13, 340.56 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
Analysis 50.83. Comparison 50 Safety, Outcome 83 Abdominal pain/discomfort/dyspepsia certolizumab 200
mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 83 Abdominal pain/discomfort/dyspepsia certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
NCT00993317 12/85 2/42 2.58 [ 0.80, 8.35 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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Analysis 50.84. Comparison 50 Safety, Outcome 84 Constipation certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 84 Constipation certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Yamamoto (a) 2014 4/116 0/114 7.46 [ 1.04, 53.63 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
Analysis 50.85. Comparison 50 Safety, Outcome 85 Skin and subcutaneous tissue disorders certolizumab
200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 85 Skin and subcutaneous tissue disorders certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Emery 2015 0/660 2/219 4.2 % 0.02 [ 0.00, 0.44 ]
NCT00993317 3/85 0/42 7.4 % 4.56 [ 0.40, 51.56 ]
Yamamoto (a) 2014 17/116 3/114 52.0 % 4.52 [ 1.81, 11.28 ]
Yamamoto (b) 2014 10/82 4/77 36.4 % 2.38 [ 0.80, 7.10 ]
Total (95% CI) 943 452 100.0 % 2.83 [ 1.46, 5.48 ]
Total events: 30 (Certolizumab 200 mg pegol), 9 (Control)
Heterogeneity: Chi2 = 10.81, df = 3 (P = 0.01); I2 =72%
Test for overall effect: Z = 3.09 (P = 0.0020)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
228Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 50.86. Comparison 50 Safety, Outcome 86 Skin and subcutaneous tissue disorders certolizumab
400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 86 Skin and subcutaneous tissue disorders certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Yamamoto (b) 2014 6/85 4/77 1.38 [ 0.38, 4.94 ]
0.5 0.7 1 1.5 2
Favours certolizumab pego Favours control
Analysis 50.87. Comparison 50 Safety, Outcome 87 Cough certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 87 Cough certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
NCT00993317 4/85 1/42 1.84 [ 0.28, 12.22 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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Analysis 50.88. Comparison 50 Safety, Outcome 88 Pruritus certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 88 Pruritus certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
NCT00993317 3/85 0/42 4.56 [ 0.40, 51.56 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
Analysis 50.89. Comparison 50 Safety, Outcome 89 Fatigue certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 89 Fatigue certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
NCT00993317 3/85 1/42 1.45 [ 0.18, 11.96 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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Analysis 50.90. Comparison 50 Safety, Outcome 90 Fatigue certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 90 Fatigue certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
CDP870-004 2001 9/124 6/119 1.46 [ 0.52, 4.15 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
Analysis 50.91. Comparison 50 Safety, Outcome 91 Periodontitis certolizumab 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 91 Periodontitis certolizumab 200 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Yamamoto (b) 2014 4/85 2/77 1.80 [ 0.35, 9.16 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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Analysis 50.92. Comparison 50 Safety, Outcome 92 Arthritis bacterial certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 92 Arthritis bacterial certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Fleischmann 2009 1/111 0/109 7.26 [ 0.14, 365.79 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
Analysis 50.93. Comparison 50 Safety, Outcome 93 Mastitis certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 93 Mastitis certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Fleischmann 2009 1/111 0/109 100.0 % 7.26 [ 0.14, 365.79 ]
Total (95% CI) 111 109 100.0 % 7.26 [ 0.14, 365.79 ]
Total events: 1 (Certolizumab pegol 400 mg), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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Analysis 50.94. Comparison 50 Safety, Outcome 94 Benign tumour certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 94 Benign tumour certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Fleischmann 2009 2/111 0/109 7.32 [ 0.46, 117.84 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
Analysis 50.95. Comparison 50 Safety, Outcome 95 Dizziness postural certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 95 Dizziness postural certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Fleischmann 2009 1/111 0/109 7.26 [ 0.14, 365.79 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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Analysis 50.96. Comparison 50 Safety, Outcome 96 Menorrhagia certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 96 Menorrhagia certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Fleischmann 2009 1/111 0/109 7.26 [ 0.14, 365.79 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
Analysis 50.97. Comparison 50 Safety, Outcome 97 Corneal perforation certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 97 Corneal perforation certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Yamamoto (b) 2014 1/85 0/77 6.73 [ 0.13, 340.56 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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Analysis 50.98. Comparison 50 Safety, Outcome 98 Conjunctivitis allergic certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 98 Conjunctivitis allergic certolizumab 400 mg
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Yamamoto (b) 2014 1/85 0/77 6.73 [ 0.13, 340.56 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
Analysis 50.99. Comparison 50 Safety, Outcome 99 Periodontitis certolizumab 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 50 Safety
Outcome: 99 Periodontitis certolizumab 400 mg
Study or subgroup
Certolizumab
pegol 400 mg Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Yamamoto (b) 2014 2/82 2/77 0.94 [ 0.14, 6.50 ]
0.01 0.1 1 10 100
Favours certolizumab pego Favours control
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Analysis 51.1. Comparison 51 Participant’s assessment of arthritis pain (VAS score 0 to 100 mm), Outcome
1 Mean change at 24 weeks certolizumab pegol 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 51 Participant’s assessment of arthritis pain (VAS score 0 to 100 mm)
Outcome: 1 Mean change at 24 weeks certolizumab pegol 200 mg
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Keystone 2008 393 -29.6 (21.81) 199 -8.1 (22.57) 59.7 % -21.50 [ -25.31, -17.69 ]
Smolen 2009 246 -23.7 (22) 127 -4.7 (21.41) 40.3 % -19.00 [ -23.63, -14.37 ]
Total (95% CI) 639 326 100.0 % -20.49 [ -23.43, -17.55 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.67, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 13.66 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours certolizumab pego Favours control
Analysis 51.2. Comparison 51 Participant’s assessment of arthritis pain (VAS score 0 to 100 mm), Outcome
2 Mean change at 24 weeks certolizumab pegol 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 51 Participant’s assessment of arthritis pain (VAS score 0 to 100 mm)
Outcome: 2 Mean change at 24 weeks certolizumab pegol 400 mg
Study or subgroup
Certolizumab





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Fleischmann 2009 (1) 111 -20.6 (42) 109 1.7 (42) 6.6 % -22.30 [ -33.40, -11.20 ]
Keystone 2008 (2) 390 -31.7 (21.72) 199 -8.1 (22.57) 55.8 % -23.60 [ -27.41, -19.79 ]
Smolen 2009 246 -26.1 (22) 127 -4.7 (21.41) 37.7 % -21.40 [ -26.03, -16.77 ]
Total (95% CI) 747 435 100.0 % -22.69 [ -25.53, -19.84 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.52, df = 2 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 15.65 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours certolizumab pego Favours control
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(1) In FAST4WARD we have obtained standard deviations from p values according to the Handbook section 7.7.3.7
(2) Data in RAPID1 from NICE report
Analysis 51.3. Comparison 51 Participant’s assessment of arthritis pain (VAS score 0 to 100 mm), Outcome
3 Mean change at 52 weeks certolizumab pegol 200 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 51 Participant’s assessment of arthritis pain (VAS score 0 to 100 mm)
Outcome: 3 Mean change at 52 weeks certolizumab pegol 200 mg





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Keystone 2008 393 -31 (22.57) 199 -8.8 (23.79) -22.20 [ -26.19, -18.21 ]
-100 -50 0 50 100
Favours certolizumab pego Favours control
Analysis 51.4. Comparison 51 Participant’s assessment of arthritis pain (VAS score 0 to 100 mm), Outcome
4 Mean change at 52 weeks certolizumab pegol 400 mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 51 Participant’s assessment of arthritis pain (VAS score 0 to 100 mm)
Outcome: 4 Mean change at 52 weeks certolizumab pegol 400 mg





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Keystone 2008 390 -33.5 (23.7) 199 -8.8 (22.57) -24.70 [ -28.62, -20.78 ]
-100 -50 0 50 100
Favours certolizumab Favours control
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Analysis 52.1. Comparison 52 Participant’s assessment of arthritis pain (VAS score 0 to 100 mm) at 24
weeks, any dose, Outcome 1 Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 52 Participant’s assessment of arthritis pain (VAS score 0 to 100 mm) at 24 weeks, any dose
Outcome: 1 Change from baseline





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 certolizumab pegol 200 mg sc
Keystone 2008 (1) 393 -29.6 (21.81) 100 -8.1 (22.57) 26.2 % -21.50 [ -26.42, -16.58 ]
Smolen 2009 246 -23.7 (22) 64 -4.7 (21.41) 18.1 % -19.00 [ -24.92, -13.08 ]
Subtotal (95% CI) 639 164 44.3 % -20.48 [ -24.26, -16.69 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.40, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 10.60 (P < 0.00001)
2 certolizumab pegol 400 mg sc
Choy 2012 (2) 124 -21.8 (51.4) 119 -8.5 (19.92) 6.7 % -13.30 [ -23.03, -3.57 ]
Fleischmann 2009 111 -20.6 (42) 109 1.7 (42) 5.1 % -22.30 [ -33.40, -11.20 ]
Keystone 2008 390 -31.7 (21.72) 99 -8.1 (22.57) 26.0 % -23.60 [ -28.54, -18.66 ]
Smolen 2009 246 -26.1 (22) 63 -4.7 (21.41) 17.9 % -21.40 [ -27.36, -15.44 ]
Subtotal (95% CI) 871 390 55.7 % -21.35 [ -25.08, -17.61 ]
Heterogeneity: Tau2 = 2.00; Chi2 = 3.44, df = 3 (P = 0.33); I2 =13%
Test for overall effect: Z = 11.20 (P < 0.00001)
Total (95% CI) 1510 554 100.0 % -21.07 [ -23.59, -18.55 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 4.01, df = 5 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 16.39 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.10, df = 1 (P = 0.75), I2 =0.0%
-100 -50 0 50 100
Favours certolizumab pego Favours control
(1) Data in RAPID1 from NICE report
(2) Calculating SD according to Handbook from p values
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Analysis 53.1. Comparison 53 Participant’s assessment of arthritis pain (VAS score 0 to 100 mm) at 52
weeks, any dose, Outcome 1 Change from baseline.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 53 Participant’s assessment of arthritis pain (VAS score 0 to 100 mm) at 52 weeks, any dose
Outcome: 1 Change from baseline





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 certolizumab pegol 200 mg sc
Keystone 2008 (1) 393 -31 (22.57) 100 -8.8 (23.79) -22.20 [ -27.37, -17.03 ]
2 certolizumab pegol 400 mg sc
Keystone 2008 390 -33.5 (23.7) 99 -8.8 (22.57) -24.70 [ -29.73, -19.67 ]
-50 -25 0 25 50
Favours certolizumab pego Favours control
(1) Data in RAPID1 from NICE report
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Analysis 54.1. Comparison 54 Withdrawals Withdrawn due to lack of efficacy: any doses any follow-up,
Outcome 1 Withdrawn due to lack of efficacy: any doses any follow-up.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 54 Withdrawals Withdrawn due to lack of efficacy: any doses any follow-up
Outcome: 1 Withdrawn due to lack of efficacy: any doses any follow-up








Atsumi 2016 0/161 1/158 0.3 % 0.33 [ 0.01, 7.97 ]
Choy 2012 16/126 45/121 9.7 % 0.34 [ 0.20, 0.57 ]
Emery 2015 19/660 14/219 6.2 % 0.45 [ 0.23, 0.88 ]
Fleischmann 2009 24/111 75/109 15.1 % 0.31 [ 0.22, 0.46 ]
Keystone 2008 151/783 125/199 30.9 % 0.31 [ 0.26, 0.37 ]
NCT00993317 18/85 18/42 9.0 % 0.49 [ 0.29, 0.85 ]
Smolen 2009 95/492 101/127 28.6 % 0.24 [ 0.20, 0.30 ]
stergaard 2015 (1) 1/27 0/13 0.3 % 1.50 [ 0.07, 34.51 ]
Total (95% CI) 2445 988 100.0 % 0.31 [ 0.26, 0.37 ]
Total events: 324 (certolizumab pegol), 379 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 10.66, df = 7 (P = 0.15); I2 =34%
Test for overall effect: Z = 12.63 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours certolizumab pego Favours Control
(1) A withdrawal after randomisation and prior to treatment. It is undisclosed in which arm
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Analysis 55.1. Comparison 55 Summary of findings: certolizumab (with or without MTX) versus placebo
(with or without MTX), Outcome 1 ACR 50 200 mg certolizumab 24 weeks.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 55 Summary of findings: certolizumab (with or without MTX) versus placebo (with or without MTX)
Outcome: 1 ACR 50 200 mg certolizumab 24 weeks
Study or subgroup
Certolizumab








Keystone 2008 144/393 15/199 25.3 % 4.86 [ 2.94, 8.04 ]
NCT00993317 35/85 8/42 20.2 % 2.16 [ 1.10, 4.24 ]
Smolen 2009 80/246 4/127 13.4 % 10.33 [ 3.87, 27.54 ]
Smolen 2015 20/96 7/98 16.7 % 2.92 [ 1.29, 6.58 ]
Yamamoto (b) 2014 45/82 13/77 24.4 % 3.25 [ 1.91, 5.54 ]
Total (95% CI) 902 543 100.0 % 3.80 [ 2.42, 5.95 ]
Total events: 324 (Certolizumab pegol 200 mg), 47 (Placebo)
Heterogeneity: Tau2 = 0.14; Chi2 = 9.05, df = 4 (P = 0.06); I2 =56%
Test for overall effect: Z = 5.82 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 55.2. Comparison 55 Summary of findings: certolizumab (with or without MTX) versus placebo
(with or without MTX), Outcome 2 HAQ change from baseline 200 mg certolizumab 24 weeks.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 55 Summary of findings: certolizumab (with or without MTX) versus placebo (with or without MTX)
Outcome: 2 HAQ change from baseline 200 mg certolizumab 24 weeks





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Keystone 2008 393 -0.58 (0.59) 199 -0.17 (0.56) 33.9 % -0.41 [ -0.51, -0.31 ]
NCT00993317 81 -0.54 (0.51) 40 -0.17 (0.7) 9.6 % -0.37 [ -0.61, -0.13 ]
Smolen 2009 246 -0.5 (0.47) 127 -0.14 (0.45) 33.7 % -0.36 [ -0.46, -0.26 ]
Smolen 2015 91 -0.25 (0.46) 91 -0.03 (0.49) 22.8 % -0.22 [ -0.36, -0.08 ]
Total (95% CI) 811 457 100.0 % -0.35 [ -0.43, -0.26 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 4.92, df = 3 (P = 0.18); I2 =39%
Test for overall effect: Z = 8.32 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 55.3. Comparison 55 Summary of findings: certolizumab (with or without MTX) versus placebo
(with or without MTX), Outcome 3 Serious adverse events certolizumab 200 mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 55 Summary of findings: certolizumab (with or without MTX) versus placebo (with or without MTX)
Outcome: 3 Serious adverse events certolizumab 200 mg sc
Study or subgroup
Certolizumab





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Smolen 2015 5/96 7/98 5.0 % 0.72 [ 0.22, 2.30 ]
Atsumi 2016 13/161 14/158 11.0 % 0.90 [ 0.41, 1.99 ]
Weinblatt 2012 52/846 12/209 17.0 % 1.07 [ 0.57, 2.02 ]
Emery 2015 70/660 20/219 26.9 % 1.17 [ 0.71, 1.94 ]
Keystone 2008 45/392 11/199 20.1 % 2.00 [ 1.12, 3.58 ]
Smolen 2009 18/248 4/125 8.2 % 2.07 [ 0.83, 5.16 ]
Yamamoto (b) 2014 4/82 1/77 2.2 % 3.21 [ 0.54, 19.00 ]
Yamamoto (a) 2014 13/116 3/114 6.6 % 3.74 [ 1.36, 10.31 ]
NCT00993317 8/85 0/42 3.0 % 4.86 [ 1.07, 22.14 ]
Total (95% CI) 2686 1241 100.0 % 1.47 [ 1.13, 1.91 ]
Total events: 228 (Certolizumab pegol 200 mg), 72 (Control)
Heterogeneity: Chi2 = 12.65, df = 8 (P = 0.12); I2 =37%
Test for overall effect: Z = 2.90 (P = 0.0037)
Test for subgroup differences: Not applicable
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Analysis 55.4. Comparison 55 Summary of findings: certolizumab (with or without MTX) versus placebo
(with or without MTX), Outcome 4 Proportion of participants achieving remission 24 weeks certolizumab 200
mg.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 55 Summary of findings: certolizumab (with or without MTX) versus placebo (with or without MTX)
Outcome: 4 Proportion of participants achieving remission 24 weeks certolizumab 200 mg
Study or subgroup
Certolizumab








Keystone 2008 (1) 45/391 3/196 38.1 % 7.52 [ 2.37, 23.89 ]
Smolen 2009 (2) 23/245 1/125 12.8 % 11.73 [ 1.60, 85.89 ]
Smolen 2015 19/96 3/98 36.3 % 6.47 [ 1.98, 21.14 ]
Yamamoto (a) 2014 19/116 1/114 12.8 % 18.67 [ 2.54, 137.17 ]
Total (95% CI) 848 533 100.0 % 8.47 [ 4.15, 17.28 ]
Total events: 106 (Certolizumab pegol 200 mg), 8 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.97, df = 3 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 5.87 (P < 0.00001)
Test for subgroup differences: Not applicable
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(1) UCB report for NICE quote Certolizumab n=391
(2) UCB report for NICE quote Certolizumab n=245
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Analysis 55.5. Comparison 55 Summary of findings: certolizumab (with or without MTX) versus placebo
(with or without MTX), Outcome 5 Radiological changes: Erosion Scores (ES) certolizumab 200 mg sc.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 55 Summary of findings: certolizumab (with or without MTX) versus placebo (with or without MTX)
Outcome: 5 Radiological changes: Erosion Scores (ES) certolizumab 200 mg sc





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 certolizumab 200 mg sc 24 weeks
Keystone 2008 353 0 (1.5) 180 0.7 (2.1) 71.9 % -0.70 [ -1.04, -0.36 ]
Smolen 2009 214 0.1 (2) 112 0.7 (2.6) 28.1 % -0.60 [ -1.15, -0.05 ]
Total (95% CI) 567 292 100.0 % -0.67 [ -0.96, -0.38 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 4.51 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 55.6. Comparison 55 Summary of findings: certolizumab (with or without MTX) versus placebo
(with or without MTX), Outcome 6 All Withdrawals:.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 55 Summary of findings: certolizumab (with or without MTX) versus placebo (with or without MTX)
Outcome: 6 All Withdrawals:








Choy 2002 2/24 6/12 1.3 % 0.17 [ 0.04, 0.71 ]
Yamamoto (b) 2014 (1) 36/167 52/77 10.9 % 0.32 [ 0.23, 0.44 ]
Smolen 2009 137/492 110/127 16.1 % 0.32 [ 0.27, 0.38 ]
Yamamoto (a) 2014 34/116 96/114 11.9 % 0.35 [ 0.26, 0.47 ]
Keystone 2008 254/783 156/199 17.0 % 0.41 [ 0.37, 0.47 ]
Fleischmann 2009 35/111 81/109 11.8 % 0.42 [ 0.32, 0.57 ]
Choy 2012 28/126 56/121 9.5 % 0.48 [ 0.33, 0.70 ]
NCT00993317 25/85 21/42 8.0 % 0.59 [ 0.38, 0.92 ]
Smolen 2015 12/96 18/98 4.6 % 0.68 [ 0.35, 1.34 ]
Weinblatt 2012 80/851 28/212 9.0 % 0.71 [ 0.48, 1.07 ]
Total (95% CI) 2851 1111 100.0 % 0.42 [ 0.36, 0.50 ]
Total events: 643 (Certolizumab pegol), 624 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 26.60, df = 9 (P = 0.002); I2 =66%
Test for overall effect: Z = 10.16 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 55.7. Comparison 55 Summary of findings: certolizumab (with or without MTX) versus placebo
(with or without MTX), Outcome 7 Withdrawals due to adverse events.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 55 Summary of findings: certolizumab (with or without MTX) versus placebo (with or without MTX)
Outcome: 7 Withdrawals due to adverse events





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Choy 2012 7/126 6/121 10.4 % 1.13 [ 0.37, 3.44 ]
Fleischmann 2009 5/111 2/109 5.7 % 2.37 [ 0.53, 10.64 ]
Keystone 2008 39/783 3/199 22.0 % 2.33 [ 1.08, 5.03 ]
NCT00993317 4/85 2/42 4.3 % 0.99 [ 0.17, 5.60 ]
Smolen 2009 17/492 2/127 10.2 % 1.88 [ 0.61, 5.82 ]
Smolen 2015 6/96 6/98 9.5 % 1.02 [ 0.32, 3.28 ]
Weinblatt 2012 33/851 6/212 20.3 % 1.34 [ 0.60, 2.99 ]
Yamamoto (a) 2014 8/116 2/114 8.1 % 3.42 [ 0.97, 12.13 ]
Yamamoto (b) 2014 13/239 3/77 9.5 % 1.38 [ 0.43, 4.44 ]
Total (95% CI) 2899 1099 100.0 % 1.66 [ 1.15, 2.37 ]
Total events: 132 (Certolizumab pegol), 32 (Control)
Heterogeneity: Chi2 = 4.11, df = 8 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 2.74 (P = 0.0061)
Test for subgroup differences: Not applicable
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Analysis 55.8. Comparison 55 Summary of findings: certolizumab (with or without MTX) versus placebo
(with or without MTX), Outcome 8 Deaths.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 55 Summary of findings: certolizumab (with or without MTX) versus placebo (with or without MTX)
Outcome: 8 Deaths





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Certolizumab pegol 200 mg
Emery 2015 (1) 1/660 0/219 7.2 % 3.79 [ 0.04, 351.89 ]
Keystone 2008 (2) 3/392 1/100 24.9 % 0.75 [ 0.07, 8.60 ]
Smolen 2009 (3) 1/246 0/63 6.3 % 3.51 [ 0.03, 455.29 ]
Smolen 2015 0/96 0/98 Not estimable
Weinblatt 2012 (4) 2/846 0/209 12.3 % 3.48 [ 0.11, 112.96 ]
Yamamoto (a) 2014 (5) 1/116 0/114 9.7 % 7.26 [ 0.14, 366.07 ]
Yamamoto (b) 2014 0/82 0/25 Not estimable
Subtotal (95% CI) 2438 828 60.3 % 2.10 [ 0.44, 10.08 ]
Total events: 8 (Certolizumab pegol), 1 (Placebo)
Heterogeneity: Chi2 = 1.26, df = 4 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
2 Certolizumab pegol 400 mg
Choy 2012 0/124 0/119 Not estimable
Fleischmann 2009 0/111 0/109 Not estimable
Keystone 2008 (6) 4/389 0/99 24.9 % 3.53 [ 0.31, 40.72 ]
Smolen 2009 (7) 1/246 0/62 6.2 % 3.50 [ 0.03, 464.09 ]
Yamamoto (b) 2014 0/65 0/25 Not estimable
Subtotal (95% CI) 935 414 31.1 % 3.53 [ 0.40, 31.39 ]
Total events: 5 (Certolizumab pegol), 0 (Placebo)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26)
3 Other doses
Choy 2002 1/24 0/12 8.6 % 4.48 [ 0.07, 286.49 ]
Yamamoto (b) 2014 0/72 0/22 Not estimable
Subtotal (95% CI) 96 34 8.6 % 4.48 [ 0.07, 286.49 ]
Total events: 1 (Certolizumab pegol), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
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n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Total (95% CI) 3469 1276 100.0 % 2.63 [ 0.78, 8.91 ]
Total events: 14 (Certolizumab pegol), 1 (Placebo)
Heterogeneity: Chi2 = 1.47, df = 7 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.56 (P = 0.12)
Test for subgroup differences: Chi2 = 0.21, df = 2 (P = 0.90), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours certolizumab pego Favours control
(1) Calculations of events were done according to the percentages of FAS (Full Analysis Set) 213 patients in placebo group and 655 in CZP group. We did AIT and
denominators were 219 and 660 in placebo and CZP group, respectively).
(2) Two deaths: one participant of hepatic neoplasm, and the other of cardiac arrest. One more died of peritonitis, cirrhosis, and general deterioration of physical health
during the post-treatment period). In Placebo 1 death (myocardial necrosis)
(3) 1 participant died of myocardial infarction
(4) Two deaths in the CZP group: one case of sigmoid diverticulitis in a 73-year-old man with pancreatitis, and one of necrotising pneumonia, both deaths were ruled as
possibly related to CZP
(5) 1 participant died of a rupture of a dissecting aortic aneurysm in the thoracic region, but UCB considered that in unlikely to have beeen related to study medication
(6) Four deaths: 1 cerebral stroke, 1 myocardial necrosis, 1 cardiac arrest and 1 atrial fibrillation)
(7) 1 participant died by fracture and shock
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Analysis 55.9. Comparison 55 Summary of findings: certolizumab (with or without MTX) versus placebo
(with or without MTX), Outcome 9 Tuberculosis.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 55 Summary of findings: certolizumab (with or without MTX) versus placebo (with or without MTX)
Outcome: 9 Tuberculosis





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Certolizumab pegol 200 mg
Emery 2015 3/660 2/219 31.3 % 0.44 [ 0.06, 3.39 ]
Keystone 2008 2/392 0/100 10.9 % 3.52 [ 0.11, 110.51 ]
NCT00993317 2/85 0/42 14.7 % 4.51 [ 0.23, 86.80 ]
Smolen 2009 3/248 0/63 16.2 % 3.53 [ 0.21, 59.55 ]
Smolen 2015 0/96 0/98 Not estimable
Weinblatt 2012 0/846 0/209 Not estimable
Subtotal (95% CI) 2327 731 73.0 % 1.53 [ 0.40, 5.77 ]
Total events: 10 (Certolizumab pegol), 2 (Placebo)
Heterogeneity: Chi2 = 2.50, df = 3 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.53)
2 Certolizumab pegol 400 mg
Fleischmann 2009 0/111 0/109 Not estimable
Keystone 2008 3/389 0/99 16.2 % 3.52 [ 0.21, 59.11 ]
Smolen 2009 2/246 0/62 10.8 % 3.51 [ 0.11, 111.96 ]
Subtotal (95% CI) 746 270 27.0 % 3.52 [ 0.40, 31.33 ]
Total events: 5 (Certolizumab pegol), 0 (Placebo)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26)
Total (95% CI) 3073 1001 100.0 % 1.91 [ 0.61, 5.96 ]
Total events: 15 (Certolizumab pegol), 2 (Placebo)
Heterogeneity: Chi2 = 2.90, df = 5 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Chi2 = 0.41, df = 1 (P = 0.52), I2 =0.0%
0.005 0.1 1 10 200
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Analysis 55.10. Comparison 55 Summary of findings: certolizumab (with or without MTX) versus placebo
(with or without MTX), Outcome 10 Upper respiratory tract infections.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 55 Summary of findings: certolizumab (with or without MTX) versus placebo (with or without MTX)
Outcome: 10 Upper respiratory tract infections





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Certolizumab pegol 200 mg
Keystone 2008 24/392 5/100 10.7 % 1.22 [ 0.48, 3.11 ]
NCT00993317 12/85 5/42 8.0 % 1.21 [ 0.41, 3.56 ]
Smolen 2009 11/248 2/62 4.9 % 1.35 [ 0.34, 5.40 ]
Smolen 2015 6/96 4/98 5.8 % 1.55 [ 0.44, 5.53 ]
Weinblatt 2012 112/846 19/209 44.3 % 1.46 [ 0.93, 2.32 ]
Yamamoto (a) 2014 3/116 4/114 4.1 % 0.73 [ 0.16, 3.29 ]
Yamamoto (b) 2014 2/82 3/38 2.5 % 0.26 [ 0.04, 1.75 ]
Subtotal (95% CI) 1865 663 80.3 % 1.28 [ 0.91, 1.80 ]
Total events: 170 (Certolizumab pegol), 42 (Placebo)
Heterogeneity: Chi2 = 3.66, df = 6 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 1.42 (P = 0.16)
2 Certolizumab pegol 400 mg
Choy 2012 4/124 4/119 4.7 % 0.96 [ 0.23, 3.91 ]
Keystone 2008 21/389 5/99 9.7 % 1.07 [ 0.40, 2.86 ]
Smolen 2009 4/246 2/63 2.3 % 0.44 [ 0.06, 3.29 ]
Yamamoto (b) 2014 3/85 3/39 3.0 % 0.41 [ 0.07, 2.37 ]
Subtotal (95% CI) 844 320 19.7 % 0.81 [ 0.41, 1.61 ]
Total events: 32 (Certolizumab pegol), 14 (Placebo)
Heterogeneity: Chi2 = 1.30, df = 3 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.60 (P = 0.55)
Total (95% CI) 2709 983 100.0 % 1.17 [ 0.86, 1.59 ]
Total events: 202 (Certolizumab pegol), 56 (Placebo)
Heterogeneity: Chi2 = 6.31, df = 10 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Chi2 = 1.36, df = 1 (P = 0.24), I2 =26%
0.01 0.1 1 10 100
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Analysis 55.11. Comparison 55 Summary of findings: certolizumab (with or without MTX) versus placebo
(with or without MTX), Outcome 11 Lower respiratory tract infections.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 55 Summary of findings: certolizumab (with or without MTX) versus placebo (with or without MTX)
Outcome: 11 Lower respiratory tract infections





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Certolizumab pegol 200 mg
Keystone 2008 3/392 0/100 7.4 % 3.53 [ 0.21, 59.02 ]
NCT00993317 2/85 0/42 6.7 % 4.51 [ 0.23, 86.80 ]
Smolen 2015 0/96 1/98 3.8 % 0.14 [ 0.00, 6.96 ]
Weinblatt 2012 7/846 1/209 19.4 % 1.59 [ 0.28, 9.09 ]
Yamamoto (a) 2014 (1) 2/116 0/114 7.6 % 7.33 [ 0.46, 117.85 ]
Yamamoto (b) 2014 1/82 1/38 6.6 % 0.43 [ 0.02, 8.48 ]
Subtotal (95% CI) 1617 601 51.6 % 1.81 [ 0.62, 5.26 ]
Total events: 15 (Certolizumab pegol), 3 (Placebo)
Heterogeneity: Chi2 = 4.13, df = 5 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.08 (P = 0.28)
2 Certolizumab pegol 400 mg
Choy 2012 3/124 3/119 22.5 % 0.96 [ 0.19, 4.83 ]
Keystone 2008 4/389 0/99 9.9 % 3.53 [ 0.31, 40.72 ]
Yamamoto (b) 2014 4/85 1/39 16.0 % 1.73 [ 0.25, 11.80 ]
Subtotal (95% CI) 598 257 48.4 % 1.52 [ 0.50, 4.59 ]
Total events: 11 (Certolizumab pegol), 4 (Placebo)
Heterogeneity: Chi2 = 0.79, df = 2 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
Total (95% CI) 2215 858 100.0 % 1.66 [ 0.77, 3.58 ]
Total events: 26 (Certolizumab pegol), 7 (Placebo)
Heterogeneity: Chi2 = 4.96, df = 8 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 1.30 (P = 0.20)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.83), I2 =0.0%
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(1) 2(1 pneumonia neumococcal and 1 pneumocystis jirobenzi pneumonia)
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Analysis 55.12. Comparison 55 Summary of findings: certolizumab (with or without MTX) versus placebo
(with or without MTX), Outcome 12 Malignancies including lymphoma.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 55 Summary of findings: certolizumab (with or without MTX) versus placebo (with or without MTX)
Outcome: 12 Malignancies including lymphoma





n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Certolizumab pegol 200 mg
Keystone 2008 (1) 7/392 1/199 32.3 % 2.61 [ 0.60, 11.41 ]
NCT00993317 (2) 0/85 0/42 Not estimable
Smolen 2009 1/248 1/125 8.1 % 0.48 [ 0.03, 9.01 ]
Smolen 2015 0/96 2/98 9.1 % 0.14 [ 0.01, 2.20 ]
Weinblatt 2012 4/846 2/209 17.4 % 0.43 [ 0.06, 3.18 ]
Yamamoto (a) 2014 0/116 1/114 4.6 % 0.13 [ 0.00, 6.70 ]
Subtotal (95% CI) 1783 787 71.5 % 0.79 [ 0.29, 2.12 ]
Total events: 12 (Certolizumab pegol), 7 (Placebo)
Heterogeneity: Chi2 = 5.32, df = 4 (P = 0.26); I2 =25%
Test for overall effect: Z = 0.48 (P = 0.63)
2 Certolizumab pegol 400 mg
Fleischmann 2009 0/111 0/109 Not estimable
Keystone 2008 (3) 4/389 1/199 20.4 % 1.86 [ 0.29, 11.96 ]
Smolen 2009 (4) 1/246 1/125 8.2 % 0.48 [ 0.03, 9.06 ]
Subtotal (95% CI) 746 433 28.5 % 1.26 [ 0.26, 6.08 ]
Total events: 5 (Certolizumab pegol), 2 (Placebo)
Heterogeneity: Chi2 = 0.58, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
Total (95% CI) 2529 1220 100.0 % 0.90 [ 0.39, 2.08 ]
Total events: 17 (Certolizumab pegol), 9 (Placebo)
Heterogeneity: Chi2 = 6.16, df = 6 (P = 0.41); I2 =3%
Test for overall effect: Z = 0.25 (P = 0.81)
Test for subgroup differences: Chi2 = 0.25, df = 1 (P = 0.62), I2 =0.0%
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(1) One patient in the arm of placebo suffered a thyroid neoplasm and 7 in the arm of certolizumab 200 mg sc suffered: three basal cell carcinomas [one with metastasis
to the central nervous system], one adrenal adenoma, one hepatic neoplasm one esophageal carcinoma, and uterine cancer
(2) Data provided by UCB
(3) In the placebo arm one patient suffered a thyroid neoplasm and 4 in the certolizumab 400 mg sc suffered two tongue neoplasm, 1 extranodal marginal zone B cell
limphoma and one papilloma.
(4) One case of malignant neoplasm was reported in each arm, namely bladder cancer in the placebo group and colon cancer in certolizumab pegol 400 mg group
Analysis 56.1. Comparison 56 Analysis of sensitivity ACR50 24 weeks, Outcome 1 Doses.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 56 Analysis of sensitivity ACR50 24 weeks
Outcome: 1 Doses








1 certolizumab 100 mg sc
Yamamoto (b) 2014 32/72 4/26 4.3 % 2.89 [ 1.13, 7.38 ]
Subtotal (95% CI) 72 26 4.3 % 2.89 [ 1.13, 7.38 ]
Total events: 32 (Certolizumab pegol), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.22 (P = 0.027)
2 certolizumab 200 mg sc
Keystone 2008 144/393 15/100 16.2 % 2.44 [ 1.50, 3.96 ]
NCT00993317 35/85 8/42 8.4 % 2.16 [ 1.10, 4.24 ]
Smolen 2009 80/246 4/64 4.1 % 5.20 [ 1.98, 13.67 ]
Smolen 2015 20/96 7/98 5.7 % 2.92 [ 1.29, 6.58 ]
Weinblatt 2012 226/851 21/212 21.4 % 2.68 [ 1.76, 4.08 ]
Yamamoto (b) 2014 45/82 4/26 4.5 % 3.57 [ 1.42, 8.97 ]
Subtotal (95% CI) 1753 542 60.1 % 2.73 [ 2.13, 3.51 ]
Total events: 550 (Certolizumab pegol), 59 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.79, df = 5 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 7.85 (P < 0.00001)
3 certolizumab 400 mg sc
Choy 2012 22/126 7/121 5.7 % 3.02 [ 1.34, 6.81 ]
Fleischmann 2009 25/111 4/109 3.6 % 6.14 [ 2.21, 17.05 ]
0.01 0.1 1 10 100
Favours control Favours certolizumab pego
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Keystone 2008 155/390 15/99 16.3 % 2.62 [ 1.62, 4.25 ]
Smolen 2009 81/246 4/63 4.1 % 5.19 [ 1.98, 13.61 ]
Yamamoto (b) 2014 46/85 5/25 5.8 % 2.71 [ 1.21, 6.07 ]
Subtotal (95% CI) 958 417 35.6 % 3.18 [ 2.29, 4.41 ]
Total events: 329 (Certolizumab pegol), 35 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.42, df = 4 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 6.94 (P < 0.00001)
Total (95% CI) 2783 985 100.0 % 2.89 [ 2.38, 3.51 ]
Total events: 911 (Certolizumab pegol), 98 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.73, df = 11 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 10.69 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.52, df = 2 (P = 0.77), I2 =0.0%
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Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 56 Analysis of sensitivity ACR50 24 weeks
Outcome: 2 Size








1 certolizumab < 200 patients
NCT00993317 35/85 8/42 8.4 % 2.16 [ 1.10, 4.24 ]
Smolen 2015 20/96 7/98 5.7 % 2.92 [ 1.29, 6.58 ]
Subtotal (95% CI) 181 140 14.1 % 2.44 [ 1.45, 4.10 ]
Total events: 55 (Certolizumab pegol), 15 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 3.37 (P = 0.00074)
2 certolizumab > 200 patients
Choy 2012 22/126 7/121 5.7 % 3.02 [ 1.34, 6.81 ]
Fleischmann 2009 25/111 4/109 3.6 % 6.14 [ 2.21, 17.05 ]
Keystone 2008 155/390 15/99 16.3 % 2.62 [ 1.62, 4.25 ]
Keystone 2008 144/393 15/100 16.2 % 2.44 [ 1.50, 3.96 ]
Smolen 2009 80/246 4/64 4.1 % 5.20 [ 1.98, 13.67 ]
Smolen 2009 81/246 4/63 4.1 % 5.19 [ 1.98, 13.61 ]
Weinblatt 2012 226/851 21/212 21.4 % 2.68 [ 1.76, 4.08 ]
Yamamoto (b) 2014 46/85 5/25 5.8 % 2.71 [ 1.21, 6.07 ]
Yamamoto (b) 2014 45/82 4/26 4.5 % 3.57 [ 1.42, 8.97 ]
Yamamoto (b) 2014 32/72 4/26 4.3 % 2.89 [ 1.13, 7.38 ]
Subtotal (95% CI) 2602 845 85.9 % 2.97 [ 2.41, 3.67 ]
Total events: 856 (Certolizumab pegol), 83 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.91, df = 9 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 10.16 (P < 0.00001)
Total (95% CI) 2783 985 100.0 % 2.89 [ 2.38, 3.51 ]
Total events: 911 (Certolizumab pegol), 98 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.73, df = 11 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 10.69 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.47, df = 1 (P = 0.49), I2 =0.0%
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Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 56 Analysis of sensitivity ACR50 24 weeks
Outcome: 3 Use of MTX









Choy 2012 22/126 7/121 5.7 % 3.02 [ 1.34, 6.81 ]
Keystone 2008 144/393 15/100 16.2 % 2.44 [ 1.50, 3.96 ]
Keystone 2008 155/390 15/99 16.3 % 2.62 [ 1.62, 4.25 ]
NCT00993317 35/85 8/42 8.4 % 2.16 [ 1.10, 4.24 ]
Smolen 2009 80/246 4/64 4.1 % 5.20 [ 1.98, 13.67 ]
Smolen 2009 81/246 4/63 4.1 % 5.19 [ 1.98, 13.61 ]
Weinblatt 2012 226/851 21/212 21.4 % 2.68 [ 1.76, 4.08 ]
Subtotal (95% CI) 2337 701 76.1 % 2.77 [ 2.21, 3.46 ]
Total events: 743 (Certolizumab pegol), 74 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.27, df = 6 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 8.94 (P < 0.00001)
2 Without MTX
Fleischmann 2009 25/111 4/109 3.6 % 6.14 [ 2.21, 17.05 ]
Smolen 2015 20/96 7/98 5.7 % 2.92 [ 1.29, 6.58 ]
Yamamoto (b) 2014 46/85 5/25 5.8 % 2.71 [ 1.21, 6.07 ]
Yamamoto (b) 2014 45/82 4/26 4.5 % 3.57 [ 1.42, 8.97 ]
Yamamoto (b) 2014 32/72 4/26 4.3 % 2.89 [ 1.13, 7.38 ]
Subtotal (95% CI) 446 284 23.9 % 3.32 [ 2.23, 4.95 ]
Total events: 168 (Certolizumab pegol), 24 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.86, df = 4 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 5.91 (P < 0.00001)
Total (95% CI) 2783 985 100.0 % 2.89 [ 2.38, 3.51 ]
Total events: 911 (Certolizumab pegol), 98 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.73, df = 11 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 10.69 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.62, df = 1 (P = 0.43), I2 =0.0%
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Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 56 Analysis of sensitivity ACR50 24 weeks
Outcome: 4 Population









NCT00993317 35/85 8/42 8.4 % 2.16 [ 1.10, 4.24 ]
Yamamoto (b) 2014 46/85 5/25 5.8 % 2.71 [ 1.21, 6.07 ]
Yamamoto (b) 2014 32/72 4/26 4.3 % 2.89 [ 1.13, 7.38 ]
Yamamoto (b) 2014 45/82 4/26 4.5 % 3.57 [ 1.42, 8.97 ]
Subtotal (95% CI) 324 119 22.9 % 2.66 [ 1.77, 4.00 ]
Total events: 158 (Certolizumab pegol), 21 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.80, df = 3 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 4.72 (P < 0.00001)
2 Other trials
Choy 2012 22/126 7/121 5.7 % 3.02 [ 1.34, 6.81 ]
Fleischmann 2009 25/111 4/109 3.6 % 6.14 [ 2.21, 17.05 ]
Keystone 2008 155/390 15/99 16.3 % 2.62 [ 1.62, 4.25 ]
Keystone 2008 144/393 15/100 16.2 % 2.44 [ 1.50, 3.96 ]
Smolen 2009 81/246 4/63 4.1 % 5.19 [ 1.98, 13.61 ]
Smolen 2009 80/246 4/64 4.1 % 5.20 [ 1.98, 13.67 ]
Smolen 2015 20/96 7/98 5.7 % 2.92 [ 1.29, 6.58 ]
Weinblatt 2012 226/851 21/212 21.4 % 2.68 [ 1.76, 4.08 ]
Subtotal (95% CI) 2459 866 77.1 % 2.96 [ 2.37, 3.70 ]
Total events: 753 (Certolizumab pegol), 77 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.71, df = 7 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 9.60 (P < 0.00001)
Total (95% CI) 2783 985 100.0 % 2.89 [ 2.38, 3.51 ]
Total events: 911 (Certolizumab pegol), 98 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.73, df = 11 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 10.69 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.20, df = 1 (P = 0.65), I2 =0.0%
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disease.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 56 Analysis of sensitivity ACR50 24 weeks
Outcome: 5 Duration of previous disease








1 Long previous disease duration (9 years or more)
Choy 2012 22/126 7/121 7.2 % 3.02 [ 1.34, 6.81 ]
Fleischmann 2009 25/111 4/109 4.6 % 6.14 [ 2.21, 17.05 ]
Subtotal (95% CI) 237 230 11.7 % 4.02 [ 2.02, 7.98 ]
Total events: 47 (Certolizumab pegol), 11 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 1.15, df = 1 (P = 0.28); I2 =13%
Test for overall effect: Z = 3.97 (P = 0.000073)
2 Short previous disease duration (less than 7 years)
Keystone 2008 144/393 15/100 20.3 % 2.44 [ 1.50, 3.96 ]
Keystone 2008 155/390 15/99 20.5 % 2.62 [ 1.62, 4.25 ]
NCT00993317 35/85 8/42 10.5 % 2.16 [ 1.10, 4.24 ]
Smolen 2009 80/246 4/64 5.1 % 5.20 [ 1.98, 13.67 ]
Smolen 2009 81/246 4/63 5.1 % 5.19 [ 1.98, 13.61 ]
Weinblatt 2012 226/851 21/212 26.8 % 2.68 [ 1.76, 4.08 ]
Subtotal (95% CI) 2211 580 88.3 % 2.75 [ 2.18, 3.47 ]
Total events: 721 (Certolizumab pegol), 67 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.23, df = 5 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 8.53 (P < 0.00001)
Total (95% CI) 2448 810 100.0 % 2.87 [ 2.31, 3.57 ]
Total events: 768 (Certolizumab pegol), 78 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.52, df = 7 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 9.47 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.05, df = 1 (P = 0.30), I2 =5%
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Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 56 Analysis of sensitivity ACR50 24 weeks
Outcome: 6 Published vs unpublished studies









Choy 2012 22/126 7/121 5.7 % 3.02 [ 1.34, 6.81 ]
Fleischmann 2009 25/111 4/109 3.6 % 6.14 [ 2.21, 17.05 ]
Keystone 2008 155/390 15/99 16.3 % 2.62 [ 1.62, 4.25 ]
Keystone 2008 144/393 15/100 16.2 % 2.44 [ 1.50, 3.96 ]
Smolen 2009 81/246 4/63 4.1 % 5.19 [ 1.98, 13.61 ]
Smolen 2009 80/246 4/64 4.1 % 5.20 [ 1.98, 13.67 ]
Weinblatt 2012 226/851 21/212 21.4 % 2.68 [ 1.76, 4.08 ]
Subtotal (95% CI) 2363 768 71.3 % 2.97 [ 2.36, 3.73 ]
Total events: 733 (Certolizumab pegol), 70 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.71, df = 6 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 9.25 (P < 0.00001)
2 Unpublished studies
NCT00993317 35/85 8/42 8.4 % 2.16 [ 1.10, 4.24 ]
Smolen 2015 20/96 7/98 5.7 % 2.92 [ 1.29, 6.58 ]
Yamamoto (b) 2014 46/85 5/25 5.8 % 2.71 [ 1.21, 6.07 ]
Yamamoto (b) 2014 45/82 4/26 4.5 % 3.57 [ 1.42, 8.97 ]
Yamamoto (b) 2014 32/72 4/26 4.3 % 2.89 [ 1.13, 7.38 ]
Subtotal (95% CI) 420 217 28.7 % 2.71 [ 1.89, 3.90 ]
Total events: 178 (Certolizumab pegol), 28 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.83, df = 4 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 5.38 (P < 0.00001)
Total (95% CI) 2783 985 100.0 % 2.89 [ 2.38, 3.51 ]
Total events: 911 (Certolizumab pegol), 98 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.73, df = 11 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 10.69 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.17, df = 1 (P = 0.68), I2 =0.0%
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Analysis 56.7. Comparison 56 Analysis of sensitivity ACR50 24 weeks, Outcome 7 Imputing to ACR50 200
mg from 24 missing values with same proportion as reported outcomes.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 56 Analysis of sensitivity ACR50 24 weeks
Outcome: 7 Imputing to ACR50 200 mg from 24 missing values with same proportion as reported outcomes
Study or subgroup Certolizumab pegol Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Imputing missing values with same proportion as reported outcomes
Keystone 2008 195/393 27/199 39.1 % 3.66 [ 2.54, 5.27 ]
NCT00993317 45/85 12/42 17.5 % 1.85 [ 1.10, 3.11 ]
Smolen 2009 103/246 7/127 10.1 % 7.60 [ 3.64, 15.84 ]
Smolen 2015 23/96 8/98 8.6 % 2.93 [ 1.38, 6.24 ]
Yamamoto (b) 2014 54/82 22/77 24.7 % 2.30 [ 1.57, 3.39 ]
Total (95% CI) 902 543 100.0 % 3.34 [ 2.68, 4.17 ]
Total events: 420 (Certolizumab pegol), 76 (Control)
Heterogeneity: Chi2 = 13.67, df = 4 (P = 0.01); I2 =71%
Test for overall effect: Z = 10.66 (P < 0.00001)
Test for subgroup differences: Not applicable
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Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 56 Analysis of sensitivity ACR50 24 weeks
Outcome: 8 Imputing to ACR50 200 mg from 24 weeks 50 % of missing outcomes
Study or subgroup Certolizumab pegol Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Imputing the 50 % of missing outcomes
Keystone 2008 213/393 93/199 43.7 % 1.16 [ 0.97, 1.38 ]
NCT00993317 48/85 19/42 9.0 % 1.25 [ 0.85, 1.83 ]
Smolen 2009 116/246 59/127 27.5 % 1.02 [ 0.81, 1.28 ]
Smolen 2015 26/96 16/98 5.6 % 1.66 [ 0.95, 2.89 ]
Yamamoto (b) 2014 53/82 39/77 14.2 % 1.28 [ 0.97, 1.68 ]
Total (95% CI) 902 543 100.0 % 1.17 [ 1.04, 1.32 ]
Total events: 456 (Certolizumab pegol), 226 (Control)
Heterogeneity: Chi2 = 3.51, df = 4 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 2.69 (P = 0.0071)
Test for subgroup differences: Not applicable
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Analysis 56.9. Comparison 56 Analysis of sensitivity ACR50 24 weeks, Outcome 9 Imputing to ACR50 200
mg from 24 weeks: the worst case.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 56 Analysis of sensitivity ACR50 24 weeks
Outcome: 9 Imputing to ACR50 200 mg from 24 weeks: the worst case
Study or subgroup Certolizumab pegol Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Analysis in the worst case. All missing values did not reach ACR50 in certolizumab group and did in placebo group
Keystone 2008 144/393 171/199 44.7 % 0.43 [ 0.37, 0.49 ]
NCT00993317 35/85 29/42 7.6 % 0.60 [ 0.43, 0.83 ]
Smolen 2009 80/246 114/127 29.6 % 0.36 [ 0.30, 0.44 ]
Smolen 2015 20/96 25/98 4.9 % 0.82 [ 0.49, 1.37 ]
Yamamoto (b) 2014 45/82 65/77 13.2 % 0.65 [ 0.52, 0.81 ]
Total (95% CI) 902 543 100.0 % 0.47 [ 0.43, 0.52 ]
Total events: 324 (Certolizumab pegol), 404 (Control)
Heterogeneity: Chi2 = 23.99, df = 4 (P = 0.00008); I2 =83%
Test for overall effect: Z = 15.55 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 57.1. Comparison 57 Analysis of sensitivity ACR50 52 weeks, Outcome 1 Doses.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 57 Analysis of sensitivity ACR50 52 weeks
Outcome: 1 Doses








1 certolizumab 200 mg sc
Atsumi 2016 116/161 81/158 30.3 % 1.41 [ 1.17, 1.68 ]
Emery 2015 (1) 405/660 112/219 31.4 % 1.20 [ 1.04, 1.38 ]
Keystone 2008 149/393 15/100 19.1 % 2.53 [ 1.56, 4.10 ]
Subtotal (95% CI) 1214 477 80.8 % 1.48 [ 1.11, 1.96 ]
Total events: 670 (Certolizumab pegol), 208 (Control)
Heterogeneity: Tau2 = 0.05; Chi2 = 9.68, df = 2 (P = 0.01); I2 =79%
Test for overall effect: Z = 2.70 (P = 0.0069)
2 certolizumab 400 mg sc
Keystone 2008 155/390 15/99 19.2 % 2.62 [ 1.62, 4.25 ]
Subtotal (95% CI) 390 99 19.2 % 2.62 [ 1.62, 4.25 ]
Total events: 155 (Certolizumab pegol), 15 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.92 (P = 0.000088)
Total (95% CI) 1604 576 100.0 % 1.69 [ 1.22, 2.33 ]
Total events: 825 (Certolizumab pegol), 223 (Control)
Heterogeneity: Tau2 = 0.08; Chi2 = 18.63, df = 3 (P = 0.00033); I2 =84%
Test for overall effect: Z = 3.17 (P = 0.0015)
Test for subgroup differences: Chi2 = 4.04, df = 1 (P = 0.04), I2 =75%
0.01 0.1 1 10 100
Favours control Favours certoluzimab pego
(1) Calculations of events were done according to the percentages of FAS (Full Analysis Set) 213 patients in placebo group and 655 in CZP group. We did AIT and
denominators were 219 and 660 in placebo and CZP group, respectively).
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Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 57 Analysis of sensitivity ACR50 52 weeks
Outcome: 2 Size








1 certolizumab <200 patients
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Certolizumab pegol), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 certolizumab >200 patients
Atsumi 2016 116/161 81/158 30.3 % 1.41 [ 1.17, 1.68 ]
Emery 2015 (1) 405/660 112/219 31.4 % 1.20 [ 1.04, 1.38 ]
Keystone 2008 149/393 15/100 19.1 % 2.53 [ 1.56, 4.10 ]
Keystone 2008 155/390 15/99 19.2 % 2.62 [ 1.62, 4.25 ]
Subtotal (95% CI) 1604 576 100.0 % 1.69 [ 1.22, 2.33 ]
Total events: 825 (Certolizumab pegol), 223 (Control)
Heterogeneity: Tau2 = 0.08; Chi2 = 18.63, df = 3 (P = 0.00033); I2 =84%
Test for overall effect: Z = 3.17 (P = 0.0015)
Total (95% CI) 1604 576 100.0 % 1.69 [ 1.22, 2.33 ]
Total events: 825 (Certolizumab pegol), 223 (Control)
Heterogeneity: Tau2 = 0.08; Chi2 = 18.63, df = 3 (P = 0.00033); I2 =84%
Test for overall effect: Z = 3.17 (P = 0.0015)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control Favours certoluzimab pego
(1) Calculations of events were done according to the percentages of FAS (Full Analysis Set) 213 patients in placebo group and 655 in CZP group. We did AIT and
denominators were 219 and 660 in placebo and CZP group, respectively).
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Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 57 Analysis of sensitivity ACR50 52 weeks
Outcome: 3 Use of MTX








1 Use of MTX
Atsumi 2016 116/161 81/158 30.3 % 1.41 [ 1.17, 1.68 ]
Emery 2015 (1) 405/660 112/219 31.4 % 1.20 [ 1.04, 1.38 ]
Keystone 2008 155/390 15/99 19.2 % 2.62 [ 1.62, 4.25 ]
Keystone 2008 149/393 15/100 19.1 % 2.53 [ 1.56, 4.10 ]
Subtotal (95% CI) 1604 576 100.0 % 1.69 [ 1.22, 2.33 ]
Total events: 825 (Certolizumab pegol), 223 (Control)
Heterogeneity: Tau2 = 0.08; Chi2 = 18.63, df = 3 (P = 0.00033); I2 =84%
Test for overall effect: Z = 3.17 (P = 0.0015)
2 Without MTX
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Certolizumab pegol), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1604 576 100.0 % 1.69 [ 1.22, 2.33 ]
Total events: 825 (Certolizumab pegol), 223 (Control)
Heterogeneity: Tau2 = 0.08; Chi2 = 18.63, df = 3 (P = 0.00033); I2 =84%
Test for overall effect: Z = 3.17 (P = 0.0015)
Test for subgroup differences: Not applicable
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Favours control Favours certoluzimab pego
(1) Calculations of events were done according to the percentages of FAS (Full Analysis Set) 213 patients in placebo group and 655 in CZP group. We did AIT and
denominators were 219 and 660 in placebo and CZP group, respectively).
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Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 57 Analysis of sensitivity ACR50 52 weeks
Outcome: 4 Population









Atsumi 2016 116/161 81/158 30.3 % 1.41 [ 1.17, 1.68 ]
Subtotal (95% CI) 161 158 30.3 % 1.41 [ 1.17, 1.68 ]
Total events: 116 (Certolizumab pegol), 81 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.71 (P = 0.00021)
2 Other trials
Emery 2015 (1) 405/660 112/219 31.4 % 1.20 [ 1.04, 1.38 ]
Keystone 2008 155/390 15/99 19.2 % 2.62 [ 1.62, 4.25 ]
Keystone 2008 149/393 15/100 19.1 % 2.53 [ 1.56, 4.10 ]
Subtotal (95% CI) 1443 418 69.7 % 1.94 [ 1.01, 3.72 ]
Total events: 709 (Certolizumab pegol), 142 (Control)
Heterogeneity: Tau2 = 0.29; Chi2 = 19.16, df = 2 (P = 0.00007); I2 =90%
Test for overall effect: Z = 1.99 (P = 0.047)
Total (95% CI) 1604 576 100.0 % 1.69 [ 1.22, 2.33 ]
Total events: 825 (Certolizumab pegol), 223 (Control)
Heterogeneity: Tau2 = 0.08; Chi2 = 18.63, df = 3 (P = 0.00033); I2 =84%
Test for overall effect: Z = 3.17 (P = 0.0015)
Test for subgroup differences: Chi2 = 0.86, df = 1 (P = 0.35), I2 =0.0%
0.01 0.1 1 10 100
Favours control Favours certoluzimab pego
(1) Calculations of events were done according to the percentages of FAS (Full Analysis Set) 213 patients in placebo group and 655 in CZP group. We did AIT and
denominators were 219 and 660 in placebo and CZP group, respectively).
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Analysis 57.5. Comparison 57 Analysis of sensitivity ACR50 52 weeks, Outcome 5 Duration of previous
disease.
Review: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults
Comparison: 57 Analysis of sensitivity ACR50 52 weeks
Outcome: 5 Duration of previous disease








1 Long previous disease duration (6 years or more)
Keystone 2008 155/390 15/99 19.2 % 2.62 [ 1.62, 4.25 ]
Keystone 2008 149/393 15/100 19.1 % 2.53 [ 1.56, 4.10 ]
Subtotal (95% CI) 783 199 38.3 % 2.58 [ 1.83, 3.62 ]
Total events: 304 (Certolizumab pegol), 30 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 5.43 (P < 0.00001)
2 Short previous disease duration (less than 1 year)
Atsumi 2016 116/161 81/158 30.3 % 1.41 [ 1.17, 1.68 ]
Emery 2015 (1) 405/660 112/219 31.4 % 1.20 [ 1.04, 1.38 ]
Subtotal (95% CI) 821 377 61.7 % 1.29 [ 1.10, 1.50 ]
Total events: 521 (Certolizumab pegol), 193 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 1.83, df = 1 (P = 0.18); I2 =45%
Test for overall effect: Z = 3.19 (P = 0.0014)
Total (95% CI) 1604 576 100.0 % 1.69 [ 1.22, 2.33 ]
Total events: 825 (Certolizumab pegol), 223 (Control)
Heterogeneity: Tau2 = 0.08; Chi2 = 18.63, df = 3 (P = 0.00033); I2 =84%
Test for overall effect: Z = 3.17 (P = 0.0015)
Test for subgroup differences: Chi2 = 13.20, df = 1 (P = 0.00), I2 =92%
0.01 0.1 1 10 100
Favours control Favours certoluzimab pego
(1) Calculations of events were done according to the percentages of FAS (Full Analysis Set) 213 patients in placebo group and 655 in CZP group. We did AIT and
denominators were 219 and 660 in placebo and CZP group, respectively).
A D D I T I O N A L T A B L E S
Table 1. Contribution of trials
Update 2014 Update 2016
Benefit (B) Harm (H) Benefit (B) Harm (H)
Atsumi 2016 - - B H
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Table 1. Contribution of trials (Continued)
CDP870-004 2001 B H B -
Choy 2002 - H - H
Choy 2012 B H B H
Emery 2015 - - B H
Fleischmann 2009 B H B H
Keystone 2008 B H B H
NCT00993317 B H B H
Smolen 2009 B H B H
Smolen 2015 B H B H
Weinblatt 2012 B H B H
Yamamoto (a) 2014 B H B H
Yamamoto (b) 2014 B H B H
Østergaard 2015 - - - H
Total trials 10 11 12 14
Total pooled 9 9 11 13
The data from the two phase II studies (CDP870-004 2001; Choy 2002) were not pooled with the rest of the studies due to the
different follow-ups and doses used.
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Notes: All randomised participants; the actual numbers vary slightly across parameters
CZP: certolizumab pegol
CV: coefficient of variation
DAS: disease activity score
DMARD: disease-modifying anti-rheumatic drug










Table 3. Flow of participants in the included Phase III trials






Atsumi 2016 ITT n = 158Safety n =
157
- ITT n = 161Safety n =
159
-
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Table 3. Flow of participants in the included Phase III trials (Continued)
Discontinued n = 15 (%)
Consent withdrawn = 3
(2% )
Lack of efficacy = 1 (0.
06%)
Adverse event = 6 (4%)
Other reasons = 5 (3%)
Moved to rescue = 70
(44%)
- Discontinued n = 12 (7,
45%)
Consent withdrawn = 2
(1% )
Lack of efficacy = 0
Adverse event = 9 (5%)
Other reasons = 1 (0,5%)
Moved to rescue = 36
(22%)
-
Completed n= 73 (46.
20%)
- Completedn = 111(
69%)
-
Choy 2012 ITT n = 121a
Safety n = 119
- - ITT n = 126
Safety n = 124
All withdrawn
n = 56 (46.3%)
Lack of efficacy = 45 (37.
2%)
Adverse event = 6 (5%)
Other reasons = 5 (4.1%)
- - All withdrawn
n = 28 (22.2%)
Lack of efficacy = 16 (12.
7%)
Adverse event = 7 (5.6%)
Other reasons = 5 (4%)
Completed
n = 65 (53.7%)
- - Completed
n = 98 (77.8%)
ITT n = 121a Safety n =
119
- ITT n = 126a Safety n =
124
Emery 2015 ITT n = 219
Safety n = 217
- ITT n = 660
Safety n = 659
-
All withdrawn
n = 76 (35%)
Lack of efficacy =14 (6%)
Adverse event = 17 (8%)
Protocol violation = 6 (
3%)
Lost to follow-up = 6
(3%)
Consent withdrawn = 15
(7%)
Other reasons = 18 (8%)
- All withdrawn
n = 160 (24%)
Lack of efficacy =19 (3%)
Adverse event = 51 (8%)
Protocol violation = 18
(3%)
Lost to follow-up = 14
(2%)
Consent withdrawn = 35
(5%)
Other reasons = 23 (3%)
-
Completed
n = 143 (65%)
- Completed
n = 500 (76%)
-
Fleischmann 2009 ITT n = 109
Safety n = 109
- - ITT n = 111
Safety n = 111
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Table 3. Flow of participants in the included Phase III trials (Continued)
All withdrawn
n = 81 (74%)
Lack of efficacy = 75 (68.
8%)
Adverse event = 2 (1.8%)
Protocol violation = 1 (0.
9%)
Lost to follow-up = 3 (2.
8%)
- - All withdrawn
n = 35 (31.5%)
Lack of efficacy = 24 (21.
6%)
Adverse event = 5 (4.5%)
Protocol violation = 4 (3.
6%)
Consent withdrawn = 2
(1.8%)
Completed
n = 28 (25.7%)
- - Completed
n = 76 (68.5%)
Keystone 2008 ITT n = 199
Safety n = 199
- ITT n = 393
Safety n = 392b
ITT n = 390
Safety n = 389b
Withdrawn at week 16
due to lack of efficacy
n = 125 (62.8%)
- Withdrawn at week 16
due to lack of efficacy
n = 83 (21.1%)
Withdrawn at week 16
due to lack of efficacy
n = 68 (17.4%)
All withdrawn
n = 156 (78.4%)
- All withdrawn
n = 138 (35.1%)
All withdrawn
n = 116 (39.7%)
Completed
n = 43 (21.6%)
- Completed
n = 255 (64.9%)
Completed
n = 274 (70.3%)
NCT00993317 ITT n = 42
Safety n = 42
- ITT n = 85
Safety n = 85
-
All withdrawn
n = 21 (50%)
Lack of efficacy = 18
(42%)
Adverse event = 2 (4.
76%)
Other reasons = 1 (2.
38%)
- All withdrawn
n = 25 (29.41%)
Lack of efficacy = 18 (21.
8%)
Adverse event = 4 (4.
70%)




n = 21 (50%)
- Completed
n = 60 (70.58%)
-
Smolen 2009 ITT n = 127
Safety n = 125
- ITT n = 246
Safety n = 248c
ITT n = 246
Safety n = 246
Withdrawn at week 16
due to lack of efficacy
n = 103 (81%)
- Withdrawn at week 16
due to lack of efficacy
n = 52 (21.1%)
Withdrawn at week 16
due to lack of efficacy
n = 52 (21.1%)
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Table 3. Flow of participants in the included Phase III trials (Continued)
All withdrawn
n = 110 (86%)
- All withdrawn
n = 72 (29.3%)
All withdrawn
n = 65 (26.4%)
Completed
n = 17 (13.4%)
- Completed
n = 174 (70.7%)
Completed
n = 181 (73.6%)
Smolen 2015 ITT n = 98Safety n = 98 - ITT n = 96Safety n = 96 -
All withdrawnn = 18 (18.
36%)
Lack of efficacy = 7 (7.
14%)
Adverse event = 6 (6.12
%)
Other reasons = 5 (5.
10%)
- All withdrawnn = 12 (12.
5%)
Lack of efficacy = 2 (2.08
%)
Adverse event = 6 (6.
25%)




n = 80 (81.63%)
- Completedn = 84 (87.
5%)
-
Weinblatt 2012 ITT n = 212
Safety n = 209
- ITT n = 851
Safety n = 846
-
All withdrawn
n = 28 (13.20%)
Lack of efficacy = 6 (2.
83%)
Adverse event = 6 (2.
83%)
Other reasons = 16 (7.
54%)
- All withdrawn
n = 80 (9.41%)
Lack of efficacy = 6 (0.
70%)
Adverse event = 33 (3.
87%)




n = 184 (86.79%)
- Completed
n = 771 (90.59%)
-
Yamamoto (a) 2014 ITT n = 114Safety n =
114
- ITT n = 116Safety n =
116
-
All withdrawnn = 96 (84.
2%)
Lack of efficacy = 2 (1.
75%)
Adverse event = 2 (1.
75%)
Other reasons (protocol
planned n = 88) = 94
(82%)
- All withdrawnn = 34 (29.
31%)
Lack of efficacy = 0 (0%)
Adverse event = 8 (6.9%)
Other reasons (protocol
planned n = 24) = 26 (22.
4%)
-
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Table 3. Flow of participants in the included Phase III trials (Continued)
Completed n = 18 (15.
8%)
- Completedn = 82 (70.
69%)
Yamamoto (b) 2014 ITT n = 77
Safety n = 77
ITT n = 72
Safety n = 72
ITT n = 82
Safety n = 82
ITT n = 85
Safety n = 85
All withdrawn
n = 52 (67.53%)
Lack of efficacy = 2 (2.
98%)






n = 21 (29.17%)
Lack of efficacy = 3 (4.
17%)





n = 16 (19.51%)
Lack of efficacy = 1 (1.
22%)






n = 20 (23.53%)
Lack of efficacy = 0 (0%)






n = 25 (32.47%)
Completed
n = 51 (70.83%)
Completed
n = 66 (80.49%)
Completed
n = 65 (76.47%)
Østergaard 2015 ITT n = 13
Safety at 12 weeks n = 13
- ITT n = 27
Safety at 12 weeks n = 27
-
Only the data obtained at
week 2 were usable
Only the data obtained at
week 2 were usable
a Manufacturers reported efficacy calculations from placebo n = 119 and certolizumab pegol n = 124.
b Two participants in each treatment group did not take study medication.
cTwo participants in the placebo group received certolizumab pegol and were included for safety in the 200 mg group. (d)
Table 4. Beneficial ACR50





RR (CI 95%) % RD NNTB
ACR50








36% 9% 3.80 (2.42 to 5.
95)
27 (20 to 33) 4 (3 to 8)
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Table 4. Beneficial ACR50 (Continued)









34% 7% 4.65 (3.09 to 6.
99)
27 (17 to 34) 4 (3 to 7)




55% 36% 1.54 (1.38 to 1.
73)
20 (15 to 24) 5 (3 to 7)
Analysis 5.1 52 weeks 400 mg:
Keystone 2008
40% 8% 5.27 (3.19 to 8.
71)
32 (26 to 38) 3 (2 to 6)
Table 5. Health-related quality of life
Follow-up Doses/study Mean differences
HAQ (0 - 3) (Best = 0; Worst = 3)
Analysis 7.1 24 weeks 200mg/ Smolen 2015;NCT00993317; Keystone
2008; Smolen 2009
-0.35 (-0.43 to -0.26)
Analysis 7.2 24 weeks 400mg/Choy 2012; Fleischmann2009;Keystone
2008; Smolen 2009
-0.38 (-0.48 to -0.28)
Analysis 9.1.1 52 weeks 200 mg/ Emery 2015; Keystone 2008 -0.27 (-0.35 to -0.20)
Analysis 9.1.2 52 weeks 400 mg/ Keystone 2008 -0.45 (-0.57 to -0.33)
SF-36 PCS (0 - 100) (Worst = 0; Best = 100)
Analysis 10.1 24 weeks 200 mg/ Smolen 2015; Keystone 2008; Smolen
2009
5.03 (3.90 to 6.16)
Analysis 10.2 24 weeks 400 mg/ Choy 2012; Keystone 2008; Smolen
2009
5.54 (4.11 to 6.97)
SF-36 MCS (0 - 100) (Worst = 0; Best = 100)
Analysis 11.1 24 weeks 200 mg/ Keystone 2008; Smolen 2009 4.18 (2.70 to 5.66)
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Table 5. Health-related quality of life (Continued)
Analysis 11.2 24 weeks 400 mg/ Choy 2012; Keystone 2008; Smolen
2009
4.05 (2.77 to 5.34)
SF-36 PCS
Analysis 12.1 52 weeks 200 mg/ Keystone 2008 6.06 (4.59 to 7.53)
Analysis 12.2 52 weeks 400 mg/ Keystone 2008 6.88 (5.42 to 8.34)
SF-36 MCS (0 - 100) (Worst = 0; Best = 100)
52 weeks 200 mg/ Keystone 2008 4.3 (2.4 to 6.2)
52 weeks 400 mg/ Keystone 2008 4.3 (2.4 to 6.2)
Participants’ VAS score (0 - 100)
Analysis 52.1 24 weeks 200 mg/ Keystone 2008; Smolen 2009 -20.48 (-24.26 to -16.69)
400 mg/ Fleischmann 2009; Keystone 2008;
Smolen 2009
-21.35 (-25.08 to -17.61)
Analysis 53.1 52 weeks 200 mg/ Keystone 2008 -22.20 (-27.37 to -17.03)
400 mg/ Keystone 2008 -24.70 (-29.73 to -19.67)
DAS-28 remission (< 2.6)
Analysis 21.2 24 weeks 200 mg/ Smolen 2015; Yamamoto (a) 2014;
Atsumi 2016; Emery 2015; Keystone 2008;
Smolen 2009
3.79 (1.90 to 7.56)
Analysis 21.3 400 mg/ Choy 2012; Keystone 2008; Smolen
2009
7.18 (3.12 to 16.50)
Analysis 21.4 52 weeks 200 mg/ Atsumi 2016; Emery 2015; Keystone
2008
1.83 (1.53 to 2.18)
Analysis 21.5 400 mg/ Keystone 2008 12.49 (3.99 to 39.12)
Table 6. Radiological changes
Follow-up Doses/study Mean differences
Modified Total Sharp Scores (mTTS) is the sum of the erosion score (ES) and the joint space narrowing (JSN) score and has
a range of 0 - 398
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Table 6. Radiological changes (Continued)
Analysis 37.1 24 weeks 200 mg/ Keystone 2008; Smolen 2009 -1.06 (-1.58 to -0.55)
Analysis 37.2 24 weeks 400 mg/ Keystone 2008; Smolen 2009 -1.32 (-1.85 to -0.78)
Analysis 36.1.1 52 weeks 200 mg/ Keystone 2008; Emery 2015 -2.4 (-4.11 to -0.69)
Analysis 36.1.2 52 weeks 400 mg/ Keystone 2008 -2.6 (-4.29 to -0.91)
Erosion Score is the sum of joint scores collected for 46 joints and has a range of 0 to 230
Analysis 29.1 24 weeks 200 mg/ Keystone 2008; Smolen 2009 -0.35 (-0.50 to -0.21)
Analysis 29.2 24 weeks 400 mg/ Keystone 2008; Smolen 2009 -0.76 (-1.14 to -0.37)
Analysis 29.3 52 weeks 200 mg/ Keystone 2008; Emery 2015 -1.14 (-1.54 to -0.74)
Analysis 29.4 52 weeks 400 mg/ Keystone 2008 -1.5 (-2.20 to -0.80)
Joint space narrowing (JSN) is the sum of joint scores collected for 42 joints and has a range of 0 to 168
Analysis 32.1 24 weeks 200 mg/ Keystone 2008; Smolen 2009 -0.45 (-0.77 to -0.13)
Analysis 32.2 24 weeks 400 mg/ Keystone 2008; Smolen 2009 -0.55 (- 0.86 to -0.24)
Analysis 32.3 52 weeks 200 mg/ Keystone 2008 -1 (-1.85 to -0.15)
Analysis 32.4 52 weeks 400 mg/ Keystone 2008 -1.2 (-1.98 to -0.42)
Table 7. Adverse events
Studies Response





rate in % (num-
ber of events)
placebo















8.4% (228) 5,8% (72) 1.47 (1.13 to 1.
91)
3 (1 to 4) 33
(25o 100)
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10% (95) 4% (31) 1.98 (1.36 to 2.
9)



















6% (147) 4% (46) 1.32 (0.95 to 1.
84)












5% (48) 2% (16) 2.01 (1.20 to 3.
36)













0.03% (8) 0.1% (1) 2.66 (0.63 to 11.
16)







0.5% (5) 0% (1) 1.87 (0.31 to 11.
34)
0 (-1 to 1) NS
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0.7% (19) 0.7% (9) 0.92 (0.40 to 2.
11)









0.6 % (5) 0.4% (2) 1.26 (0.26 to 6.
08)
















35% (891) 29% (389) 1.27 (1.10 to 1.
46)
7 (1 to 13) 14
(8 to 58)
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34% (298) 21% (183) 1.43 (1.03 to 1.
98)
10 (1 to 20) 10 (5 to 44)
A P P E N D I C E S
Appendix 1. MEDLINE search strategy
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) <1946 to Present>
Search Strategy:
1 (CDP870 or CDP 870 or ”certolizumab pegol“ or certolizumab or CDP-870 or cimzia).mp. (393)
2 (”Rheumatoid Arthritis“ or (Caplan$ and Syndrome?) or (Felty$ and S?ndrome) or (Rheumatoid and Nodule?) or (Sjogren$ and
S?ndrome?) or (Sicca$ and S?ndrome?) or (Ankylos$ and Spondylit$) or (Spondylarthritis and Ankylopoietica) or (Rheumatoid$ and
Spondylit$) or (Bechterew$ and Disease?) or (Marie-Struempell and Disease?) or (Adult and Onset and Still$ and Disease?)).mp.
(98824)
3 exp Arthritis, Rheumatoid/ (94528)
4 2 or 3 (126632)
5 1 and 4 (131)








14 5 and 13 (114)
15 limit 14 to yr=”2009 -Current“ (99)
Search date: 2009 - February 12, 2013
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Appendix 2. Embase search strategy
1. ’rheumatoid arthritis’/exp/
2. ’certolizumab pegol’/exp/
3. (CDP870 OR ’CDP 870’ OR CDP-870 OR ’certolizumab pegol’ OR certolizumab OR cimzia).mp.
4. 2 OR 3
5. 4 AND 1
6. random:.tw.
7. clinical trial:.mp.
8. exp health care quality
9. or/6-8
10. 5 AND 9
Search date: 2009 - February 12, 2013
Appendix 3. CINAHL search strategy
1.’rheumatoid arthritis’/exp/
2.”rheumatoid arthritis“.mp.
3. (CDP870 OR ’CDP 870’ OR CDP-870 OR ’certolizumab pegol’ OR certolizumab OR cimzia).mp.






Search date: 2009 - February 12, 2013
Appendix 4. Search strategy for CDSR and CENTRAL, HTA, DARE, NHS EED
Last search in November 2009
#1 certolizumab or cimzia
#2 cdp870
#3 cdp next 870
#4 (#1 OR #2 OR #3)
#5 rheumatoid next arthritis
#6 MeSH descriptor Arthritis, Rheumatoid explode all trees
#7 (#5 OR #6)
#8 (#4 AND #7)
Search date: 2009 - February 12, 2013
Appendix 5. SCOPUS search strategy
Search strategy for benefits:
SCOPUS will be searched up to August of 2007, without limits of years:
KEY((certolizumab OR cimzia OR CDP-870 OR CDP870 OR ”CDP 870“) AND (”rheumatoid arthritis“ ))
Web of Knowledge (WOK), was searched up to August of 2007, without limits of years. The search strategy is as follows:
topic=((certolizumab OR cimzia OR CDP-870 OR CDP870 OR ”CDP 870“) AND (”rheumatoid arthritis“ )
Databases=MEDLINE, Current Contents Connect, Web of Science, Derwent Innovations Index, ISI Proceedings; Timespan=All Years
Search date: 2009 - February 12, 2013
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Appendix 6. TOXLINE (TOXNET) search strategy
Search strategy for safety:
TOXLINE (TOXNET) will be searched up to October 2007. The search strategy will combine index and text terms for CDP870:
#1. certolizumab OR ”certolizumab pegol“ OR CDP870 OR CDP-870 OR ”CDP 870“ OR cimzia
Search date: 2009 - February 12, 2013
Appendix 7. Web of Knowledge
Web of Knowledge (Science Citation Index and Social Science Citation Index) 1900 - February 2013
Search terms: TS= (certolizumab OR cimzia OR or CDP870 OR cdp 870) and (“rheumatoid arthritis”)
Search date: 2009-February 12, 2013
Appendix 8. Results of searches 2013
Database name and coverage Search date Total Retrieved
Ovid MEDLINE(R) In-Process & Other
Non-Indexed Citations and Ovid MED-
LINE(R) 1946 to present
2009-February 12, 2013 315
Ovid Embase Classic+Embase
1947 to 2013 January 16
2009 - February 12, 2013 1365
Wiley Cochrane Library - CENTRAL
Issue 1 of 12- Jan. 2013
2009 - February 12, 2013 11
EbscoHost CINAHL
1982-January 2013
2009 - February 12, 2013 32
Toxline (TOXNET) 2007 - February 12,
2013
34




1966 to 2013 January
2009 - February 12, 2013 814
Total 2760
Total without duplicates 1300
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Appendix 9. Searches updated to June 2014
Database name and coverage Search date Total Retrieved Total without Duplicates
Ovid MEDLINE(R) In-Pro-
cess & Other Non-Indexed Ci-
tations and Ovid MEDLINE
(R)
2013-2014
June 5, 2014 29 28
Ovid Embase Classic+Embase
2013-2014
June 5, 2014 208 192
EbscoHost CINAHL
2013-2014
June 5, 2014 1 1
Wiley Cochrane Library -
CENTRAL
2013-2014
June 6, 2014 4 4
SCOPUS
2013-2014
June 10, 2014 233 124
Web of Knowledge
2013-2014
June 10, 2014 94 54
Total 569 403
Appendix 10. Medline search strategy January 25, 2016
MEDLINE Total retrieved = 70
1. exp Arthritis, Rheumatoid/
2. ((Arthritis adj2 Rheumatoid) or (caplan* adj2 s?ndrome?) or (Familial and felty* and s?ndrome?) or (felty* adj2 s?ndrome?) or
(Rheumatoid and arthritis and splenomegaly and neutropenia) or (rheumatoid and nodul*) or (rheumatoid and vasculiti*) or (sicca*
and s?ndrome?) or (sjogren* and s?ndrome?) or (adult* and onset and still* disease?) or (ankylo* and spondylarthriti*) or (ankylo* and
spondylistis) or (ankylosing and spondylorthriti*) or (spondylitis and rheumatoid) or (bechterew* and disease?) or (marie* struempell
and disease?) or (rheumatoid and spondylitis) or (spondylarthriti* and ankylo*)).mp
3. exp Spondylitis, Ankylosing/
4. exp Certolizumab Pegol/
5. (pegylated tumo?r necrosis factor alpha antibody Fab fragment or pha 738144 or (870* adj1 cdp*) or cdp?870? or certolizumab
pegol* or cimzia* or pegol* adj1certolizumab).mp. [mp=title, abstract, original title, name of substance word, subject heading word,
keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]
6. 4 or 5
7. 1 or 2 or 3
8. 6 and 7
9. limit 8 to yr=”2014 -Current“
10. Clinical trial.pt. or randomized.ab. or placebo.ab. or dt.fs. or randomly.ab. or trial.ab. or groups.ab
11. 9 and 10
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Appendix 11. Embase search strategy January 25, 2016
EMBASE Total retrieved= 304
1. ((Arthritis adj2 Rheumatoid) or (caplan* adj2 s?ndrome?) or (Familial and felty* and s?ndrome?) or (felty* adj2 s?ndrome?) or
(Rheumatoid and arthritis and splenomegaly and neutropenia) or (rheumatoid and nodul*) or (rheumatoid and vasculiti*) or (sicca*
and s?ndrome?) or (sjogren* and s?ndrome?) or (adult* and onset and still* disease?) or (ankylo* and spondylarthriti*) or (ankylo* and
spondylistis) or (ankylosing and spondylorthriti*) or (spondylitis and rheumatoid) or (bechterew* and disease?) or (marie* struempell
and disease?) or (rheumatoid and spondylitis) or (spondylarthriti* and ankylo*)).mp
2. (arthritis deformans or arthrosis deformans or (beauvais adj2 disease?) or (chronic adj2 poly?arthritis) or (chronic adj2 rheumatoid
adj2 arthritis) or inflammatory arthritis or (polyarthritis adj2 primary adj2 chronic) or (progressive adj2 polyarthritis adj2 chronic)
or rheumarthritis or rheumatism, chronic articular or (rheumatic adj2 arthritis) or (rheumatic adj1 polyarthritis)).mp
3. 1 or 2
4. exp rheumatoid arthritis/
5. exp pneumoconiosis/
6. exp Felty syndrome/
7. exp rheumatoid nodule/
8. exp rheumatoid vasculitis/
9. exp Sjoegren syndrome/
10. exp adult onset Still disease/
11. exp ankylosing spondylitis/
12. or/4-11
13. 3 or 12
14. exp certolizumab pegol/
15. (pegylated tumo?r necrosis factor alpha antibody Fab fragment or pha?738144 or (870* adj1 cdp*) or cdp?870? or certolizumab
pegol* or cimzia* or pegol* adj1certolizumab).mp. [mp=title, abstract, heading word, drug trade name, original title, device manu-
facturer, drug manufacturer, device trade name, keyword]
16. 14 or 15
17. 13 and 16
18. limit 17 to yr=”2014 -Current“
19. random:.tw. or clinical trial:.mp. or exp health care quality/
20. 18 and 19
Appendix 12. Central search strategy January 22, 2016
COCHRANE retrieved =36
#1 (870* next cdp*) or cdp?870? or certolizumab or cimzia*
#2 MeSH descriptor: [Arthritis, Rheumatoid] explode all trees
#3 ((Arthritis next Rheumatoid) or (caplan* next syndrome*) or (Familial and felty* and syndrome*) or (felty* next syndrome*) or
(Rheumatoid and arthritis and splenomegaly and neutropenia) or (rheumatoid and nodul*) or (rheumatoid and vasculiti*) or (sicca*
and syndrome*) or (sjogren* and s*ndrome*) or (adult* and onset and still* disease*) or (ankylo* and spondylarthriti*) or (ankylo* and
spondylistis) or (ankylosing and spondylorthriti*) or (spondylitis and rheumatoid) or (bechterew* and disease*) or (marie* struempell
and disease*) or (rheumatoid and spondylitis) or (spondylarthriti* and ankylo*))
#4 arthritis deformans or arthrosis deformans or (beauvais next disease*) or (chronic next polyarthritis) or (chronic next rheumatoid
next arthritis) or inflammatory arthritis or (polyarthritis next primary next chronic) or (progressive next polyarthritis next chronic)
or rheumarthritis or rheumatism, chronic articular or (rheumatic next arthritis) or (rheumatic next polyarthritis)
#5 #2 or #3 or #4
#6 #1 and #5
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#7 ((Arthritis next Rheumatoid) or (caplan* next syndrome*) or (Familial and felty* and syndrome*) or (felty* next syndrome*) or
(Rheumatoid and arthritis and splenomegaly and neutropenia) or (rheumatoid and nodul*) or (rheumatoid and vasculiti*) or (sicca*
and syndrome*) or (sjogren* and s*ndrome*) or (adult* and onset and still* disease*) or (ankylo* and spondylarthriti*) or (ankylo* and
spondylistis) or (ankylosing and spondylorthriti*) or (spondylitis and rheumatoid) or (bechterew* and disease*) or (marie* struempell
and disease*) or (rheumatoid and spondylitis) or (spondylarthriti* and ankylo*))
Appendix 13. WOK search strategy January 22, 2016
WOK retrieved =
Web of Knowledge (Science Citation Index and Social Science Citation Index) 1900 - January 2016
#1 Topic: ((((((((((((((((((Arthritis NEARRheumatoid) OR (caplan* NEAR s?ndrome?)) OR ((Familial AND felty*) AND s?ndrome?
)) OR (felty*NEAR s?ndrome?)) OR (((Rheumatoid ANDarthritis) AND splenomegaly) ANDneutropenia)) OR (rheumatoid AND
nodul*)) OR (rheumatoid AND vasculiti*)) OR (sicca* AND s?ndrome?)) OR (sjogren* AND s?ndrome?)) OR ((adult* AND onset)
AND still* disease?)) OR (ankylo* AND spondylarthriti*)) OR (ankylo* AND spondylitis)) OR (ankylosing AND spondylorthriti*)
) OR (spondylitis AND rheumatoid)) OR (bechterew* AND disease?)) OR (marie$struempell AND disease?)) OR ((rheumatoid
AND spondylitis spondylarthriti*) AND ankylo*)) OR (((((((((((arthritis deformans OR arthrosis deformans) OR (beauvais NEAR
disease?)) OR (chronic NEAR poly?arthritis)) OR ((chronic NEAR rheumatoid) NEAR arthritis)) OR inflammatory arthritis) OR
((polyarthritis NEAR primary) NEAR chronic)) OR ((progressive NEAR polyarthritis) NEAR chronic)) OR rheumarthritis) OR
rheumatism, chronic articular) OR (rheumatic NEAR arthritis)) OR (rheumatic NEAR polyarthritis)))
limit=2016
#2 Topic: ((pegylated tumo?r necrosis factor alpha antibody Fab fragment or pha?738144 or (870* NEAR cdp*) or cdp?870? or
certolizumab pegol* or cimzia* or (pegol* NEAR certolizumab)))
Time=2016
#3 #2 AND #1
#4 Refined by: Document (CLINICAL TRIAL)
Appendix 14. Search strategy Clinicaltrials.gov
certolizumab pegol AND Rheumatoid arthritis
Appendix 15. Searches on International Clinical Trials Registry Platform
certolizumab pegol/Intervention AND Rheumatoid arthritis/Condition | Studies updated from to 12/31/2016
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Appendix 16. Results of searches updated to January 2016
Database name and coverage Search date Total Retrieved
Ovid MEDLINE(R) In-Process & Other
Non-Indexed Citations and Ovid MED-
LINE(R)
2014-2016
January 25, 2016 70
Ovid Embase Classic+Embase
2014-2016
January 25, 2016 304
Wiley Cochrane Library - CENTRAL
2014-2016
January 25, 2016 36
Web of Knowledge
2014-2016
January 25, 2016 25
Clinicaltrials.gov
2014-2016
January 25, 2016 28
Total 463
Appendix 17. Results of searches updated to September 2016
Database name and coverage Search date Total Retrieved
Ovid MEDLINE(R) In-Process & Other
Non-Indexed Citations and Ovid MED-
LINE(R)
From 1 January 2016 to 26 September
2016




1947 to 2016 26 September 2016
September 26, 2016 97
Wiley Cochrane Library - CENTRAL
From 1 January 2016 to 26 September
2016
September 26, 2016 4
Web of Knowledge
From 1 January 2016 to 27 September
2016
September 27, 2016 2
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(Continued)
Clinicaltrials.gov
From 1 January 2016 to 27 September
2016
October 1, 2016 28
ICTRP
to 31 December 2016
Decemeber 31, 2016 42
Total 194
WH A T ’ S N E W
Last assessed as up-to-date: 26 September 2016.
Date Event Description
26 September 2016 New citation required but conclusions have not
changed
For this update, we changed the authors in the team:
José Antonio Bernal is new
26 September 2016 New search has been performed We include 14 trials, 3 more than in the previous re-
view. All of them have information about harm, but
we have only pooled 12 trials. 12 trials gave informa-
tion on benefits, but we have only pooled 11. We have
more information regarding the quality of trials be-
cause UCB© gave us further data. We have used this
information to update our assessment of the quality of
trials
For the new trials we obtained unpublished data about
the quality and results, includingwithdrawals and seri-
ous adverse events from clinicaltrials.gov. We checked
this information with UCB©.
H I S T O R Y
Protocol first published: Issue 1, 2009
Review first published: Issue 2, 2011
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Date Event Description
3 April 2008 New search has been performed CMSG ID: C001-R
C O N T R I B U T I O N S O F A U T H O R S
Design the protocol: Juan Cabello; Vicente Ruiz; Amanda Burls
Write the Background: Paloma Vela and José Antonio Bernal
Develop the search strategy: Tamara Rader
Trial search (two people): Vicente Ruiz; Sylvia Bort
Obtain copies of the trials: Sylvia Bort
Selection of trials for inclusion (two plus one): Vicente Ruiz; Sylvia Bort. If data discrepancies were to be resolved by involvement of a
third person: Amanda Burls
Retrieval of trial data on benefits (two plus one): Vicente Ruiz; Sylvia Bort. If data discrepancies were to be resolved by involvement of
a third person: Amanda Burls
Data input in Review Manager 5: Sylvia Bort
Carry out analyses: Vicente Ruiz
Interpret analyses: Vicente Ruiz
Write up results: Vicente Ruiz; ; Paloma Vela; Amanda Burls; Juan Cabello; Sylvia Bort; José Antonio Bernal
Update review: Vicente Ruiz; José Antonio Bernal; Paloma Vela
D E C L A R A T I O N S O F I N T E R E S T
UCB paid Dr Vicente Ruiz’s registration for the Cochrane meeting in Madrid 2011. In 2011 and 2012 he attended the UCB Advisory
Board meetings in Madrid when the sponsor explained details and preliminary results for the new trials of certolizumab pegol. He did
not receive any economic or other kind of compensation for these meetings.
Burls A: none known.
Cabello JB: none known.
Vela Casasempere P: ”I have participated as a member of advisory boards for Roche and Pfizer. I have also received fees for development
of educational presentations for Roche, Abbvie, UCB, BMS and MSD, and travel and accommodations expenses to attend scientific
meetings from Pfizer, Abbvie and Roche“.
Bort-Marti S: none known.
Bernal JA: ”I have received travel and accommodations expenses to attend scientific meetings from Pfizer and MSD“.
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S O U R C E S O F S U P P O R T
Internal sources
• Grant from, Spain.
Instituto de Salud Carlos III. Ministerio de Sanidad. FIS number PI08˙90617 in the first previous systematic review.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Types of participants
Protocol specified adults with RA who have persistent disease activity, despite current or previous use of conventional DMARDs. We
have included two studies (Atsumi 2016; Emery 2015) with MTX-naïve participants. This approach is now considered justified in
early RA, as data are available showing differences in outcome when remission is obtained as soon as possible.
Types of outcomes
In the protocol we stated that we ”We will review also this list of adverse events: headache, fever, blood disorders, laboratory disorders,
abdominal pain, nasopharyngitis, nausea, respiratory tract infections, urinary tract infections, neck pain, congestive heart failure,
pruritus and anaphylaxis“. In the previous update and with the approval of the editors, we made serious adverse events, DAS and
radiological changes of major outcomes. DAS28 is used as an indicator of RA disease activity and a response to treatment.
Searches
We did not perform the searches in CINHAL nor in SCOPUS, because although we covered these database in the original protocol
they did not yield any additional information in our previous searches. Following MECIR criteria, we conducted searches on theWHO
international clinical trials registry platform.
Data synthesis
We decided to perform a random-effects model analysis, despite low values of the I2 statistic. Although the trials used the same drug,
there was clear clinical heterogeneity (different doses, allowing MTX or not, different follow-up, different duration of RA, etc.).
Subgroup analysis
Subgroup analyses were planned for the duration of the illness (approximately three years evolution), participants’ sex, drug dose and
administration, and methodological quality; but we performed only a subgroup analysis for dosage of certolizumab pegol. All Phase
III trials were conducted in participants with a long mean duration of RA (from 6.1 to 9.5 years) and we could not obtain any data
categorised by sex. All Phase III trials allowed previous DMARD treatment (mean 1.2 to 2 years). We rated all the Phase III trials
included in the meta-analysis as high quality and so we did not perform subgroup analysis based on methodological quality.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Antibodies, Monoclonal, Humanized; Antirheumatic Agents [∗therapeutic use]; Arthritis, Rheumatoid [∗drug therapy]; Immunoglob-
ulin Fab Fragments [∗therapeutic use]; Methotrexate [therapeutic use]; Polyethylene Glycols [∗therapeutic use]; Randomized Con-
trolled Trials as Topic
MeSH check words
Adult; Humans
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